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Abstract 
Labour onset results from a complex interplay between hormonal and inflammatory signals. 
Untimely activation of these pathways can cause preterm labour (PTL) and premature birth 
(<37 weeks of gestation), the primary cause of infant mortality. Throughout gestation, uterine 
quiescence is maintained by progesterone and its withdrawal at term induces pro-labour 
genes and activation of uterine contractions. Infection and inflammation are frequently 
associated with PTL. Recognition of bacteria by the maternal innate immune system involves 
activation of nuclear factor kappa-B (NFκB) and activator protein-1 (AP-1), which regulate 
inflammatory and pro-labour genes. The aim of this thesis was to determine the contribution 
of inflammatory and hormonal pathways to parturition in murine models by comparing 
molecular changes in myometrium throughout term gestation, PTL induced by 
lipopolysaccharide (LPS; inflammation-induced PTL), and RU486-induced PTL by 
progesterone withdrawal (non-inflammatory PTL). Term gestation was shown to involve 
sequential activation of NFκB and AP-1. Different LPS serotypes induced heterogeneous 
maternal and fetal responses in the LPS-induced PTL model. LPS O111:B4 caused the most 
severe phenotype of PTL within 7h and total fetal demise. This involved JNK/AP-1-mediated 
activation of uterine inflammation, without NFκB activation. TLR-4 ablation rescued this 
phenotype and JNK inhibition delayed PTL. RU486 caused PTL without modulation of 
inflammatory pathways. RNA-Seq was used to characterize dynamic uterine transcriptome 
changes antecedent to term labour or PTL (RU486 or LPS-induced). Strong similarity was 
observed within term gestation and RU486-induced PTL transcriptomes, while the LPS 
model involved distinctive inflammatory gene changes. Positive correlation was found 
between human and murine transcriptomes. This thesis shows that LPS-induced 
inflammation can override repressive effects of progesterone on pro-labour genes while 
abrogation of progesterone signalling prompts PTL without inflammatory gene activation. 
These data support the paradigm of a common terminal pathway of labour yet provides new 
evidence that inflammatory gene activation is not necessary for labour. 
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1 INTRODUCTION 
 
1.1 Parturition: the importance of timing for an healthy start to life  
Parturition, from Late Latin “parturīre” to be in labour, is a tightly regulated transitional 
process involving cervical remodelling and dilatation, fetal membrane rupture and activation 
of uterine contractions that collectively permit delivery of the fetus [1]. This process involves 
dramatic structural and functional changes within the uterine tissues that are regulated by a 
complex interplay between hormonal, mechanical and inflammatory signals, much of which 
remains poorly understood. Gestation has evolved in different species accordingly to ensure 
development in utero of a healthy offspring, timely delivery and continued survival of the 
species. Importantly, successful delivery is dependent upon appropriate birth timing. At the 
time of delivery a newborn must adjust rapidly to a different environment outside of the 
uterus. The time at which this challenge is presented to the fetus is of crucial importance to its 
survival. Fetal viability, defined as the potential of the fetus to survive outside the womb after 
delivery, be it either natural or induced, is heavily dependent on degree of maturation of fetal 
organs as well as environmental conditions [2]. Therefore newborns delivered preterm will 
have a reduced chance of survival and will often face long-term morbidities and disabilities. 
Clinically, the limit of viability is defined as the gestational age at which a premature fetus 
has 50% chances of surviving ex-utero [2]. The timing of birth is particularly crucial 
considering that while in high-income countries 50% of babies delivered before 24 weeks 
survive, this rate is not reached until 32 weeks of gestation in low-resource countries, due to 
differences in the quality of post-natal care. In fact, over 90% of very preterm babies in these 
settings will die in the neonatal period [3]. A major change has occurred in the last decade as 
the timing of child deaths has moved closer to the time of birth and neonatal period, with 
44% of global child deaths occurring at this time [4]. This shift indicates that while 
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substantial advances have been made in reducing infection-induced deaths, prevalence of 
neonatal mortality caused by prematurity is rising in many countries. Even when advances in 
neonatal care have contributed to increase the chances of survival of very preterm babies, the 
burden of preterm birth is increasing, as estimated for 65 countries in Europe, the Americas 
and Australasia from 1990 to 2010, together with an increased number of preterm babies 
developing long-term disabilities [5, 6]. 
 
1.1.1 The problem: Preterm labour 
Preterm labour (PTL) consists in activation of uterine contractions and cervical dilatation that 
start at less than 37 completed weeks of gestation. Birth occurring before 37 weeks of 
gestation is termed preterm birth (PTB). PTB is now the primary cause of death in children 
under five years of age [4]. Immediate complications of prematurity include infections, 
respiratory difficulties, anaemia and hyperbilirubinemia [7]. Long-term complications include 
learning and behavioural difficulties, cerebral palsy, lung problems, vision and hearing loss 
[6]. Premature babies are also at greater risk of developing hypertension and diabetes later in 
life establishing a cycle of risk impacting on the health of future generations [8]. 
In September 2000, during the UN Millennium Summit, 147 heads of state signed the United 
Nations Millennium Development Goals (MDGs) that are eight goals responding to the 
world’s main development challenges [9]. Among these, MDGs 4 and 5 consisted in reducing 
child mortality by two-thirds between 1990 and 2015, and improving maternal health 
reducing by three-fourths the maternal mortality ratio. The final report summarising 
achievements of this global effort reported a decrease in child mortality rate by about half 
with 12.7 million of deaths in children less than five years in 1990 to almost 6 million in 
2015 worldwide. Similarly, the maternal mortality rates were declined by 45 % with most of 
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the reduction occurring since 2010 [10]. While substantial progresses in reducing child and 
maternal mortality have been made, the MGD4 has to-date not been fully achieved in most 
countries [4]. A striking difference from 1990 is that now PTB, not pneumonia, is the leading 
cause of death in children under five years of age therefore significantly fewer PTBs must 
occur in order to attain the goal originally set by the MGD4. Basic research into the 
biological mechanisms of term and preterm birth constitutes a necessary foundation for 
translating discoveries into diagnostic, treatment and preventions strategies and to target more 
effectively PTL and improve health of future generations. 
 
1.1.2 Epidemiology of preterm labour 
1.1.2.1 Definitions 
The clinical precursors of PTB include medically indicated delivery for maternal or fetal 
indications (30-35%), spontaneous PTL with intact membranes (40-45%) and preterm 
premature rupture of membranes (PPROM, 25-30%) [11]. Spontaneous preterm births 
include both PTL with intact membranes and PPROM cases. Depending on gestational age at 
delivery, preterm births are classified as late preterm (34-36 weeks, 60-70%), early preterm 
(32–33 weeks, 20%), very early preterm (28–31 weeks, 15%) or extremely preterm (<28 
weeks, 5%) [11]. Birth weight was previously used to categorised degrees of prematurity but 
recently has been replaced by more accurate calculations of gestational age determined by 
taking into account the date of last menstrual period and ultrasound fetal biometry [12].  
 
Figure 1.1 Prenatal development and associated fetal viability rate. Timeline of human pregnancy 
by gestational age (weeks/months after conception). 
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1.1.2.2 Incidence of preterm birth 
The worldwide incidence of PTB is estimated to be approximately 11% but ranges from 5% 
in some European countries to 18% in parts of Africa. This equates to more than 15 million 
premature babies born each year [6]. USA has a preterm delivery rate generally higher than 
Europe of about 12-13%. This rate has increased dramatically since 1981 when only 9.5% of 
deliveries were preterm. Since 2000 however, this rate has decreased [13]. Many preterm 
cases in singleton pregnancies are caused by the increased number of elective preterm 
deliveries, frequently for conditions such as pre-eclampsia, intrauterine growth restriction or 
maternal illness [14]. Increased use of assisted reproduction and consequent multiple 
pregnancies has similarly raised the rate of PTBs in developed countries [15]. Further, 
singleton pregnancies derived from in vitro fertilisation have also been shown to have a 
greater risk of being preterm [16]. PTB rates differ by ethnicity and race. For example 
PPROM is more frequent in black women [17]. In United Kingdom the rates of PTB are 
greater for Africans and Asians compared to white Europeans [18]. Similar results are 
observed in Canada where 8.9% and 5.9% of infants were born to black and white mothers 
respectively as well as the USA (12.7% black, 8.0%, white) [19]. These data are consistent 
with a recently published study predicting the global incidence of PTB, which estimated 85% 
of all PTB cases to occur in Africa and Asia in 2005 [20]. Systematic analysis of incident 
rates with projections until 2030 (Fig. 1.2) revealed that although rates of PTB are slowly 
decreasing, if trends continue in this fashion 4.4 million children younger than 5 years will 
still die in 2030. Furthermore, sub-Saharan Africa will have 33% of the global births, 60% of 
which will be followed by deaths in 2030 [4]. 
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Figure 1.2 Preterm birth statistics. (A) Global cause-specific mortality in 2013 with projections to 
2030 and (B) distribution of livebirths and under-5yr old deaths in 2013 and 2030 grouped by MDG 
(Millennium Development Goal) region. Adapted from [4]. Image reproduced with permission of the 
rights holder, Elsevier. 
  
1.1.3 Health and economic burden of preterm birth 
Advancements in neonatal care have allowed a greater number of preterm babies to survive, 
however this has translated into a rising number of babies with an increased risk of health and 
socio-development problems later in their adult life. These complications include severe 
motor and sensory impairment, chronic lung disease, acute gastro-intestinal problems, 
cerebral palsy, infections, attention deficit disorders and learning difficulties [21]. In US, the 
annual cost for preterm deliveries was at least 26.2 billion in 2005, i.e. approximately 51600 
USD per preterm infant [7]. Additional costs include an estimated USD 3800 for health 
service for maternal delivery costs, USD 1200 towards early interventions such as 
emotional/physical support and USD 2200 for special education services. Indirect costs in 
terms of loss of labour force due to disability are estimated to cost around USD 11200 per 
child. A report by Hodek JM et al. investigated the magnitude of the PTB burden going 
beyond evaluating the very expensive costs of the initial hospitalisation and associated 
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neonatal intensive care [22]. Importantly, this work analysed for the first time the economic 
burden of prematurity to society by evaluating the impact of long-term costs after the initial 
period of hospitalisation, including re-hospitalisation, pharmaceutical, medical aids as well as 
non-medical expenses such as the cost of providing special education, transportation, and 
indirect costs when considering labour force losses associated with disabling conditions. This 
study highlighted the large extent of the burden experienced by the parents of a preterm child 
consisting in considerable out-of-pocket expenditures as well as emotional burden arising 
from a dramatically changed quality of life for both children and families. 
 
1.2 Physiological mechanisms of labour onset 
1.2.1 Phases of parturition 
Parturition can be divided in four phases including quiescence (phase 0), activation (phase 1), 
stimulation (phase 2), and involution (phase 3) [23]. For about 95% of pregnancy the uterus 
is quiescent (phase 0), the cervix remains closed and the fetal membranes provide a 
protective barrier to shelter the developing fetus from the external environment. This 
protective environment is maintained by the synergic action of several inhibitors for example: 
progesterone [24], relaxin, cAMP, PTH-related peptide, prostacyclin, nitric oxide, 
corticotropin releasing hormone (CRH), all acting on different aspects of myometrium 
physiology to promote quiescence. Others inhibitors such as calcitonin gene-related peptide, 
vasoactive intestinal polypeptide, and endogenous β-adrenergic agonists promote quiescence 
by elevating levels of cAMP and decreasing intracellular calcium availability. At term, the 
uterus undergoes a profound transformation known as activation (phase 1) that primes it to 
respond to uterotonic agonists and to start powerful and synchronised contractions. This 
phase is triggered by mechanical stimuli such as stretch as well as endocrine signals 
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involving activation of the fetal hypothalamic-pituitary-adrenal (HPA) axis [25], and 
promoted by the simultaneous expression of several proteins known as uterine activation 
proteins (UAPs). These typically include ion channels that regulate the excitability of 
myometrial cells such as K
+
 channels [26, 27], agonist/receptor systems such as prostaglandin 
endoperoxide synthase-2 (PTGS-2) also known as cyclooxygenase 2 (COX-2), prostaglandin 
(PG) FP receptor (PTGFR), PGF2α receptor (PGF2αR), oxytocin (OT) and oxytocin receptor 
(OTR) [28], and gap junctions proteins that allow cell coupling such as connexin 43 (CX-43) 
[29, 30]. During phase 2 the previously primed uterus is thus receptive for contractile stimuli 
provided by uterotonins including PGs, CRH and oxytocin (OT). Upon initiation of rhythmic 
and regular contractions, the fetus can be delivered. Birth is followed by involution (phase 3), 
during which placenta separation takes place and the uterus involutes gradually to its non-
pregnant state. 
 
1.2.2 The common pathway of parturition 
A current paradigm defines parturition as a multifactorial transition process culminating in 
activation of a “common pathway” that permits the expulsion of the fetus [1]. The common 
pathway of parturition involves interplay between anatomical, biochemical, immunological 
and endocrine events that occur in the mother and fetus in both term and PTL [31]. The 
uterine components of the common pathway include decidual/membrane activation and 
rupture, cervical remodelling and dilatation, and activation of uterine contractions. It has been 
proposed that while term labour derives from “physiologic activation” of this common 
pathway, PTL results from the “pathologic activation” that untimely activates one of more 
components of the common pathway [32]. 
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1.2.2.1 Decidual/Membrane activation 
Chorioamniotic membranes include amnion and chorion that surround and protect the 
growing fetus [33]. Together they are known as the amniotic sac, which acts as a barrier 
against infections as well as mediating exchange of nutrients together with the placenta. The 
amnion is the innermost layer of the fetal membranes, in contact with the amniotic fluid. The 
chorion is the outer membrane and provides support by surrounding both amnion and embryo 
as well as contributing to placental development. Both chorion and amnion are surrounded by 
the decidua which is a thick layer of endometrial cells that form the underlying of the uterus 
during pregnancy. Decidual/membrane activation consists in a complex sequence of 
anatomical and biochemical events that culminate with the separation of the lower end of the 
fetal chorioamniotic membranes from the decidua of the lower uterine segment and, 
eventually, to rupture of the membranes and delivery of the placenta. Casey and MacDonald 
firstly hypothesised decidual activation to be an early event in labour [34]. 
During pregnancy, the chorioamnionic membranes and the decidua are joined together. Near 
term, a series of events takes place to allow their separation, including degradation of heavily 
glycosylated cellular fibronectin present at their interface [35], increased expression and/or 
activation of metalloproteinases (MMPs) such as MMP-1, MMP-2, MMP-3, MMP-8, MMP-
9 and other proteases that promote proteolytic degradation of the decidual and 
amniochorionic extracellular matrix (ECM) [36], increased apoptosis [37] and general 
structural weakening, especially in the portion overlying the cervix. In many mammals, 
activation of the fetal membranes is accompanied by an inflammatory response. Increased 
inflammatory cytokine secretion has been associated with membrane activation in both term 
and PTL complicated by chorioamnionitis [38, 39]. Alterations in the fetal ECM structure 
and integrity are influenced by the endogenous production of the pro-inflammatory cytokines 
IL-1β and IL-8 that are increased in human during labour in the amnion while IL-6 and IL-8 
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are increased in the choriodecidua [40] where they induce in turn the production of 
endogenous ECM-degrading MMPs. Similarly, murine fetal membranes exhibited increased 
expression of IL-1β [41] late in gestation. Pro-inflammatory cytokines including IL-1β and 
IL-6 induce also expression of pro-labour genes such as COX-2 and PGE2 in the amnion [42-
44]. In mice, a peak in recruitment of macrophages associated with a reduced density of 
collagen was seen prior to term labour [45] while number of neutrophils was unchanged in 
both mice [46] and human [47], suggesting that different subsets of immune cells may play a 
different role in fetal membranes remodelling. 
 
1.2.2.2 Cervical dilatation 
To allow the fetus through the birth canal, the cervix has to undergo an extensive remodelling 
phase that facilitates dilatation.  Similarly to the fetal membranes, the cervix starts to efface 
due to a combination of mechanical forces, biochemical changes and activation of 
inflammation. Collagen synthesis is reduced, along with an increase in collagenases and 
MMPs activity [48, 49]. Cervical ripening is an early event in term human labour and 
coincides with a remarkable infiltration of leukocytes in the cervical stroma [50]. Infiltrating 
leukocytes promote ECM remodelling by releasing proteolytic enzymes that stimulate 
cervical elasticity and dilatation [51]. Our understanding of the mechanisms of cervical 
ripening has been greatly improved through the use of murine models that permit assessment 
of inflammatory cells composition and localisation throughout normal and preterm gestation 
[52]. Recent murine data have shown that in contrast with what was traditionally believed, 
cervical ripening does not require inflammatory cells infiltration [53]. By allowing samples 
collection across gestation, murine models have permitted the identification of changes in 
collagen structure occurring prior to the onset of labour [54]. The study of immune cells 
infiltration into the cervical tissue has provided insights into the role played by each subset of 
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immune cells prior and following the onset of spontaneous term labour [55]. Comparison of 
the mechanisms underlying cervical remodelling in term and PTL has further contributed to 
understand that preterm cervical ripening is a different mechanism from term spontaneous 
cervical ripening [56]. 
 
1.2.2.3 Uterine contractility 
The middle layer of the uterine wall, known as myometrium, is considered the engine of 
parturition due to its ability to switch at term from a quiescent state to a contractile state that 
is characterised by powerful and coordinated contractions of sufficient force to expel the 
fetus through a dilated cervix. Although a basal contractile activity can be detected in the 
uterus in both non-pregnant and pregnant women, it appears that the contractile patterns 
differ in the two states: non-pregnant uterus produces “waves-like activity” throughout the 
menstrual cycle involving the sub-endometrial layer [57]. In contrast, the pregnant uterus is 
characterised by contractions of irregular pattern with weak intensity throughout gestation 
and very strong and powerful at term. Two types of myometrial activity were identified in 
rhesus monkey and are believed to be conserved in most species [58]: contractures, low-
amplitude, long-lasting uterine activity characterising most of gestation, and contractions, 
high-amplitude and short duration characterising uterus during labour [59]. 
Myometrial contractions in the uterus of all species are established from spontaneous action 
potentials due to transient changes in the plasma membrane permeability mediated by the 
opening of ion channels and co-transporters of individual myometrial cells that allow the 
passage of ions such as Ca
2+
, Na
+
, Cl
-
 and K
+
, down their respective electrochemical 
gradients [60, 61]. The increase in intracellular concentrations of Ca
2+
 is particularly 
important for the action-potential-driven myometrial contraction in mouse, rat and human 
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[62]. Ca
2+
 ions affect association between the contractile filaments of myometrial smooth 
muscle cells. Myosin (thick filaments) consist of two heavy chains (MHC), two regulatory 
subunits light chains (MLC20), and two essential light chains (MLC17). Thin filaments are 
composed by alpha helical coil of actin, associated with other proteins such as tropomyosin, 
caldesmon and calponin [63, 64]. When levels of intracellular Ca
2+
 increase they bind to the 
protein calmodulin and activate intracellular myosin light-chain kinase (MLCK)-mediated 
phosphorylation of the regulatory protein MLC20. These events culminate with interaction 
between myosin and actin filaments and activation of contractions. When Ca
2+
 levels 
decrease this process is inhibited by the action of MLC phosphatases (MLCP), which 
dephosphorylate MLCs thus inducing relaxation. To establish and maintain successful 
propagation of contractions, myometrial cells have to be highly interconnected. This 
electrical coupling as well as metabolic communication is achieved by increased formation of 
intercellular bridges composed by connexins such as CX-43, CX-45 and CX-26 [65]. These 
proteins are upregulated in both preterm and term labour in human myometrium [66] as well 
as in animal models [65, 67, 68]. Oxytocin and prostaglandin F2 alpha cooperate in activating 
contractions by altering the activity ratio of MLCK and MLCP thus regulating the sensitivity 
of myometrial cells to calcium ions [69, 70]. 
 
1.2.3 Regulation of myometrial activation 
1.2.3.1  Progesterone withdrawal 
Progesterone (from the Latin pro- + gestare, “to carry”) is a steroid hormone with a key role 
in pregnancy establishment, maintenance and labour in virtually all mammalian species. At 
the beginning of pregnancy, progesterone contributes to the preparation of the implantation 
site, supports uterine growth and remodelling and maintains the uterus quiescence throughout 
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most of the pregnancy by suppressing expression of UAP genes and by inhibiting synthesis of 
uterotonic agonists [71]. In most animals, onset of labour coincides with a fall in systemic 
progesterone levels [72]. In rodents progesterone is produced by corpora lutea and its 
withdrawal in late gestation [73] follows luteolisis caused by PGF2α produced in the murine 
decidua. In women however progesterone levels remain high until birth where an apparent 
loss of progesterone responsiveness provides a “functional progesterone withdrawal” [74-76]. 
Four non-mutually exclusive hypotheses have been formulated to explain this mechanism: (1) 
catabolism of progesterone in the uterus into metabolites that regulate relaxant pathways 
independent of PR action [77]; (2) altered expression of progesterone receptor isoforms that 
drives a labour-associated switch from PR-B to PR-A dominance and subsequent 
upregulation of UAPs gene expression [75, 78]; (3) changes in cofactor proteins levels 
affecting PR transactivation [79, 80]; and (4) inflammation-induced trans-repression of PR by 
nuclear NFκB [80]. Despite having different mechanisms of progesterone withdrawal, animal 
models, especially mice, have been extensively used to explore the molecular contributors by 
which progesterone regulates gestation maintenance and labour onset. Removal of 
progesterone signalling by ovariectomy or administration of PR antagonists such as RU486 
induces PTL and termination of pregnancy in the mouse [81] and the same molecule is an 
effective abortifacient in humans [82, 83]. In rats, administration of progesterone or its analog 
medroxyprogesterone acetate (MPA) inhibits expression of UAPs and ECM remodelling 
factors and blocks the onset of labour [84, 85]. Therefore replication of functional 
progesterone withdrawal in animal models can enable the study of the targets modulated by 
progesterone throughout gestation in a time-course manner. Lye et al. have indeed reported in 
rat myometrium the ability of progesterone to suppress expression of UAPs and genes 
involved in cell/matrix growth, remodelling, and pro-inflammatory signalling during labour 
as well as inflammatory transcription factors such as activator protein-1 (AP-1) [86]. Levels 
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of other hormones for example estrogen and androgens also vary throughout gestation and 
have been implicated in regulating UAPs and myometrial contractions in both human and 
mice [87, 88]. Expression levels of both estrogen and androgen receptors have been found to 
change throughout gestation in rodents. In humans, high estrogen levels near labour are 
thought to have a role in functional progesterone withdrawal possibly through ERα-mediated 
upregulation of the PR-A isoform, which block progesterone action [75]. Finally, the anti-
inflammatory properties of progesterone have been proposed to regulate the maternal 
immune system during pregnancy by promoting tolerance of the allogeneic fetus [89, 90]. 
Interestingly, in vitro studies performed on human myometrial cells showed that while 
inflammation antagonises genes normally upregulated by progesterone, progesterone is not 
able to inhibit genes activated by inflammatory stimuli [91]. 
 
1.2.3.2 Estrogen 
Estrogen increases expression of genes associated with uterine activation throughout 
pregnancy. Similarly to progesterone, estrogen is produced and metabolized by human fetal 
membranes and decidua. In human and various other animal models, increased levels of 
estrogen at term are thought to influence myometrial contractility [92] through upregulation 
of UAPs expression including the oxytocin receptor [93] and CX-43 [66, 94]. Estrogen also 
increases the levels of mRNA encoding the AP-1 subunit c-fos in the rat myometrium that in 
turn upregulates CX-43 [95]. While most mammals display an increased in serum estrogen 
levels towards the end of pregnancy, humans maintain relatively high levels of estrogens 
throughout gestation [96], with no change before and after the onset of term labour [97]. A 
link with functional progesterone withdrawal has been proposed, according to which the 
increased expression of the inhibitory isoform PR-A at term may be involved in functional 
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estrogen activation thus promoting activation of contractions possibly through increased 
expression of estrogen receptor A and changes in the ratio of estriol to estradiol [75, 98]. 
 
1.2.3.3 Corticotropin-releasing hormone 
In humans, the placenta synthesizes corticotropin-releasing hormone (CRH), an hypothalamic 
peptide which is also produced by placenta and uterus in primates [99] and increases 
exponentially in maternal plasma reaching a peak coinciding with parturition onset [100] an 
rapidly declining to non-pregnant state following delivery [101]. CRH binding protein 
(CRHBP) normally sequesters CRH thus limiting its bioavailability. Near term, during the 
third trimester of pregnancy, CRHBP levels drop freeing CRH in maternal circulation [102]. 
CRH levels are higher in women delivering preterm [103], leading to the formulation of the 
“placental clock” theory according to which CRH may determines the length of gestation and 
the onset of labour in humans [100]. In mice, CRH is mainly involved in fetal development in 
utero as shown in CRH-KO mice, which as a consequence are also glucocorticoid-
insufficient and exhibit neonatal lethality due to respiratory insufficiency as a result of 
abnormal pulmonary development, which can be rescued by prenatal administration of 
glucocorticoids [104]. 
 
1.2.3.4 Uterine stretch 
The uterus is sensitive not only to biochemical stimuli but also to mechanical forces and its 
responses are different in the non-pregnant and pregnant state and during labour. While the 
non-pregnant uterus contracts in response to stretch, during pregnancy these responses are 
tightly regulated to stabilise the excitability of the myometrial cells and maintain uterine 
quiescence to permit fetal growth within the womb. In rodents, uterine development reaches a 
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plateau near term while the fetus continues to grow [105, 106]. In numerous animal models 
and human in vitro models, increased uterine tension is believed to promote myometrial 
activation through up-regulation of myometrial AP-1 transcription factor as shown in rat 
[107], in human [108], and in mouse [109]. In turn, this leads to upregulation of UAPs [110], 
ECM ligand proteins [111], focal adhesion kinases [106, 112], and MAPKs signalling [113, 
114]. MAPKs activation, in turn, induces prostaglandin synthesis, as demonstrated in human 
myometrial cells [115]. 
 
1.2.4 Regulation of myometrial stimulation 
 
1.2.4.1 Oxytocin 
Oxytocin (from a Greek word meaning “rapid birth”) was discovered in the early 1900s, 
when biochemists found that this hormone secreted by the posterior pituitary gland could 
promote labour contractions and lactation. Later in 1979, studies revealed that administration 
of oxytocin to virgin female rats had a remarkable behavioural impact as injected animals 
acquired maternal behaviour [116]. Nowadays the role of oxytocin as uterotonic agent is 
widely recognised and this hormone is routinely administered to induce labour [117] given its 
effectiveness in increasing frequency, duration and force of myometrial contractions [118]. 
Oxytocin activates its specific receptor OTR leading to the activation of Phospholipase C 
(PLC) at the level of plasma membrane of myometrial smooth muscle cells (SMCs) with 
subsequent production of inositol triphosphate (IP3) and diacylglycerol (DAG), which in turn 
prompts release of Ca
2+
 from intracellular stores, membrane depolarization, and contractions. 
Oxytocin also inhibits Ca
2+
 release from the intracellular compartments effectively promoting 
the prolongation of contractions. At term, uterine sensitivity to oxytocin is dramatically 
increased by augmented expression of its receptors OTRs as shown in mouse [119], rat [120], 
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sheep [121] and human [122]. mRNA encoding for oxytocin is also found increased at labour 
onset in rat uterus [123], human amnion, chorion and decidua [124]. Additionally, oxytocin 
promotes contractions by stimulating prostaglandin release from decidua and fetal 
membranes [125] and activation of NFκB-regulated inflammatory pathways [126]. 
 
1.2.4.2 Prostaglandins 
Prostaglandins (PGE2 and PGF2α) play multiple roles in parturition by promoting cervical 
dilatation [127], regulating myometrial contractility [128], placenta separation [129], and 
fetal membrane rupture [130]. Prostaglandins are bioactive lipids formed from membrane 
arachidonic acids through activation of phospholipase A2 or C and cyclooxygenases (COX). 
Two types of COX enzymes exist: COX-1, constitutively expressed, and COX-2, inducible 
and specifically upregulated in uterine tissues and responsible for production of the two 
major contractions agonists PGE2 and PGF2α during labour. Similarly to oxytocin, 
prostaglandins stimulate Ca
2+ 
mobilization through activation of G-protein coupled receptors 
and PLC/IP3 pathway [131]. PGF2α and its receptor FP, as well as PGE2 and its receptors EP1 
and EP3 activate contractions while the inhibitory receptors EP2 and EP4 promote myometrial 
relaxation by stimulating adenylate cyclase-induced cAMP levels [132, 133]. cAMP can, in 
turn, increase COX-2 levels and prostaglandins production [134]. Recent data has highlighted 
that spontaneous and PGE2-induced myometrial contractility occurs via the EP3 receptor 
rather than the EP1 [135]. A region-dependent, temporal and tissue-specific heterogeneous 
expression and distribution of contractile and relaxant prostanoid receptors and 
cyclooxygenase was found in the non-pregnant porcine myometrium [136], in the bovine 
uterus [137] and  in the baboon where the pro-relaxant receptor EP2 was found upregulated in 
the lower uterine segment while pro-contractile receptors were mostly enriched in the fundus 
[138]. Similarly this was also seen in humans [139]. In rat [140], mouse [141], and human 
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uterus [142], expression of EP2 and EP4 was observed during implantation. Studies in both 
human primary cells and in murine models showed a primary role for COX-2 rather than 
COX-1 in producing prostaglandins and labour at term [143, 144]. Accordingly, expression 
of COX-2 RNA and activity was found increased towards labour in many systems [145-148]. 
COX-2 is considered therefore the rate limiting enzyme in regulating PG synthesis and 
consequently both its mRNA levels as well as activity are tightly regulated. The short half-
life of COX-2 mRNA (<3.5 hours) appears to be one of the key regulatory mechanisms to 
keep this system under control [149]. Cytokines are believed to play a role in COX-2 
activation in stimulating prostaglandins production [150]. IL-1 and TNF-α were shown to 
enhance prostaglandins production from amnion [151], chorion [152], decidua [153], and 
myometrium [154]. IL-6 also was shown to have a similar enhancing role in human amnion 
and decidua [44]. 
 
1.2.5 Myometrial inflammation 
Human myometrium is infiltrated by inflammatory cells, predominantly neutrophils and 
macrophages, during spontaneous labour at term [40]. The presence of neutrophils in 
myometrium and reproductive tissue is well documented in human, mouse and rat [155-157]. 
Levels of CXCL8, a major neutrophil chemoattractant, are increased in human myometrium 
at term and accordingly, neutrophil influx is observed at term [158]. Macrophages also play a 
relevant role in the uterus during parturition as their number increases in mouse uterus at 
gestational day 15 compared to non-pregnant controls though these numbers dropped to non-
pregnant levels just prior to birth [45]. Similarly, a greater number of macrophages is 
observed late in gestation in rat [156] and human myometrium [155]. Shynlova and 
colleagues reported similar inflammatory activation and immune cell recruitment in a murine 
model of term gestation as well as RU486-induced PTL model [157]. They observed 
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macrophages recruitment in mouse myometrium before term labour, followed by increased 
number of monocytes and neutrophils together with increased mRNA expression of pro-
inflammatory cytokines and chemokines such as TNFα, IL-1β, CXCL1, and CXCL2 at 
labour onset. Protein levels of these genes increased post-partum, suggesting a role for 
inflammatory mediators in uterine involution rather than labour initiation. By providing time-
course data, animal studies have therefore facilitated some clarification as to whether 
inflammation may be a consequence or a cause of labour. In favour of the former, inhibition 
of some immune cells populations including neutrophils, mast cells and polymorphonuclear 
leukocytes has recently been shown to not effect successful gestation and labour in mice 
[159-162]. 
The role of adaptive immune cells, specifically T and B cells, in the context of pregnancy and 
parturition has also been investigated. Both T and B cells are found in the human 
myometrium and their number increases with the onset of labour [163, 164]. Treg cells have 
also been shown to promote maintenance of healthy gestation [165] as shown in animal 
models where depletion of these cells induced pregnancy loss and reintroduction of Treg cells 
rescued the phenotype [166, 167]. Other subpopulations of T cells, such as Th17 cells, CD4+ 
cells and CD8+ cytotoxic T cells have also been identified at the maternal-fetal interface, but 
their role in gestation is still unknown [168]. Additionally, it has been speculated that uterine 
stretch may lead to augmentation of inflammatory response and recruitment of immune cells 
in vivo. Using the rat model, it was shown that mechanical stretch of uterine horn in vivo 
caused a significant increase in the number of immune cells [155]. In summary, although 
neutrophils, mast cells and T cells have all been involved with gestation and parturition, their 
functional redundancy together with functional redundancy between pro-inflammatory 
cytokines and chemokines produced by these immune cells is currently limiting our 
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understanding of their specific role, as depletion of each of the cell population does not 
produce a parturition phenotype. 
 
1.2.6 TLR signalling in pregnancy and term parturition 
Toll-like receptors (TLR) are evolutionarily conserved receptors that recognize pathogen 
specific molecular pattern (PAMPs) and initiate a specific immune pathway cascade that 
culminates with the activation of antigen-specific adaptive responses [169] (Fig. 1.3).  
 
Figure 1.3 TLRs signalling and parturition. TLRs activate expression of pro-inflammatory 
cytokines and chemokines as well as uterine activation proteins regulating parturition. 
 42 
 
TLRs are type I transmembrane glycoproteins consisting of extracellular domains containing 
leucine-rich-repeat (LRR) motifs, a trans membrane segment and a cytoplasmic signalling 
domain named the Toll/IL-1R homology (TIR) domain. TLRs are classified according to 
their intracellular localisation and relative ligands. Specific TLRs (TLR1, TLR2, TLR4, 
TLR5, TLR6 and TLR11) are expressed on the cell surfaces where recognise mainly 
microbial membrane components. Other (TLR3, TLR7, TLR8, TLR9 and TLR13) are 
exclusively expressed on intracellular compartments such as endoplasmic reticulum and 
lysosomes where they mediate response to foreign nucleic acids such as viral RNA. 
Upon binding of their ligands, an intracellular cascade is activated through MyD88 dependent 
or MyD88 independent (TRIF dependent) pathways. All TLRs apart from TLR3 use MyD88 
pathways, while TLR4 can activate either MyD88 dependent or independent pathways [170]. 
After engagement of the adapter molecule MyD88, downstream effectors including IL-1 
receptor associated kinases (IRAKs), TNF receptor associated factors (TRAFs), mitogen 
activated protein kinases (MAPKs) and the inhibitory kappa B kinase (IKK) are activated 
leading to phosphorylation and activation of inflammatory transcription factors such as NFκB 
and AP-1 which, upon nuclear translocation, regulate expression of pro-inflammatory genes 
and/or type 1 interferons. Similar target genes are regulated by the MyD88–independent 
pathway which involves the recruitment of TRAFs and IRF3. Although the role of TLRs in 
reproductive tissue has been mostly characterised in the context of infection-induced PTL, a 
role for these receptors in normal parturition has recently acquired interest. Several studies 
revealed that expression of TLRs is not restricted to immune cells but is detectable in 
different reproductive tissues, including myometrium [171], placental tissue, trophoblast and 
non-leukocytic lineages [172-174], as well as in leukocytes present in the uterine tissues 
[175, 176]. TLRs expression can be altered through different phases of the menstrual cycle, 
suggesting an involvement of sex hormones in controlling the pattern of their expression 
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within the uterus [177]. Ten TLRs are present in the uterus but TLR-2 and TLR-4 are the 
most highly expressed. TLR-2 and TLR-4 mRNA are significantly upregulated in pregnant 
myometrium at term compared to preterm and TLR-2 protein is higher during labour [90]. In 
both mouse and human, expression of TLR-4 increases throughout gestation in the maternal 
and fetal compartments, and decreases postpartum [174, 178]. A recent in vivo study showed 
that TLR-4 is essential for parturition in mice since its absence delays the onset of normal 
labour in knock-out (KO) mice [179]. In a population of Finnish and South American 
women, an allelic variation in TLR-4 was significantly associated with increased rate of PTB 
[180, 181]. 
In addition to pathogen recognition, TLR-4 and TLR-2 can be activated by endogenous 
mediators of tissue damage called damage-associated molecular patterns (DAMPs) such as 
the heat shock protein-70 (hsp70), gp96 and hsp60 that stimulate production of 
proinflammatory cytokines through both TLR-2 and TLR-4 [182-184]. It is plausible that 
release of DAMPs subsequent to sterile stressors such as uterine stretch may stimulate TLR 
signalling to activate protective, rather than pathogenic, inflammatory responses. An example 
supporting this hypothesis is the release of fetal or amniotic fluid-derived DAMPs which can 
occur due to mechanical stretch of the uterus at term [185]. The entry of amniotic fluid 
components into the uterine vessel circulation is regarded as a common physiologic 
mechanism of labour at term and it can activate a “sterile” immune response in gestational 
tissue. Whether this response is a cause of a consequence of labour is still unclear. 
 
1.2.7 Transcriptional control of labour-associated genes  
Many of the labour-associated genes discussed above, including OTR, COX-2, CX-43 and 
IL-8, are regulated at the transcriptional level by specific transcription factors throughout 
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gestation and during labour. Transcription factors involved in parturition such as NFκB, AP-1 
and C/EBP display a dual role as they regulate expression of pro-inflammatory genes as well 
as pro-contractile genes. Several studies have therefore aimed to characterise the role played 
by these transcription factors in the context of term labour, as well as PTL of different 
aetiologies, to identify their downstream gene targets, and to test whether inhibition of their 
activity could represent a successful strategy in delaying or blocking PTL [186-188]. To date, 
only few transcription factors have been characterised and associated with parturition. 
 
1.2.7.1 Cyclic AMP signalling 
Cyclic AMP (cAMP) signalling pathway promotes uterine quiescence throughout gestation 
until the onset of labour [189, 190] by inhibiting calcium mobilization and the contractile 
apparatus [191] through activation of the cAMP-dependent protein kinase (PKA) which in 
turn phosphorylates cellular substrates e.g. myosin light chain kinase thus promoting muscle 
relaxation [192, 193] (Fig. 1.4). 
 
Figure 1.4 The myometrial cAMP-PKA signalling pathway. Activation of Gs-protein coupled 
receptors (GPCR) activates adenylyl cyclase (ADCY) which catalyses the conversion from ATP to 
cAMP. cAMP induces uterine relaxation via activation of protein kinase A (PKA). 
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Throughout gestation, levels of cAMP are maintained by a combination of up-regulation of G 
proteins leading to increased cAMP synthesis and decrease in cAMP-phosphodiesterase 
activity mediated by progesterone [194]. Increased cAMP levels during gestation are thought 
to influence myometrial gene expression through phosphorylation and activation of the major 
cAMP response elements (CRE) binding protein cAMP-Responsive Element-Binding Protein 
(CREB), a bZIP transcription factor that requires phosphorylation to become biologically 
active [195], cAMP responsive element modulator (CREM) and activating transcription 
factor family (ATF) [194]. These factors regulate expression of target genes containing CRE 
binding sites within their promoters. Members of the CREB/CREM/ATF family are 
differentially and spatially expressed in the human myometrium throughout gestation and 
labour and evidences suggest that CREB and CREM may promote quiescence during 
gestation, whereas ATF-2 may promote contraction. 
 
1.2.7.2 NFκB signalling 
Nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) was discovered 
around thirty years ago as the nuclear factor binding a 10-bp sequence of DNA in the 
promoter region associated with the light chain (kappa) of the B-cell-derived 
immunoglobulins, upon stimulation with bacterial lipopolysaccharide (LPS) [196]. Following 
this study, Sen and Baltimore reported evidence that NFκB activity was inducible and, 
importantly, not only restricted to B lymphoid cells [197]. Since then NFκB has emerged as a 
prototypical proinflammatory transcription factor, based on its ability to induce expression of 
several proinflammatory genes including cytokines, chemokines and adhesion molecules 
[198]. Recent studies have also proposed a role for NFκB as an anti-inflammatory factor, 
which contributes to the resolution of inflammatory process by promoting leukocyte 
apoptosis and inducing expression of anti-inflammatory genes [199, 200].  
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NFκB exists in a homo/heterodimeric state, composed by five members of the NFκB family, 
namely p65, RelB, c-Rel, p50/p105 and p52/p100 [201]. NFκB is most commonly found in 
its heterodimeric state, formed by two basic subunits: p50 and p65 [201]. Under physiologic, 
non-stimulating conditions, NFκB molecules are confined within the cytoplasmic 
compartment in an inactive state, sequestered in complexes with the IκB family of inhibitor 
proteins including 7 members: IκBα, IκBβ, BCL-3, IκBε, IκBγ, p105 and p100 [202]. 
Depending on the activating stimulus, NFκB activation occurs through three alternative 
pathways (Fig. 1.5) [201]. 
 
Figure 1.5 NFκB signalling pathways. The three alternative NFκB signalling pathways, canonical, 
atypical and non-canonical are illustrated.  
 
The canonical pathway is stimulated by most physiological NFκB stimuli for example 
microbial agents through TLR signalling [203]. Upon ligand binding, an IKK complex 
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comprising IKKα and/or IKKβ catalytic subunits and two molecules of NEMO is recruited 
and activated. The IKK complex then phosphorylates IκB leading to its proteasomal 
degradation. NFκB then translocates to the nucleus to activate transcription. Transcriptional 
activity of nuclear NFκB is further enhanced by post-translational modifications [204]. 
The non-canonical pathway is mostly implicated in cell and lymphoid organs’ development 
where it mediates the activation of p100/RelB complexes. These stimuli induce IKKα-
mediated phosphorylation of p100, which associates with RelB, leading to partial processing 
of p100 and the generation of transcriptionally active p52-RelB complexes. IKKα activation 
and phosphorylation of p100 depends on NF-kappa-B-inducing kinase (NIK), which in 
resting conditions is targeted for degradation by TRAF3. Following stimulation of the 
pathway, TRAF3 itself undergoes degradation (mediated by TRAF2 and cIAP) thus freeing 
NIK, which can cooperate with IKKα in inducing phosphorylation and proteasomal 
processing of p100, thereby leading to formation of p52-contanining NFκB dimers. 
The third type of NFκB signalling pathway is referred to as the atypical pathway since it was 
shown to be IKK-independent. Stimuli such as DNA damage, hydrogen peroxide or 
pervanadate induce phosphorylation of IκB via p38-activated casein kinase II [205]. 
TRAF proteins represent a point of divergence for differential activation of NFκB and AP-1 
transcription factor pathways. Different TRAFs are involved in downstream activation of 
either canonical NFκB or AP-1 signalling (TRAF2, TRAF5, TRAF6), and non-canonical 
(TRAF3) NFκB signalling (Fig. 1.3 and 1.5). Scheidereit and colleagues were the first to 
suggest that some NFκB/Rel proteins, particularly p65, are post-translationally regulated 
[206]. Phosphorylation of p65 was shown to occur on different sites. Serine residues are the 
most commonly modified, especially those located on the 276 (74), 529 (75) and 536 (76) 
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sites. Inhibition of specific kinases responsible for the phosphorylation of these residues 
decreases NFκB transcriptional activity [207]. 
NFκB plays a critical role during the late stages of gestation and labour. NFκB activation via 
the canonical pathway occurs in both mouse and human myometrium [74, 187, 208] and fetal 
membranes [209] prior to the onset of labour. Lee et al. showed an additional mechanism of 
activation in human amnion, where NFκB is sequestered in the nucleus in an activated state 
through binding with the IκBβ protein [42]. Phosphorylation of p65 monomer stimulates 
binding to the promoter region of various labour-associated genes including the 
proinflammatory cytokines IL-6 [210] and IL-1β [211, 212] as well as pro-contractile genes 
such as COX-2 [74, 213, 214], prostaglandin F2α receptor [215] and oxytocin receptor (OTR) 
[216, 217]. Some of the genes associated with NFκB-activation can also be regulated by 
CCAAT/enhancer-binding protein beta (C/EBPβ) [218] and by the inducible transcriptional 
complex of AP-1 [219]. C/EBPβ has been previously shown to induce expression of pro-
labour genes synergistically with NFκB in both myometrium and amnion [220], however its 
DNA binding properties were unchanged prior and following the onset of labour in human 
myometrium suggesting a secondary role played by this factor in inducing expression of pro-
labour genes [221]. Recently work from Di Stefano et al. identified cross-talk between 
glucocorticoid (GR) signalling and the non-canonical NFκB pathway RelB/p52 and showed 
epigenetic regulation of CRH and COX-2 genes by GR/ RelB/p52 [222]. 
A role for NFκB in functional progesterone withdrawal in human was also proposed as this 
transcription factor was shown to upregulate the progesterone receptor inhibitory isoform PR-
C in human myometrium [223]. Taken together these evidences indicate a key role for NFκB 
in the regulation of inflammatory pathways and pro-labour genes activation during parturition 
[224]. 
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1.2.7.3 Activator protein-1 
Many of the inflammatory and pro-labour genes induced by NFκB are similarly induced by 
AP-1 [219]. AP-1 is typically constituted by dimeric basic region-leucine zipper (bZIP) 
proteins belonging to the Jun (c-Jun, JunB, JunD), Fos (c-Fos, FosB, Fra-1 and Fra2), Maf (c-
Maf, MafB, MafA, MafG/F/K and Nrl) and Atf (Atf2, Lrf1/ATF3, B-Atf, Jdp1, Jdp2) sub-
families [225]. Among these members, c-Jun is the most transcriptionally active [226] and it 
frequently forms heterodimers with c-Fos, a member of the Fos family that cannot 
homodimerise and acts as DNA binding enhancer for c-Jun. A variety of stimuli including 
growth factors, cytokines, infection, physical and chemical stress induce AP-1 activation 
through mitogen activated protein kinase (MAPK) cascade [227]. The three best-
characterised subfamilies of MAPKs are ERK, JNK and p38. While these are all able to 
activate AP-1, different MAPKs are regulated by distinct extracellular stimuli resulting in a 
substantial complexity in terms of upstream AP-1 regulation. JNK-mediated phosphorylation 
releases c-Jun from an inhibitory complex and allows regulation of gene transcription, 
however its nuclear translocation is independent of its phosphorylation status [228]. 
Accumulating evidence from both animal models and human samples has greatly contributed 
to elucidating the role of AP-1 in parturition. In rat myometrium, increased oestrogen levels 
induce expression of c-Fos, c-Jun, JunD and JunB mRNA [229] while c-Fos, FosB, Fra-1 and 
Fra-2 mRNA are upregulated at term [107]. Otr and Cx-43 genes contain AP-1 binding sites 
in their promoter, further implicating AP-1 in the regulation of pro-labour genes. As shown in 
rat myometrium, a positive correlation was found between Cx-43 and c-Fos expression; 
moreover, over-expression of c-Fos and c-Jun in myometrial cells induces Cx-43 expression 
through binding at the AP-1 promoter site [230]. In humans, levels of AP-1 are significantly 
increased in the fetal membranes before the onset of labour and can regulate MMP-9 
expression, an enzyme involved in fetal membrane remodelling [231]. AP-1 also regulates 
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COX-2 expression in human amnion (94). In human myometrium, AP-1 has been reported to 
stimulate the expression of IL-8 together with NFκB [232]. In vitro mechanical stretch 
experiments performed in rat myometrium as well as in human, showed upregulation of 
COX-2 alongside increased expression of c-fos, fosB, fra-1, c-jun and junB mRNA, as well 
as AP-1 activation [86, 108], suggesting that AP-1 may mediate not only endocrine but also 
mechanical signals at labour onset. 
 
1.3 Pathophysiological mechanisms of preterm labour 
Preterm parturition is a multifactorial disorder with genetic and environmental influences that 
can independently or collectively modulate underlying risk of premature delivery [32]. 
Although numerous risk factors have been associated with the PTL syndrome, a causal 
relationship is yet to be proven in most cases. 
 
1.3.1 Risk factors associated with preterm labour syndrome 
A previous PTB represents the most significant risk factor for preterm delivery. The risk 
increases by 15-20% and proportionally to the number of prior preterm deliveries [11, 233]. 
An inverse correlation exists between gestational age of the previous PTB and the risk of a 
future PTB. However most of preterm deliveries still occur in primiparous women. Increased 
risk of PTB is also observed when two gestations occur in close proximity- an inter-
pregnancy interval less than 6 months increases preterm birth risk by two-fold in the second 
pregnancy [234]. Nutritional status prior to the gestational period has also been correlated to 
the time of delivery and women with a low BMI have a greater risk of delivering preterm 
[235]. Similarly, women with depletion of iron, folate or zinc have higher risk of PTB [236, 
237]. Ethnicity is also an important risk factor. In the USA and in the UK, black, Afro-
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Caribbean and African-American women have a 16-18% rate of preterm deliveries, 
drastically higher when compared with white women who display a rate between 5-9%. 
Black women also have a higher chance to experience a very early preterm delivery 
compared to other ethnic groups. East Asian and Hispanic women display typically lower rate 
of preterm delivery [238]. Although a link between ethnic group and incidence of PTB does 
seem to exist, the causal mechanisms responsible for this remain largely unknown. 
Differences in environmental and social factors between ethnic groups are two potential 
confounding factors that make the determination of causality difficult. Other maternal 
demographic risk factors associated with higher rates of preterm delivery include low socio-
economic and educational status, low or high maternal age and single marital status [239, 
240]. Although a link between ethnic group and incidence of PTB does seem to exist, the 
exact mechanisms behind are yet unknown and differences in environmental and social 
factors represent two considerable confounding factors when trying to discriminate the 
genetic variations responsible for a certain phenotype. Substance abuse (tobacco [241], 
alcohol [242] and other drugs) use have all been associated with increased rates of PTB. 
Finally, multiple pregnancy is an important cause of PTB as women carrying twins will 
deliver them prematurely in 60% of cases, accounting for 15–20% of all preterm births, most 
likely due to uterine over-distension, resulting in preterm contractions and PPROM [243]. 
 
1.3.2 Cervical insufficiency 
Cervical insufficiency is defined as the failure to maintain a pregnancy due to dilatation of 
the cervix in the absence of uterine contractions. Together with preterm PROM and preterm 
contractions, cervical insufficiency is one of the three clinical manifestations of preterm 
activation of the common pathway of parturition. 
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Traditionally, cervical insufficiency is a cause of mid-trimester abortion and may results from 
a broad spectrum of conditions including congenital disorders (e.g. hypoplastic cervix), 
previous surgical trauma (e.g. conisation) or from a spontaneous trauma such as repeated 
cervical dilatation [244]. Additionally, pathologic conditions such as infection have been 
reported in 50% of the patients with cervical insufficiency. These conditions may weaken the 
cervix thus resulting in pathological and premature activation of cervical dilatation. 
 
1.3.3 Maternal and fetal stress 
Maternal stress is defined as the combination of life events, anxiety, depression, or any 
physical challenge perceived as stressful and that may therefore threaten the homeostasis of 
the patient [245]. Fetal stress may be due to structural factors such as abnormal placentation 
and intrauterine growth restriction. In both cases, stress results in the activation of the 
maternal or fetal hypothalamic-pituitary-adrenal axis, corticotropin release and has been 
associated with premature delivery. 
 
1.3.4 Overdistension of the uterus 
As mentioned previously, multifetal gestations are associated with an increased rate of PTB. 
Similarly, women with uterine structural abnormalities, polyhydramnions or macrosomia are 
at greater risk of spontaneous PTL and delivery [32]. Uterine overdistension appears to be a 
key driver of PTB in all of these conditions, as stretch has been shown to induce premature 
activation of the common pathway of parturition not only acting on myometrium, but also 
inducing premature cervical dilatation and membrane rupture. For example, mechanical stress 
to myometrial cells in vitro induces activation of calcium channels, G-proteins, enhanced 
binding of AP-1 and expression of uterine activation proteins such as CX-43 and COX-2, and 
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prostaglandins [114, 246-248]. Similarly, stretch of fetal membranes triggers upregulation of 
inflammatory mediators including IL-8, PGE2 [249, 250]. The cervix of women carrying 
multiple fetuses is also subjected to an excessive overload, which may result in premature 
cervical ripening. 
 
1.3.5 Vascular disorders: uterine ischemia and haemorrhage 
Vascular lesions are the most common pathological features found in women delivering 
preterm with no sign of infection and intact membranes [32]. Bleeding is most typically 
located either in the decidua, at the interface between decidual parietalis and chorion or 
between the basal plate of the placenta and the decidua. The latter case, when particularly 
extensive, causes placental abruption, a condition found more frequently in women delivering 
preterm than those delivering at term [251]. The release of thrombin is thought to be 
primarily responsible for uteroplacental ischemia as well as decidual haemorrhage. This 
mechanistic link was demonstrated in vivo in rats, where administration of whole blood 
induced PTL while heparinised blood (void of thrombin) did not [252]. Further, myometrial 
cell contractility in vitro can be induced by exposure to fresh blood and partially attenuated 
by concomitant administration of hirudin, a thrombin inhibitor [253].  
Thrombin treatment in decidual cells induces expression of tissue remodelling enzymes 
MMP-3 and MMP-1 [254, 255], as well as inflammatory genes such as IL-8 and IL-11 in 
decidual cells [256, 257].   
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1.3.6 Infection and inflammation 
Infection and consequent inflammation are so far the only pathologic conditions for which a 
firm causal link with PTL has been established [31]. Microbiologic studies suggest that 
infection may account for 25% to 40% of all preterm deliveries but this increases with shorter 
gestation [258]. It is estimated that 80% of women delivering prior to 30 weeks have 
evidence of infection in the amniotic fluid and/or fetal membranes while only 30% of women 
delivering after 37 weeks have similar signs [259]. 
Evidence supporting the causative link between infection, PTL and PTB is extensive. 
Intrauterine infection or systemic administration of bacteria-derived molecules to pregnant 
animals readily induces PTL and delivery [260]. Systemic extra-uterine maternal infections 
during pregnancy including malaria [261], pneumonia [262] and periodontal diseases [263] 
are associated with higher rates of PTB. Subclinical non-overt intrauterine infections are also 
associated with increased rates of PTB [264]. Pregnant women with intra-amniotic 
infection/inflammation in the mid-trimester exhibit elevated levels of intra-amniotic pro-
inflammatory cytokines and matrix-remodelling enzymes and experience greater risk of PTB 
[265-267]. Treatment of infections by antibiotics can prevent associated inflammation in 
some models of chorionamnionitis and lower incidence of PTB in women with intact 
membranes [268, 269]. Finally, the treatment of asymptomatic bacteriuria has been shown to 
prevent PTB [270, 271].  
Although the amniotic cavity is generally considered sterile, mycoplasma and endotoxins are 
commonly found in the amniotic fluid of patients experiencing PTL [272-274]. In particular, 
endotoxin can induce a strong and potentially harmful inflammatory response in both mother 
and fetus [275]. Intrauterine infection may occur because of ascending bacteria through the 
vagina, haematogenous spread through the placenta, infection through the fallopian tubes 
from the peritoneal cavity or may arise from invasive procedures such as amniocentesis. 
 55 
 
Additionally, an increasing number of studies have showed that improved stability of the 
vaginal microbiome during gestation by mean of Lactobacilli dominance may play a 
protective role against infection [276, 277]. These new insights into the implications of 
vaginal microbiota on pregnancy outcomes indicate that imbalance in resident microbial 
populations may also influence risk of delivering preterm [278]. These evidences are 
consistent with increased dysbiosis and bacterial vaginosis associated with depletion of 
Lactobacilli population and an increased rate of PTB [279]. Microorganisms and their 
associated molecules are recognised by innate immune system through soluble pattern 
recognition receptors (PRRs), C-reactive proteins and lectin; transmembrane PRRs, including 
scavenger receptors and TLRs; and intracellular PRRs, including Nod1 and Nod2, which 
recognise intracellular pathogens such as viruses [32]. Among these, TLRs are the PPRs best 
characterised in the context of inflammatory response in reproductive tissues seen in term and 
PTL. Data from animal and human studies provide a consistent picture of how 
infection/inflammation can result in spontaneous preterm delivery. TLR-mediated 
recognition of bacteria in gestational tissues leads to the activation of the host innate immune 
response leading to inflammatory cell recruitment, release of cytokines and chemokines, 
secretion of prostaglandin and matrix-remodelling enzyme that promotes the acquisition of a 
labouring phenotype [280]. Consistent with this, expression of TLR-1, TLR-2, TLR-4 is 
increased in the fetal membranes of women presenting chorionamnionitis [178, 281]. Soluble 
TLR-2 proteins were also found in amniotic fluid of pregnant women and have been shown 
to modulate the intra-amniotic inflammatory response to infection [282]. Of note, majority of 
the evidences supporting a role for TLRs in human infection-induced PTB derive from 
indirect association, since preterm labour and infection are often accompanied by presence of 
inflammatory mediators secreted as a result of TLRs stimulation by bacterial products [272]. 
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1.3.6.1 Cytokines and preterm labour 
Inflammatory mediators, including chemokines such as IL-8, the pro-inflammatory cytokines 
IL-1β and TNF-α, platelet activating factor and prostaglandins play a central role in 
infection/inflammation-induced preterm parturition. The first cytokine implicated with 
infection-induced PTL was IL-1 as it was shown to be secreted by human decidua upon 
stimulation with bacteria-derived agents [151]. Treatment of pregnant mice with IL-1 
effectively induces PTL [283] and this phenotype is rescued by blocking the IL-1 receptor 
with a specific antagonist [284]. Both IL-1α and IL-1β stimulate prostaglandins production in 
human amnion and decidua and their concentrations are higher in amniotic fluid of women 
experiencing infection-induced PTL [151]. IL-6 is significantly increased in amniotic fluid of 
women presenting an upper genital tract infection [285], as well as in maternal cervical fluids 
or serum, and is to date the most reliable cervical marker for infection-induced PTB [286]. 
Increased levels of IL-6 in the cervix at 24 weeks of gestation in asymptomatic women are 
also predictive of subsequent preterm delivery before 32 weeks of gestation [287].  
IL-8 is a potent neutrophil attractant and neutrophils are, in turn, active producers of matrix-
remodelling enzymes such as MMP-8, MMP-9 and reactive oxygen radicals that contribute to 
extracellular matrix degradation facilitating preterm membrane rupture [288]. IL-8 levels are 
significantly higher in cervical fluid of women presenting intra-amniotic infection and 
inflammation and in women delivering before 34 weeks of gestation [289], as well as in 
amniotic fluid in the presence of chorionamnionitis [290]. Increase amniotic concentrations 
of IL-8 were also correlated with development of fetal bronchopulmonary dysplasia [291]. 
TNF-α is also strongly associated with PTL and its levels increased in human decidua upon 
stimulation with bacterial products [292]. TNF-α induces prostaglandin secretion in amnion, 
decidua, and myometrium [293], and women experiencing PTL and intra-amniotic infection 
exhibit higher intra-amniotic concentrations of TNF-α during labour [294]. 
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In vitro, treatment of amniocytes leads to increased expression of MMPs implying TNF-α 
may contribute to cervical remodelling and membrane rupture [295]. Similar evidence has 
been generated in animal models. In guinea-pigs, cervical administration of TNF-α induces 
ripening-like structural changes [296]. In murine models TNF-α induces PTL [297]. 
Increased levels of various other cytokines have also been described in the context of 
pathological PTB including IL-16, IL-18, colony-stimulating factors, RANTES, C-reactive 
protein and the anti-inflammatory cytokine IL-10 [1]. Amniotic IL-10 levels were increased 
in women with intra-amniotic inflammation suggesting a protective role for this cytokine in 
reducing the inflammatory response and ensuring a balance between host response to 
pathogens and maintenance of the pregnancy [298]. 
 
1.3.6.2 Fetal inflammatory response syndrome 
Fetal inflammatory response syndrome (FIRS) describes an elevated inflammatory response 
of the fetus to the presence of maternal inflammation/infection, associated with impending 
preterm delivery, infection in the amniotic cavity and increased chances of perinatal 
morbidity and mortality [299]. Fetuses with FIRS are at greater risk of developing severe 
diseases and long-term disabilities including respiratory distress syndrome, neonatal sepsis, 
pneumonia, bronchopulmonary dysplasia, intraventricular hemorrhage, necrotising 
enterocolitis, and brain damage leading to periventricular leukomalacia and cerebral palsy 
[299]. In PPROM, the FIRS manifests as increased activated populations of neutrophils and 
monocytes [300], elevated levels of fetal plasma concentrations of IL-6 and C reactive 
protein [301, 302]. Furthermore, umbilical cord blood samples collected from neonates 
showing clinical signs of infection exhibit a higher number of TH1 cells and increased 
proportion of IFNɣ–secreting cells [303, 304]. Microbial invasion of the fetus can ultimately 
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lead to a systemic fetal inflammatory response effecting many organs including the 
hematopoietic system, heart, brain, lungs, adrenal glands and skin risking dysfunction [299]. 
 
1.3.6.3 Fetal brain damage associated with maternal inflammation 
The long-term consequences associated with fetal brain damage make it one of the most 
debilitating and impactful intra-uterine insults. Several studies have reported a strong 
correlation between in-utero exposure of infectious/inflammatory agents and brain injury 
including intraventricular haemorrhage, white matter damage, and neurodevelopment 
disability (mainly cerebral palsy) [299]. For example, FIRS often precedes spontaneous 
infection induced-PTB [305], chorionamnionitis is associated with greater risk of cerebral 
palsy [306], women with spontaneous PTL frequently deliver babies carrying white matter 
lesions and cognitive impairments [307] and intra-amniotic increase of pro-inflammatory 
cytokines correlates with increased risk of developing long-term brain damage and fetal 
vasculitis (inflammation of the cord vessels) [308]. A study by Kaukola et al. investigating 
levels of pro-inflammatory cytokines in plasma collected from children without or with 
cerebral palsy showed that the latter group exhibits elevated cord blood levels of ciliary 
neurotrophic factor, IL-5, IL-12p40, IL-12p70, IL-13, IL-15, macrophage migration 
inhibitory factor, and TNF [309]. In mouse models, maternal administration of LPS induces 
fetal brain damage, as supported by increased expression of the astrogliosis marker glial 
fibrillary acidic protein (GFAP), and decrease levels of proteolipid protein (PLP), the major 
myelin protein of the central nervous system [310, 311]. 
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1.4 Animal models of parturition 
Among all species of mammals, humans are one of the few experiencing PTB [312]. Given 
the importance of successful reproductive outcome to the survival of human species, 
development of effective PTB therapeutic strategies represent a research goal of utmost 
importance, which cannot be achieved before a deeper understanding of the molecular 
pathways regulating the timing of birth is reached. Experimental procedures and 
manipulations required for such studies cannot be performed in human patients for obvious 
ethical consideration however animal models can contribute greatly to the investigation of 
physiological and/or pathophysiological mechanisms underlying term and preterm 
parturition.  
For over 60 years the steroid hormone progesterone has been recognised as a key regulator of 
gestational length as it is thought to exert a “block” on myometrial activation thus 
maintaining uterine quiescence throughout gestation [24]. Using rabbit and rat models, 
pioneering work by Csapo and colleagues demonstrated that progesterone withdrawal from 
the maternal circulation was necessary and sufficient to cause the uterine and cervical 
changes culminating with parturition [313]. In mice, rats and rabbits progesterone withdrawal 
depends on the PGF2α-induced involution of the corpus luteum, the principal source of 
progesterone, before the onset of parturition. Consistently, in ovariectomised mice, 
progesterone levels fall and parturition can start. In human, up to the seventh week of 
pregnancy, the corpus luteum is also the main source of progesterone and lutectomy induces 
a rapid drop in plasma progesterone level and abortion [314]. Therefore progesterone plays a 
similar role, at least in the first weeks of gestation in both human and rodents, although these 
pathways diverge consequently to the “luteo-placental shift,” when the developing human 
placenta becomes the main site of progesterone synthesis and continues maintaining high 
levels of progesterone until delivery [315]. 
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The mechanism of progesterone withdrawal at term differs in other mammals. In the sheep, 
maturation of the fetal hypothalamic-pituitary axis drives an increase in circulating 
adrenocorticotropic hormone (ACTH) thus stimulating cortisol synthesis from fetal adrenal 
glands which, in turn, induces lung maturation as well as production of the placental enzyme 
P450C17 [316]. This enzyme mediates conversion of progesterone through estrogen ultimately 
resulting in fall of progesterone levels and increase in estrogen. This mechanism is not 
exhibited in human gestation. While in most animal models, apart from guinea pig, maternal 
serum concentrations of progesterone decline with proximity to labour onset, in humans 
progesterone circulates at high and increasing concentrations throughout pregnancy without 
an apparent decline at labour onset [96, 97] (Fig. 1.6).  
 
Figure 1.6 Progesterone levels throughout pregnancy in animal models and human. Adapted 
from [72]. 
 
Even though levels of circulating progesterone remain high in humans throughout parturition, 
several studies have proposed the existence of a “functional” progesterone withdrawal 
occurring before term labour in human and non-human primates [75, 76, 317] (see Par. 
1.2.3.1). Although some clinical trials have demonstrated a moderate effectiveness of 
progesterone administration in reducing the risk of PTB in patients with high risk of PTB, 
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treatment in singleton or twin gestations are not effective, suggesting that mechanisms other 
than progesterone-regulation are crucial to determining onset of labour in human pregnancy 
[318]. Nevertheless, chemically-induced progesterone withdrawal via treatment with the 
progesterone receptor antagonist mifepristone (RU486) is effective in causing early 
termination of pregnancy if administered in the early trimester, as well as cervical ripening 
and spontaneous delivery within 48 hours in women at term [82, 319]. Similarly, in mice, 
inhibition of progesterone receptor by RU486 causes PTL [81] and is the most commonly 
used model of sterile PTL induction in these animals. 
Much evidence supports a role for inflammation at term in both humans and animal models 
of parturition, however the detailed sequence of molecular events responsible for triggering 
activation of contractions and delivery has yet to be fully elucidated. Several animal studies 
were designed to explore this connection and particularly to address two key questions: 1) 
what is the link between immune response activation, inflammation and labour (cause-effect 
or simply association?) and 2) are the mechanisms of infection and sterile inflammation 
leading to labour the same? 
While it is well recognised that infection/inflammation can cause PTB, and prompt delivery 
appears as the safer option for both fetus and mother, the role of inflammation in spontaneous 
PTB is less clear and prolongation of gestation in some cases may be beneficial. The 
substantial lack of knowledge on basic mechanisms of parturition is currently impairing our 
ability to treat this condition. Bacterial components such as LPS are often used to mimic local 
or systemic infection in rodents and non-human primate models of PTL enabling 
investigation of inflammatory mechanisms that would be impossible to achieve in humans 
due to obvious ethical reasons [260]. By allowing temporal examination of inflammatory 
responses activated throughout gestation, animal models, particularly rodents have helped to 
demonstrate a link between inflammation and activation of contractile machinery in the 
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uterus. As shown in rabbit, rat and mouse, intrauterine inflammation promotes up-regulation 
of both contraction-associated proteins and inflammatory mediators in the uterus, as well as 
induces cervical remodelling and ripening by activating expression of matrix-remodelling 
enzymes in the cervix [320-322]. Intra-amniotic infection also induces PTB in rhesus 
monkeys [323]. 
 
1.4.1 Murine models: a system to dissect the molecular mechanisms regulating 
pregnancy maintenance and labour onset 
Despite several structural and hormonal differences regulating mouse and human pregnancy, 
the genetic tractability of the mouse together with a number of similarities at the level of both 
immune and reproductive systems, make the mouse a convenient and relevant model for PTB 
studies [324]. Several components of the parturition cascade are conserved in both mice and 
humans, including the principal uterotonic agent i.e. prostaglandins, which stimulate uterine 
contractions and are essential for successful delivery, and contraction-associated proteins 
(CAPs), which activate the myometrium and enable response to stimulants. Additionally, 
progesterone withdrawal, be it either systemic as mice, or functional as in humans, is a shared 
mechanisms of parturition [325]. 
Some advantages to using murine models include a short gestational length (from 18 to 22 
days), ease of breeding, genome completely sequenced, possibility of genetic manipulation to 
generate knockout and transgenic mice, a well characterised immune system and importantly, 
similar biochemical changes in the uterus at the time of labour including activation of uterine 
activation proteins (OTX, OTR, CX-43, COX-2, prostaglandins) [324, 326]. 
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1.4.2 Uterine anatomy and gestational differences of pregnant mouse and human 
While mice have a duplex uterus (Fig. 1.7) consisting of two horns with one fallopian tube 
each, most of primates including humans and chimpanzees have a simplex uterus whereby 
the uterus is fused into a single organ. Very rarely, women may have a bicornuate uterus 
which is a uterine malformation derived from the failure to fuse two separate parts of the 
uterus during fetal development [327]. 
 
Figure 1.7 Anatomy of (A) human and (B) murine pregnant uterus with developing fetus. 
Modified from Encyclopedia Britannica & The Anatomy of the Laboratory Mouse by Margaret J. 
Cook. 
  
The endometrium in mouse consists of a simple mucosa with columnar epithelium extending 
to branched tubular glands into the myometrium, however in the human its shape and 
thickness varies along the menstrual cycle [328]. The murine myometrium consists of an 
inner circular layer perpendicular to the long axis of the uterus, and an outer longitudinal 
layer of smooth muscle cells running parallel to the long axis of the uterus. The internal 
lining of the murine uterus is the endometrium, also named decidua in pregnant mice. In the 
human only a single muscular layer is found. The basic functional unit responsible for human 
uterine contractions is the smooth muscle cell, or myocyte. Collectively, myocytes form 
muscular fibers that are organised in bundles, which in turn constitute fascicles, the 
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macroscopic functional element of the myometrium, which are embedded into the ECM with 
blood vessels and nerves [329]. Myocytes are aligned to the bundles and the fascicles and 
these are in turn interlaced in ill-defined layers resulting in a muscular architecture much 
more complex than in mice. Mice are considered a particularly useful model for parturition as 
they have a short gestation time (18.5-21 days), while in human gestation lasts for 37-42 
weeks. A summary of gestation and placentation differences are illustrated below (Table 1.1). 
Table 1.1 Gestation and placentation features of human and mouse. 
 Mouse Human 
Length of gestation 18.5-21 days 37-42 weeks 
Fetal size 2 cm 20 cm 
Placental morphology, Maternal–
fetal interdigitation 
Hemotrichorial, labyrinthine Hemomonochorial, villous 
discoid 
Trophoblast populations Labyrinth trophoblast  
Spongiotrophoblast  
Giant cell trophoblast  
Syncytiotrophoblast 
Cytotrophoblast  
Extravillous trophoblast  
Progesterone withdrawal Yes No 
 
1.4.3 Mouse models of sterile PTL 
Sterile PTL can be induced by hormonal changes or inflammatory responses in the absence of 
microorganisms and is frequently reported in women experiencing PTL with intra-amniotic 
inflammation but intact membranes [330]. Progesterone is a key hormone in mouse 
pregnancy, as shown by ovariectomy experiments in which the removal of the source of 
progesterone (corpora lutea within the ovaries) causes termination of pregnancy [331] while 
administration of progesterone delays parturition [332]. Treatment of mice with the 
progesterone receptor antagonist RU486 robustly induces PTL and delivery and is considered 
a useful model of hormonal withdrawal, non-inflammatory or “sterile PTB” [81]. In treated 
rodents, PTB coincides with early increase in CX-43 levels [333], macrophage infiltration 
into the myometrium [157], decidua [46], and cervix [46]. These events are also accompanied 
by increased levels of several pro-inflammatory cytokines and chemokines [46, 157]. 
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The enzyme 20α-hydroxysteroid dehydrogenase (20α-HSD) expressed in the ovary catalyses 
the conversion of progesterone into inactive metabolites. Levels of 20α-HSD increase at term 
and the 20α-HSD KO mice display delayed labour due to failure of progesterone withdrawal 
[334]. Administration of 20α-HSD-KO mice with progesterone receptor antagonist RU486 
rescued the phenotype inducing labour at term, in presence of high concentrations of systemic 
progesterone. The essential role of luteolysis for progesterone withdrawal and labour was 
further corroborated by studies performed in mice lacking the PGF2α receptor (FP). FP-KO 
animals establish and maintain pregnancy, yet fail to go into labour successfully at term as 
progesterone levels do not decline due to absence of luteolysis caused by impaired PGF2α 
signalling [335]. 
Another progesterone metabolism enzyme, 5α-reductase type 1, is expressed in various 
reproductive tissues and the 5α-R1-KO mice exhibit higher localised levels of progesterone 
in uterus and cervix and display defects in cervical ripening leading to delay in the onset of 
labour by 2-3 days compared to wild type. The prolonged labour phenotype can be rescued 
by RU486 treatment or ovariectomy as well as by 5α-reduced steroids, relaxin (RLX), or 
oxytocin (OT) [336, 337]. The cervix in 5α-R1-KO mice is denser and constituted by a more 
compact matrix of collagen fibers. Compared to wild type, KO mice do not exhibit the 
increase in expression of aquaporins and tight junction proteins, suggesting a role for these 
proteins in changing cervical water content and allowing ripening [338, 339]. Taken together, 
these findings highlight the importance of systemic and localised progesterone withdrawal in 
efficient onset of labour and cervical dilatation. However, the importance of inflammatory 
mediators in inducing PTB in the absence of infection may still represent a potential 
mechanism of labour induction and consistent with this, a recent study reported that the 
injection of the damage-associated molecular pattern (DAMP) molecule termed HMGB1 
induces PTB [340]. 
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1.4.4 Infection-induced preterm labour models 
Numerous studies utilised murine models to investigate the pathogenesis of 
infection/inflammation-induced PTL. The majority of these studies used heat-killed 
Escherichia coli (E. coli) bacteria, LPS, a component of the outer membrane of gram-
negative bacteria, or peptidoglycan, a component of the outer membrane of gram-positive 
bacteria or inflammatory molecules [341]. In the majority of mouse models these stimulants 
are administered either systemically or locally. Systemic administration via intra-peritoneal 
or subcutaneous injection is used in an attempt to mimic human PTL associated with 
systemic conditions such as sepsis or viral infection, a scenario that is relatively rather rare. 
Therefore alternative models have been developed that are designed to reproduce localise 
infection/inflammation within the gestational tissues, a situation more often found in clinical 
practice. This scenario can be achieved in vivo by intra-cervical, intra-uterine or intra-
amniotic administration. Additionally, a less invasive ultrasound-guided intrauterine LPS 
injection method was recently developed by Stock and colleagues [342]. This novel method 
avoided inflammation induction caused by laparotomy yet reliably induced PTB as well as 
triggered the local inflammatory response observed in the laparotomy models. Hirsch and 
colleagues were the first to establish a model of localised intrauterine infection/inflammation-
induced PTB through inoculation of heat-killed E. coli by laparotomy, although this model 
induced a high rate of maternal mortality [343]. The model was further developed by Elovitz 
who injected CD-1 pregnant mice with 250 μg of LPS and induced consistently PTB without 
maternal death but with total fetal demise [311, 344]. Additionally, this phenotype was 
associated with activation of NFκB in maternal uterus and fetal brain, increased 
prostaglandins and cytokines release as well as PTL [186]. Briefly, surgery was performed on 
day 16 of gestation, corresponding to 80% of the gestational length experienced by CD-1 
mice who normally deliver at term on day 19 of gestation. Mice were kept under deep 
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anaesthesia and a mini-laparotomy was performed in the lower abdomen. The right uterine 
horn was exposed through the incision and LPS was injected into the uterus between the 
lower two gestational sacs, out of the amniotic cavity. The uterus was then returned to the 
abdomen, peritoneal tissue and skin were stitched, and animals were allowed to recover. 
Madan et al. subsequently reported an alternative model using a “low” LPS dose of 25 μg 
that was able to induce PTB in a proportion of those animals treated [345]. This model 
became useful to study the effects of in-utero exposition of inflammatory agents, which is 
known to increase greatly the risk of fetal brain injury [311]. Exposure to inflammation-
induced PTB in mice results in increased cytokine mRNA expression in whole fetal brain and 
is associated with disrupted fetal neuronal morphology [346]. This remains the case when the 
LPS dose is not sufficient to induce PTB [347], as shown by the increased levels of white 
matter damage marker GFAP and decrease of the major myelin protein proteolipid protein 
(PLP) in fetal brains [311]. 
Heat-treated bacteria, LPS and peptidoglycan are all able to trigger host innate immune 
responses through TLRs activation leading to expression of pro-inflammatory cytokines, 
chemokines and prostaglandins, ultimately culminating in PTB. Among all types of TLRs, 
the best characterised in the context of infection-induced PTB is TLR-4. Mice deficient for 
TLR-4 (TLR4-KO) are protected against PTL induced by intrauterine infusion of E. coli or 
LPS injection [344]. Mice lacking the TLR-4 adaptor molecule MyD88 are similarly 
protected against preterm delivery [348]. Mice injected with LPS also exhibit increased 
expression of TLR-4 in uterus, placenta, and fetal membranes further supporting a protective 
role against bacterial infection during pregnancy [349]. 
Knock-out murine models have also been used to investigate the function of other potential 
key inflammatory triggers of infection-induced PTB. While systemic administration of 
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interleukin-1 induces PTB [283], IL-1β-KO mice injected intracervically with E. coli LPS 
exhibited similar rates of pregnancy loss compared to wild-type and mice are equally 
susceptible to PTL [350]. Pregnant mice lacking functional IL-1β receptors have been shown 
to deliver at a similar time compared to wild-type mice [351] and fetal survival rates are not 
affected [352] although mice double KO for IL-1/TNF experience PTL suggesting functional 
redundancy in at least some cytokines networks. This indicates that multiple inflammatory 
signals, rather than one stimulus alone, are more likely to trigger PTL [297]. The double KO 
for IL-1/TNF also exhibits a reduction in myometrial COX-2 expression. IL-6 is dispensable 
for infection-induced PTL as IL-6-KO and wild type mice are equally susceptible to PTL 
induced by intrauterine injection of heat-killed E. coli [353]. However, a recent study showed 
that IL-6 is essential for on-time parturition in normal term gestation [354]. Thus to date, no 
cytokines have been identified that appear essential for preterm delivery in the mouse [324] 
and TLR-4 with its adaptor MyD88 are the only components of the inflammatory response 
that have been undoubtedly linked with both preterm and term parturition in mice [179]. 
 
1.4.5 Knock-out of genes involved in gestation and labour. 
Surprisingly, few studies have been undertaken that have targeted specifically genes involved 
in myometrial contractility and parturition. Table 1.2 summarise KO mouse models 
developed to investigate parturition. As previously mentioned, the key role of prostaglandins 
in mouse parturition was demonstrated using FP-KO mice who display prolonged gestation 
as a result of the failure in inducing luteolysis and progesterone withdrawal at term [335]. 
This phenotype can be rescued by ovariectomy or by oxytocin administration, suggesting 
PGF2α is necessary for luteolysis but has a dispensable role in parturition [355]. The 
important role of prostaglandins in parturition has been further confirmed using mice 
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deficient in cytosolic phospholipase A2 (cPLA2) who exhibit delayed parturition and fail to 
deliver healthy offspring [356, 357].  
Table 1.2 Summary of knock-out mice developed to investigate parturition  
 
Ablation of the COX-1 gene also prolongs gestation and induces neonatal death, whereas 
COX-1/oxytocin (OT) rescues the phenotype restoring luteolysis without increase in PGF2α 
levels [358]. Interestingly, single KO of either OT or OTR does not affect the timing of 
gestation and delivery [362, 371]. Inactivation of the cannabinoid receptor CB1 leads to the 
reduced secretion of CRH, thus generating unbalance in progesterone and estrogen levels and 
resulting in PTB [372]. Levels of circulating CRH rise exponentially with advancing human 
parturition, yet in the mouse it is dispensable for term parturition [360]. Even less work has 
been reported investigating KOs of contractile associated proteins. A dominant loss-of-
function in CX-43 gene encoding for the connexin mediating myometrium cells 
Mouse Genotype Phenotype Refs 
20α-Hsd-KO Delayed parturition; fetal demise; no P4 withdrawal [334] 
Pgf2α receptor FP-KO Fail to start labour; fetal demise; no P4 withdrawal [335] 
cPla2-KO Delayed parturition; fetal demise; no P4 withdrawal [357] 
Cox-1-KO Delayed parturition; fetal demise; no P4 withdrawal [358] 
Klf9-KO Delayed parturition; fetal demise; no P4 withdrawal [359] 
CRH-KO Normal parturition; Higher rate of fetal demise [360] 
Ot-KO Normal parturition [361] 
Otr-KO Normal parturition [362] 
Cox2-KO Normal parturition [363] 
Cox-1/Ot-KO Prolonged labour starting at term [358] 
Cx-43-KO Delayed parturition; fetal demise [364] 
15-Hpgd-KO Early labour; premature PGF2α increase; no P4 withdrawal [365] 
Rlx-KO Non-productive labour (no milk production, interpubic ligament does 
not relax during pregnancy, higher plasma osmolality) 
[366] 
RLX-binding GPCR 
Lgr7-KO 
Impaired nipple development and parturition [367] 
5α-R1 Delayed and prolonged labour; impaired cervical ripening [337] 
Il-1R-KO Predisposed to bacterially induced PTL [368] 
Il-1β-KO Predisposed to bacterially induced PTL [350] 
Il-6-KO Predisposed to bacterially induced PTL [353] 
Il-1R/Tnfsrsfa-KO Less prone to bacterially induced PTL [297] 
Tlr4-mutant Resistant to bacterially induced PTL [369] 
Tlr4-KO Resistant to bacterially induced PTL; delayed parturition [179] 
Sirh7/Ldoc1-KO Placental P4 overproduction and delayed parturition [370] 
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interconnectivity at term, impairs parturition and prolong pregnancy [364]. Over-expression 
of the small conductance calcium-activated K
+
 channel isoform 3 (KCNN3), normally 
promoting relaxation, negatively affects myometrial contractility of transgenic mice and 
inhibited delivery in two models of term [373] and PTL [374]. 
 
1.4.6 Murine models and prevention of PTB 
The remarkable similarities between human and mouse parturition make this model a 
valuable tool to test potential therapeutic treatments. For example, treatment with MPA, a 
synthetic variant of progesterone, down-regulated infection-induced expression of pro- and 
anti-inflammatory cytokines, COX-2 and CX-43, and inhibited cervical ripening [375], 
supporting an anti-inflammatory role for progesterone in the context of 
infection/inflammation-induced PTB. Norman et al. similarly showed that prolonged 
administration of progesterone in vivo inhibits myometrial expression of CX-43 and 
decreases CD11b (a marker of leukocyte activation) expression on circulating monocytes, 
suggesting a dual role for progesterone in inhibiting synchronous myometrial contractility as 
well as reducing leukocyte influx into the uterus [376]. The co-administration of LPS with 
the anti-inflammatory prostaglandin 15d-PGJ2 was shown to be effective in delaying PTB 
and improving fetal survival rate [186]. A tocolytic effect has also been demonstrated for the 
Rho-kinase inhibitor, Y-27632 [377]. As evident from the KO models, often the deletion of a 
single effector is not sufficient to impair the whole parturition cascade. Therefore some 
studies have investigated the effects of affecting multiple chemokine signalling pathways 
through the use of broad-spectrum chemokine inhibitors [378, 379] than can effectively 
inhibit influx of neutrophils in mouse myometrium and inflammatory response in 
reproductive tissue thus successfully inhibiting PTB [380]. 
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1.5 The use of high-throughput approaches to achieve a comprehensive 
description of the molecular pathways controlling birth timing 
High-throughput approaches allow simultaneous examination of systemic changes occurring 
in the genome (DNA), transcriptome (messenger RNA), proteome (proteins), metabolome 
(metabolites) or in the epigenome (epigenetic profile) in a biological sample. The suffix 
“ome” thus refers to the study of the complete set of genes, mRNA, proteins, metabolites or 
epigenetic marks characterising a specific organism/tissue/cell in its entirety, which is 
influenced by space, time and context. Therefore, “omics” science represents the study of 
these entities as a system rather than as single parts [381, 382]. While the scientific approach 
to new discoveries has been traditionally based on “reductionist” or hypothesis-driven 
approaches, recent advances in high-throughput technologies have paved the way for a more 
comprehensive and systematic approach to new biological questions, a so called “discovery-
driven research approach” through omics technologies. These are particularly appealing since 
they allow a global rather than limited description of all changes characterising an organism 
as a whole, do not require a specific hypothesis and are, in theory, unbiased. 
The main purpose of applying genomics approaches to the investigation of PTB is to identify 
genetic traits associated with increased risk of developing this syndrome. Ultimately, this 
information could be used to develop personalized medicine approaches that maximize the 
benefits of an intervention and/or modify a certain behavior to decrease the risk of developing 
the syndrome in the presence of a genetic predisposition. Allen et al. performed the first 
experimental approach aimed to investigate the association between genome and reproductive 
traits, in this case length of gestation of equine breeds [383]. This study showed that both 
genetic and environmental factors influenced the length of gestation as thoroughbred fetuses 
grown in ponies exhibited classical signs of intrauterine growth restriction that were not 
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observed when grown in thoroughbred mares. Epidemiology studies also suggest a role for 
genetic factors in the pathogenesis of PTB as rates are variable across different ethnic groups 
[384]. Family studies have indicated a genetic predisposition may underpin some PTB 
aetiologies since women with sisters who delivered preterm had an 80% increased rate of 
delivery preterm [385]. This is also true for women previously born preterm as shown in a 
genealogy database containing PTB rates of 28 families in the state of Utah [386]. 
Additionally, several polymorphisms have been associated with either increased risk of 
spontaneous PTB including TNF/IL6/IL6R (-3448/-7227/33314) [387], IL6 (G/C-174) [388], 
and IL-10 (A/G -1082) [389]; or decreased risk of PTB such as TGFB1 (G/C -800, G/C -509 
haplotype) and TNFRSF6 (AG/GA -1377, -670 haplotype) [390]. 
The first proteomic study of parturition was performed with SELDI-TOF mass spectrometry 
and aimed to identify biomarkers of intra-amniotic inflammation [391] to distinguish between 
women with PTL from those with PPROM [392]. Other studies were instead focused on 
marker detectable in blood or vaginal fluids and were successful in differentiating women 
delivering preterm with intact membranes from those with PTL but delivering at term. 
Similarly, MacIntyre et al. showed differing proteomes in human myometrium collected from 
spontaneous and induced labour [393]. 
Epigenomics studies of PTB have also gained interest in the last few years. Epigenomics is 
the comprehensive examination of heritable changes in gene expression that happen in the 
absence of modification of genomic DNA sequence [394]. Recently, a link between 
epigenetics and PTB was shown in an animal model whereby administration of histone 
deacetylase inhibitor (trichostatin A) to pregnant mice from gestational day 15 to 19 delayed 
the onset of parturition of 24-48 hours [79]. Interestingly, differences in epigenetic profiles 
were observed in preterm infant compared to not-preterm, although this difference was 
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resolved by 18 years of age [395]. While few studies have highlighted the role of specific 
epigenetic traits in pathological pregnancy [396, 397], a global approach has not yet been 
reported. 
 
1.5.1 Transcriptomics: genome-wide transcriptional profiles characterising term and 
preterm labour 
Transcriptomics has experienced somewhat of a revival in recent years due to substantial 
advances in the technology, particularly in next generation sequencing methods. Capturing 
gene expression snapshots of reproductive tissues across time or in different pathological 
conditions serves three main purposes; 1) it enables comparison of different conditions 
allowing discrimination between, e.g. women in labour at term compared to preterm; 2) can 
be used to predict pregnancy outcome based on the observed differences to ultimately 
identify one or more “classifier” and 3) to discover subgroups of changes within a conditions 
that share similar features that can potentially be targeted by a specific treatment or used for 
prognostic aims. Additionally, understanding the whole set of gene changes occurring 
throughout pregnancy and parturition is invaluable as it improves greatly the understanding 
of how the functional elements of the genome (genes) respond to different physiological and 
patho-physiological stimuli [398, 399]. 
Aguan et al. were the first to use functional genomics for the study of parturition [400] and 
compared myometrium from three women at term in spontaneous labour with those not in 
labour. Only 21 differentially expressed genes were identified between the two conditions, on 
a total of 588 genes present on the array. More recently, Bukowski et al., who compared the 
transcriptome of the uterine fundus, lower uterine segment, and cervix before and during 
labour [401] found sets of genes similarly changing across all tissues, thus overcoming one of 
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the main pitfalls of these studies, i.e. the intra-patient variability derived from tissue 
heterogeneity. As found by Haddad et al., chorionamnion from women in spontaneous labour 
exhibits an increase in inflammatory genes including IL-6, IL-8 and TLR-2, in the absence of 
histologic chorionamnionitis [402]. Transcriptome studies of human cervix at term not in 
labour compared with those collected after spontaneous labour show that the latter group is 
characterised by increased expression of genes involved in apoptosis, epidermis development 
and steroid metabolism [403]. To date, a total of 134 genome-wide studies have been 
performed to investigate human pregnancy and PTL, most of them are focused on placenta 
(82/134, 61%), fetal membranes (16/134, 12%) or myometrium (17/134, 12%) [399]. 
However, the overlap between these studies is minimal, even when considering those 
deriving from the same tissue, and most of them are actually focused on the least frequent 
variants of PTB, i.e. preeclampsia or intra-uterine growth restriction. Surprisingly, only 10 
out of 134 studies investigated spontaneous PTB, which is the most common scenario. 
Additionally, studies of human gestational tissues have been limited to the comparison of 
samples collected before and after labour onset [401, 404-409]. The majority of these 
discrepancies are due to the relatively modest resolution of the microarray approaches. Thus, 
next generation sequencing technologies such as RNA-Seq are increasingly replacing 
hybridization-based techniques such as microarray to study genome-wide gene expression 
changes since they provide an unbiased, accurate and reproducible catalogue of gene 
expression data across a wide dynamic range [410]. To date, only one study has reported 
RNA-Seq analysis of gene expression changes characterising human myometrium prior and 
following labour onset [406].  
Characterisation of temporal uterine transcriptome changes throughout human pregnancy is 
obviously not possible yet this severely limits our understanding of large-scale changes 
associated with and potentially causative of parturition, which are likely to be manifested 
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prior to the initiation of contractions. Animal models, particularly mice, therefore offer the 
capacity to gain novel insights into the mechanisms involved in different forms of preterm 
parturition as well as term normal gestation. Previous microarray time-course studies of gene 
expression changes in the murine pregnant uterus have been highly informative yet limited by 
the comparatively low specificity, sensitivity and resolution of the hybridization based 
techniques [411-413]. 
 
1.6 Hypotheses and aims 
The transition of the uterus from quiescence to contractions results from a complex interplay 
between inflammatory and hormonal signals, much of which remains poorly understood. 
Intrauterine inflammation is strongly associated with term parturition and its untimely 
activation leads to PTL that is frequently associated with fetal brain damage. TLR-4 
stimulation results in downstream activation of two main inflammatory transcription factors: 
NFκB and AP-1. NFκB has been implicated with the onset of labour, since it regulates 
inflammatory and pro-labour genes. AP-1 was also shown in vitro to regulate similar genes in 
both myometrium and fetal membranes. LPS is often used to mimic infection/inflammation-
induced PTL in the murine model; however inconsistencies in maternal and neonatal 
responses are frequently reported. We hypothesised that: 1) AP-1 plays an important role in 
vivo in activating molecular pathways culminating with the onset of term labour as well as 
PTL in the murine model; 2) different LPS serotypes may induce differential maternal and 
neonatal responses that account for inconsistencies reported in the literature using similar 
models and; 3) activation of inflammatory pathways underlies both term and PTL, 
representing a common pathway of parturition. 
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The aims of this study are: 
 To investigate the role of AP-1 activation in term and PTL in the mouse; 
 To test whether inhibition of AP-1 signalling may block PTL; 
 To examine the maternal and fetal impact of inducing PTL using four different 
Escherichia coli LPS serotypes; 
 To perform a RNA-Seq analysis of global transcriptome changes characterising 
myometrium in three different murine models: term gestation, PTL induced by 
RU486, and PTL induced by LPS; 
 To analyse similarities and differences between myometrium profiles from the three 
murine models and to compare them to human myometrium transcriptome changes 
acquired with spontaneous labour. 
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2 MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Chemicals and solvents 
Chemical Supplier 
Quick Load DNA ladders BioLabs 
Dithiothreitol (DTT)  Bio-Rad 
NuPage sample buffer 4x Dye Invitrogen 
Agarose            Invitrogen 
SYBR safe DNA gel stain Invitrogen 
HistoClear National Diagnostics 
Non-fat dried milk powder  Sigma-Aldrich 
TEMED  Sigma-Aldrich 
Triton X-100  Sigma-Aldrich 
Dimethyl Sulfoxide (DMSO) Sigma-Aldrich 
Acrylamide                                                                         Sigma-Aldrich
Bovine serum albumin (BSA) Sigma-Aldrich 
Tween 20 Sigma-Aldrich 
Formalin Sigma-Aldrich 
Ammonium Persulphate (APS) Sigma-Aldrich 
Deoxycholic acid SouthernBiotech 
CHAPS hydrate VWR 
Fluoromount-G VWR 
Methanol  VWR 
Absolute Ethanol                                                                  VWR
SlowFade
®
 Gold Thermo Fisher Scientific 
4’,6-diamidino-2-phenylindole (DAPI)   Thermo Fisher Scientific 
 
2.1.2 Antibodies 
Antibody Epitope Dilution used
*
 Catalogue number Supplier 
Primary Antibody    
α-SMA 1:500 (IF) ab5694 Abcam 
β-actin 1:50000 ab6276 Abcam 
COX-2 1:2000 sc-1745 Santa Cruz 
GAPDH 1:20000 SAB2100894 Sigma-Aldrich 
CX-43 1:1000 3512 Cell Signaling 
p-C/EBPβ Thr235 1:1000 3084 Cell Signaling 
Phospho-CREB (S133) 1:1000 (WB)/1:600 (IF) 9198 Cell Signaling 
Phospho-c-Fos (Ser32) 1:1000 5348 Cell Signaling 
Phospho-c-Jun (Ser73) 
(D47G9) XP
®
 
1:200 (IF) 3270 Cell Signaling 
Phospho-c-Jun (Ser73) 1:1000 9164 Cell Signaling 
Phospho-p65 (Ser536) 1:50 (IF) ab131109 Abcam 
Phospho-p65 (Ser536) 1:1000 3031 Cell Signaling 
Phospho-JNK 1:1000 9252 Cell Signaling 
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(Thr183/Tyr185) 
Phospho-ERK 
(Thr202/Tyr204) 
1:1000 9101 Cell Signaling 
Phospho-p38 
(Thr180/Tyr182) 
1:1000 9211 Cell Signaling 
IL-1β 
 
1:1000 AF-401-NA R&D System 
 
Secondary Antibody 
   
Donkey anti-goat IgG 1:2000 sc-2020 Santa Cruz 
Goat anti-rabbit IgG 1:2000 7074 Cell Signaling 
 
*
Dilutions used in WB (Western Blotting) experiments, unless otherwise stated. IF: 
immunofluorescence. 
 
2.1.3 Treatments and inhibitors 
Compound Supplier 
Protease inhibitor cocktail  Sigma-Aldrich 
JNK inhibitor (SP600125) Calbiochem 
Morphine Sigma-Aldrich 
E.Coli LPS serotype O111:B4 Sigma-Aldrich 
E.Coli LPS serotype O55:B5 Sigma-Aldrich 
E.Coli LPS serotype O127:B8 Sigma-Aldrich 
E.Coli LPS serotype O128:B12 Sigma-Aldrich 
Mifepristone (RU486) Sigma-Aldrich 
 
2.1.4 Kits 
Kit Supplier 
NucleoSpin
®
 Tissue Genomic DNA purification kit                        Macherey-Nagel 
Nucleospin
®
 miRNA kit                                                                    Macherey-Nagel 
Truseq
®
 Stranded mRNA Sample preparation kit                          Illumina 
 
2.1.5 Reagents and buffers 
General buffers  
Phosphate Buffered Saline (PBS)                                               140mM NaCl
 2.5mM KCl         
 1.5mM KH2PO4 
 10mM Na2HPO4 
 pH 7.2 
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Tris-EDTA (TE)                                                               10mM Tris-HCl 
 1mM EDTA     
 pH 8.0 
                                                                                                     
Tris Buffered Saline (TBS)                                                           50mM Tris-HCl        
 150mM NaCl 
 pH 7.5 
                                                                                                     
10Mm Sodium Citrate                                                                 Tri-sodium citrate (dihydrate) 
 Tween 20   
 Distilled water 
 pH 6.0 
 
2.1.6 Softwares and R scripts 
Software/script Function 
Illumina
®
 experiment manager Check compatibility of library adapters 
combinations 
rSamtool Data importer 
Burrows-Wheeler Alignment Tool  Alignment of reads to the mouse genome 
FastQC Reads alignment quality control 
GenomicRange  Reads count 
EdgeR  Identification of differentially expressed genes 
Gclus Hierarchical clustering 
Prcomp  Principal Component Analysis 
pls OSC-PLS modelling 
Ingenuity Pathway Analysis (IPA
®
) Data mining 
Metacore
®
 Data mining 
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2.2 Methods 
2.2.1 Murine models of parturition and ethics statement 
Animal studies were performed under UK Home Office License 70/6906, in conditions 
compliant with the Animals Scientific Procedures Act of 1986 and with approval of the 
Imperial College and University College London Ethical Review Committees. A personal 
licence was obtained from the Home Office to perform my work (Ref. PIL 70/24807). 
CD1 (Charles River) outbred virgin females mice were timed mated and used for all 
experiments unless otherwise specified. The presence of a copulatory plug was classified as 
day 0 (E0) of gestation. Mice were housed in open cages at 21 ± 1C with ad libitum access 
to standard rodent food and water and were exposed to a 12:12 light-dark cycle regimen. 
Unless otherwise stated, at least four biological replicates were collected for all experimental 
groups. 
 
2.2.1.1 TLR4 knock-out murine model 
TLR4-KO mice were generated on a CD-1 background by replacing the transmembrane and 
cytoplasmic coding sequences of the TLR4 gene with a reporter gene encoding for neomycin 
resistance, as previously described by Hoshino et al. [414]. This strain was generously 
donated by Dr. Claudia Monaco, University of Oxford. 
 
2.2.1.2 Inflammation-induced preterm labour model 
Pregnant (E16) female mice were anaesthetised with isofluorane and administered a 
subcutaneous injection of morphine (2.5 mg/kg) 20 minutes prior to surgery.  Mice were 
permitted to recover for 15 minutes to allow morphine to be effective. Following recovery 
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mice were kept under constant flow of isofluorane and an abdominal mini laparotomy was 
performed under aseptic conditions. Both uterine horns were exteriorised and the number of 
live fetuses per horn recorded (Fig. 2.1). 
 
Figure 2.1 Pregnant mouse anesthetised undergoing a mini-laparotomy. Uterine horns were 
exteriorised briefly and LPS (or PBS control) was administered between the first and second amniotic 
sacs of the right horn by Hamilton syringe. Point of injection is indicated by the red arrow. Image 
adapted from Sykes L., 2013 [415]. 
 
An intra-uterine injection of 20 μg (25 μl total volume in PBS) of either E. coli 
lipopolysaccharide (LPS) serotype O111:B4, O55:B5, O127:B8, O128:B12, (Sigma Aldrich, 
Gillingham, UK) or sterile PBS was injected in the right horn between the two most distal 
pups, with care not to enter the amniotic cavity. Alternatively, control mice received an 
injection of vehicle (PBS). Consistent with recently published literature, a concentration of 
LPS designed to enable robust and reproducible preterm birth was used [161, 416]. This 
concentration was significantly lower than previously reported models that used between 50 
μg to 250 μg of LPS to induce preterm delivery [311, 344, 347]. 
Following injection, the peritoneum was sutured with continuous non-locking sutures with 
2/0 vicryl, and the skin was stitched with interrupted 2/0 vicryl. Mice were allowed to recover 
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in a warm incubator until seen active and were then housed separately in a clean cage. 
Animals were continuously monitored post-surgery remotely via an infrared CCTV camera 
system until tissue collection or the onset of spontaneous labour and birth. Onset of labour 
was defined as delivery of the first pup. 
 
2.2.1.3 Functional progesterone withdrawal (via RU486)-induced preterm labour model 
E16 pregnant mice received a subcutaneous injection of 150 μg RU486 (Sigma) in DMSO or 
20 μl DMSO (Sigma) as previously described [81], and were allowed to deliver 
spontaneously (under continuous infrared CCTV monitoring).  
 
2.2.2 Tissue collection 
Mice were anaesthetised and culled by cervical dislocation and a laparotomy immediately 
performed. Live fetuses were counted prior to sacrifice by decapitation in accordance with 
the project licence. Uteri were incised longitudinally, pups, placentas and vasculature 
removed and myometrial samples from the upper, middle and lower uterine horn (both left 
and right) excised and snap frozen. Prior to culling, pup viability was qualitatively assessed 
using a scoring system as follows: pups displaying full body spontaneous movement when 
removed from the myometrium/amniotic sac = 3, pups with partial body movement i.e. lower 
half or full body movement when gently prodded with forceps = 2, pups exhibiting partial 
body movement or movement of limbs only in response to forceful prodding/squeezing of a 
limb with forceps = 1. Pups with no response when forcefully prodded/limbs squeezed = 0. 
For normal gestation studies tissue myometrium samples were collected from non-pregnant 
(NP) mice, or mice on gestational day 6 (E6), E11, E14, E16, E18, during active labour 
(LAB) or <24 h post-partum (PP). In all models, labour was considered active following 
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delivery of the first pup. For the LPS-induced PTL model, myometrium and fetal brain 
samples were collected at 1, 2, 4 and 6 hours post-injection and during active labour. For the 
RU486-induced PTL model myometrium was collected at 1, 2, 4, 6, 12 and 18 hours post-
injection and during active labour. Tissue was stored at -80°C until processing for either 
RNA or protein extraction. Alternatively, samples to be analysed with immunofluorescence 
were fixed in formalin for 24 hours and stored in 70% absolute EtOH. Unless otherwise 
stated, myometrium from the upper right uterine horn was used for downstream analysis. 
 
2.2.3 Tissue extraction 
2.2.3.1 Genomic DNA extraction 
Genomic DNA was extracted from myometrium samples using NucleoSpin
®
 Tissue Genomic 
DNA purification kit (Macherey-Nagel). Frozen myometrium samples were ground under 
liquid nitrogen and a total of 25 mg of tissue powder was placed in a microcentrifuge tube.  
Samples were pre-lysated with a solution containing 180 µL of Buffer T1 (SDS-based buffer) 
and 25 µL of Proteinase K. Samples were briefly vortexed to facilitate mixing followed by 
incubation at 56 °C for 3 hours. 200 µL of Buffer B3 was added, samples mixed vigorously 
and incubated at 70ºC for 10 min. To adjust DNA binding conditions, 210 µL of 100% EtOH 
were added to the samples and vortexed vigorously. Samples were then loaded on a 
NucleoSpin
®
 Tissue column and centrifuged for 1 min at 11,000 × g. Collection tube 
containing the flow-through was discarded and the column placed in a new collection tube. 
Samples were stored at -20°C until further use. Two washes were then performed to wash the 
silica membrane. A first wash was performed by adding 500 µL of Buffer BW and 
centrifuging 1 min at 11,000 × g. The flow-through was discarded and the column was placed 
back in the collection tube. A second wash was performed using 600 µL of Buffer B5 (5 mM 
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Tris/HCl, pH 8.5). The flow-through was discarded and the column was placed back in the 
collection tube. Silica membrane was spun 1 min at 11,000 × g to dry the column thus 
ensuring removal of residual EtOH. NucleoSpin
®
 Tissue column is then placed into a 1.5 mL 
microcentrifuge tube and 100 µL of Buffer B5 added. Following 1 min incubation the column 
was centrifuged 1 min at 11,000 × g to elute pure genomic DNA. Samples were stored at -
20°C until use. 
 
2.2.3.2 RNA extraction 
Myometrium and neonatal brains samples were pulverised in liquid nitrogen. Nucleospin 
miRNA kit (Macherey-Nagel) was used to isolate separate fractions of large (>200 
nucleotides, e.g. 18S, 28S and pri-miRNA) and small (<200 nucleotides) RNA, according to 
the manufacturer’s instructions (Fig. 2.2). Briefly, 30 mg of ground tissue were mixed and 
mechanically disrupted with lysis buffer ML (400 µL) and incubated for 5 min. Lysates were 
clarified by centrifugation for 1 min × 11,000 g with a purification column to eliminate cell 
debris. Binding conditions for large RNA were adjusted with 150 µL of absolute EtOH 
followed by brief mixing and incubation for 5 min at RT. Samples were loaded onto a 
NucleoSpin
®
 RNA Column (blue ring) where DNA and large RNA bound the column, while 
small RNA fraction was eluted by centrifugation. From this point onwards, large and small 
RNA fractions were treated separately. Columns containing large RNA and DNA were 
treated with DNase to eliminate any genomic DNA contamination. The small RNA fractions 
were treated with Protein Precipitation Buffer MP to allow separation of protein pellets which 
were removed by filtering through a NucleoSpin® Protein Removal Column. 
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Figure 2.2 RNA extraction protocol. RNA was purified in two separate fractions (small and 
large RNA). Image adapted from NucleoSpin
®
 miRNA protocol by Macherey Nagel. 
 
After two series of washes small RNA and large RNA were eluted with RNase-free water. 
RNA concentrations were measured with a NanoDrop 1000 spectrophotometer (Thermo 
Scientific) and RNA integrity was assessed using BioAnalyzer 2100 (Agilent Technologies, 
Inc. Santa Clara, CA, United States). All samples displayed a 260/280 ratio greater than 2.0 
and RNA integrity numbers (RIN) ≥8.0. RNA extracts were stored at -80°C until further use. 
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2.2.4 Reverse transcriptase-mediated cDNA synthesis 
cDNA synthesis was performed using 2 µg of RNA in a 20 µl sample volume using M-MLV 
Reverse Transcriptase (Sigma). RNA was incubated with 1 µl of 0.5 µg/µl Oligo(dT)23 
Primers Anchored (Sigma) and 1 µl of 10 mM dNTP mix (Sigma) for 10 min at 70°C before 
being transferred onto ice. A total of 10 µl of a master mix containing 6.5 µl of nuclease free 
water, 2 µl of 10x M-MLV RT buffer (Sigma), 0.5 µl of human ribonuclease inhibitor 40000 
units/mL (Sigma) and 1 µl of 200 units/µl M-MLV RT (Sigma) was added to each RNA 
sample and incubated at room temperature for 15 minutes, then at 37°C for 50 min followed 
by 10 min at 85°C to inactivate the enzyme. Isolated cDNA was stored at −20°C. 
 
2.2.5 Real-time PCR  
Real-time PCR was performed using Applied Biosystems 7900HT (Thermo Fischer 
Scientific). Standard curves were run for each primer to determine appropriate dilution of 
cDNA template. The optimal cDNA dilution corresponded to 1 µL of cDNA stock and 9 µL 
of RNAse free water. Primers (Invitrogen, Table 2.1) were designed using NCBI database 
(www.ncbi.nlm.nih.gov/tools/primerblast/). 
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Table 2.1 Sequences of PCR primers used in real-time PCR. 
 
Primer efficiencies were tested on serial dilutions of a pooled sample. Only primers 
displaying efficiency rates in the range of 85-105% were used in further experiments. All 
cDNA samples were diluted accordingly and aliquoted in 384-well plates. Each well 
contained a total volume of 10 µl including 2.6 µl of nuclease free water, 0.1 µl of reference 
dye (Sigma), 0.15 µl of forward primer (20 µM), 0.15 µl reverse primer (20 µM), 5 µl SYBR 
Green JumpStart Taq ReadyMix (Sigma) and 2 µl of cDNA. Reactions were run in duplicate 
using the following thermal cycling parameters: 2 min 94°C, 40 cycles of 15 sec at 94°C, 60 
sec at 60°C, 60 sec at 72°C; dissociation curve: 15 sec at 95°C, 1 min at 60°C and 15 sec at 
95°C. Results were obtained through the software ABI 7900HT SDS 2.4 and analysed with 
Microsoft Excel and GraphPad Prism Version 5. Gene expression levels were normalised to 
the expression levels of the housekeeping gene β-actin. The comparative Ct method was used 
to determine relative expression differences [417]. 
Gene Forward sequence Reverse sequence 
β-ACTIN AGAGGGAAATCGTGCGTGAC CAATAGTGATGACCTGGCCGT 
COX-2 CTG ACC CCC AAGGCTCAAAT AAGTCCACTCCATGGCCCAG 
MMP3 GCTGTCTTTGAAGCATTTGGGTT CACAGGATGCCTTCCTTGGAT 
MMP10 CACCCTCAGGGACCAACTTA TAGCTGGGCTTGTGGAGAAC 
CXCL2/IL8 GCCCAGACAGAAGTCATAGCC AGGCTCCTCCTTTCCAGGTC 
IL6 TCCTCTCTGCAAGAGACTTCC GGTCTGTTGGGAGTGGTATCC 
IL1β AGCTTCCTTGTGCAAGTGTCT GCAGCCCTTCATCTTTTGGG 
TNFα ATGGCCTCCCTCTCATCAGT CTTGGTGGTTTGCTACGACG 
CX-43 GCCCGAACTCTCCTTTTCCT CATGTCTGGGCACCTCTCTTT 
NOS2 (iNOS) GTGTTCCACCAGGAGATGTTG CTCCTGCCCACTGAGTTCGTC 
TLR-2 TGG TTG CAG AAA ATG CCA GG AGGAACTACCTCTATGCAGGGAT 
TLR-4 ATGGCCTCCCTCTCATCAGT   CTTGGTGGTTTGCTACGACG 
TNF-α ATGACTTCCAAGCTGGCCGTG  TCTCAGCCCTCTTCAAAAACT 
IL-10 GCCGGGAAGACAATAACTGC TGTTGTCCAGCTGGTCCTTT 
PLP TACAAGACCACCATCTGCGG CCACAAACTTGTCGGGATGTC 
NO3 GCTCCCAACTGGACCATCTC TCTTGCACGTAGGTCTTGGG 
GFAP AGGGCGAAGAAAACCGCATC GGTGAGCCTGTATTGGGACA 
FOS TTTCAACGCCGACTACGAGG GCGCAAAAGTCCTGTGTGTT 
JUN GCACATCACCACTACACCGA GGGAAGCGTGTTCTGGCTAT 
PTGDR CAGGCTCAGACTACAGGCAC CGCACGATAAATTAAAGGCAGG 
PTGFR GTCCCTTTCTGGTAACAATGGC CTGATTCCACGTTGCCATGC 
OXTR TAGGACCCTCAGGTTCGGAG CGCTCTGCCTTCGTCCAA 
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2.2.6 Agarose gel electrophoresis 
Agarose (2%) gels were prepared using 1.5g agarose powder (Fisher Scientific) dissolved in 
100μl of 1% Tris/Borate/EDTA buffer (BTE) and 10 μl SYBR safe DNA gel stain 
(Invitrogen). To test primer specificity, PCR products were run for 20 minutes at 150V, 
alongside 1Kb and 100bp Quick Load DNA ladders (BioLabs). Visualisation of fluorescent 
bands was performed with a UV light transilluminator (BioDoc-It System, Appleton Woods). 
 
2.2.7 Protein extraction 
Myometrial and whole pup brain protein lysates were prepared by pulverising tissue under 
liquid nitrogen in a mortar and pestle. Samples were then homogenised with Rotor Stator 
Homogenizer in a modified RIPA buffer (1% Triton X-100, 1% CHAPS, 0.1% SDS, 1% 
deoxycholic acid, 50mM NaF, 1mM phenylmethylsulfonyl fluoride (PMSF), protease 
inhibitor cocktail (Sigma-Aldrich), 25mM Tris pH 7.4, 150mM NaCl) at a ratio of 1ml 
buffer: 100 mg tissue. The homogenate was incubated on ice for 15 minutes to allow cell 
lysis. Protein extracts were then centrifuged at 13,000 × g at 4°C and supernatants containing 
proteins were stored at -20°C. 
 
2.2.7.1 Protein quantification 
Protein concentrations were quantified by Bradford method using Bio-Rad protein assay 
reagents (Bio-Rad), following the manufacturers protocol. Bovine serum albumin (BSA) 
standards of known concentrations were used as reference to determine concentrations of 
samples. Bradford assay results were analysed with a microplate reader and protein 
concentrations were calculated in Excel using the concentration of the standards as reference. 
Protein samples were aliquoted and stored at -80°C in order to avoid freeze-thaw cycles. 
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2.2.8 SDS-polyacrylamide gel electrophoresis and Western Blotting 
A total of 20 μg (myometrium) or 40 μg (pup brains) of extracted protein were mixed with 
1.5 μl dithiothreitol (DTT) reducing agent (Thermo Scientific), 3.75 μl NuPage sample buffer 
4x Dye (Invitrogen) and distilled water in a final volume of 15 μl. After protein denaturation 
by incubating at 90ºC for 10 minutes, proteins were resolved on either 10% Tris-glycine 
sodium dodecyl sulphate (SDS) polyacrylamide gels or Mini-PROTEAN
®
 TGX™ Precast 
Gels (Biorad). Samples were loaded together with a calibrator sample consisting of a pool of 
different samples. The calibrator sample was loaded in every gel as to account for inter-gel 
variation. Following electrophoresis, proteins were transferred onto MeOH activated 
polyvinylidene fluoride (PVDF) membranes (Immobilon
®
-P, Millipore) at 300mA constant 
current for 90 minutes.  Membranes were then incubated with a blocking buffer solution (5% 
non-fat milk powder dissolved in 1% Tris-buffered saline with Tween (TBST) for 1 h at 
room temperature followed by overnight incubation in primary antibody at 4ºC. All 
membranes were then washed 5 times for 5 minutes in 1% TBST, followed by 90 minutes 
incubation in horseradish peroxidase (HRP) conjugated secondary antibody (1:2000 in 1% 
BSA-TBST or 1% milk-TBST depending on the preparation of the primary antibody 
solution). All membranes were also re-probed for β-actin to confirm equal loading in each 
lane. Imaging of immunoreactive protein bands was performed using a LAS4000 (GE 
Healthcare) imager, after incubating for 5 minutes with a mixture of enhanced 
chemiluminescent 2 (ECL2) solution A and B (Thermo Scientific, 1:40 ratio). Densitometric 
analysis of immunoreactive bands was performed using ImageQuant TL (GE Healthcare, 
UK).  
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2.2.9 Sequential Immunofluorescence 
2.2.9.1 Paraffin embedding and slides preparation 
Formalin-fixed myometrium samples were stored in 70% EtOH. To dehydrate samples, 
specimens were submerged in sequential washes of 70% EtOH, 100% EtOH and Histoclear. 
After dehydration, samples were placed in culture plates, covered with melted paraffin and 
incubated for 1 hour at 60º C. Samples were then transferred into clean wells containing fresh 
paraffin and incubated for another hour. Finally, samples were transferred in paraffin-filled 
plastic moulds and were gently pressed down into a block using a plastic cassette lid. The 
paraffin was allowed to solidify at room temperature and the blocks were then stored at room 
temperature. Sections of 5 mm thickness were cut on a microtome and placed on poly-lysine 
covered slides. Sequential sections were prepared for immunofluorescence staining. 
 
2.2.9.2 Deparaffinization and antigen retrieval 
To eliminate paraffin prior to the staining procedure, slides were immersed twice for 3 
minutes in HistoClear solution (National Diagnostics). To progressively allow rehydration of 
the samples, two incubations of 3 minutes each in 100% EtOH were performed. Samples 
were then incubated for 3 minutes in 70% EtOH, followed by incubation in 50% EtOH for 3 
minutes. Slides were rinsed in distilled water and then placed for 10 min under cold running 
tap water to remove residual EtOH. Sodium Citrate Buffer (10Mm Sodium Citrate, 0.05% 
Tween 20, Sigma, pH 6.0 in distilled water) was used as antigen retrieval agent to unmask 
antigenic sites within the tissue samples. Slides were immersed in a staining dish and 
microwaved at full power until a sub-boiling temperature was reached before (about 2 
minutes). Heating-up was continued on low power for a further 8 minutes. Slides were then 
left to cool down in the solution for 30 minutes at room temperature, on an ice-filled tray. 
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Following temperature stabilization at room temperature, samples were washed twice for 5 
minutes each, with gentle agitation (50 revolutions/min), in a 1% TBS (Tris-buffered saline) 
solution. 
 
2.2.9.3 Blocking and antibodies incubation 
To confine reagent incubation to the tissue region, a circle was drawn around each section on 
every slide using a hydrophobic PAP pen for immunostaining (Sigma). To avoid non-specific 
binding of the antibodies, a blocking solution prepared from normal goat serum (1:20) in 
BSA 0.2% (Bovine Serum Albumin, Sigma) was applied onto the sections. Normal goat 
serum was used as secondary antibodies were raised in goat. The slides were incubated for 1 
hour at room temperature in an incubation chamber to avoid evaporation of the solutions. 
Following blocking, slides were first rinsed in a solution of TBS 1%. Primary antibodies of 
the following dilutions were then applied: rabbit p-c-Jun (S73) (3270S, 1:200 in 0.2% BSA, 
Cell Signaling Technology, USA), rabbit p-p65 (ab131109, 1:50 in 0.2% BSA, AbCam, UK) 
and rabbit p-CREB (S133) (9198S, 1:600 in 0.2% BSA, Cell Signaling Technology). Each 
primary antibody was applied on a different section. One section per slide was used as a 
negative control and antibody solution (0.2% BSA) without antibody was applied. The slides 
were incubated in a wet incubation chamber overnight at 4ºC. 
After the overnight incubation, slides were washed twice for 5 minutes in TBS 1% solution 
with gentle agitation. To block the endogenous peroxidase activity of the samples, a 3% in 
PBS H2O2 solution was applied on the tissue sections for 10 minutes. Slides were then rinsed 
with a 1% TBS solution, prior to incubation with the secondary antibody (Anti-rabbit IgG, 
Horseradish peroxidase (HRP)-linked, Cell Signaling Technology, 7074S, 1:1000 in 0.2% 
BSA) in a wet incubation chamber for 1 hour at room temperature. Following incubation, 
slides were washed three times for 5 minutes in a 1% TBS solution with gentle agitation. 
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2.2.9.4 Tyramide Signal Amplification (TSA) System: 1st TSA Amplification 
Following overnight incubation with the secondary antibody, slides were incubated for 10 
minutes at room temperature with Cyanine 5 (FP1171) dissolved in Dimethyl Sulfoxide 
(DMSO), mixed 1:50 with Plus Amplification Diluent, Perkin Elmer, USA). HRP bound to 
the secondary antibody catalyses the deposition and covalent binding of several TSA signal 
molecules on proteins immediately proximal to the target, leading to signal amplification 
(Fig. 2.3). 
 
Figure 2.3 Double indirect immunofluorescence staining with TSA amplification. A primary 
antibody raised in rabbit was used to detect the transcription factor of interest (p-c-Jun or p-p65 or p-
CREB) and the smooth muscle cell marker α-SMA. A goat-raised anti-rabbit HRP-conjugated 
secondary antibody was used for indirect staining. HRP catalyses the covalent binding of tyramide 
molecules tagged with the fluorophores Cy5 and Fluorescein, to the target, resulting in signal 
amplification. TSA: Tyramide Signal Amplification; α-SMA: alpha-smooth muscle acting; HRP: 
Horseradish peroxidase; T: Tyramide; Fluo: Fluorescein; Cy5: Cyanine 5. 
 
Slides were then quickly rinsed in distilled water to stop the reaction. To block antibody 
cross-reactivity before applying the 2
nd
 primary antibody and to disable the HRP of the first 
secondary antibody bound (all primary antibody were raised in rabbit), microwave treatment 
with Sodium Citrate was used as shown previously [418]. Slides were placed in a plastic 
container with a loose fitting lid filled with Sodium Citrate Buffer (10Mm Sodium Citrate, 
0.05% Tween 20 BioXtra, Sigma, pH 6.0) and were microwaved until boiling temperature 
 94 
 
was reached. Slides were left to cool down in the solution for 30 minutes at room 
temperature, followed by a 5 minutes wash in TBS 1%. 
 
2.2.9.5 2nd antibody incubation and TSA amplification 
Following Sodium Citrate treatment, a primary antibody against the smooth muscle cell 
marker α-SMA (rabbit anti-mouse α-SMA, ab5694, 1:500 in 0.2% BSA, Abcam) was applied 
to all slides. Sections were incubated in the wet incubation chamber for 45 min at room 
temperature. Following incubation, slides were washed twice for 5 minutes in TBS 1%.  
Slides were incubated in a wet incubation chamber for 45 minutes at room temperature with a 
secondary anti-rabbit IgG, HRP-linked (7074S, 1:1000 in 0.2% BSA, Cell Signaling 
Technology). One section per slide was used as a negative control, which consisted of 
incubating secondary antibody alone. Slides were then rinsed three times for 5 minutes each 
in 1% TBS. The TSA system was used with a different fluorescent label to allow distinction 
between the two sequentially stained targets. Slides were incubated for 10 minutes at room 
temperature with Fluorescein (FP1168) dissolved in DMSO (1:50 in Plus Amplification 
Diluent, Perkin Elmer). All slides were then rinsed in distilled water to stop the reaction. 
Nuclei were counterstained with 4’,6-diamidino-2-phenylindole (DAPI) and SlowFade® Gold 
(Thermo Fisher Scientific, USA) was applied for 10 minutes at room temperature on all 
sections, followed by a 2 minutes wash in TBS 1%. Fluoromount-G (0100-01, 
SouthernBiotech, USA) mounting medium was added to the slides. All slides were sealed 
with cover slips (22x50mm, Menzel-Gläser, Germany) and stored at 4º C until examination. 
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2.2.9.6 Confocal microscopy and imaging 
Imaging was performed using a Leica SP5 Confocal Microscope. Sequential scanning was 
performed to detect the presence of three different fluorophores (Cy5, fluorescein, DAPI) in 
the same sample. The power for each of the three lasers was set at 20%. The photomultiplier 
tube (PMT) was placed according to the expected emission of each fluorophore. The 
expected emissions, as defined by the pre-set fluorophore parameters of the Leica LAS AF 
software, were the following: 455mm for DAPI, 496mm for fluorescein and 633mm for Cy5. 
A total of 10 images were captured for each slide. Presence of myometrium was confirmed 
using α-SMA positive staining. 
 
2.2.9.7 Staining quantification 
Quantification of nuclear staining was performed using the software ImageJ version 1.49. For 
each image taken, the software calculated the number of nuclei that was positively stained 
with DAPI and the amount of nuclei that was positively stained with p-c-Jun, or p-p65, or p-
CREB. This allowed the calculation of percentages of nuclei across the section positively 
stained for p-c-Jun, p-p65 and p-CREB. Statistical analysis was performed using GraphPad 
Prism 5. Statistical significance was determined by 2-way ANOVA and Student’s t test. 
Differences with a P-value<0.05 were considered significant. Images were assessed by two 
independent observers to confirm consistency in counting. 
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2.2.10 RNA-Seq to study differential gene expression 
RNA-Seq is a technology that enables highly sensitive analysis of gene expression across the 
full range of mRNA molecules (transcriptome) expressed by a cell or within a tissue [419]. A 
typical RNA-Seq experimental workflow is shown in Fig. 2.4. 
 
 
Figure 2.4 RNA-Seq experiment workflow. Crucial steps in a typical RNA-Seq experiment. 
 
Two types of information can be gained by RNA-Seq: qualitative information, known as 
“annotation” that is the identification of expressed transcripts, and quantitative data for 
example by measuring gene expression differences across experimental groups. An RNA-Seq 
experiment involves producing a collection of cDNA fragments that are reverse-transcribed 
from an RNA pool, and flanked by specific sequences (adapters) that are necessary for 
sequencing, and a unique sequence (index) that provide each sample with a unique 
identification label. This collection of cDNA fragments is referred to as the “library” that will 
be sequenced producing millions of short sequence reads corresponding to each individual 
cDNA fragment. The Illumina
® 
sequencing technology consists of two phases: a “solid-phase 
bridge amplification” phase which creates up to 1000 copies of an individual cDNA molecule 
in close proximity (clusters); and a “sequence by synthesis” phase, through which four 
fluorescently labelled nucleotides are added to sequence the cDNA clusters on the flow cell 
(Fig 2.5). 
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Figure 2.5 Illumina
®
 RNA-Sequencing technology. Diagram illustrating solid-phase amplification 
and sequencing by synthesis characterising the Illumina
®
 RNA-Seq technology. 
 
Firstly, the cDNA library molecules are denatured and attached to the flow cell by binding to 
specific primers complementary to the adapters (P7/P5). In each sequencing cycle, unlabelled 
nucleotides and polymerase enzyme are added to create several copies from an individual 
cDNA molecule (amplification). The adapter region is cleaved from one end and sequencing 
reagents added including primers, polymerase and fluorescently labelled reversible 
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terminator-bound nucleotides (dNTPs). After each dNTP incorporation cycle, the fluorescent 
dye is imaged to identify the base and later enzymatically cleaved to allow incorporation of 
the next nucleotide. Unincorporated bases are removed and the second cycle can start. The 
end result is a number of reads produced from the whole length of each cDNA molecule 
accurately sequenced base-by-base. RNA-Seq is recognised as a “deep-sequencing” 
technique as it permits to achieve an high number of sequence reads spanning the entire 
transcript several times (Fig. 2.6) therefore allowing even coverage across each transcript and 
unequivocal attribution of the sequenced reads to each transcript/gene. Reads are aligned with 
the reference genome and classified as junction reads, exonic reads and poly-A end reads. 
 
Figure 2.6. Analysis of RNA-Seq reads. Sequenced reads are aligned to a reference genome to allow 
assignment of each read to a specific exon/gene. Quantification and normalisation of reads counts 
allow identification of gene expression differences. 
 
These are used to generate a base-resolution profile for each gene, allowing quantification of 
reads associated with each gene. Since counts are proportional to the transcript length times 
the mRNA expression level, reads numbers are normalised to the length of each transcript. 
Additionally, the sequencing depth represents another source of bias: the higher is the 
 99 
 
sequencing depth, the higher will be the number of reads. Therefore reads counts are 
normalised to account for differences in the depth of the sequencing characterising each 
library. Normalised reads counts can then be used to identify genes that have significantly 
changed in their expression levels across experimental conditions. 
 
2.2.11 RNA-seq library preparation 
cDNA libraries were prepared from mouse myometrium RNA using Truseq Stranded mRNA 
Sample preparation kit (Illumina), following manufacturer’s instructions (Fig. 2.7) 
 
 
Figure 2.7 RNA-Seq library prep workflow.  RNA samples are enriched for poly-A molecules by 
magnetic beads-capture. Isolated mRNAs are fragmented and converted to double-stranded 
complementary DNA (cDNA). cDNA molecules are ligated to platform-specific adaptor sequences 
(P5 and P7) at either end of each molecule. A unique barcode (index) is also attached to tag each 
sample and libraries are amplified by PCR prior to sequencing. 
 
Sample preparation and run was randomized by model and treatment, i.e. samples from 
different treatments and gestational days were randomly processes and sequenced to avoid 
pooling of samples belonging to the same experimental group. Briefly, samples containing 2 
μg of purified large RNA fraction (>200 nucleotides) were enriched for poly-A mRNA using 
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oligo-dT coated magnetic beads and a 96 well plate magnetic stand. Following purification, 
mRNA was randomly fragmented at 94 °C for 8 min to obtain fragments within a range of 
insert length of around 200 base pair (bp) and an average final library size of 300 bp 
(insert+adapters). First-strand complementary DNA synthesis was performed using random 
primers (Illumina) and SuperScript II Reverse-Transcriptase (Invitrogen) followed by second 
strand synthesis with RNaseH and DNA polymerase I (Illumina). Adapters provided were 
used to tag each sample with a different DNA sequence, to allow distinction between samples 
pooled together on the sequencing machine. Compatibility between adapters was checked 
with Illumina Experiment Manager
®
 to allow subsequent pooling of three samples in each 
lane during sequencing. cDNA libraries with an insert length of 300 bp were amplified by 10 
cycles of PCR. PCR cycling was performed as follows: 98°C for 30 seconds, 10 cycles of: 
98°C for 10 seconds, 60°C for 30 seconds, 72°C for 30 seconds, 72°C for 5 minutes, hold at 
4°C. AMPure XP Beads (Beckman Coulter, Inc.) were used to purify PCR products. 
Libraries were quantified using Qubit
®
 dsDNA HS Assay Kit and a Qubit
®
 Fluorometer 
(Thermo Fisher Scientific). The high sensitivity of this assay allows accurate detection of 
DNA concentrations from 10 pg/µL to 100 ng/µL. The quality and fragment size of each 
library was then validated using a 2100 BioAnalyzer (Agilent). Fig. 2.8 illustrates validation 
of a RNA-Seq library assessed by BioAnalyzer. 
 
Figure 2.8 Validation of mRNA library. Bioanalyzer trace showing an example of mRNA library 
prepared for RNA-Seq. 
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Validated libraries were multiplexed by three by pooling equal amount for each library. Pools 
were normalised to 10 nM with Tris-HCl 10 mM, pH 8.5 and stored at -20ºC before 
sequencing. Paired-end sequencing (2×100 bp) was performed on an Illumina HiSeq2000 
machine. The final pooling arrangement in the flow-cell and combination of indexes used is 
provided in Table 2.2. 
Table 2.2 Libraries indexes combination and pooling design in the RNA-Seq flow-cells. 
A pool including three samples with compatible indexes was sequenced in each lane of a 
flow cell. 
Flow 
cell 1     
Flow 
cell 2     
Flow 
cell 3     
Lane Sample Index Lane Sample Index Lane Sample Index 
1 E14_1 CGATGT 1 E14_3 ACAGTG 1 E14_4 GCCAAT 
1 LC2_1 CAGATC 1 LC6.2 AGTTCC 1 LT6.2 CTTGTA 
1 RC6_1 GTGAAA 1 RT6_3 GTCCGC 1 RC6_4 AGTCAA 
2 E14_1 ACAGTG 2 E14_3 GCCAAT 2 LAB_4 CGATGT 
2 LAB_LPS_1 GCCAAT 2 LT6.3 CTTGTA 2 RC18_4 CAGATC 
2 RC18_1 ATGTCA 2 RC18_3 AGTCAA 2 LC2_4 GTGAAA 
3 E14_1 GCCAAT 3 LAB_3 GCCAAT 3 LT2.3 ACAGTG 
3 LT2.1 CTTGTA 3 LAB_LPS_2 ATGTCA 3 LC6.1 ATGTCA 
3 RT6_2 AGTTCC 3 RT18_3 GTCCGC 3 LAB_RU486.1 GTGAAA 
4 LAB_1 ACAGTG 4 E14_3 TGACCA 
   4 LT6.1 AGTCAA 4 LT.2.4 ACAGTG 
   4 RT18_1 GTCCGC 4 LAB_RU486.2 AGTCAA 
   5 E14_2 TGACCA 5 RC18_2 CGATGT 
   5 LC2_2 CCGTCC 5 E14_4 TGACCA 
   5 RC6_2 CGATGT 5 LAB_LPS_3 CCGTCC 
   6 E14_2 TGACCA 6 RC6_3 CGATGT 
   6 LAB_LPS_4 ACAGTG 6 LT6.4 CAGATC 
   6 RT18_4 AGTCAA 6 LAB_RU486.3 GTGAAA 
   7 E14_2 GCCAAT 7 LC6.4 GCCAAT 
   7 LC6.3 CTTGTA 7 RT18_2 AGTTCC 
   7 LAB_RU486.5 GTCCGC 7 LAB_2 GTCCGC 
   8 LAB_RU486.4 CGATGT 8 LC2_3 CGATGT 
   8 LT2.2 CAGATC 8 E14_4 CAGATC 
   8 RT6_4 GTGAAA 8 RT6_1 GTGAAA 
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2.2.12 Processing of RNA-Seq data  
RNA-Seq reads were aligned to the reference genome of Mus musculus GRcm38 from 
ENSEMBL release 73 using the software package Burrows-Wheeler Aligner (v0.75a) [420]. 
The command line utility Picard was used to sort the resulting BAM alignment files [420]. 
Samples were quality-assessed using FastQC [317]. Gene level read counts were generated in 
R using the GenomicRanges and Rsamtools Bioconductor packages against the Mus 
musculus GTF annotation file GRCm38 (release 73) [421-423]. A total of 269 Gigabytes of 
sequencing data from 57 samples was generated with an average 87.9 million reads for each 
sample. See Appendix B-Table B.1 reporting total number of reads detected for each sample. 
Outliers were detected based on the distance from the centroid (see next paragraph for details 
on the method). While no outliers were detected in the term gestation model, two samples 
were classified as outliers (P<0.01, Bonferroni post-hoc test) in the RU486 and LPS-induced 
PTL model (6h DMSO and 6h LPS) and excluded from further analysis.  
 
2.2.13 Outlier detection for multidimensional data 
We developed a new method for the detection of outliers in a multivariate dataset. This 
method takes as input the data and the relative information about the association of each 
sample to each group, and it gives as output the probability of each sample of not being  an 
outlier. This probability is calculated comparing the Euclidean distance of each samples 
(distance x) with the Euclidean distance of all other samples belonging to the same group 
(distances A=[a1,a2,a3,a4,…,an]) from the centroid of the group. The probability will be then 
given by the probability that the distance x belong to a Gaussian distribution with mean 
µ=mean(A) and variance σ2=(n-1)/n * variance(A). The R script relative to the function is 
provided in Appendix B-Table B.2. 
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2.2.13.1 Multivariate data analysis 
For multivariate analysis, genes with zero read counts were excluded and the remaining were 
mean-centered and unit variance-scaled. Principal Component Analysis (PCA) was 
performed on transcriptome changes using the standard algorithm as implemented in the 
prcomp function included in the R library stats. Transcriptome changes specifically 
associated with progression of gestation characterising each murine model were identified 
and modeled using orthogonal signal correction-partial least squares (OSC-PLS) regression 
modelling [424]. OSC-PLS is a supervised method that aims to maximize the variance 
between groups in the in the output data (i.e., score). It also provides as output an indication 
(i.e., loadings) of the importance of the variables in the regression. Analyses were carried out 
in R and OSC-PLS modelling was applied to expression levels of 4142 genes (FDR<0.001) 
including those changing in at least one pairwise comparison within a model. Model 
goodness of fit was assessed by calculating the correlation coefficients (r) using Pearson 
linear correlation and P values were also calculated for each prediction. Hierarchical 
clustering was performed using the Ward’s method [425]. The number of clusters was 
calculated using Silhouette algorithm [426].  
2.2.13.2 Identification of differential expressed genes (DEGs) 
Gene read counts were normalized for the library size using Trimmed Mean of M-values 
(TMM) scaling implemented in the Bioconductor package followed by transformation into 
log2 counts per million. DEGs were identified in R using the negative binomial differential 
expression method edgeR [427]. P values were adjusted for multiple testing with the 
Benjamini–Hochberg correction and FDR cutoffs of 0.001 or 0.01 were used. 
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2.2.13.3 Analysis of human myometrium RNA-Seq data 
A human myometrium RNA-Seq dataset deposited by Chan et al. was re-analyzed in this 
thesis [406] to permit comparison of murine transcriptome data with human data. This dataset 
was derived from samples of lower segment human myometrium samples collected at term 
(38-40 weeks of gestation) from women in spontaneous labour (n=5, IL) and from women 
not in labour undergoing elective Caesarean section (n=5, NIL). Women in the IL group 
required Caesarean section for undiagnosed breech or cephalopelvic disproportion, without 
labour augmentation. Count data were accessed at NCBI Gene Expression Omnibus data base 
using the series accession number GSE50599 and genes differentially expressed when 
comparing IL versus NIL were identified using EdgeR with a FDR value <0.001. 
Orthologous genes were identified by comparing differentially expressed genes (DEGs) 
associated with human labour onset to murine myometrial transcriptome data in at least one 
of the following pairwise comparisons: E16 vs E18, E16 vs LAB and E18 vs LAB for the 
term gestation model; 6h RU486 vs 18h RU486, 6h RU486 vs LABRU486 and 18h RU486 vs 
LABRU486 for the RU486-induced PTL model; 2h LPS vs 6h LPS, 2h LPS vs LABLPS and 6h 
LPS vs LABLPS for the LPS-induced PTL model. Shared DEGs were further analysed using 
OSC-PLS modelling to test for congruence between human and murine datasets across a 
time-course leading to labour. In the mouse, term labour occurred at gestational day E18.5 
corresponding to a human term gestation of approximately 270 days/38.5 weeks. E18 
corresponded to 263 days/37.5 weeks of human gestation and thus in the absence of labour, 
was considered equivalent to the NIL human sample group (term, not in labour). Both LPS 
and RU486 treatments induced PTL at E16 within 7 and 20 hours following injection 
respectively, corresponding to 234 days/33 weeks of a human gestation (preterm). Temporal 
gene expression changes relative to each murine model of gestation were alternatively used 
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as training set against which the human datasets were tested using OSC-PLS modelling. 
Pearson correlation scores and P values were derived for each test. A positive Pearson score 
was indicative of a positive correlation between genes similarly changing as a function of 
gestational age in the mouse and in the human samples. Loadings derived from the OSC-PLS 
analyses were indicative of the importance of variables (genes) for discrimination between 
different sample groups. Hierarchical clustering of loadings was performed to identify 
profiles consistent between human and murine gestational models and to identify gene 
clusters similarly expressed across gestational time-course in both organisms.  
 
2.2.13.4 Pathway analysis 
Biological functions enriched with differentially expressed genes were identified using two 
manually-curated databases of signalling and metabolic pathways represented on networks 
(Process Network analysis by MetaCore
®
, Thomson Reuters [428] or on canonical pathways 
maps (Canonical Pathways analysis by Ingenuity
®
 Pathway Analysis, IPA
®
, QIAGEN 
Redwood City). Process Network analyses were performed to identify biological functions 
significantly enriched by differentially expressed genes. A threshold P value less than 0.05 (-
log10=1.3) was used as cut-off. Overrepresented canonical pathways were also identified 
using IPA
® 
(QIAGEN Redwood City) which in addition to identifying enriched biological 
function, allows prediction of the activation status for each specific pathway. Canonical 
pathways were considered significantly enriched when P<0.05 and activated/inhibited when 
Z-score≥|2.0|. 
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2.2.13.5 Causal Network analysis 
IPA was used to identify upstream regulators potentially responsible for the observed gene 
expression changes. Upstream regulators were predicted using IPA
 
Causal Network Analysis 
by calculating a regulation Z-score and an overlap P value which predict the activation or 
inhibition state of regulators based on downstream differentially expressed genes and known 
directionality of expression [429]. Upstream regulators with overlap P≤0.05 and an IPA 
activation Z-score≥|2.0| were assumed significantly activated/inhibited). The overlap P value 
(Fisher’s exact test) threshold is used to identify possible upstream regulators based on 
significant overlap between DEGs and known targets regulated by a given upstream 
regulator. The activation Z‐score is used to infer likelihood of activation status of upstream 
regulators based on evidence from DEGs in our dataset for which the direction of the 
observed expression change is consistent with that expected from the literature. 
 
2.2.14 Statistical analysis 
Statistical analysis was performed with GraphPad Prism v5 (GraphPad Software, San Diego, 
CA). Unpaired t test (Student’s) was used to compare the means of two unmatched groups, 
assuming that the values follow a Gaussian distribution. One-way or two-way ANOVA was 
used to compare three or more groups followed by multiple comparison (post-hoc) tests to 
compare pairs of group means. One-way ANOVA was used when comparing one 
independent variable (1 factor) with > 2 conditions/treatments (e.g. Chapter 4). Tukey’s post-
hoc test was used when comparing all pairs of columns. Bonferroni’s post-hoc test for 
selected pairs of columns was used only when comparing certain column pairs (e.g. treatment 
vs control). Two-way ANOVA was used when testing for significant differences dependent 
on 2 independent variables (factors). Each variable can have multiple conditions (e.g. 
treatment and time, each assessed at a different time-point as shown in Chapter 5). 
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3 Characterization of contraction-associated and inflammatory 
mediators expression in a murine model of term gestation 
 
Introduction 
Successful pregnancy and term birth are the result of a balance between pathways controlling 
uterine quiescence and those inducing uterine contractility [430]. Although the exact 
molecular mechanisms controlling this fine equilibrium remain incompletely defined, many 
components orchestrating this remarkable transformation have been revealed and represent a 
complex interplay between second messengers, steroid hormones, and inflammation. The 
cyclic AMP (cAMP)-CREB/ATF signalling pathway is thought to maintain myometrium 
quiescence throughout gestation by inhibiting calcium mobilization and the contractile 
apparatus [191, 194]. CREB is of interest since it mediates both Ca
2+
- and cAMP-dependent 
gene transcription [431, 432], thus playing an important role at the interface between 
transcriptional and functional regulation of contractility. 
The transition from quiescence to activation allows the myometrium to become sensitised to 
contractile stimuli such as prostaglandins and oxytocin and to respond with powerful 
rhythmic contractions [23]. While precise mechanisms controlling this transition are not yet 
fully understood, labour in both humans and in animal models is accompanied by activation 
of inflammation within the gestational tissues [40, 433]. Previous studies showed up-
regulation of proinflammatory genes in both fetal membranes [402, 434] and myometrium 
[406, 411, 435]. Computational approaches have also been used to predict possible causes of 
labour in the human and pointed towards an inflammatory origin of labour [436]. Nuclear 
factor-kappa B (NFκB) is widely considered as prototypical proinflammatory transcription 
factor, based on its ability to induce expression of several proinflammatory genes encoding 
for cytokines, chemokines and adhesion molecules [198]. Transcriptional activity of NFκB is 
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further enhanced by post-translational modification such as phosphorylation of the p65 
monomer that stimulates its binding to the promoter region of various labour-associated 
genes including the proinflammatory cytokines IL-6 [210] and IL-1β [211, 212] as well as 
pro-contractile genes such as COX-2 [74, 213, 214], PF2α receptor [215] and oxytocin 
receptor (OTR) [216, 217]. Some of the genes associated with NFκB activation are similarly 
regulated by CCAAT/enhancer-binding protein beta (C/EBPβ) [218] and by the inducible 
transcriptional complex of AP-1 [219]. AP-1, formed by c-jun/c-fos heterodimers is the most 
transcriptionally active complex [226, 437] and can be induced through mitogen activated 
protein kinase (MAPK) by a variety of stimuli including growth factors, cytokines, 
infections, physical and chemical stress [227]. Overlapping between NFκB and AP-1 
activation has been shown in vitro and in vivo. Both NFκB and AP-1 are required for IL-1β-
induced expression of COX-2 in WISH amnion cells [438] and mechanical stretch of human 
amnion stimulates expression of COX-2 in association with AP-1 activation [248]. 
Expression of COX-2, OTR and interleukin-8 (IL-8) concurrently with AP-1 following in 
vitro myometrial stretch has also been observed in human myometrium strips [108, 246, 247]. 
The gap junction connexin 43 (CX-43) mediates myocytes coupling thus facilitating 
propagation of contractile signals at term in both human and animal models [67, 439]. The 
promoter region of the Cx-43 gene contains two AP-1 binding sites that are conserved in 
mouse, rat and humans. AP-1 regulates CX-43 expression in myometrial cells therefore 
enhancing myometrial coupling and promoting propagation of contractile stimuli [437, 440]. 
Although collective evidences support a role for NFκB and AP-1 in both humans and animal 
models of PTL, the relative contribution of these inflammatory transcription factors in 
inducing pro-labour genes at term is not fully understood. Thus, the objective of this study 
was to utilise a murine model of spontaneous labour at term to determine which inflammatory 
mediators may be involved in the activation of myometrial contractility. 
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Results 
 
3.1 Murine labour is preceded by NFκB activation and involves activation of AP-1 
Protein lysates were prepared from myometrium samples collected from non-pregnant mice, 
and at E6, E11, E14, E16, E18 throughout gestation, during term labour (LAB), and post-
partum (PP) and analysed via Western blotting. The activated phosphorylation forms of three 
inflammatory transcription factors, NFκB, AP-1 and C/EBPβ, were assessed in myometrium 
samples collected at various stages throughout gestation and labour, as well as post-partum in 
a murine model of spontaneous term labour (Fig. 3.1). The time of implantation (embryonic 
day 6, E6) was characterised by activation of all three transcription factors (Fig. 3.1 A). 
Phosphorylation of the NFκB subunit p65 decreased on E11 before being up-regulated 
throughout the rest of gestation, peaking on E18 just prior to the onset of labour (Fig. 3.1 A, 
B). In contrast, an opposite pattern was exhibited by the activated AP-1 subunit, p-c-Jun, 
which decreased throughout gestation before rising at labour onset (Fig. 3.1 A, C). The AP-1 
subunit p-c-Fos also showed a similar pattern, peaking at the time of implantation (E6) before 
declining at E11 by 6 and 1.8 fold respectively (Fig. 3.1 A, D). A 6-fold increase was 
detected in the levels of p-c-Fos at E18, prior to labour, compared to E16. Phosphorylation of 
the transcriptional activator C/EBP-β liver-enriched activator protein (LAP) isoform [441] 
was increased only on E6 with low levels detected at all other gestational time points (Fig. 
3.1 A, E). Activation of the functional LAP antagonist, liver-enriched inhibitory protein (LIP) 
remained unchanged throughout gestation. 
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Figure 3.1 Term murine labour involves c-Fos and c-Jun activation. Western blot analysis of 
inflammatory transcription factors activation in mouse myometrium throughout gestation. A total of 
20 µg of myometrial tissue protein lysates were collected from non-pregnant (NP) or pregnant mice 
on gestational/embryonic (E) day E6, E11, E14, E16, E18, during term labour (LAB) and 24 h post-
partum (PP). (A) Representative Western blots for the phosphorylated NFκB monomer p-p65, AP-1 
subunits (p-c-Jun and p-c-Fos), and p-C/EBP-β isoforms liver-enriched activator protein (LAP) and 
liver-enriched inhibitory protein (LIP). Graphs show quantitation of p-p65 (B), p-c-Jun (C), p-c-Fos 
(D) and p-C/EBP-β (E) protein expression levels as assessed by densitometric analysis. β-actin was 
used as loading control. A pool containing an aliquot from all samples was used as calibrator (CAL) 
to account for variability between different gels. Data are displayed as mean ± SD, n=4. Letters on 
bars represent statistical significance between gestational time points as assessed by 1-way ANOVA 
with Bonferroni's post hoc test, 
*
P<0.05). For all conditions with the same letter, the difference 
between the means is not statistically significant. If two conditions have different letters, they are 
significantly different. 
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3.2 Subcellular localisation of NFκB remains unchanged throughout normal murine 
gestation 
Since transcription factors require nuclear translocation upon activation to enable them to 
regulate gene transcription [442], the subcellular localisation of activated p65 was examined 
by immunofluorescence staining of formalin-fixed myometrium samples (Fig. 3.2 A). 
 
Figure 3.2. Subcellular localisation of NFκB in mouse myometrium is not altered throughout 
gestation. (A) Tissue samples from mouse myometrium were collected on E6, E11, E14, E16, E18 
and during active labour (LAB) and sections (5 μm) were analysed by immunofluorescence staining 
to detect subcellular localisation of p-p65. (-) CTRL: primary antibody is omitted. α-SMA: alpha 
smooth muscle actin marker. Nuclei were counterstained with DAPI (blue). Scale bar = 20μM. 
Images acquired with Inverted Leica SP5 confocal system, Magnification 63x (oil). (B) Quantification 
analysis revealed no significant changes in the relative number of nuclei positively stained for p-p65. 
Statistical significance was assessed by 1-way ANOVA with Bonferroni post hoc test, (
*
P<0.05). 
Data are displayed as mean ± SD,  n=3. Performed in collaboration with Ioannis Pavlidis, MSc. 
 113 
 
A primary antibody targeting phosphorylated p-p65 (Serine 536) was used to investigate 
expression and subcellular localisation of activated NFκB. A secondary antibody tagged with 
the fluorophore Cyanine 5 (Cy5) was used to visualise p-p65 within the myometrial cells. 
Sections were co-labelled using a primary antibody recognizing alpha-smooth muscle actin 
and a secondary antibody tagged with the fluorophore fluorescein to permit visualisation of 
myometrial smooth muscle cells. Phosphorylated-p65 was shown to be localised in both the 
cytoplasm and the nuclei of myometrial cells throughout gestation and that the proportions of 
p-p65 positive (+) nuclei remained unchanged throughout gestation with 26.44±2.29% of 
cells positive for p-p65 on E6, 19.16±9.37% on E11, 28.14±13.20% on E14, 30.74±5.90% on 
E16, 19.20±8.41% on E18 and 26.09±3.39% during active labour (Fig. 3.2 B). Of note, while 
during early pregnancy the myocytes were quite densely packed, throughout mid- and late-
gestation, myocytes became more sparsely distributed and enlarged, indicative of the 
hypertrophic process the uterus undergoes during pregnancy which allows fetal growth and 
facilitate uterine contractions at term [443]. 
 
3.3 Labour onset is associated with AP-1 nuclear translocation  
In contrast with the NFκB subcellular localisation pattern, p-c-Jun was detected specifically 
in the nuclear compartment of uterine myocytes throughout the course of gestation (Fig. 3.3 
A). The proportions of nuclear p-c-Jun translocation was largely unchanged before E14, with 
25.66±1.88% of cells positive for p-c-Jun at E6, 26.91±13.65% on E11 and 24.03±12.78% at 
E14. The number of nuclei positively stained for nuclear p-c-Jun at E16 and E18 was 
39.80±26.78% and 32.06±21.16%, respectively. Active labour was characterised by the 
highest percentage of p-c-Jun nuclear translocation, displaying AP-1 translocation in half of 
the total number of nuclei (50.25±8.78%). 
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Figure 3.3 Activated AP-1 translocates to the nucleus at term labour onset. (A) Tissue samples 
from mouse myometrium were collected on E6, E11, E14, E16, E18 and during active labour (LAB) 
and sections (5 μm) were analysed by immunofluorescence staining to detect subcellular localisation 
of p-c-Jun. (-) CTRL: primary antibody is omitted. α-SMA: alpha smooth muscle actin marker. Nuclei 
were counterstained with DAPI (blue). Scale bar = 20 μM. Images acquired with Inverted Leica SP5 
confocal system, Magnification 63x (oil). (B) Quantification revealed no significant changes between 
time-points in the relative number of nuclei positively stained for p-c-Jun, although nuclear 
translocation was observed towards labour onset. Statistical significance was assessed by 1-way 
ANOVA with Bonferroni post hoc test, (
*
P<0.05). Data are displayed as mean ± SD,  n=3. Performed 
in collaboration with Ioannis Pavlidis, MSc. 
 
3.4 CREB activation peaks at mid-gestation before diminishing around the time of 
labour 
CREB has been associated with the maintenance of uterine quiescence in human 
myometrium, being highly expressed in samples collected from pregnant women not in 
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labour, compared with those collected during active labour [194]. We therefore aimed to test 
whether a similar pattern could also be observed throughout murine pregnancy and to identify 
the specific time point at which this activation occurred. Expression pattern of 
phosphorylated/activated p-CREB (Serine 133) was assessed in myometrium samples 
collected from non-pregnant mice as well as pregnant mice throughout gestation, during term 
labour (LAB) and post-partum (PP) and analysed via Western blotting. Levels of p-CREB 
were increased during gestation, peaking at E14 followed by a 9-fold decrease at E16 and 
E18. Very low levels of p-CREB protein were detected at labour onset (Fig. 3.4 A, B). 
 
Figure 3.4 Term murine labour involves CREB inhibition. Western blotting analysis showing p-
CREB and p-ATF1 expression in mouse myometrium throughout gestation. A total of 20 µg of 
myometrial tissue lysates were prepared from non-pregnant (NP) or pregnant mice on E6, E11, E14, 
E16, E18, during term labour (LAB) and 24 h post-partum (PP). (A) Representative blot is shown for 
p-CREB and p-ATF-1. Expression levels of (B) p-CREB and (C) p-ATF-1 were quantified by 
densitometry. β-actin was used as loading control. 1-way ANOVA with Bonferroni post-hoc test, 
(
*
P<0.05). Error bars indicate standard deviation, n=4. CAL= calibrator. 
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The activation status of activating transcription factor 1 (ATF-1) was also examined (Fig. 3.4 
A, C). ATF-1, CREM and CREB share high sequence homology and similarity in the cellular 
functions they control. ATF-1 and CREB in particular were shown to mediate cellular signals 
essential for successful embryonic development at early stages [444]. Consistent with these 
data, p-ATF-1 exhibited a similar activation pattern to CREB; while high levels of p-ATF-1 
were detected at the time implantation (E6), p-ATF-1 levels progressively decreased at later 
time points up until labour, where no ATF-1 activation was detected. 
 
3.5 CREB subcellular localisation is not altered throughout gestation 
Immunofluorescence staining was then used to examine subcellular localisation of p-CREB 
(Serine 133). Similarly to p-c-Jun, p-CREB was primarily localised in the nuclear 
compartment (Fig. 3.5 A). Upon quantification the following percentages of p-CREB positive 
(+) nuclei were detected: 25.13±14.48% on E6, 37.59±17.04% on E11, 31.07±8.21% on E14, 
45.94±43.30% on E16, 27.22±9.27% on E18 and 41,53±9.90% during term labour (Fig. 3.5 
B). The proportion of p-CREB positive (+) nuclei did not significantly change throughout 
gestation. No significant differences in p-CREB subcellular localisation were detected 
throughout the time course. 
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Figure 3.5 CREB subcellular localisation is not altered throughout gestation. (A) Tissue samples 
from mouse myometrium were collected on E6, E11, E14, E16, E18 and during active labour (LAB) 
and sections (5 μm) were analysed by immunofluorescence staining to detect subcellular localisation 
of p-CREB. (-) CTRL: primary antibody is omitted. α-SMA: alpha smooth muscle actin marker. 
Nuclei were counterstained with DAPI (blue). Scale bar= 20 μM. Images acquired with Inverted 
Leica SP5 confocal system, Magnification 63x (oil). (B) Quantification showed that the levels of 
nuclear p-CREB remained largely unchanged throughout gestation. Statistical significance was 
assessed by 1-way ANOVA with Bonferroni post hoc test, (
*
P<0.05). Data are displayed as mean ± 
SD,  n=3. Performed in collaboration with Ioannis Pavlidis, MSc. 
 
3.6 Levels of contraction-associated COX-2 and CX-43 increase with labour 
NFκB and AP-1 control the expression of the uterine activation proteins (UAPs) COX-2 and 
CX-43. Western Blotting was therefore used to analyse COX-2 and CX-43 protein expression 
levels throughout gestation. COX-2 protein concentrations were significantly increased from 
 118 
 
E16 onwards, peaking at labour onset (Fig. 3.6 A, B). CX-43 levels peaked at E6 and E11and 
then decreased at E16 and E18 before increasing again at labour onset (Fig. 3.6 A, C). These 
results were consistent with previous studies reporting an increased expression of CX-43 in 
both human and rat myometrium at term [66, 445]. 
 
Figure 3.6 Levels of pro-labour proteins COX-2 and CX-43 increase as labour approaches. (A) 
A total of 20 µg of myometrial tissue lysates were prepared from non-pregnant (NP) or pregnant mice 
on E6, E11, E14, E16, E18, during term labour (LAB) and 24 h post-partum (PP), and analysed by 
Western blotting for expression levels of the uterine activation proteins COX-2 and CX-43. Levels of 
COX-2 (B) and CX-43 (C) were quantified by densitometry. β-actin was used as loading control. A 
pool containing an aliquot from all samples was used as calibrator (CAL) to account for variability 
between different gels. Data are displayed as mean ± SD. n=4. Letters on bars represent statistical 
significance between gestational time points as assessed by 1-way ANOVA with Bonferroni's post 
hoc test, 
*
P<0.05). For all conditions with the same letter, the difference between the means is not 
statistically significant. If two conditions have different letters, they are significantly different. 
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3.7 The MAPK c-Jun-N-terminal kinase (JNK) is activated at labour onset 
Transcriptional activation of AP-1 is primarily modulated by mitogen-activated protein 
kinases (MAPKs). To investigate the relative involvement of these upstream regulators of 
AP-1, activation patterns of the three principal MAPKs involved in AP-1 phosphorylation 
and subsequent activation were examined (Fig. 3.7 A). Phosphorylation of c-Jun-N-terminal 
kinase (JNK) was significantly increased in myometrial samples collected during term labour 
compared to early gestation (Fig. 3.7 A, B). A similar increase in extracellular signal-
regulated kinase (ERK) (Fig. 3.7 A, C) was observed in labouring myometrium however p-
p38 levels remained unchanged throughout gestation and labour (Fig. 3.7 A, D). 
 
Figure 3.7 JNK is activated at labour onset at term in mouse myometrium. (A) Western Blotting 
was used to assess the activation status of the three MAPKs JNK, ERK, and p38 in myometrium 
collected from non-pregnant (NP) mice, on gestational day 6 (E6), E11, E16, E18, during active term 
labour (LAB) or <24 h post-partum (PP). (B) Densitometry showed a significant increase in p-JNK 
levels at labour onset. GAPDH was used as a loading control instead of β-actin due to overlap in 
migration pattern with the MAPKs. A pool containing an aliquot from all samples was used as 
calibrator (CAL) to account for variability between different gels. Data are displayed as mean ± SD, 
n=4. Letters on bars represent statistical significance between gestational time points as assessed by 1-
way ANOVA with Bonferroni's post hoc test, 
*
P<0.05). For all conditions with the same letter, the 
difference between the means is not statistically significant. If two conditions have different letters, 
they are significantly different. 
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Summary and discussion 
 
It is widely recognised that the onset of labour at term involves activation of inflammatory 
pathways within the uterus [446]. Since human samples of gestational tissues are not readily 
available, animal models, particularly mice, offer the possibility to investigate time-
associated changes throughout gestation, representing a valuable experimental tool to explore 
the temporal changes associated with parturition. Here we examined the activation status of 
transcription factors known to be involved in inflammatory processes associated with 
myometrial transition from quiescence to contraction to explore the timing of their activation 
pattern. We showed that activation of inflammatory transcription factors NFκB, AP-1 and 
C/EBP-β constitutes an early event in mouse gestation coinciding with embryo implantation 
at E6 (Fig. 3.1), consistent with evidence of implantation being an inflammatory process 
[447]. 
Our group has previously shown that NFκB activation in human amnion precedes the onset of 
labour [209], with similar levels of activated NFκB seen prior to and during labour. 
Consistent with these findings, our results show that NFκB activation in the mouse uterus 
occurs prior to the onset of labour on E18 (Fig. 3.1 A, B). We speculate that the relatively 
lower levels of activated NFκB at labour in mouse myometrium may represent a control 
mechanism aimed to prevent exacerbation of the inflammatory response within the uterus. 
Such mechanism is likely not required in fetal tissues such as amnion where elimination of 
NFκB activation will eventually be achieved with delivery of the membranes at term [209]. 
NFκB activation prior to the onset of labour implies that it is likely to regulate genes involved 
in myometrial activation and contraction. Similar observations have been reported by Condon 
et al. who showed increased nuclear localisation of NFκB monomers p50 and p65 in mouse 
uterus as term approaches [187]. 
 121 
 
It has been suggested that both preterm and term labour are initiated by the release of the co-
repression between progesterone receptors (PRs) and activation of NFκB, suggesting anti-
inflammatory properties of progesterone promote successful maintenance of pregnancy [448]. 
In support of this hypothesis Kalkhoven E. et al. demonstrated physical interaction between 
PR and NFκB resulting in trans-repression of the transcriptional activity of both factors [80]. 
This hypothesis, if true, is consistent with data presented in this chapter. Progesterone 
withdrawal in the mouse is initiated on E16 with levels of circulating progesterone reaching a 
low point on E18 [73], concurrent with activation of NFκB. While our data showed that 
NFκB activation is a relatively early event in the normal sequence of events leading to 
parturition, it remains unclear whether this event is contributing to or is affected by 
progesterone withdrawal. Two hypotheses are thus plausible and not necessarily mutually 
exclusive: progesterone withdrawal caused by regression of the corpus luteum starting from 
E16 could lead to a release of the progesterone block on NFκB activation, thus prompting the 
onset of labour. Conversely, NFκB activation could exert its effects by inhibiting 
progesterone signalling at term thus promoting myometrial contractions over quiescence. 
This last hypothesis finds support in a study by Condon et al. showing that activated NFκB 
induced up-regulation of the inhibitory PR-C isoform may lead to functional progesterone 
withdrawal in both human fundus and mouse myometrium [223]. We have shown via 
immunofluorescence (Fig. 3.2) that while no significant changes were detected in p-p65 
subcellular localisation across gestation, the highest proportion of nuclear staining for p-p65 
was observed at E16, which corresponds to the highest levels of circulating progesterone. 
Since the highest levels of nuclear p-p65 are evident prior to progesterone withdrawal, it is 
possible to speculate a role for NFκB in regulating progesterone signalling, rather than vice 
versa. 
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A different localisation pattern was exhibited by AP-1 activation which, after peaking at E6, 
declined throughout gestation before increasing again at labour onset (Fig. 3.3). Unlike p-
p65, whose expression was observed in both cytoplasm and nuclei, p-c-Jun localisation was 
limited to the nuclear compartment. While the role of NFκB in inflammation and labour has 
been extensively studied, the involvement of alternative inflammatory transcription factors 
such as AP-1 has been often overlooked. Progesterone receptors have been implicated in 
modulating AP-1 activity as shown in vitro in human endometrial adenocarcinoma cells 
[449]. In this study, unliganded PRs were able to stimulate AP-1 transcriptional activity and 
this event was reversed in the presence of progesterone. Here we showed that labour onset at 
term is consistently associated with AP-1 and JNK activation in the myometrium, which was 
reduced post-partum (Fig. 3.1 A, C). These results suggest that normal term labour involves 
the sequential activation of NFκB followed by AP-1. Whilst it is possible that AP-1 
activation occurs as a consequence of labour, an alternative hypothesis is that the lower 
progesterone systemic levels present at late gestation may allow unliganded progesterone 
receptor to positively modulate AP-1 transcriptional activity thus resulting in activated AP-1 
at labour onset. A role for AP-1 in modulating genes associated with labour onset has been 
previously reported. For example, AP-1 regulates expression of the gap junction protein CX-
43 in rodents and humans [437, 440]. Our data showed that CX-43 levels peak at E6 and 
subsequently decrease until E18, before significantly rising at the time of labour (Fig. 3.6 A, 
C). This pattern is mirrored by both AP-1 (Fig. 3.1 A, C) and JNK activation (Fig. 3.7 A, B), 
suggesting their involvement in CX-43 expression. On the other hand, COX-2 protein levels 
in the mouse myometrium were steadily increased throughout gestation (Fig. 3.6 A, B) with 
high levels being maintained from E16 to beyond labour consistently with previous studies 
on human samples and mice which suggest an involvement of COX-2 in late stages of labour 
rather than its initiation [145, 450].  Although COX-2 gene promoter carries both NFκB and 
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AP-1 binding sites [438], neither the pattern of NFκB nor AP-1 activation reflected that of 
COX-2 throughout gestation. The relatively short half-life of COX-2 RNA (<3.5 hours) may 
account for the observed pattern of COX-2 protein expression [149]. 
We also showed that early gestation is characterised by high expression of CREB (Fig. 3.4 A, 
B), which consistently decreased with the onset of myometrial contractions. These results are 
in agreement with previously published data reporting down-regulation of CREB in human 
myometrium collected during labour, compared to samples collected from women at term but 
not in active labour which suggests a role for this transcription factor in regulating genes 
important for maintenance of myometrial quiescence [194]. However, Western blotting 
results were not consistent with immunofluorescence analysis of p-CREB localisation (Fig. 
3.5) where a sustained expression of p-CREB was detected throughout gestation. Of note, the 
same antibody (Phospho-CREB Ser133, rabbit mAb #9198, Cell Signaling) was used for 
immunofluorescence experiments and Western blotting. Due to high structural similarity, this 
antibody is able to recognise p-ATF1, as highlighted in the product datasheet and as showed 
in our Western Blotting experiments (Fig. 3.4). While we were able to discriminate these two 
targets in western blotting due to their different molecular weights, such discrimination was 
not possible in the immunofluorescence experiments, where the immunoreactive protein 
detected may represent both pCREB and p-ATF1. 
In summary, the data described in this chapter show that key inflammatory transcription 
factors exhibit differential activation patterns in the uterus across gestation. CREB activation 
most likely occurs in the early stages of gestation whereas term parturition is characterised by 
the sequential activation of NFκB and JNK/AP-1 prior to and during labour onset. The 
following two chapters describe experiments undertaken to understand the role of these 
factors in murine models of PTL and to test whether their inhibition could represent an 
effective strategy to block PTL. 
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4 Specific Escherichia Coli lipopolysaccharide serotypes differentially 
impact maternal and fetal outcomes 
 
Introduction 
The experiments described in chapter three demonstrated that murine term delivery is 
associated with activation of inflammatory transcription factors immediately prior to and at 
labour onset. Evidence from human patients and animal studies indicate that activation of 
inflammatory pathways in gestational tissues is associated with both normal and pre-term 
birth [451-453]. Intrauterine inflammation is also frequently associated with fetal brain injury 
even in the context of term labour [347], and it has been linked with long-term neurological 
disorders such as cerebral palsy [454, 455]. Furthermore, several studies have reported the 
presence of inflammation, also without overt infection, in most cases of PTB in clinical 
practice [330]. For example, Miralles et al. reported that two out of ten cases of spontaneous 
PTL without bacteria presence in intrauterine compartments is still associated with increased 
concentration of IL-6 and IL-8 in placental tissue, fetal membranes, and cord blood serum 
[456]. Previous work from our group has also shown increased levels of IL-1β and IL-8 in 
myometrium, amnion and chorion decidua in PTL samples in the absence of clinically overt 
signs of infection [457]. More recently, Romero et al. showed a higher prevalence of sterile 
intra-amniotic inflammation compared to microbial-associated intra-amniotic inflammation 
[330]. Transcriptomics studies of amnion tissue collected from women without histological 
chorioamnionitis has also reported increased inflammatory gene expression following onset 
of spontaneous labour [402]. 
Previous studies performed by our group and others have shown that the inflammatory 
transcription factor NFkB modulates many pro-inflammatory cytokines including IL-1β [213] 
and TNF-α [458]. NFkB is also readily stimulated by such inflammatory cytokines as well as 
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other inflammatory stimuli such as LPS [224, 459]. Activation of NFkB can thus precipitate a 
positive feed-forward loop resulting in further increase in expression of inflammatory 
cytokines and further NFkB activation. NFkB also plays a crucial role in the regulation of 
various pro-labour genes such as the prostaglandin synthase enzyme COX-2 [74], an 
inducible enzyme with a pivotal role in prostaglandins synthesis that promotes cervical 
ripening and dilatation and stimulate myometrial contractions as labour approaches [215, 
460]. Other inflammatory transcription factors such as AP-1 and C/EBPβ have also been 
shown to play a role in regulating many of the same inflammatory pathways stimulated by 
NFkB. Site-directed mutagenesis performed to target the promoters of specific genes such as 
IL-8 revealed that its expression in human myometrial cells is strongly affected by disruption 
of the NFkB and AP-1 sites, but not C/EBPβ [232]. Our group has also previously 
demonstrated that in vitro stretch of primary human uterine myocytes results in AP-1-
dependend increase of COX-2 activity and prostaglandins synthesis [108]. 
Infection/inflammation-induced PTL and associated fetal brain injury are often simulated in 
animal models through the administration of the gram-negative bacterial cell wall component 
LPS. This can be administered systemically to recapitulate systemic bacterial infection during 
pregnancy, or locally via an intra-uterine injection to mimic ascending vaginal infection 
and/or chorioamnionitis [311, 342, 344, 347, 349, 369, 461-463]. Binding of LPS by toll-like 
receptors (TLRs) expressed within the gestational tissues [344, 369] and maternal blood 
monocytes [175] trigger production of proinflammatory cytokines and release of 
prostaglandins, cytokines and chemokines promoting cervical ripening, uterine activation and 
contractility [464, 465]. Although the inflammatory response to LPS appears to be 
consistently achieved in mouse models of PTB, inconsistencies between studies in terms of 
maternal and neonatal responses to LPS are frequently reported. Only a small proportion of 
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this variation appears to be attributed to variations in experimental designs (e.g. LPS dose, 
gestation age at time of injection, animal species or strain, site of administration). 
The LPS molecule is composed of three structural domains: the lipid A, a complex glycolipid 
comprised of a phosphorylated glucosamine disaccharide with multiple fatty acids chains that 
is generally conserved among gram-negative bacteria; the core oligosaccharide which 
connects lipid A to the third domain, and the O-antigen, the hydrophilic portion of the LPS 
molecule. The sugar composition of the polysaccharide chain of the O-antigen chain 
determines the serological specificity of the molecule whilst the lipid A group typically 
confers toxicity [466]. 
Previous studies conducted in rat models of hypothermia and albumin extravasation have 
reported functional differences caused by LPS serotype specificity [467, 468]. Treatment of 
fever with the selective COX-2 inhibitor, 4-[5-(4-chlorophenyl)-3-(trifloromethyl)-1H-
pyrazol-l-yl]benzenesulfonamide (named SC-58236), is effective in the initial phases for 
treating animals administered with E. coli O55:B5 LPS, but not those administered with E. 
coli O111:B4 LPS [469, 470]. Furthermore, different E. coli LPS serotypes are associated 
with distinct clinical syndromes of enteric/diarrheal disease [471, 472]. Collectively these 
data indicate serotype-specific activation of inflammatory pathways that corresponds to 
variable phenotypic responses. In the context of animal models of inflammation-induced 
PTL, this could imply differential activation of inflammatory pathways preceding labour thus 
potentially leading to the variance observed in maternal and neonatal outcomes.  
Taken together these observations led us to hypothesise that different LPS serotypes may 
induce differential activation of inflammatory pathways thus resulting in specific maternal 
and neonatal innate immune responses and outcome. This chapter reports experiments aimed 
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to explore the nature of the inflammatory response triggered by the most widely used E. coli-
derived LPS serotypes in mouse models of PTB. 
 
Results 
 
4.1 Intra-uterine injection of four E. coli LPS serotypes exerts differential effects on 
the time of delivery and pup survival rate in a murine model of preterm labour 
Pregnant mice received an upper-intrauterine injection of 20 μg of E. coli-derived LPS 
serotype O111:B4, O55:B5, O127:B8 or O128:B12 on E16. Treated mice were left to deliver 
spontaneously and the time of labour was determined. Control mice receiving vehicle control 
(PBS) delivered at term approximately 60 ± 15 hours post-injection (p.i.), whereas those 
administered LPS O111:B4 delivered 7 ± 2 hours p.i., O55:B5 delivered 10 ± 3 hours p.i., 
O127:B8 delivered 16 ± 10 hours p.i. and O128:B12 delivered 17 ± 2 hours p.i. (data are 
shown as means ± SD, Fig. 4.1 A). 
 
Figure 4.1 Specific E. coli LPS serotypes induce different maternal responses and neonatal 
outcomes in a murine model of preterm labour. (A) Mean time of delivery of control pregnant 
mice receiving at E16 an upper intra-uterine injection of PBS or treated mice injected with 20 µg of 
either LPS O111:B4, O55:B5, O127:B8 or O128:B12. p.i.: post-injection. (B) Pup viability rates at 6 
hours p.i. 
***
P<0.001 indicate significant differences compared to PBS-injected control mice, 
§
P<0.05 
indicate significant differences between LPS treatment groups; One-way ANOVA with Tukey’s post-
hoc test, n=5. 
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While all LPS serotypes were able to induce PTL (defined as delivery before 36 hours p.i.), 
LPS O111:B4 exhibited the most robust and reproducible induction of PTL. The 
administration of different LPS serotypes had profoundly different effects on neonatal 
outcome (Fig. 4.1 B). Animals were alternatively sacrificed 6 h post injection to assess the 
rate of fetal demise following treatment with different LPS serotypes or vehicle control 
(PBS). Pup survival rate at 6 h post injection was 100% for PBS and O128:B12 treated mice 
with pups found to be alert, responsible to mechanical stimulus and displaying respiratory 
effort. In contrast, 100% pup mortality was observed in mice treated with LPS O111:B4. Pup 
survival rates for O55:B5 and O127:B8 serotypes were 80% and 95% respectively. Although 
alive, pups isolated from O55:B5 injected animals were less physically active than O127:B8 
and O128:B12 treated animals and displayed reduced response to mechanical stimuli. 
 
4.2 Effects of LPS serotypes on inflammatory and contraction-associated mediators 
in mouse myometrium 
 
4.2.1 Myometrial AP-1 activation, but not NFκB or C/EBPβ activation, is strongly 
induced by LPS serotype O111:B4 
To investigate the molecular mechanisms responsible for the observed differential maternal 
responses to distinct LPS serotypes, we first used Western blotting to examine activation 
status of the key inflammatory transcription factors (NFκB, AP-1 and C/EBPβ) in 
myometrium samples collected from treated and control animals 6 h after injection, prior to 
delivery (Fig. 4.2 A). Administration of LPS O111:B4 led to a 3.4-fold increase in 
phosphorylation levels of AP-1 subunit p-c-Jun, compared with PBS control (means ± SD, 
7.9 ± 6.2 au and 2.3 ± 1.6 au, respectively; P < 0.05) (Fig. 4.2 A, B). P-c-Jun levels were also 
5.3-fold higher than levels achieved by LPS O127:B8 (1.5 ± 2.5 au, P<0.05) and 26-fold 
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higher than LPS O128:B12 (0.3 ± 0.1 au, P<0.05). No difference in AP-1 activation was 
detected in animals injected with either O55:B5 (3.0 ±3.0 au), O127:B8 or O128:B12 
compared to control mice (2.3 ±1.6 au). 
 
Figure 4.2 LPS O111:B4 induces AP-1 activation in the myometrium prior to the onset of 
preterm labour. Protein lysates prepared from myometrium samples collected 6 hours following 
intra-uterine injection of either PBS or LPS (serotypes O111:B4, O55:B5, O127:B8 or O128:B12) 
were analysed by Western blotting for the phosphorylated forms of AP-1 subunit p-c-jun (A, B), 
NFκB subunit p-p65 (A, C), and C/EBPβ isoforms, liver-enriched activating protein LAP and liver-
enriched inhibitory protein LIP (A, D). A pool of all samples was prepared and used as calibrator 
(CAL) to account for inter-gel variability.
 *
P<0.05 indicate significant differences compared to PBS-
injected control mice, 
§
P<0.05 indicate significant differences between LPS treatment groups. One-
way ANOVA with Tukey’s post-hoc analysis, n=5. Error bars indicate standard deviation. au: 
arbitrary units. (E) Linear regression analysis of p-c-Jun levels versus time to labour. 
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Levels of activated NFκB in control and treated animals remained largely unchanged (Fig. 
4.2 A, C). While levels of C/EBPβ activation between PBS control and LPS treated animals 
also remained unchanged, significantly less phosphorylation of both the transcriptionally 
active C/EBP-β isoform, liver-enriched activator protein (LAP), and the functional LAP 
antagonist, liver-enriched inhibitory protein (LIP), was observed in the myometrium of mice 
who received intrauterine injection of LPS serotypes O127:B8 (LAP: 0.8 ±0.5 au, LIP: 0.7 
±0.3 au) and O128:B12 (LAP: 0.6 ±0.1 au, LIP: 0.5 ±0.1 au respectively) compared to 
O111:B4 treated animals (LAP: 1.7 ±0.7 au, LIP: 1.9±1.0 au), (Fig. 4.2 A, D). Linear 
regression analysis showed a moderate correlation (r
2
=0.37, P<0.001) between p-c-Jun levels 
and time of delivery, indicating that higher levels of p-c-Jun are associated with rapid labour 
onset (Fig. 4.2 A, E). 
 
4.2.2 LPS serotypes induce variable expression of proinflammatory and pro-
contraction genes in mouse myometrium 
To investigate the LPS serotype-specific effects on the premature activation of uterine 
contractions, real-time PCR was used to analyse mRNA expression of pro-inflammatory and 
pro-contractile genes 6 hours after intrauterine injection of vehicle control (PBS) or different 
LPS serotypes. Compared to PBS control, an increase in mRNA levels of the labour-
associated genes encoding the prostaglandin synthase enzyme, Cox-2, was observed 
following LPS O111:B4 (21.1-fold change, P<0.001), O55:B5 (15.5-fold change, P<0.001), 
O127:B8 (20.1-fold change, P<0.001) and O128:B12 (6.8-fold change, P<0.01) injection 
(Fig. 4.3 A). Levels of Cox-2 mRNA were also found to be 3.1-fold higher in LPS O111:B4 
treated animals compared to O128:B12 (P<0.05). Cx-43 mRNA levels were increased 2-fold 
following injection of O127:B8 (P<0.01) compared to control animals while levels in LPS 
O55:B5 and O128:B12 remained similar to PBS-injected control mice (Fig. 4.3 B). Injection 
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of LPS O111:B4 induced a 1.7-fold increase in Cx-43 mRNA expression. Increased Tnf-α 
mRNA levels were also detected following treatment with all LPS serotypes with the highest 
response induced by LPS O111:B4 (11.3-fold change, P<0.001) compared to control (Fig. 
4.3 C).  
 
Figure 4.3 Different serotypes of LPS induce variable expression of proinflammatory and 
procontractile genes in mouse myometrium. Pregnant mice were sacrificed at E16, 6 hours 
following intrauterine injection of either PBS control or LPS (serotypes O111:B4, O55:B5, O127:B8 
or O128:B12) and tissue collected for RT-PCR analysis of procontractile and inflammatory genes 
associated with labour onset including Cox-2 mRNA (A), Cx-43 mRNA (B), Tnf-α mRNA (C), Il-1β 
mRNA (D), Il-6 mRNA (E), Il-8 mRNA (F), Mmp3 mRNA (G), Mmp10 mRNA (H) and inducible 
nitric oxide synthase, iNOS mRNA (I). Gene expression levels were normalised to β-actin mRNA 
levels and expressed relatively to PBS control. 
*
P<0.05, 
**
P<0.01,
 ***
P<0.001 indicate significant 
differences compared to PBS-injected control mice; 
§
P<0.05,
 §§
P<0.01 indicate significant differences 
between LPS treatment groups. One-way ANOVA with Tukey’s post-hoc analysis. Error bars indicate 
standard deviation, n=5 
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A similar pattern of Il-1β mRNA induction was observed in response to LPS treatments 
however results were not statistically significant due to high variability in responses (Fig. 4.3 
D). LPS serotype-specific activation of Il-6 mRNA was observed with LPS O111:B4 with a 
52-fold increase (P<0.001) detected compared to PBS control animals while O55:B5, 
O127:B8 and O128:B12 induced a 14- (P<0.01), 31- (P<0.001), and 12-fold (P<0.01) 
increase compared to control levels respectively (Fig. 4.3 E). Levels of Cxcl2 mRNA, the 
functional murine homologue of the human IL-8 gene (referred to as IL-8 herein) were 
consistently increased between 13- and 26-fold (P<0.001) following all LPS serotype 
treatments compared to PBS control mice (Fig. 4.3 F). mRNA levels of the extracellular 
matrix degradation (ECM) enzymes, metalloproteinases Mmp3 and Mmp10, were also 
increased but to differing levels depending on the LPS serotype injected. While all serotypes 
promoted Mmp3 mRNA expression, LPS O111:B4 (6.6-fold increase; P<0.001) and 
O127:B8 (8.6-fold change; P<0.001) led to significantly higher induction than O55:B5 (2.9-
fold) or O128:B12 (3.4-fold) (Fig. 4.3 G). Similarly, Mmp10 mRNA expression levels were 
significantly higher 6h post-injection with LPS O111:B4 (5.2-fold change; P<0.05) and 
O127:B8 (3.7-fold change; P<0.05) yet no change in Mmp10 mRNA levels was detected 
between control and O55:B5 or O128:B12 treatments (Fig. 4.3 H). mRNA levels of inducible 
nitric oxide synthase (iNOS mRNA) were consistently increased following treatment with 
LPS O111:B4 (38.2-fold change, P<0.001), O55:B5 (21.5-fold change, P<0.001), O127:B8 
(29.8-fold change; P<0.001) and O128:B12 (31.8-fold change; P<0.001) (Fig. 4.3 I). 
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4.2.3 Characterisation of IL-1β, COX-2 and CX-43 protein levels following treatment 
with different serotypes 
 
Myometrium protein lysates from tissues collected 6h post-intrauterine injection of PBS 
control or LPS serotypes O111:B4, O55:B5, O127:B8 or O128:B12 were analysed for the 
inflammatory interleukin IL-1β and the uterine activation proteins COX-2 and CX-43 (Fig. 
4.4 A). 
 
Figure 4.4 LPS serotypes differentially affect levels of pro-labour proteins in mouse 
myometrium. Protein lysates prepared from myometrium samples collected 6 hours post intra-uterine 
injection of either PBS or LPS (serotypes O111:B4, O55:B5, O127:B8 or O128:B12) were analysed 
by Western blotting for IL-1β (A-C), COX-2 (A, D) and CX-43 (A, E). A pool of all samples was 
prepared and used as calibrator (CAL) to account for inter-gel variability. 
***
P<0.001 indicate 
significant differences compared to PBS-injected control mice, 
§
P<0.05 indicate significant 
differences between LPS treatment groups. One-way ANOVA with Tukey’s post-hoc analysis, n=5. 
Error bars indicate standard deviation. 
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Densitometric analysis of immune-reactive protein bands showed that levels of the IL-1β 
precursor, pro-IL-1β (relative molecular mass, Mr = 31,000), were significantly induced by 
LPS O111:B4 compared to PBS control animals (2.0 ± 0.9 and 0.2 ± 0.1 au respectively, 
P<0.001, Fig. 4.4 A, B). Furthermore, LPS O111:B4 significantly increased the expression of 
pro-IL-1β compared to O55:B5 (0.8 ± 0.3 au, P<0.05), O127:B8 (1.0 ± 0.2 au, P<0.05) and 
O128:B12 (0.9 ± 0.4 au, P<0.05). Increased processing of the pro-IL-1β into the cleavage 
product IL-1β (Mr = 28,000) compared to PBS (0.1 ± 0 au) was observed following LPS 
O127:B8 (2.1 ±0.7 au, P<0.01) and O128:B12 (1.7 ± 1.0 au, P<0.05) treatments (Fig. 4.4 A, 
C). COX-2 protein levels were unchanged after treatment with LPS O111:B4 and O55:B5 
compared to control (1.1 ± 0.3 au), but diminished levels were detected in the myometrium of 
those animals administered O127:B8 (0.7 ±0.1 au) compared to O111:B4 (1.3 ± 0.3 au, 
P<0.05) or O128:B12 (0.8 ±0.1 au) compared to O55:B5 (1.2 ±0.4 au, P<0.05, Fig. 4.4 A, 
D). Levels of total CX-43 remained similarly unchanged in all treatment groups (Fig. 4.4 A, 
E). 
 
4.3 Effect of LPS serotypes on neonatal brain inflammation 
4.3.1 Characterisation of AP-1 and NFκB activation in neonatal brain in response to 
upper-uterine injection of different E. coli LPS serotypes 
To investigate the mechanism behind the LPS-induced fetal death observed with specific LPS 
serotype treatments, activation patterns of the pro-inflammatory transcription factors AP-1, 
NFκB and CEBP/β were assessed. Pup brains collected from pregnant mice 6 hours p.i. with 
PBS control or specific LPS serotypes were analysed by Western Blotting to assess 
phosphorylation status of the AP-1 subunit p-c-jun, the NFκB subunit p-p65, as well as the 
LIP and LAP isoforms of CEBP/β (Fig. 4.5 A). No change in the levels of phosphorylated 
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AP-1 or NFκB was identified in pup brain following LPS administration (Fig. 4.5 A-C). The 
CEBP/β isoforms LIP and LAP were not detected in pup brain protein lysates. 
 
Figure 4.5 Levels of activated AP-1 and NFκB remain unchanged in fetal brain following intra-
uterine injection of different LPS serotypes. Whole fetal brain tissue samples were collected at 
E16, 6 hours post intrauterine injection of either PBS or LPS (serotypes O111:B4, O55:B5, O127:B8 
or O128:B12). Western Blotting was used to examine levels of activated AP-1 p-c-Jun (A, B) and 
NFκB p-p65 (A, C). Densitometry of immune-reactive protein bands was performed and levels were 
normalised to β-actin. CAL, calibrator. + Ctrl: myometrium sample collected from mice injected with 
LPS O111:B4. One-way ANOVA with Tukey’s post-hoc analysis, n=5. Error bars indicate standard 
deviation. 
 
4.3.2 Gene expression patterns of inflammatory mediators and neuronal damage in 
fetal brain 
Activation of inflammatory pathways in the fetal brain is the primary cause of neonatal brain 
injury in the context of PTL [473]. Real time PCR was used to explore gene expression 
pattern of inflammatory cytokines (Il-6, Il-8, Il-1β and Tnf-α mRNA) whose exacerbated 
expression in neonatal brain during the gestational period has been implicated in the 
development of fetal inflammatory response syndrome and increased risk of 
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neurodevelopmental disorders after birth [474]. Additionally, neuronal markers for brain 
damage including glial fibrillary acidic protein (Gfap mRNA) and myelin proteolipid protein 
(Plp mRNA) as well as inducible NO synthase (iNOS mRNA) were assessed. RNA integrity 
was confirmed using BioAnalyzer (Fig. 4.6). 
 
Figure 4.6 BioAnalyzer analysis of RNA integrity. BioAnalyzer traces of pup brain (sample 1-10) 
and myometrium (sample 11-12) RNA samples. 
 
LPS O111:B4 treatment caused a significant increase in Il-8 mRNA expression in the 
neonatal brain compared to control (6.6-fold change, P<0.01) and this increase was also 
significantly higher compared to O128:B12 treatment (4.1-fold change, P<0.01), (Fig. 4.7 A). 
No significant changes were detected in the levels of Il-6, Il-1β and Tnf-α mRNA after LPS 
treatment (Fig. 4.7 B-D).Maternal LPS administration did not alter expression of any of the 
assessed brain damage markers including Gfap, Plp, iNos mRNA (Fig. 4.7 E-G). A 
significant decrease in Nos3 mRNA levels was observed in pup brains collected from mice 
treated with LPS O127:B8 (Fig. 4.7 H) compared to PBS control. 
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Figure 4.7 Real time PCR analysis of inflammatory gene expression in the fetal brain tissue 
following maternal administration of LPS. Expression levels of the inflammatory genes Il-8 mRNA 
(A), Il-6 mRNA (B), Il-1-β mRNA (C), Tnf-α mRNA (D), and neutropic factors including glial 
fibrillary acidic protein (Gfap mRNA, E), proteolipid protein (Plp mRNA, F), inducible nitric oxide 
synthase (iNOS mRNA, G) and endothelial Nos (Nos3 mRNA, H) were assessed by real time PCR in 
fetal brain tissue harvested 6 hours post-surgery from pregnant mice injected with either PBS or LPS 
(serotypes O111:B4, O55:B5, O127:B8 or O128:B12). Target gene expression levels were normalised 
to β-actin mRNA levels and expressed relatively to PBS control. **P<0.01, *P<0.05; One-way 
ANOVA with Tukey’s post-hoc test, n=5. Error bars indicate standard deviation. 
 
Similar results were observed in samples collected from pups isolated 4 hours following LPS 
O111:B4 intrauterine injection, where only IL-1β was significantly increased compared to 
PBS (3-fold change, P<0.05), prior to any fetal demise (Fig. 4.8). Efforts were made to assess 
protein levels of both full length and cleaved IL-1β in pup-brain protein extracts however 
immune-reactive protein was not detected (Fig. 4.9). 
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Figure 4.8 LPS O111-induced upregulation of proinflammatory genes in the fetal brains occurs 
prior to the onset of labour. Inflammatory gene expression was assessed by real time PCR in fetal 
brain tissue harvested 4 and 6 hours post-surgery from pregnant mice injected with either PBS or LPS 
(serotypes O111:B4, O55:B5, O127:B8 or O128:B12). Tnf-α mRNA (A), Il-6 mRNA (B), Il-1β 
mRNA (C), glial fibrillary acidic protein Gfap mRNA (D), proteolipid protein Plp mRNA (E) and 
inducible nitric oxide synthase iNOS mRNA (F). Fold changes relative to PBS control are normalised 
to β-actin mRNA levels. Two-tailed Student’s t-test control versus treatment, n=5. *P<0.05. Error bars 
indicate standard deviation. 
 
 
 
Figure 4.9 Western blotting of IL-1β in pub brain extracts isolated 6 h following intra-uterine 
injection of PBS or LPS. Whole fetal brain tissue samples were collected at E16, 6 hours post 
intrauterine injection of either PBS or LPS (serotypes O111:B4, O55:B5, O127:B8 or O128:B12). 
Western Blotting was used to examine levels of IL-1β. β-actin was used as loading control. Neither 
full length nor cleaved IL-1β expression was detected in pup brain samples. Myometrial protein 
extract was included as positive control (+ CTRL). 
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Summary and discussion 
The experiments described in this chapter were designed to investigate the effects of 
intrauterine injection into pregnant mice of four different E. coli LPS serotypes (O111:B4, 
O55:B5, O127:B8 and O128:B12) upon time of delivery and fetal outcome. Intrauterine 
injection was selected as route of administration as it best mimics the most frequently 
observed clinical scenario of localised infection/inflammation in the decidua/myometrial 
compartment caused from ascending bacterial infection [475, 476]. E. coli-derived LPS was 
specifically chosen since it is the most frequently used agent for studying intrauterine 
inflammatory responses in animal models of PTB [343, 344]. Of note, E. coli infection in the 
clinical setting of PTB is relatively less frequent than other infections such as those caused by 
Ureaplasma spp. [477]. Nevertheless, colonisation of the maternal vaginal flora and the 
urinary tract by E. coli is associated with increased rate of PTL and poor pregnancy outcomes 
[478, 479]. Furthermore, E. coli is the most commonly isolated bacteria in women 
undergoing preterm delivery and exhibiting asymptomatic bacteriuria (defined as more than 
100,000 colonies of a single bacterial species per mL of urine, cultured from midstream 
sample) [480] and the bacteria most frequently isolated from neonates who develop sepsis or 
meningitis post-partum [481]. 
While all E. coli serotypes tested in this study led to PTL, latency between time of injection 
and onset of labour varied markedly between serotypes (Fig. 4.1 A). This suggests that subtle 
changes in the sugar composition of the O-antigen may differentially activate molecular 
pathways that precede myometrial activation, culminating in different timing of labour onset. 
Recognition of LPS derived from Gram-negative bacteria such as E. coli is achieved 
primarily through interaction with TLR-4, which is expressed in the myometrium and other 
gestational tissues [171, 369]. Bӓckhed and colleagues have previously shown an association 
between differences in LPS structure and its endotoxic properties suggesting that the 
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polysaccharide O-antigen element may interfere with lipid A recognition by the TLR4 
receptor complex [482]. Structural variances in the O-antigen may thus change the interaction 
between LPS molecules and the TLR4 receptor complex, resulting in differential activation 
of downstream inflammatory pathways. Evidence for this includes the acquisition of bacterial 
immune evasion properties through modulation of O-antigen composition that alters 
macrophage recognition and phagocytosis of LPS molecules [483, 484]. 
Salminen et al. have previously reported similar rates of infection/inflammation induced PTB 
in mice where LPS O111:B4 was administered intraperitoneally (25 μg/mouse) on either E16 
or E17 [349]. However in this model pup survival rates were reduced from 58% at E17 to 
39% at E16, suggesting a correlation between gestational age and survival rate and that 
survival was in part dependent upon the degree of prematurity. In our study pup survival rates 
were consistently assessed on E16, precisely 6 hours post-LPS administration, and showed 
that despite sharing the same gestational age, offspring were differentially susceptible to 
intrauterine fetal death depending on the serotypes used to induce PTL. These data indicate 
that fetal death is influenced by the LPS serotype used, which should be considered when 
designing studies aimed to investigate fetal outcome in the context of infection/inflammation-
induced PTL. 
Consistent with the serotype-dependent heterogeneity seen in the labouring phenotype, we 
identified differences in activation of inflammatory transcription factors between LPS-
serotype treatments as well as differential activation of downstream targets, including both 
inflammatory and uterine activation genes and proteins. For example, LPS O111:B4 
treatment led to the stronger response in terms of AP-1 activation (Fig. 4.2) and 
consequently, robust induction of Tnf-α, Il-6, Il-8 and Mmp10 mRNA expression (Fig. 4.3). 
Although substantially less AP-1 activation was observed in the myometrium collected after 
LPS O127:B8 treatment, high increase in mRNA levels of Tnf-α, Il-6, Il-8 and Mmp10 as 
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well as Cx-43 and Mmp3 were detected 6 hours following injection. These results indicate 
differences in transcriptional regulation of inflammatory pathway activation induced by the 
different LPS serotypes. These differences appear to influence downstream expression of 
proteins involved in contractility and inflammation (Fig. 4.4). For example, although 
comparable levels of Il-1β mRNA were observed between LPS treatments, significant 
variation in the levels of pro-IL-1β and cleaved IL-1β was identified. Western blotting 
revealed that protein expression levels of the cytokine IL-1β were significantly increased by 
LPS O111:B4 treatment. IL-1β is synthetised as a precursor of 31 KDa that is cleaved upon 
activation of the inflammasome complex [485]. The inflammasome activation produces a 28 
KDa intermediate product that is retained in the cells longer than the mature form. Its 
detection can be used as an indication of the production and secretion of the mature IL-1β 
peptide (17 KDa) [486]. Inflammation in the fetal brain and secretion of inflammatory 
cytokines such as IL-1β and TNF-α are two events linked with adverse neonatal outcome in 
premature neonates [487]. Using a similar murine model where PTL was achieved via 
intrauterine injection of LPS, Elovitz and colleagues previously showed activation of 
TH1/TH2 cytokines and inflammatory markers in the fetal pup brain 6h after injection of a 
high dose of 250 μg LPS O55:B5 [311]. Another study demonstrated that using a “low dose” 
of 50 μg LPS O55:B5 was enough to induce a modest increase of inflammatory mRNA 
markers expression in the pup brain 7 days after delivery [347]. The relatively low dose of 
LPS used in our study (20 μg) may partly account for the lack of differences in levels of 
phosphorylated NFκB and AP-1 in pup brain extracts at 6 hours following injection of  LPS 
O111:B4 and in the increase in one (Il-8 mRNA) of eight inflammatory and brain injury 
markers tested (Fig. 4.5). Possibly the activation of inflammatory transcription factors in the 
pup brain occurs prior to the 6 hours sampling time point examined. Since mice injected with 
LPS O111:B4 deliver around 7 hours post-injection, this might not be enough time to develop 
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an inflammatory response detectable in pup brains. Conversely, it is possible that pup brain 
inflammation may be detectable in animals treated with LPS O55:B5, O127:B8 or O128:B12 
at later stages following injection. Regardless, the drastically different rates of fetal loss 
between LPS-serotypes need to be taken into consideration, especially in those studies where 
LPS is used in in vivo models of neonatal brain damage. Other authors have proposed that 
intra-uterine fetal death in response to LPS treatment may be mediated by maternal factors 
that influence susceptibility to LPS and efficiency of LPS passage through the placenta to the 
fetus [488]. Inflammatory mediators of maternal origin may reach the fetus and elicit Fas-
mediated apoptosis of placental cells [489]. This mechanism may be responsible for the 
increased Il-8 mRNA levels observed in the pup brain and may explain the difference in 
neonatal outcomes observed in our study in the absence of any inflammatory transcription 
activation (Fig. 4.6 and 4.7). These findings, that E.coli-derived LPS serotypes elicit specific 
activation of TLR4-mediated inflammatory activation in the pregnant host and neonate, may 
be of important clinical relevance. Bacterial serotypes represent different variations within 
species that are classified primarily due to surface antigen properties. Sub-species 
classification of bacteria on the basis of their serotype has long been recognised as an 
important factor in terms of clinical outcome. For example, Group B streptococci (GBS) are 
known to cause serious bacterial infections in newborns [490, 491]. Differences in GBS 
virulence are associated with production of serotype-specific capsular polysaccharide, which 
inhibits deposition of host complement factor C3b and subsequent opsonophagocytosis [492], 
thus facilitating the evasion of the host immune response. Similarly, pneumococcal isolates of 
serotypes 1 and 5 are associated with invasive disease whereas serotypes 6B and 23F are 
associated with carriage [493, 494]. 
In summary, there are major differential effects induced by the four E. coli serotypes most 
commonly used in murine models of PTB, in terms of time of delivery and fetal outcome 
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[495]. Specific LPS serotypes induce differential activation of inflammatory transcription 
factors and mediators in both the myometrium and neonatal pup brain. These data not only 
provide important information explaining the reported variability in murine models of 
infection/inflammation-induced PTL developed by different research groups, but furthermore 
suggest that the use of selective LPS serotypes may constitute a useful tool to target specific 
inflammatory response and investigating molecular mechanisms underlying different mouse 
models of PTB and associated neonatal brain damage. 
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5 The effects of LPS on myometrial activation in a murine model of 
inflammation-induced preterm labour 
 
Introduction 
As shown in the previous chapter, injecting pregnant mice with E. coli-derived LPS serotype 
O111:B4 consistently induces PTL within 7 hours following treatment and it provides a 
robust model of PTL associated with the highest rate of pup mortality. This severe and 
consistent model was selected to mimic a phenotype of inflammation-induced-PTL and 
complete fetal demise for further exploration of the relative contribution of inflammatory 
activation in the uterus to the PTL phenotype. As previously described, NFκB regulates 
various labour associated genes including the proinflammatory cytokines IL-6 [210] and IL-
1β [211, 212] as well as pro-contractile genes such as the prostaglandin synthase enzyme 
COX-2 [213, 214], prostaglandin F2α receptor [215] and oxytocin receptor (OTR) [217]. In 
turn, these downstream mediators drive labour onset by promoting cervical ripening and fetal 
membrane remodelling as well as through stimulation of uterine contractions. NFκB 
activation in the human and mouse myometrium [187, 208] and the fetal membranes [209] 
occurs prior to labour onset. While NFκB has been widely implicated in the inflammatory 
activation of labour, AP-1 is also able to regulate many inflammatory and pro-labour genes 
and thus may also play and important role in labour onset. Both NFκB and AP-1 promote IL-
1β-induced expression of COX-2 in WISH amnion cells [438]. Stretch of human amnion 
induces expression of COX-2 as well as AP-1 activation [248]. In vitro myometrial stretch is 
also able to induce COX-2, OTR and interleukin-8 (IL-8) expression that is associated with 
AP-1 activation [108, 246, 247]. Gene encoding for the gap junction CX-43 also contains 
AP-1 binding sites in the promoter region that are conserved in mouse, rat and humans [496]. 
Different research groups have shown AP-1-dependent expression of CX-43 in myometrial 
cells thus demonstrating a role for AP-1 in promoting myometrial cells coupling at term [95, 
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440, 497]. Previous data from our group have showed that intrauterine injection of a TLR-4-
specific lipopolysaccharide (Salmonella abortus LPS, 581-009-L002) induced PTL in the 
mouse that was associated with activation of both NFκB and AP-1 in the myometrium [186]. 
Condon et al. previously reported that intra-amniotic injection of the NFκB inhibitor peptide 
SN50 [498] delays surfactant protein A-induced PTL [187]. 
In this chapter are described experiments set out to characterise the uterine inflammatory 
response activated by LPS serotype O111:B4, and to test whether inhibition of selected 
inflammatory transcription factors may be able to delay the onset of PTL. 
 
Results 
 
5.1 Induction of preterm labour by LPS (E. coli O111:B4) is characterised by 
myometrial AP-1 activation and nuclear translocation, but not NFκB activation 
We used an in vivo model of infection-induced PTL in which pregnant CD-1 mice received 
an intrauterine injection of 20 μg of LPS serotype O111:B4 on gestational day 16 (E16) or 
PBS control and were allowed to go into labour spontaneously under CCTV monitoring. This 
dose led to PTL 7 h ± 2 h post-injection of LPS (mean ± SD) while vehicle controls delivered 
at term (60 h  ± 1 h post injection; Fig. 5.1 A). 
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Figure 5.1 Induction of preterm labour by LPS (Escherichia coli O111:B4) involves AP-1 
activation, but not NFκB activation. (A) Administration of an intra-uterine (i.u.) injection of 20 µg 
of LPS (n=6) on gestation day 16 (E16) induced preterm labour (PTL) 7 h post-injection (p.i) while 
PBS control mice (n=6) delivered at term, 60 h p.i. (B) Myometrium samples collected at 1, 2, 4, 6 h 
following i.u. injection of PBS/LPS or during LPS-induced PTL (LABLPS) were analysed by Western 
blotting for the activated monomers of NFκB and AP-1. Densitometry analysis was performed on 
immune-reactive bands of (C) p-p65, (D) p-c-Jun and (E) p-c-Fos. (F) p-c-Jun levels were examined 
in both the left (L) and right (R) horn of the uterus 1 h p.i. with either PBS or LPS. β-actin was used 
as loading control. A pool containing an aliquot from all samples was used as calibrator (CAL) to 
account for inter-gel variability. (G) Levels of p-c-Jun were significantly increased in both horns in 
response to LPS. Asterisks denote statistical significance between treatments at each time point as 
assessed by two-way ANOVA with Bonferroni post-hoc test. (
*
P<0.05,
 ***
P<0.001). Letters on bars 
represent statistical significance (P<0.05) as assessed by Student’s t-test. For all conditions with the 
same letter, the difference between the means is not statistically significant. If two conditions have 
different letters, they are significantly different. Error bars indicate standard deviation, n=4 unless 
otherwise stated.  
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Activation of the inflammatory transcription factors NFκB and AP-1 was assessed via 
Western Blotting in myometrium samples collected from the upper right myometrium 
segment (Fig. 5.1 B). While levels of the activated NFκB monomer p-p65 were not affected 
by LPS treatment (Fig. 5.1 B, C), AP-1 monomers, p-c-Jun (Fig. 5.1 B, D) and p-c-Fos (Fig. 
5.1 B, E), were rapidly phosphorylated following LPS administration and remained 
significantly activated in LPS-treated myometrium throughout the time-course until labour 
onset. Activation of AP-1 in response to LPS was comparable in both horns of the uterus, as 
assessed 1 hour post treatment (Fig. 5.1. F, G). 
Immunofluorescence staining of p-c-Jun was then used to investigate the effect of LPS 
treatment on the subcellular localisation of activated AP-1 (Fig. 5.2 A). Myometrium samples 
were analysed at 1, 2, 4, and 6 hours after intra-uterine injection of LPS or PBS control, and 
during LPS-induced PTL (LABLPS). LPS treatment induced an increase in the levels of 
nuclear p-c-Jun (Fig. 5.2 B). P-c-Jun was localised in the nuclei starting from 1 hour after 
treatment with LPS, when the percentage of p-c-Jun positive nuclei was doubled compared to 
PBS control samples (74.86±17.04% vs 35.93±27.11% respectively), although this increase 
was not statistically significant. Similar results were observed 2 hours following LPS 
treatment, when 65.27±10.90% of nuclei were p-c-Jun positive, compared to PBS 
(43.12±29.62%). By 4 hours post LPS injection, p-c-Jun nuclear translocation was 
significantly increased (3-fold) compared to PBS control group (72.40±10.01% vs 
24.15±14.03% respectively, P<0.05) and this increase was maintained 6 hours post-LPS 
injection (70.83±10.20% LPS vs 22.51±29.56% PBS, P<0.05) and during labour (67.23 LPS 
±10.39% PBS). Activated NFκB subunit P-p65 was detected in the nucleus as well as in the 
cytoplasm, similarly to what was observed in the myometrium of mice labouring 
spontaneously at term. No significant increase in the levels of nuclear activated NFκB was 
observed (Fig. 5.3 A, B). 
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Figure 5.2 Intrauterine injection of LPS O111:B4 induces AP-1 nuclear translocation in murine 
myometrial cells. (A) Tissue samples from mouse myometrium were collected at 1, 2, 4, 6 hours 
following intrauterine injection of PBS/LPS or during LPS-induced PTL (LABLPS). Sections (5 μm) 
were analysed by immunofluorescence staining to detect subcellular localisation of p-c-Jun. (-) 
CTRL: primary antibody is omitted. α-SMA: alpha smooth muscle actin marker. Nuclei were 
counterstained with DAPI (blue). Scale bar = 20μM. Images acquired with Inverted Leica SP5 
confocal system, magnification 63x (oil). (B) Quantification analysis representing relative percentages 
of nuclei positively stained for P-c-Jun. Statistical significance was assessed by two-way ANOVA 
with Bonferroni's post-hoc test. (
*
P<0.05), Error bars indicate standard deviation, n=3. Performed in 
collaboration with Ioannis Pavlidis, MSc. 
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Figure 5.3 Intrauterine injection of LPS O111:B4 does not significantly alter subcellular NFκB 
localisation in murine myometrial cells. (A) Tissue samples from mouse myometrium were 
collected at 1, 2, 4, 6 hours following intrauterine injection of PBS/LPS or during LPS-induced PTL 
(LABLPS). Sections (5 μm) were analysed by immunofluorescence staining to detect subcellular 
localisation of activated NFκB (p-p65). (-) CTRL: primary antibody is omitted. α-SMA: alpha smooth 
muscle actin marker. Nuclei were counterstained with DAPI (blue). Scale bar = 20μM. Images 
acquired with Inverted Leica SP5 confocal system, magnification 63x (oil). (B) Quantification 
analysis representing relative percentages of nuclei positively stained for p-p65. Statistical 
significance was assessed by two-way ANOVA with Bonferroni's post-hoc test. Error bars indicate 
standard deviation, n=3. Performed in collaboration with Ioannis Pavlidis, MSc. 
 
 150 
 
5.2 TLR4 modulates LPS (E. coli O111:B4)-induced PTL 
5.2.1 TLR4-KO mice are resistant to LPS-induced preterm labour 
To study the role of TLR4 in E. coli O111:B4 LPS-induced PTL model, TLR4 knock-out 
(KO) mice were generated as described by Hoshino K. et al. [414] by outbreeding KO mice 
onto a CD1 background to allow comparison with the LPS-induced PTL wild type model 
(Fig. 5.4 A). Validation of KO by PCR confirmed successful deletion of the TLR4 gene (Fig. 
5.4 B). Pregnant TLR4-KO mice were shown to be hyporesponsive to LPS challenge and 
delivered at term following intrauterine injection of LPS on E16, 42 hours post injection (Fig. 
5.4 C). In comparison, PBS treated equivalents delivered approximately 65 hours post 
injection. No significant difference was observed between PBS and LPS treated groups. 
 
Figure 5.4 TLR4-KO mice are resistant to LPS-induced preterm labour. (A) Schematic 
representation of the knockout strategy used to generate full-body TLR4-KO mice. TLR4 wild type 
allele was mutated by insertion of a cassette containing the neomycin-resistance gene (NeoR) which 
allowed disruption of TLR4 function and led to LPS hypo-responsiveness. (B) Genotyping of both 
wild type and mutated alleles by PCR performed on myometrium samples collected from TLR4 wild-
type (TLR4-WT) mice, and homozygous TLR4-knockout (TLR4-KO) mice. (C) TLR4-KO mice 
received an intrauterine injection of either PBS (n=6) or LPS serotype O111:B4 (n=14), and time to 
labour was determined. Error bars indicate standard deviation. 
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5.2.2 Effect of LPS E. coli O111:B4 on pup mortality in WT and KO mice 
LPS administration in WT mice led to 100% fetal demise, as assessed 6 hours following 
treatment (Fig. 5.5). In contrast, pup survival at 6 hours post LPS injection was restored to 
100% in TLR4 KO animals. In both WT and KO mice, PBS treatment did not impact pup 
mortality with 100% of pups alive at 6 hours post injection. 
 
Figure 5.5 TLR4-KO mice deliver live pups. The lethal effects on the progeny after intrauterine 
administration of LPS in WT mice are rescued in TLR4-KO mice, as 100% of pups were found alive 
6 hours following LPS injection. 
 
 
5.2.3 LPS (E. coli O111:B4) in TLR4-KO mice induces transient activation of AP-1  
Experiments described previously in paragraph 5.1 were replicated in TLR4-KO mice and 
Western Blotting used to assess expression levels of activated AP-1 (monomers c-Jun and c-
Fos) and NFκB (monomer p65) in the myometrium. As anticipated, absence of TLR4 
impaired activation of both inflammatory transcription factors (Fig. 5.6). Levels of p-c-Jun 
(Fig. 5.6 A, B) and p-c-Fos (Fig. 5.6 A, C) were transiently increased following LPS 
treatment however rapidly returned to control levels at 2 hours following LPS injection. 
Myometrial NFκB activation did not differ between LPS and PBS treatments throughout the 
time course (Fig. 5.6 A, D). 
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Figure 5.6 LPS administration does not induce a sustained activation of AP-1 and NFκB in 
TLR4-KO mice myometrium. (A) Western blot analysis of the active NFκB monomer p-p65 and 
AP-1 subunits p-c-Jun (48KDa) and p-c-Fos (62KDa) in myometrium of TLR4-KO mice. Tissue 
samples were collected 1, 2, 4, 6, 12 and 18 hours following intrauterine injection of either PBS 
control or LPS. β-actin (43KDa) was used as gel loading control. Expression levels of (B) p-c-Jun, 
(C) p-c-Fos and (D) p-p65 relative to β-actin were determined by densitometry. Asterisks represent 
statistical significance between LPS and PBS treated samples. Letters indicate difference within 
treatment group comparisons. For all conditions with the same letter, the difference between the 
means is not statistically significant. If two conditions have different letters, they are significantly 
different. Two-way ANOVA with Bonferroni post-hoc test (
*
P<0.05). Error bars indicate standard 
deviation, n=4.  
 
5.2.4 Nuclear translocation of activated AP-1 is impaired in TLR4-KO mice 
Immunofluorescence was then used to investigate whether the observed transient activation 
of AP-1 seen at 1 hour following LPS injection was accompanied by nuclear translocation. 
While minimal levels of activated AP-1 were observed in the nuclei 1 hour following LPS 
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injection, no nuclear staining was observed at later time points in the myometrium of TLR4-
KO animals injected with either PBS control or LPS (Fig 5.7).  
 
Figure 5.7 Double immunofluorescence staining of activated AP-1 (p-c-Jun) in TLR4-KO 
myometrium following LPS treatment. (A) Myometrium samples from TLR4-KO mice were 
collected at 1, 2, 4, 6 hours following intrauterine injection of PBS/LPS. Sections (5 μm) were 
analysed by immunofluorescence staining to detect subcellular localisation of activated AP-1 (p-c-
Jun). (+) CTRL: myometrium collected from wild type mouse 4 h post-LPS. α-SMA: alpha smooth 
muscle actin marker. Nuclei were counterstained with DAPI (blue). Scale bar = 20μM. Images 
acquired with Inverted Leica SP5 confocal system, magnification 63x (oil), n=3. Performed in 
collaboration with Ioannis Pavlidis, MSc. 
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5.3 LPS (E. coli O111:B4)-induced preterm labour occurs via JNK activation 
5.3.1 Intrauterine injection of LPS induces rapid activation of the MAPK JNK 
To investigate the role of MAPKs potentially responsible for phosphorylation and activation 
of AP-1, levels of the phosphorylated MAPKs JNK, ERK and p-38 were examined using 
Western Blotting (Fig. 5.8 A). Consistent with its role in downstream AP-1 activation, a 3.5-
fold increase was observed in JNK phosphorylation 1 hour post LPS treatment (Fig. 5.8 A, 
B). Both ERK (Fig. 5.8 A, C) and p-38 (Fig. 5.8 A, D) phosphorylation remained consistent 
throughout the assessed time points in both LPS and PBS treated mice. 
 
Figure 5.8 LPS (E. coli O111:B4)-induced p occurs via rapid activation of the MAPK JNK in 
murine myometrium. (A) Myometrium samples collected at 1, 2, 4, 6 hours following intrauterine 
injection of either PBS or LPS or during LPS-induced PTL (LABLPS) were analysed by Western 
blotting. Immuno-reactive bands representing (B) p-JNK, (C) p-ERK or (D) p-p38 were quantified by 
densitometric analysis. GAPDH was used as loading control. A pool containing an aliquot from all 
samples was used as calibrator (CAL) to account for inter-gel variability. Error bars indicate standard 
deviation, n=4. Asterisks indicate statistical significance between treatments at each time point 
(P<0.05). Letters indicate difference within treatment group comparisons. If two conditions have 
different letters, they are significantly different. Two-way ANOVA with Bonferroni post-hoc test 
(
*
P<0.05). 
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5.3.2 Inhibition of JNK activity by systemic administration of SP600125 prior LPS 
treatment delays preterm labour 
Since JNK and AP-1 activation were detected in the myometrium of LPS (E. coli O111:B4)-
treated animals, we hypothesized that inhibition of JNK activation would inhibit downstream 
phosphorylation of AP1 and thus block PTL resulting in prolongation of gestation in LPS 
treated animals. To test this, the selective JNK inhibitor, SP600125 (anthra[1,9-cd]pyrazol-
6(2H)-one; 30 mg/kg), was administrated intraperitoneally 2 hours prior to LPS treatment. 
SP600125 significantly delayed PTL by 6 hours compared to untreated animals (Fig. 5.9). 
 
Figure 5.9 Inhibition of JNK activation delays LPS-induced preterm labour. Pregnant mice were 
administered an intraperitoneal injection of the JNK inhibitor SP600125 (30mg/kg; n=6) 2 hours prior 
to intrauterine (i.u.) LPS injection. Negative control animals (-ve control) received SP600125 i.p. and 
PBS i.u. Graph illustrates time to labour (hours) following treatment with vehicle or JNK inhibitor. 
(
*
P<0.05; Student’s t-test; n=6), p.i.: post-injection. Error bars indicate standard deviation. 
 
5.4 LPS-stimulated AP-1 activation via JNK induces expression of proinflammatory 
and procontractile genes in the myometrium 
To further investigate the mechanism by which AP-1 activation promotes PTL in LPS (E. 
coli O111:B4)-treated animals, we next used real-time PCR to assess the relative gene 
expression changes of key inflammatory and contractile genes in the myometrium in response 
to LPS stimulation (Fig. 5.10). The analysis was focused on a set of genes containing AP-1 
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binding sites within the promoter region, encoding for inflammatory, anti-inflammatory and 
contractile mediators known to be involved in the process of labour. Levels of Cox-2 mRNA 
were significantly increased by LPS stimulation compared to control animals (Fig. 5. 10 A). 
 
Figure 5.10 LPS-induced activation of AP-1 via JNK coincides with increased expression of pro-
inflammatory and pro-labour genes in murine myometrium. Real time PCR was used to examine 
the relative gene expression levels of pro-contractile genes including (A) Cox-2 and (B) Cx-43, 
pro/anti-inflammatory genes including (C) Tnf-α, (D) Il-1β, (E) Il-6, (F) Il-8, (G) Il-10, and key genes 
involved in membrane remodelling and cervical ripening including (H) Mmp3, (I) Mmp9 and (L) 
Mmp10 mRNA. Gene expression levels were normalised to the housekeeping gene β-actin and fold 
changes relatively to PBS control were calculated. Asterisks denote statistical significance between 
treatments at each time point as assessed by two-way ANOVA with Bonferroni post-hoc test, 
(
*
P<0.05, 
**
P<0.01, 
***
P<0.001). Letters indicate statistically significant differences within treatment 
groups across the time-course. Error bars indicate standard deviation, n=4. 
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Cox-2 levels were increased 5-fold 1 h post LPS injection, with significantly higher levels at 
subsequent time points, peaking at 6 h and during labour. Expression levels of Cx-43 were 
consistent throughout the assessed time points, although increasing significantly just before 
the onset of PTL, at 6 h post LPS administration (3.5-fold increase, Fig. 5.10 B). The 
expression levels of a group of inflammatory genes known to be upregulated in the 
myometrium in both term and preterm human labour were then investigated. 
Proinflammatory genes including Tnf-α, Il-1β, Il-6, Il-8, and the anti-inflammatory ll-10, 
were significantly induced with LPS stimulation, throughout the majority of the time points 
and during labour, compared to PBS- injected control mice (Fig. 5.10 C-G, respectively). 
Stromelysin-1 (Mmp3) levels were significantly increased compared to PBS controls, at 4, 6 
h post LPS injection and during labour (Fig. 5. 10 H). No significant differences were 
observed in Mmp9 and Mmp10 expression patterns (Fig. 5.10 I, L). 
 
5.4.1 LPS (E. coli O111:B4)-induced activation of pro-inflammatory and pro-
contractile genes is TLR4 mediated 
As described in paragraph 5.2.3, AP-1 activation in response to LPS was detected in TLR4-
KOs, although this response was not sustained beyond 1 h p.i. Real time PCR showed that 
downstream gene expression was only transiently induced in LPS-treated animals. Il-8 
expression was similarly increased upon LPS treatment in both WT and KO animals at 4 h 
and 6 h post LPS treatment compared to PBS control (P<0.01 and P<0.001 respectively, Fig. 
5.11 A). While LPS further stimulates IL-8 expression at labour in WT mice (about 7 h post-
injection), Il-8 mRNA levels were markedly decreased in TLR4-KO animals at 12 h and 18 h 
following LPS treatment. Levels of Il-8 in myometrium collected from PBS-injected 
remained unchanged. A marked increase in Cox-2 expression was detected in WT animals 
following LPS injection from 2 h onwards, remaining high until labour (Fig. 5.11 B). 
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Figure 5.11 LPS-induced activation of pro-inflammatory and pro-contractile genes is TLR4-
mediated. Real time PCR analysis of relative mRNA expression levels of (A) Il-8, (B) Cox-2, (C) Il-
1β, (D) Tnf-α, (E) Cx-43, (F) Il-10 and (G) Mmp3 in TLR4-KO (blue) and WT (black) murine 
myometrium. Gene expression levels were normalised to the housekeeping gene β-actin and fold 
changes were represented relative to PBS controls. Asterisks represent statistical significance between 
PBS (discontinuous lines) and LPS (continuous lines, 
***
P<0.001, 
**
P<0.01,
*
P<0.05). Letters indicate 
difference between LPS treatment across the time-course. Two-way ANOVA with Bonferroni post-
hoc test. Error bars indicate standard deviation, n=4. PCRs performed in collaboration with Andrea 
Charalambous, MSc. 
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In contrast, Cox-2 mRNA levels remained low in both PBS- and LPS-treated TLR4-KO 
animals, as well as in PBS-treated WT animals. A significant increase in Cox-2 expression 
was only observed in LPS treated TLR4-KO animals at 6 h compared to PBS equivalents 
(P<0.01). While Il-1β expression in WT mice was rapidly induced 1 h and 2 h following LPS 
injection, Il-1β mRNA levels in KO mice remained relatively low and unchanged at all time 
points assessed apart from 6 h where a significant increase was identified compared to PBS 
control mice (P<0.001, Fig. 5.11 C). Both PBS and LPS-treated mice exhibited significant 
lower Il-1β mRNA levels close to labour (P<0.05). 
A rapid increase in TNF-α expression was detected 1 h following LPS injection in both WT 
and TLR4-KO mice (P<0.01, Fig. 5.11 D). While LPS treated WT animals exhibited high 
levels until labour, TNF-α mRNA levels in LPS-treated KO mice were decreased from 2 
hours post-injection until delivery. A significant difference in TNF-α expression between 
PBS- and LPS-treated KO mice was detected at 1 h, 6 h and 18 h (1 h, 6 h: P<0.01; 18h: 
P<0.05), while PBS-treated mice showed lower expression levels throughout the time course. 
LPS (E. coli O111:B4) treatment in WT mice induced a significant increase in Cx-43 
expression 6 h post injection. In TLR4-KO mice Cx-43 expression was increased at 2 h in 
both PBS and LPS treated populations, with statistical significance at 1 h post-PBS compared 
to LPS (P<0.05, Fig. 5.11 E). Cx-43 levels remained comparable between treatments at all 
other time points. 
The anti-inflammatory cytokine Il-10 was significantly induced by LPS at 1, 2 and 12 h 
following LPS injection in KO mice, compared to PBS treated KO mice (1h: P<0.05; 2h: 
P<0.001; 12h: P<0.05, Fig. 5.11 F). Although both WT and KO mice treated with LPS 
exhibited higher initial expression levels of IL-10, a rapid decline was observed in KO mice 
by 4 h following treatment, where levels comparable to control WT and KO mice were 
 160 
 
detected. Statistical significance between time points relative to PBS-injected TLR4-KO mice 
is not presented on Fig. 5.11 for the sake of clarity but are as follows; 1h v 2h (P<0.05), 1h v 
6h (P<0.001), 1h v 12h (P<0.0001), 1h v 18h (P<0.0001), 2h v 12h (P<0.05), 2h v 18h 
(P<0.05), 4h v 12h (P<0.01), 4h v 18h (P<0.01). These results indicate that a minimal anti-
inflammatory response is also detectable in control animals, although this was not maintained 
throughout gestation and is reduced by 2 hours post treatment. 
Expression levels of the metalloproteinase Mmp3 were initially low across all time points and 
treatments in WT and KO mice (Fig. 5.11 G). In WT animals, Mmp3 levels increased prior to 
labour onset 4 hours following LPS treatment, however in TLR4-KO mice this increase was 
delayed and manifested 6 h post-LPS injection (P<0.01). Mmp3 expression steadily declined 
in TLR4-KO mice after 6 h to reaching low levels comparable to PBS-injected animals, at 18 
h post-LPS treatment.  
 
5.5 LPS (O111) induced TLR2 expression in the myometrium of WT mice 
Since LPS is able to promote increase expression of the TLR receptors 2 and 4 in pregnant 
mouse uterus [349] possibly enhancing the downstream inflammatory response, we aimed to 
test whether the sustained inflammatory response observed in wild type mice was a 
consequence of an increase in the levels of TLR4. To a lesser extent, TLR2 can act as an off-
target receptor and be activated by LPS. We therefore used real-time PCR analysis to 
examine the relative expression levels of TLR2 and TLR4 mRNA in the myometrium of both 
WT and TLR4-KO mice upon LPS treatment. Since no difference was reported between PBS 
and LPS at each time point, the average gene expression values from 1h, 2h, 4h and 6h post 
PBS and LPS treated mice are reported in Fig. 5.12. No change was observed in TLR4 
expression between WT and KO (Fig. 5.12 A). In comparison, TLR2 expression significantly 
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increased in LPS treated WT mice when compared to PBS treated WT mice (P<0.05, Fig. 
5.12 B). However, this was not the case for KO mice as both TLR4 and TLR2 expression 
remained unchanged between treatments. 
 
Figure 5.12 TLR2 expression increases with LPS stimulus in WT, but not in TLR4-KO mice. 
Real time PCR was used to measure the relative gene expression of (A) TLR4 and (B) TLR2 in WT 
(grey) and KO animals (blue) treated with LPS or PBS control. Average data from all time points are 
presented and divided between controls and treated mice. One-way ANOVA with Bonferroni post-
hoc test, 
 *
P<0.05. Error bars indicate standard deviation, n=4. 
  
5.6 Myometrial AP-1 activation correlates with increased CX-43 and pro-IL-1β 
protein levels and IL-1β processing 
We next sought to determine whether AP-1 activation is associated with increased levels of 
uterine activation proteins COX-2 and CX-43 [145, 499]. Western blotting was used to 
analyse protein expression changes associated with LPS treatment and PTL (Fig. 5.6 A). 
Although LPS-induced PTL was associated with a marked increase in Cox-2 gene expression, 
COX-2 protein levels remained unchanged throughout the time course in both control and 
LPS-treated animals (Fig. 5.13 A, B). As described earlier, IL-1β is initially synthetised as an 
inactive precursor (pro-IL-1β) of about 31 KDa. Upon activation by the specific caspase-
activating complex known as the “inflammasome”, the inactive precursor is cleaved and the 
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bioactive 17 KDa component is release into the extra cellular environment to exert its 
function [500]. 
 
Figure 5.13 LPS-induced AP-1 activation correlates with upregulation of CX-43 and IL-1β 
protein levels and IL-1β processing. (A) Western Blotting was used to examine protein levels in 
lysates prepared from myometrium samples collected from LPS and PBS treated animals at 1, 2, 4 ,6 
hours following treatment and during LPS-induced PTL (LABLPS). Densitometry analysis was 
performed on (B) COX-2, (C, D) IL-1β and (E) CX-43 immune-reactive bands. β-actin was used as 
loading control. A pool including an aliquot from each sample was used as calibrator (CAL) to 
account for variability between gels. Asterisks denote statistical significance between treatments at 
each time point as assessed by two-way ANOVA with Bonferroni post-hoc test. (
*
P<0.05,
 
***
P<0.001). Letters indicate difference within treatment group comparisons. For all conditions with 
the same letter, the difference between the means is not statistically significant. If two conditions have 
different letters, they are significantly different. Mr=Relative molecular mass ×1000. Error bars 
indicate standard deviation, n=4.  
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Although it was not possible to quantify the amount of active IL-1β secreted using Western 
blotting, the antibody used in these experiments enabled the detection of the processed 28 
KDa IL-1β peptide. This permitted an estimation of pro-IL-1β processing to be determined. 
LPS treatment led to a significant increase in pro- IL-1β (Fig. 5. 13 A, C) and processed IL-
1β (Fig. 5. 13 A, D) protein expression. CX-43 protein levels were increased just prior to 
labour, 6 hours following LPS injection as well as during active PTL (Fig. 5. 13 A, E). 
 
5.7 IL1- β proteolytic cleavage is abrogated in TLR4KO mice 
TLR4-KO mice hypo-responsiveness was also confirmed at the protein level. In the absence 
of a functional TLR4, IL-1β processing into an active form was impaired as shown by the 
absence of the 28 kDa cleavage product (Fig. 5.14 A, B). 
 
Figure 5.14 Processing of IL-1β is abrogated in TLR4-KO mice. (A) Western blot analysis of IL-
1β and COX-2 in myometrium in TLR4-KO following intrauterine injection of 20 µg of LPS 
(O111:B4) or PBS control. (B) Expression levels of pro-IL-1β and (C) COX-2 relative to β-actin as 
determined by densitometry. Asterisks represent statistical significance between LPS and PBS treated 
samples. Letters indicate difference within treatment group comparisons. If two conditions have 
different letters, they are significantly different. 2-way ANOVA with Bonferroni post-hoc test 
(
*
P<0.05). Error bars indicate standard deviation, n=4.  
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In contrast, levels of pro-IL-1β protein were significantly higher 6 h following LPS injection 
compared to PBS control (P<0.05). Similarly to gene expression data, protein levels of IL-1β 
decreased significantly at 12 h and 18 h following LPS injection compared to earlier time 
points. Consistent with observations in WT mice, COX-2 protein levels were found 
unchanged throughout the time-course regardless of the treatment (Fig. 5. 14 A, C). 
 
5.8 JNK/AP-1 activation is not mediated by progesterone receptor. 
5.8.1 Progesterone withdrawal by RU46 induces preterm labour 
As discussed in the introduction of this thesis, evidences suggest that there exists cross-talk 
between progesterone signalling and inflammatory activation at the onset of labour [80, 91, 
501]. Therefore, to test if JNK activation of AP-1 may be progesterone-regulated, we induced 
chemical progesterone withdrawal in mice at E16 using the progesterone receptor antagonist 
mifepristone (RU486) and examined levels of the phosphorylated JNK and c-Jun, as well as 
p-p65, in murine myometrium at various time points until labour. Mice treated with RU486 
consistently delivered preterm 20 hours (±1.6 h) post-injection (p.i., mean ± SD) while 
control mice receiving dimethyl sulfoxide (DMSO) delivered at term 60 h p.i. (Fig. 5.15, 
P<0.05, n=6). 
 
Figure 5.15 Functional progesterone withdrawal by RU486 induces preterm labour at E16. 
Pregnant mice received a subcutaneous injection of progesterone receptor antagonist RU486 at E16 or 
vehicle control (DMSO). Student’s T-test, *P<0.05, n=6. Error bars indicate standard deviation. 
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5.8.2 Activation of myometrial JNK/AP-1 occurs at labour onset in the RU486-
induced preterm labour model 
To test whether premature induction to labour via functional progesterone withdrawal via 
RU486 had any effect on inflammatory mediators activation, levels of activated NFκB (Fig. 
5.16 A, B), AP-1(Fig. 5.16 A, C) and JNK (Fig. 5.16 A, D) were assessed using Western 
Blotting. While no difference was observed in the activation status of any of these proteins 
following RU486 treatment, a significant increase in activated AP-1 (p-c-Jun) was detected at 
labour onset in the myometrium of mice induced to PTL by RU486 treatment (Fig. 5. 16 A, 
C).  
 
Figure 5.16 Preterm labour induced by chemical progesterone withdrawal is associated with 
myometrial AP-1 activation. Myometrial tissue samples were collected at 1, 2, 4, 6, 12, 18 hours and 
during active labour after RU486 treatment (LABRU486). Protein extracts were analysed by Western 
blotting for levels of activated NFκB (p-p65, A-B), AP-1 (p-c-Jun, A, C) and the MAPK p-JNK (A, 
D). Two-way ANOVA with Bonferroni post-hoc test, 
*
P<0.05. Error bars indicate standard deviation, 
n=4. 
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5.8.3 Functional progesterone withdrawal is not responsible for increased AP-1 
nuclear translocation in the myometrium at labour onset. 
To examine the effect of functional progesterone withdrawal upon nuclear translocation of 
the inflammatory transcription factors NFκB and AP-1, immunofluorescence staining 
experiments were performed on myometrium collected 6 h and 18 h after subcutaneous 
injection with either RU486 or DMSO control and during RU486-induced PTL (Fig 5.17). 
 
Figure 5.17 RU486-induced preterm labour does not induce NFκB nuclear translocation. (A) 
Tissue samples from mouse myometrium were collected at 6 and 18 h following subcutaneous 
injection of DMSO/RU486 or during RU486-induced PTL (LABRU486). Sections (5 μm) were 
analysed by immunofluorescence staining to detect subcellular localisation of activated NFκB (p-
p65). (-) CTRL: primary antibody is omitted. α-SMA: alpha smooth muscle actin marker. Nuclei were 
counterstained with DAPI (blue). Scale bar = 20μM. Images acquired with Inverted Leica SP5 
confocal system, magnification 63x (oil). (B) Quantification analysis representing relative percentage 
of nuclei positively stained for p-p65. Statistical significance was assessed by two-way ANOVA with 
Bonferroni's post hoc test. (
**
P<0.01). Error bars indicate standard deviation, n=3. Performed in 
collaboration with Ioannis Pavlidis, MSc. 
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Primary antibodies against the phosphorylated NFκB monomer p-p65 (Fig. 5.17 A) and AP-1 
monomer p-c-Jun (Fig. 5.18 A) were used. In agreement with Western Blotting results, p-p65 
nuclear translocation was not significantly increased 6 hours after RU486 treatment, 
compared to DMSO controls (14.14±6.42% vs 7.83±0.63%, respectively, (Fig. 5.17 B). No 
changes were detected 18 hours after treatment (26.72±13.57% vs 17.96±5.53%, RU486 
compared to DMSO, respectively).  
 
Figure 5.18 RU486-induced preterm labour is associated with increased AP-1 nuclear 
translocation. (A) Tissue samples from mouse myometrium were collected at 6 and 18 h following 
subcutaneous injection of DMSO/RU486 or during RU486-induced PTL (LABRU486). Sections (5 μm) 
were analysed by immunofluorescence staining to detect subcellular localisation of activated AP-1 (p-
c-Jun). (-) CTRL: primary antibody is omitted. α-SMA: alpha smooth muscle actin marker. Nuclei 
were counterstained with DAPI (blue). Scale bar = 20μM. Images acquired with Inverted Leica SP5 
confocal system, magnification 63x (oil). (B) Quantification analysis representing relative percentage 
of nuclei positively stained for p-c-Jun. Statistical significance was assessed by two-way ANOVA 
with Bonferroni's post hoc test. (
*
P<0.05). Error bars indicate standard deviation, n=3. Performed in 
collaboration with Ioannis Pavlidis, MSc. 
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Similarly, p-c-Jun nuclear translocation was not significantly altered with RU486 treatment at 
6 hours (p-c-Jun: 20.66±10.86% vs 16.67±5.51% respectively, (Fig. 5.18 B); or 18 hours 
after treatment (p-c-Jun: 36.58±18.01% to 22.83±11.69%, RU486 compared to DMSO 
respectively). A significant increase in nuclear translocation of P-c-Jun was observed when 
comparing 6 h DMSO group against LABRU486 (7.83±0.63% vs 45.14±9.48%, DMSO vs 
LABRU486 respectively, P<0.05). 
 
Summary and discussion 
Data reported in this chapter show that LPS O111:B4-induced PTL is preceded and 
accompanied by activation of JNK/AP-1-mediated inflammatory response in the murine 
myometrium (Fig. 5.1, 5.2 and 5.8). In contrast, levels of activated NFκB remained 
unchanged following LPS O111:B4 treatment as well as at labour onset (Fig. 5.1 and 5.3). 
AP-1 activation was associated with increased expression of inflammatory and anti-
inflammatory cytokines (Il-1β, Tnfα, Il-8, Il-6, Il-10), uterine activation proteins (Cox2, CX-
43), and remodelling enzymes (Mmp3, Mmp9 and Mmp10) (Fig. 5.10). While most of the 
inflammatory cytokines were induced shortly after AP-1 activation, other targets such as 
Mmp3, Cox-2 and Cx-43 exhibited a different activation pattern and were induced closer to 
the onset of labour. These results are in agreement with other studies showing Mmp3 
upregulation late in gestation. An increase in Mmp3 expression has also been reported in 
human myometrium samples collected from women following active labour onset [502]. In 
mice, Mmp3 was found to be downregulated throughout term gestation compared to non-
pregnant samples and upregulated only in the postpartum period [413]. Data presented in this 
chapter show that LPS treatment anticipates multiple inflammatory and contractile gene 
changes typically occurring close to the onset of spontaneous term labour. 
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The strong induction of myometrial Cox-2 mRNA in response to LPS treatment was not 
consistent with Cox-2 protein levels (Fig. 5.13 A, B). This is likely due to the short half-life 
of this enzyme that is able to catalyse a limited number of prostaglandin synthetic reactions 
before being quickly degraded [503]. AP-1-binding sites are present in both mouse and 
human CX-43 promoter region and the role of AP-1 in regulating CX-43 expression as labour 
approaches is well described [95, 440, 497]. Consistent with the increased myocyte 
connectivity and coupling required for synchronised uterine contractions at labour onset 
[504], both mRNA and protein levels of CX-43 were increased in response to LPS at 6 h 
post-injection and at labour onset (Fig. 5.13 A, E). These results suggest a role for AP-1 in 
regulating not only expression of inflammatory genes but also key pro-labour genes encoding 
for proteins essential to promote myometrial contractility. Consistently with these findings, 
data from Hutchinson and colleagues also showed that another E. coli-derived LPS serotype 
(EH100, Ra) stimulates in vitro human myocyte contractility via activation of Rho/ROCK 
signalling pathways [505]. 
Increased IL-1β mRNA and protein levels are frequently found in gestational tissue and 
amniotic fluid of women with infection-induced PTL and with spontaneous parturition at 
term [506]. Although systemic administration of IL-1β to pregnant mice induces preterm 
delivery [283], studies performed in IL-1β KO mice by Hirsch and colleagues demonstrated 
that maternal IL-1β is dispensable for infection-induced PTL [368]. Nevertheless active IL-
1β induces the expression of matrix remodelling enzymes such as MMP1, MMP3 and MMP9 
[507], prostaglandin levels, uterine activation proteins ultimately leading to PTL [508, 509]. 
IL-1β is synthesised as an inactive precursor (pro-IL-1β; Mr = 31 000) that becomes active 
once cleaved by caspase-1 which forms the “inflammasome” complex [510]. Processing of 
pro-IL-1β at the Asp116 -Ala117 results in the production of active IL-1β (Mr = 17 000) [511, 
512]. IL-1β processing can also yield various intermediate products with molecular masses of 
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Mr = 28 000, 14 000, 11 000 and 3 000 [486]. The intermediate of Mr = 28 000 was detected 
in myometrial protein extracts collected from LPS-injected mice (Fig. 5.13 A, C-D). It is 
probable that the mature Mr = 17 000 form was also produced but rapidly excreted from the 
cell and therefore not detected in the tissue extracts [513]. Cleaved IL-1β was not found in 
TLR4-KO mice (Fig. 5.14 A, B), indicating a crucial role for this receptor and activation of 
its associated pathway in IL-1β processing. Besides resulting in impaired IL-1β processing, 
absence of a functional TLR4 negatively affected activation of inflammatory transcription 
factors AP-1 and NFκB (Fig. 5.6), as well as the expression of downstream pro-labour and 
inflammatory genes (Fig. 5.11). Knock-out of TLR4 rescued the phenotype and mice 
delivered at term when injected with either PBS control or LPS (Fig. 5.4). Pup survival rates 
were also fully recovered in TLR4-KO mice challenged with LPS (Fig. 5.5), confirming an 
important role for this receptor and associated downstream pathways in the molecular 
mechanisms underlying infection/inflammation-induced PTL and associated fetal demise. 
Although was not possible to inhibit labour completely, PTL was delayed by about 6 hours 
by inhibiting JNK and subsequent AP-1 activation following LPS treatment [514] (Fig. 5.9). 
A proposed mechanism involving the JNK/AP-1 axis in LPS-induced PTL is illustrated in 
Fig. 5.19. 
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Figure 5.19 Proposed mechanism of LPS (Escherichia coli O111:B4)-induced preterm labour 
via AP-1 activation. Recognition of LPS by TLR4 leads to JNK phosphorylation and activation that 
drives phosphorylation of the AP-1 subunits c-Jun and c-Fos. Upon activation, the subunits dimerise 
and translocate to the nucleus where they regulate expression of pro-labour and pro-contractile genes 
culminating with the onset of PTL. Inhibition of JNK by SP600125 is effective in delaying premature 
onset of labour.  
 
Previous studies have suggested that a decline in progesterone function or systemic levels at 
the end of gestation promotes myometrial switch from quiescence [75, 515]. A previous 
study from our laboratory demonstrated that, although able to control genes involved in tissue 
remodelling and quiescence, progesterone receptor downregulation does not repress 
inflammatory genes in human myometrial cells [91]. The functional progesterone withdrawal 
hypothesised in the human scenario can be mimicked in the murine model by antagonising 
the function of progesterone receptor thus leading to functional progesterone withdrawal. 
Mifepristone (RU486) was administered via subcutaneous injection in pregnant mice at E16 
and was able to induce PTL within 18 hours following administration (Fig. 5.15). In 
agreement with our previous human data, NFκB and AP-1/JNK were not affected by RU486 
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treatment (Fig. 5.16). Nevertheless their phosphorylation levels increased during labour. 
Immunofluorescence experiments also confirmed nuclear translocation of both these 
inflammatory transcription factors near the time of labour (Fig. 5.17 and 5.18). These data 
suggest two possibilities: either low levels of progesterone, normally acquired from E16 
onwards in a normal murine gestation [73], may be needed to allow AP-1 activation at term; 
or AP-1 activation is associated with labour onset regardless of progesterone signalling. 
Taken together, data from both LPS and RU486 models showed that myometrial AP-1 
activation is associated with PTL regardless of the stimulus (hormonal or inflammatory) and 
its premature activation can be blocked by JNK inhibitor thus resulting in delayed onset of 
PTL [68]. 
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6 Transcriptome changes throughout term and preterm gestation in 
murine myometrium define the relative contribution of hormonal and 
inflammatory pathways to parturition 
 
Introduction 
The murine models described in this thesis are widely recognized by the research community 
to mimic physiologic processes of human parturition [260]. Progesterone withdrawal, be it 
either functional or systemic, results in the release of progesterone block and activation of 
uterine contractions in both human and animal models [81, 319]. Infection is frequently 
associated with PTB, accounting for 30% of all cases [1, 11]. Therefore, as it was also shown 
in previous chapters, bacterial-derived molecules such as LPS can be used to recapitulate the 
inflammatory response established in response to infection and to induce PTL in animal 
models, without changes in the levels of circulating progesterone [516, 517]. Although 
numerous studies describe term human labour as a pro-inflammatory event [168] it remains 
unclear whether uterine inflammation is a cause or a consequence of parturition. As described 
in earlier chapters, activation of uterine inflammation induces PTL in the mouse yet 
progesterone withdrawal induced by RU486 treatment is not accompanied by a similar 
activation of inflammatory transcription factors in the uterus. Recent studies in animal 
models investigating the relative importance of subsets of immune cells in the onset of labour 
indicate that parturition-associated inflammation may not be causative of labour, but rather be 
involved in supporting host response to pathogens and in the activation of tissue repair 
mechanisms necessary for uterus remodelling following delivery [159-162, 518].  
Discovery-driven methods such as “omics” approaches including GWAS studies, 
transcriptomics, proteomics and metabolomics have become of crucial and complementary 
importance to more reductionist and hypothesis-driven approaches [519]. Such systems-based 
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analyses are likely to play a critical role in elucidating the complexity of the molecular 
mechanisms underpinning labour. Transcriptomics permits the generation of a comprehensive 
catalogue of genes differentially expressed between conditions thus allowing the 
identification of novel candidates with a potential role in the pathogenesis of PTL. 
Longitudinal sampling of the human uterus throughout gestation is not possible. Therefore 
studies of gestational tissues (myometrium, cervix and chorioamniotic membranes) have been 
limited to the comparison of samples collected before and after labour onset. The lack of time 
course data in human has greatly limited our knowledge of large-scale gene expression 
changes initiating the onset of labour most of which are likely to be manifested some time 
prior to labour onset. 
Results in this chapter describe the transcriptomes changes characterising mouse 
myometrium throughout term gestation and spontaneous term labour, and in the context of 
PTL induced by either an inflammatory stimulus (LPS) or functional progesterone 
withdrawal (induced by RU486). Murine data were then tested for similarities with a 
published dataset derived from pregnant human myometrium transcriptome data [406] to 
evaluate the relative contribution of progesterone-regulated and inflammatory pathways to 
the physiology of human parturition. 
 
Results 
 
6.1 Multivariate modelling of genome-wide expression changes associated with three 
models of parturition: term, LPS-and RU486-induced preterm labour 
To characterise the uterine transcriptome profile associated with the dynamic process of 
myometrial activation at labour, a time-course RNA-Seq experiment was designed. 
Transcriptome profiling by RNA-Seq was performed on murine myometrial samples 
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collected from mice undergoing spontaneous term labour or PTL following chemically 
induced (RU486) progesterone withdrawal or inflammation-induced (LPS) PTL. Tissue 
collection time points from each mouse model were carefully considered as to permit 
comparisons of the transcriptomes at times proportional to the onset of labour (Fig. 6. 1 A). 
 
Figure 6.1 Principal component analysis (PCA) of genome-wide expression changes associated 
with three models of parturition. (A) Study design: myometrium samples were collected from three 
mouse models of parturition: term labour (blue), progesterone withdrawal/RU486-induced PTL (grey) 
and inflammatory/LPS-induced PTL (yellow). (B) PCA of transcriptome changes represented along 
principal component (PC)1 (30.7% of total variance) and PC2 (23.3% of total variance). 
Transcriptome profiles of samples of samples belonging to the same experimental group are shown as 
symbols of the same shape. Lines indicate the direction of changes observed in the myometrium as 
gestation progresses towards labour. Both term labour and RU486-induced PTL exhibit similar 
trajectories of transcriptome changes whereas mice experiencing LPS-induced PTL undergo a 
divergent trajectory. (C-E) Single PCA of transcriptome profiles of murine myometrium collected 
throughout (C) term gestation, (D) following DMSO/ RU486 subcutaneous injection and during 
RU486-induced PTL (LABRU486), (E) following PBS/LPS intrauterine injection and during LPS-
induced PTL (LABLPS), n=4 biological replicates for each experimental group. 
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In normal mouse gestation, circulating concentrations of progesterone peak on E16, before 
falling to the lowest level on E18 [73]. Therefore myometrium samples were collected at 
specific time points spanning these physiologic changes characterising term gestation: E14, 
E16, E18 prior to labour, and E18.5 after the onset of labour (LAB, after the delivery of the 
first pup). As described in chapter 5, in the preterm models LPS and RU486 induced labour 
onset on E16, 7 and 20 hours post-injection respectively. Transcriptome changes in each of 
the models occurred across radically different time frames that were related to the time by 
which labour had started; three days in the term labouring mice, 20 hours in the RU486 
model and 7 hours in the LPS model. To obtain transcriptome data at time points 
proportionally comparable on the time course to labour in both models, samples were 
collected at 2, 6 hours following LPS injection and during active preterm labour; 6, 18 hours 
following RU486 injection and during active preterm labour. These collection time points 
correspond respectively to 30%, 90%, and 100% of the time interval between the injection 
and the onset of PTL (Fig. 6.1 A). Principal component analysis (PCA) of RNA-Seq data 
showed that both term and PTL following progesterone withdrawal exhibit similar 
trajectories of uterine transcriptome changes preceding labour onset (Fig. 6.1 B). In contrast, 
in mice experiencing inflammation-induced PTL, myometrium samples exhibited remarkably 
different transcriptome profiles preceding the onset of labour as well as during active labour.  
A myometrial transcriptome signature associated with gestational age was detected although 
high heterogeneity was observed in samples collected on gestational day 18 before labour 
(Fig. 6.1 C). In animals treated with RU486, minimal change to the myometrial transcriptome 
was observed 6 hours post-treatment compared to DMSO control-injected animals however a 
major shift in the transcriptome signature was detected 18 hours after injection. No further 
gene changes were observed in samples collected during active labour (Fig. 6.1 D). LPS 
treatment led to substantial, rapid gene expression changes within 2 hours following injection 
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(Fig. 6.1 E).  Differences in the transcriptomes of PBS control animals compared to 
analogous time points from normal term gestation and RU486-induced PTL model likely 
reflected gene changes occurring as a consequence of the laparotomy procedure. Similarly to 
the RU486 model, the majority of gene changes induced by LPS occurred prior to labour 
onset while similar transcriptome profiles characterised samples collected 6 hours post-
injection and during LPS-induced labour. 
 
6.2 Identification of differentially expressed genes  
 
EdgeR [427] was used to identify differentially expressed genes (DEGs) (up- or down-
regulated) between the following pairwise comparisons: E14 vs E16, E14 vs E18, E14 vs 
LAB, E16 vs E18, E16 vs LAB and E18 vs LAB for the term gestation model; ; 6h DMSO vs 
6h RU486, 18h DMSO vs 18h RU486, 6h RU486 vs 18h RU486, 6h RU486 vs LABRU486 
and 18h RU486 vs LABRU486 for the RU486-induced PTL model; 2h PBS vs 2h LPS, 6h PBS 
vs 6h LPS, 2h LPS vs 6h LPS, 2h LPS vs LABLPS and 6h LPS vs LABLPS for the LPS-
induced PTL model. A false discovery rate (FDR) threshold of 0.001 was used to filter for the 
most significantly changing genes. Comparisons not exhibiting significant gene changes (6h 
DMSO vs 6h RU486 and 6h LPS vs LABLPS) were excluded from further analyses. Venn 
diagrams were used to illustrate overlap in gene changing in each pairwise comparison as 
detected in the term gestation model, the RU486 model, and the LPS model. The majority of 
DEGs identified throughout term gestation were detected at time points close to labour onset 
(Fig. 6.2 A). As expected, the higher number of DEGs (a total of 2172) was identified when 
comparing the two time-points at the extreme ends of the time-course, between E14 and 
during active labour (LAB). The majority of these 2172 genes changing between E14 and 
LAB were also differentially expressed immediately prior to labour at E18 and earlier at E16. 
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In particular, around 80% (1301/1662) of all genes changing between E16 and LAB were 
also differentially expressed between E14 and LAB. High overlap was also observed for 
genes changing between E18 and LAB, 85% (212/247) and those changing between E14 and 
LAB. These observations indicate that the majority of gene changes occurring at labour onset 
are modulated at discrete time points prior to the onset of labour itself. 
 
Figure 6.2 Venn diagrams depicting number of genes differentially expressed: across term 
gestation (A), in the RU486 (B), and LPS model (C). FDR<0.001, n≥4 for each experimental group. 
 
In the RU486 model, no significant gene changes were detected 6 hours post-treatment (Fig. 
6.2 B). However, a considerable number of genes were found to be differentially expressed 
between 18 h DMSO and 18 h RU486. Of these only 30% (506/1611) were exclusively 
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changed 18 h post RU486 treatment compared to 18 h DMSO while about 70% (1105/1611) 
were also changed between 6 h RU486 and 18 h RU486, and between 6 h RU486 and 
LABRU486. Treatment with LPS induced a strong response in gene expression changes as 
early as 2 h following treatment, as depicted in Fig. 6.2 C. Similarly to the RU486 model, the 
majority of gene changes were observed prior to labour onset 6 h post-LPS compared to 6 h 
PBS control and compared to 2 h LPS. 
 
6.3 Validation of RNA Sequencing by real-time PCR 
Real time PCRs were performed on myometrium samples collected at E14, E16, E18, and 
during active labour (LAB) throughout a normal term gestation and expression levels of a 
panel of nine pro-inflammatory and pro-contractile genes associated with parturition were 
assessed (Fig. 6.3). This panel included c-Fos, c-Jun, cyclooxygenase 2 (Cox2), prostaglandin 
D2 receptor (Ptgdr), prostaglandin F receptor (Ptgfr), connexin-43 (Cx-43), chemokine (C-C 
motif) ligand 24 (Ccl24), tumor necrosis factor alpha (Tnf-α) and oxytocin receptor (Oxtr). 
Trends and fold changes of each gene as detected by both RNA-Seq and real time PCR were 
tested for correlation and showed a significantly positive score (Pearson’s coefficient=0.9266, 
Table 6.1). These data suggest that results from RNA-Seq analysis are robust. 
Table 6.1 Correlation test between fold changes as detected by real-time PCR and RNA-Seq. 
1
q-PCR Average fold change calculated by log2(2
ΔCT
 at gestational day (E)x /2
ΔCT 
at E14); 
2
RNA-Seq normalised fold change = log2(normalised readcounts at gestational day (E)x /normalised 
readcounts at E14). 
 Real Time PCR mean fold changes 
1
 RNA-Seq normalised fold changes 
2
 
Gene E16 vs E14 E18 vs E14 LAB vs E14 E16 vs E14 E18 vs E14 LAB vs E14 
TNFα -1.6051161 -0.384252 1.6612184 -1.46713 0.145851 1.529334 
COX2 -0.0853006 -0.108604 2.6724308 -0.29514 0.479941 2.551965 
c-Fos 0.4940178 2.4226739 4.2016215 0.76186 3.06257 5.406838 
c-Jun 0.4573313 -0.206499 0.2914016 -0.0117 0.04704 0.729541 
Cx-43 0.4067711 2.4107125 3.2833953 0.138876 1.568497 2.654812 
Ptgfr -0.2469443 0.2859933 1.3236578 -0.14975 0.219487 1.536753 
Ptgfr -1.5612245 -3.020813 -5.072283 -1.04282 -2.54133 -6.71331 
Oxtr 0.4035763 2.8733511 3.047778 3.140275 5.929827 6.156639 
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Figure 6.3 A. Real time PCR validation of RNA-Seq on a panel of pro-inflammatory and pro-
contractile genes. Statistical significance assessed by 1-way ANOVA, Bonferroni's post hoc test, n=4 
(
*
P<0.05, 
**
P<0.01, 
***
P<0.001). mRNA expression levels were normalised to β-actin. Fold changes 
relative to E14 are shown. Data are expressed as average ± SD. 
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Figure 6.3 B. Real time PCR validation of RNA-Seq on a panel of pro-inflammatory and pro-
contractile genes. Statistical significance assessed by 1-way ANOVA, Bonferroni's post hoc test, n=4 
(
*
P<0.05, 
**
P<0.01, 
***
P<0.001). mRNA expression levels were normalised to β-actin. Fold changes 
relative to E14 are shown. Data are expressed as average ± SD. 
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6.4 Hierarchical clustering of differentially expressed genes highlights similarities and 
differences between gene expression patterns in murine models of parturition 
Taking into account the high degree of overlap between DEGs in the various pairwise 
comparisons considered, as well as to focus our analysis on those gene changes associated 
with each of the models along the time-course, only DEGs detected in specific pairwise 
comparisons were further considered for analysis: E16 vs E18, E18 vs LAB, E16 vs LAB for 
the term gestation model; 6h RU486 vs 18h RU486, 6h RU486 vs LABRU486 and 18h RU486 
vs LABRU486 for the RU486-induced PTL model; 2h LPS vs 6h LPS, 2h LPS vs LABLPS and 
6h LPS vs LABLPS for the LPS-induced PTL model. A total of 4142 DEGs were identified 
across all comparisons. Expression patterns characterising these genes were analysed using 
hierarchical clustering to examine temporal changes characteristic of each model of 
parturition (Fig. 6.4). 
 
Figure 6.4 Hierarchical clustering analysis of differentially expressed genes. Hierarchical 
clustering was used for unsupervised identification of gene expression patterns characterising mouse 
myometrium collected from (A) term labour, (B) RU486-induced PTL and (C) LPS-induced PTL. 
The number of clusters was calculated using Silhouette algorithm. n≥4 mice for each experimental 
group, FDR<0.001. 
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A marked shift in the uterine transcriptomic signature associated with late stages of gestation 
and spontaneous, term labour onset was detected (Fig. 6.4 A). Three main gene clusters were 
identified representing groups of genes either increasing (Cluster 1) or decreasing (Cluster 3) 
close to labour or genes exhibiting variable change across the time-course (Cluster 2). 
Comparable dynamics changes in these gene clusters were detected in mice undergoing 
RU486 induced PTB (Fig. 6.4 B). In contrast, hierarchical clustering revealed unique 
transcriptome changes associated with LPS-induced PTB (Fig. 6.4 C). In the LPS model, 
Cluster 1 could be further subdivided into two groups representing genes increased only with 
the onset of labour (Cluster 1a) similarly to normal term and RU486-induced labour or genes 
increased upon administration of LPS or PBS but decreased following labour onset (Cluster 
1b). A comparable labour-associated decrease in Cluster 3 gene expression and an increase in 
Cluster 2 gene expression levels were observed. Process network analysis [520] (MetaCore
®
, 
Thomson Reuters) was used to identify biological functions significantly enriched by 
differentially expressed genes. Cluster 2 genes showed significant enrichment of pathways 
associated with cellular adhesion-platelet endothelium-leucocyte interactions (P= 8.70×10
-9
), 
proteolysis and connective tissue degradation (P=1.53×10
-6
), and enrichment of several 
inflammatory pathways (immune response-TH17-derived cytokines, P=2.25×10
-3
; 
inflammation-IL-6 signalling, P=3.57×10
-3
; inflammation-kallikrein-kinin system, 
P=3.99×10
-3
; and immune response-phagocytosis, P=1.02×10
-2
), (Fig. 6.5). 
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Figure 6.5 Process Network analysis by Metacore
®
. Process Network analysis was performed on 
genes exclusively changing 6 hours post-LPS treatment and during LPS-induced PTL. Bar length 
indicates significance and is equal to the negative logarithm of enrichment P value. A P value less 
than 0.05 (-Log10P>1.3) was applied as cut-off and it is indicated by the dashed line. 
 
6.5 Canonical Pathway analysis by Ingenuity Pathway Analysis (IPA®) 
Canonical Pathway analysis of the DEGs was performed using QIAGEN’s Ingenuity 
Pathway Analysis (IPA
®
, www.qiagen.com/ingenuity) which allowed the identification of 
groups of biological pathways similarly activated or inhibited across time in the three models 
of murine parturition. A total of 46 canonical pathways were detected as significantly over-
represented (P<0.05, Z-score>|2|). Hierarchical clustering allowed visualization of trends and 
clusters of significantly enriched pathways based on their enrichment P-values (Fig. 6.6 and 
Appendix B - Table B.3) and activation Z-scores calculated based on directionality of gene 
changes (Fig. 6.7 and Appendix B - Table B.4). Hierarchical clustering of the 46 pathways 
highlighted a strong similarity in enrichment profiles characterising genes changing between 
E16 and labour, between 6 and 18 hours following RU486 and during RU486-induced 
labour. Additionally, this analysis revealed that RU486 modulates biological functions 
similarly to those seen during normal spontaneous labour (Fig. 6.6).  
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Figure 6.6 Hierarchical clustering of canonical pathway enrichment P values by IPA
®
. Canonical 
pathways identified as significantly enriched with genes differentially expressed in the following 
pairwise comparisons: E16 vs E18, E16 vs LAB, E18 vs LAB, 6h RU486 vs 18h RU486, 6h RU486 
vs LABRU486, 18h RU486 vs LABRU486, 2h LPS vs 6h LPS and 2h LPS vs LABLPS. P values 
(P<0.05) indicate enrichment significance. 
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While a number of pathways were similarly represented, as shown in the normal gestation 
and RU486 model, DEGs detected between 2 and 6 hours following LPS and during LPS-
induced labour exhibited a distinctive enrichment profile. The top represented pathways were 
enriched for inflammatory pathways including role of pattern recognition receptors in 
recognition of bacteria and viruses”, interferon signalling, death receptor signalling, acute 
phase response signalling and UVA-induced MAPK signalling. Hierarchical clustering of 
activation Z-scores showed that these inflammatory pathways are predicted as activated by 
LPS treatment (Fig 6.7), while no significant Z-score for these pathways was associated with 
either normal gestation or RU486-induced PTL models. 
The pathways most significantly activated following RU486 treatment were LXR/RXR 
activation, agrin interactions at neuromuscular junction, PAK signalling and cardiac 
hypertrophy signalling. LXR/RXR pathways as well as Wnt/β-catenin signalling, inhibition 
of angiogenesis by TSP1 and retinoic acid-mediated apoptosis signalling pathways were 
among the most significant pathways enriched with genes changing throughout a normal term 
gestation. 
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Figure 6.7 Hierarchical clustering of canonical pathway enrichment Z-score by IPA
®
. Canonical 
pathways identified as significantly enriched with genes differentially expressed in the following 
pairwise comparisons: E16 vs E18, E16 vs LAB, E18 vs LAB, 6h RU486 vs 18h RU486, 6h RU486 
vs LABRU486, 18h RU486 vs LABRU486, 2h LPS vs 6h LPS and 2h LPS vs LABLPS. P values 
(P<0.05) indicate enrichment significance. 
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6.6 Identification of a core set of differentially expressed genes associated with term 
and preterm labour 
DEGs detected in the pairwise comparisons described in Par. 6.2 were analysed to identify 
sets of genes mutually regulated between models, or unique to each of them (Fig. 6.8 A). 
A core set of genes changing across all models was identified, 95 of which were upregulated 
(Table 6.2), while 148 were downregulated (Table 6.3). Process networks analysis 
(Metacore
®
) on this core set of genes showed enrichment of signalling pathways involved in 
tissue remodelling (P=1.12×10
-3
), muscle contraction (P=1.49×10
-2
), cell proliferation 
(P=1.94×10
-7
) and apoptosis (P=9.190×10
-3)
, (Fig. 6.8 B). This group included genes 
previously associated with myometrial contractility and included upregulation of 
prostaglandin-endoperoxide synthase 2 (Ptgs2), prostaglandin E synthase 2 (Ptges2) [119] 
and apolipoproteins [521], and downregulation of potassium voltage-gated channels [27], G-
protein coupled receptors and leukemia inhibitory factor receptor. These findings are 
consistent with a compensatory mechanism involving the attenuation of the sensitivity of the 
myometrium to pro-contraction signals around the time of labour [522-525]. Process network 
analyses performed on those genes exclusively changing throughout normal murine gestation 
(341 upregulated, 260 downregulated, Fig. 6.8 C and Appendix B – Table B.5) showed 
enrichment of biological pathways associated with pregnancy such as muscle contraction 
pathways that included genes encoding for G-protein coupled receptors, guanylate cyclase-
activating protein and dystroglycan; genes involved in gonadrotopin regulation i.e. family 
members of the AP-1 family (JunB, Fos, FosB), chemotaxis and inflammation i.e. chemokine 
(C-X-C motif) ligand (Cxcl) 1, Cxcl2, Cxcl10, Cxcl16, and Tnfα. Genes exclusively 
modulated in the RU486 model (286 upregulated, 303 downregulated, Fig. 6.8 D and 
Appendix B – Table B.6) were enriched in cell adhesion and proteolysis pathways and 
included genes encoding for structural proteins such as collagen (Col5a2 and Col6a4) and 
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cadherins (Cdh4,Cdh13, Cdh17, Pcdha11 and Pcdha12) as well as remodelling enzymes i.e. 
metallopeptidases (Mmp) 2, Mmp20, Mmp27 and numerous genes encoding for Adam (a 
disintegrin and metallopeptidase domain) family members (Adam5, Adam10 and Adam19). 
Approximately 80% (1848/2312) of the LPS-induced gene changes were solely changed 
upon LPS stimulus (Fig. 6.8 E and Appendix B – Table B.7) and included genes participating 
to inflammatory pathways such as interferon signalling (i.e. Irf7, Stat1, Stat2 and Stat5, 
iNOS, and caspase-1); Notch signalling (i.e. platelet derived growth factor B (PDGF-B) and 
PDGF receptor; platelet-endothelium-leucocyte interactions (i.e. P-selectin, E-selectin, L-
selectin, and CD47); NFκB-mediated apoptosis (including the genes c-IAP1, TNFRSF17, IL-
15RA, and I-kB) and Immune response-TH17 derived cytokines pathway. These results 
suggest that LPS-induced PTL involves activation of a greater number of genes compared to 
RU486 treatment and normal gestation, the majority of which are inflammatory and whose 
expression levels do not change throughout normal gestation or in RU486-induced PTL. 
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Figure 6.8 Identification of a core set of genes differentially expressed in normal term labour 
and preterm labour models. (A) Venn diagram depicting overlap between differentially expressed 
genes as detected in term labour (blue), RU486-induced (grey) and LPS-induced (yellow) PTL 
models. Process network analysis (Metacore
®
) was performed on the core set including those genes 
differentially expressed in all models of parturition (B), on genes changing only in the term labour 
model (C), genes exclusively changing with RU486 treatment (D), and on genes exclusively changing 
following LPS treatment (E). Bar length indicates significance and is equal to the negative logarithm 
of enrichment P value. A P-value cut-off less than 0.05 (-Log10P>1.3) was applied and is indicated by 
the dashed line. 
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Table 6.2 Core set of gene changes upregulated throughout gestation in all models of 
parturition. Gene name, gene description and Ensembl gene identification number are reported for 
each gene.  
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 Table 6.3 Core set of gene changes downregulated throughout gestation in all models of 
parturition. Gene name, gene description and Ensembl gene identification number are reported for 
each gene. 
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6.7 Functional progesterone withdrawal via RU486 anticipates most non-
inflammatory gene changes observed prior and during labour in term gestation 
As shown in the previous paragraph, normal term gestation and RU486 models exhibit the 
greatest number of shared differentially expressed genes. The analyses presented below were 
performed to investigate to what extent and at what stage RU486 was exercising its greatest 
effect on gene expression. Genes differentially expressed between E16 and E18 and between 
E18 and labour were compared with those changing in response to RU486 from 6 to 18h, 
which represents the time points exhibiting the majority of gene changes detected in the 
RU486 model. Two groups of genes were identified, one including 55% of the genes 
(187/342, Appendix B - Table B8 and Appendix B - Table B9) changing between E16 and 
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E18 and 18h post-RU486 treatment (early changing genes), and a second group including 
63% of the genes (295/466, Appendix B - Table B10 and Appendix B - Table B11) similarly 
changing between E18 and labour and 18h post-RU486 treatment (late changing genes) (Fig. 
6.9 A, FDR<0.01). 
 
Figure 6.9 Functional progesterone withdrawal via RU486 anticipates the majority of gene 
changes observed prior and during the onset of labour in term gestation. (A) Venn diagram 
representing overlap between gene changes characterising term gestation (E16 vs E18 and E18 vs 
LAB) and genes changing between 6 h and 18 h following RU486 treatment. FDR<0.01. (B) Top 5 
putative upstream regulators of differentially expressed genes identified by Causal Network analysis 
(IPA
®
). Network depth is reported in the first column and indicates the nature of the connection 
between the expressed genes and the predicted regulator (1=direct connection, 2=one intervening 
regulator, 3=two intervening regulators). Upstream regulators with a significant overlap (P≤0.05) and 
an activation Z-score≥|2.0| were considered significantly activated/inhibited. (C) Process Network 
Analysis performed on DEGs similarly changing between E16 and E18 and between 6 h RU486 and 
18 h RU486; between E18 and LAB and 6 h RU486 and 18 h RU486 (D). Bar length indicates 
significance and is equal to the negative logarithm of enrichment P value. A P value cut-off less than 
0.05 (-Log10P>1.3) was applied and is indicated by the dashed line. 
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Causal Network Analysis by IPA
® 
identified potential upstream regulators of DEGs detected 
in each pairwise comparison. As expected the main upstream regulator predicted to modulate 
gene changes associated with RU486-induced progesterone withdrawal was mifepristone (Z 
score6h RU486 vs 18h RU486 =6.6, Fig. 6.9 B). Mifepristone was comprised within the top 15 
putative regulators predicted to have an impact on DEGs as detected between E16 and E18 in 
the term labour model (Z-scoreE16 vs E18=2.9). Mifepristone was also significantly predicted to 
regulate DEGs as detected between E18 and LAB (Z-scoreE16 vs E18=2.2). Other top predicted 
regulators included Calcium/Calmodulin-Dependent Protein Kinase (CaMKI), Epidermal 
Growth Factor (EGF) and its receptor (EGFR). Process networks analysis showed that while 
early response genes were primarily involved in extracellular matrix remodelling 
(P=6.16×10
-3
), cell adhesion (P=6.61×10
-3
) and blood vessel morphogenesis (P=1.37×10
-2
), 
(Fig. 6.9 C), late response genes were involved in muscle contraction (P=3.10×10
-4
), 
regulation of cytoskeleton rearrangement (P=1.96×10
-3
) and potassium transport (P=9.87×10
-
3
), (Fig. 6.9 D). 
6.8 Orthogonal signal correction - partial least squares (OSC-PLS) modelling of 
gene expression changes associated with contractile phenotype acquisition 
Orthogonal signal correction-partial least squares (OSC-PLS) analysis [424]  was used as a 
supervised modelling approach to identify time-associated variations in gene expression 
changes characterising each model of parturition. OSC-PLS is a regression and prediction 
method that uses information defined as variables X (in this instance gene expression values) 
to predict known information specified as variables Y (experimental groups, i.e. E16, E18 
and LAB, 2h-6h LPS and LABLPS, or 6-18h RU486 and LABRU486). OSC-PLS modelling 
finds correlation patterns that differentiate groups and estimates the relative contribution of 
each gene to the discrimination by assigning a loading value (positive indicating direct 
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correlation, and negative indicating inverse correlation). This method is therefore able to 
separate the systematic variation in X in two parts, one correlating, therefore predictive of Y, 
and one not correlated (orthogonal) to Y. This approach allows filtering of variation not 
directly related to the response [526], thereby improving the predictive potential of the model 
and enabling study of only discriminatory variation associated with different experimental 
groups.  
Genes with zero read counts were excluded and only DEGs in at least one of the following 
pairwise comparisons were considered: E14 vs E16, E14 vs E18, E14 vs LAB, E16 vs E18, 
E16 vs LAB and E18 vs LAB for the term gestation model; 6h DMSO vs 6h RU486, 18h 
DMSO vs 18h RU486, 6h RU486 vs 18h RU486, 6h RU486 vs LABRU486 and 18h RU486 vs 
LABRU486 for the RU486-induced PTL model; 2h PBS vs 2h LPS, 6h PBS vs 6h LPS, 2h LPS 
vs 6h LPS, 2h LPS vs LABLPS and 6h LPS vs LABLPS for the LPS-induced PTL model. As 
described previously, a total of 4142 genes were identified and relative expression changes 
were used in the OSC-PLS modelling. The OSC-PLS model was independently trained on the 
three different murine models: term gestation, PTL induced by RU486, and PTL induced by 
LPS. Subsequently, the two remaining models were used as test sets to assess time-associated 
gene correlations between models. A Pearson’s correlation coefficient (r) and its relative P 
value were calculated for each analysis between the gestation time and the predicted scores of 
the test sets to indicate positive, negative or absence of correlation between the training and 
the test set. If two models shared a similar set of genes consistently changing throughout the 
time-course the correlation score would be positive and a similarity in the transcriptional 
mechanisms underlying labour onset may be inferred. 
Firstly, genes changing as a function of time in mice labouring spontaneously at term were 
used to develop the training set (Fig. 6.10 A).  
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Figure 6.10 OSC-PLS analysis illustrates gene expression changes associated with progression 
of term gestation and PTL models. OSC-PLS analysis illustrating correlations between time-
associated gene changes characterising term gestation (blue), RU486 (grey) and LPS models (yellow). 
(A) Term gestation was used as training set and a positive correlation was found when using either 
RU486 or LPS models as test sets. (B) Using the RU486 model as training set, a positive correlation 
was found with both term and LPS models. (C) When the LPS model was used as the training set no 
significant correlation was found with either RU486 or term labour models. Correlation coefficients 
(r) were calculated using Pearson linear correlation (P<0.05). 
 
The RU486 and LPS models were then used as test sets and a strong positive correlation was 
found with the training in both cases (r=0.752, P=0.003 and r=0.731, P=0.011 respectively) 
indicating a robust similarity between major gene changes associated with progression of 
gestation and those changes observed with premature parturition induced by RU486 and LPS. 
Similar results were observed when the RU486 model was used as the training set (Fig. 6. 10 
B) with a strong positive correlation found between the normal gestation model (r=0.768, 
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P=0.004) and to a lesser extent the LPS model (r=0.613, P=0.045). In contrast, when the LPS 
model was used as the training set (Fig. 6.10 C) no significant correlation was found with 
either RU486 (r=0.553, P=0.05) or normal gestational (r=0.204, P=0.525) models indicating 
that the majority of genes induced by LPS stimulus are unique to this model. 
 
6.9 Comparison of murine and human myometrial transcriptome changes 
To study the relationship between transcriptome changes characterising murine myometrium 
with those observed in humans, DEGs identified in murine myometrium across three models 
of gestation were analysed together with a recently published human data set [406]. The 
human dataset comprised myometrium transcriptome changes occurring prior to and 
following the onset of spontaneous term human labour [406]. EdgeR analysis was repeated to 
identify DEGs with a homogenous FDR threshold of less than 0.001, which was applied to 
both human and murine datasets. A total of 357 DEGs shared between mouse and human was 
identified and selected for further analysis (Fig. 6.11 A). A full list of gene names is provided 
in Appendix B – Table B.12. OSC-PLS analysis was used to investigate the relationship 
between time-associated gene changes observed in mouse myometrium and changes 
associated with human parturition. Gene expression variations across term murine gestation, 
and those identified following RU486 or LPS treatment served as training sets against which 
the corresponding gene changes in human myometrium were tested (Fig. 6.11 B). The OSC-
PLS model showed clear separation between human samples collected prior to and following 
the onset of labour when each of the murine models was alternatively used as training set. 
These results indicate the existence of temporal similarities in gene changes characterising 
murine and human myometrial evolution towards a contractile phenotype regardless of the 
nature of the gestation (term or preterm). 
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Figure 6.11 Identification of DEGs shared between murine and human myometrial 
transcriptomes and OSC-PLS modelling. (A) Venn diagram depicting a total of 357 orthologous 
genes significantly changing in the myometrium of murine models of term gestation, RU486-, and 
LPS-induced PTL, and at the onset of spontaneous term labour in human. DEGs were selected if 
significantly changing in at least one of the following comparisons: E16 vs E18, E18 vs LAB and E16 
vs LAB in the term gestation model (TERM GEST); 6h RU486 vs 18h RU486, 18h RU486 vs 
LABRU486 and 6h RU486 vs LABRU486 in the RU486-induced PTL model (RU486); 2h LPS vs 6h LPS, 
6h LPS vs LABLPS, 2h LPS vs LABLPS in the LPS-induced PTL model (LPS). (FDR<0.001); and in 
myometrium samples collected prior (NIL) and following (IL) the onset of spontaneous labour. The 
total number of DEGs identified in murine models and in human samples is reported in squared 
brackets. (B) OSC-PLS modelling of murine and human myometrium transcriptome changes 
associated with activation of contractions and labour. Murine gene expression changes associated with 
each model of gestation were used as a training set and gene changes characterising the onset of 
spontaneous human term labour were tested against each model. (r) Pearson’s correlation coefficient. 
Correlation between training set and test sets is considered significant if P<0.05.  
 
The relative contribution of each gene to the gestational models was then analysed using 
corresponding loading scores that were analysed through hierarchical clustering analysis (Fig. 
6.12 A). Among the 357 orthologous DEGs, about 60% exhibited similar degree and 
directionality of change upon LPS treatment in the murine model and labour onset in the 
human (clusters 1, 2, 3, 5, and 6). Hierarchical clustering also revealed that compared to 
normal gestation or RU486-induced PTB, LPS-induced PTB in the mouse is more similar to 
the transcriptome changes observed in the human with labour onset. 
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Figure 6.12 Hierarchical clustering of loadings values identified 8 clusters of gene expression 
patterns across gestation. (A) Hierarchical clustering of loadings values from OSC-PLS models 
allowed the identification of 8 clusters (color-coded side bar) of genes with similar expression 
patterns throughout murine gestation and in human myometrium samples prior to and following the 
onset of spontaneous term labour. (B) Gene read counts (normalized to the maximum value) 
belonging to each cluster are displayed separately as gene expression patterns throughout term 
gestation (blue), RU486- (grey) and LPS-induced PTL (yellow) and during term human labour 
(black). (C) Top Networks identified by Process Network analysis relative to each cluster. Gene 
patterns associated with each cluster are summarised by the color-coded arrows displayed in the first 
column of the table (blue: term gestation, grey: RU486 model; yellow: LPS model). Enrichment is 
considered significant if P <0.05.  
  
 204 
 
Examination of the expression patterns of these gene clusters throughout the time course 
towards labour in mouse (blue, grey and yellow line graphs) and human (black line graphs) 
allowed the study of the temporal dynamics of the myometrial transcriptome and the 
identification of eight clusters with specific fluctuations in gene expression across the time-
course (Fig. 6.12 B). Process Network analysis was performed to identify biological 
functions enriched in each of these clusters (Fig. 6.12 C). Genes down-regulated throughout 
gestation in all mouse models and with labour onset in the human (Cluster 1, Appendix B - 
Table B13) were highly represented in neuromuscular junction and cell adhesion pathways. 
Genes specifically decreased (Cluster 2, Appendix B - Table B14) in both LPS induced PTL 
and human labour were enriched in pathways related to circadian rhythm, chromatin 
modification and GABAergic neurotransmission. Cluster 3 (Appendix B - Table B15) genes 
specifically up-regulated only in LPS-induced PTL were overrepresented in muscle 
development and cell adhesion pathways. Cluster 4 (Appendix B - Table B16) contained 
genes upregulated only with the onset of human labour and were enriched in multiple 
stress/damage pathways including response to unfolded proteins, proteolysis and blood 
coagulation. Similarly, genes increased in both LPS-induced PTL model and human (Cluster 
5, Appendix B - Table B17) were enriched for proteolysis and cell adhesion pathways. Genes 
found consistently increased across gestation in all murine models and human (Cluster 6, 
Appendix B - Table B18) were enriched in immune response, chemotaxis and cell 
proliferation pathways.  In the murine model of term labour, the majority of genes were 
raised between E18 and labour. In contrast, these genes were shown to be rapidly upregulated 
in both PTL models prior to labour onset. Cluster 7 (Appendix B - Table B19) included genes 
up-regulated throughout murine gestation but down-regulated with human labour onset and 
included genes highly enriched in angiogenesis, muscle contraction and progesterone 
signalling pathways. Finally Cluster 8 (Appendix B - Table B20), including genes 
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downregulated only in the murine LPS model, was over-represented in reproduction, cell 
cycle and angiogenesis pathways. 
 
6.10 Summary and discussion 
The results described in this chapter reveal novel insights into the transcriptome changes 
preceding the acquisition of a labouring phenotype in three models of mouse parturition; term 
gestation and PTL induced by either functional progesterone withdrawal (RU486) or 
inflammation (LPS). Further, they provide a comparison with gene changes observed in 
human myometrium at the onset of spontaneous term labour. These results allowed the 
evaluation of the relative contribution of specific gene changes to each model of parturition, 
denoting a prominent role for progesterone-modulated pathways in both term gestation and 
non-inflammatory PTB.  
Studies performed on human or animal samples collected before and after labour onset are 
likely to provide very limited insights into transcriptome changes occurring prior to labour 
onset. Importantly, studies on material obtained from the human uterus are often 
characterised by intra- and inter-patient variability, as suggested by studies showing 
heterogeneity in gene expression profiles from different areas of the uterus as labour 
approaches, as well as differences in the degree of functional responses observed within these 
tissues and across patients [401, 527-529]. Gene expression changes characterising murine 
myometrium throughout gestation have been previously investigated using microarrays [411-
413]. Although very informative, these studies are limited by the comparatively low 
specificity, sensitivity and dynamic range of hybridization-based techniques [419]. These 
studies therefore do not provide a comprehensive picture of gene changes causative of labour. 
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It is plausible that many gene expression changes detected in samples collected during labour 
may occur as a consequence of labour itself or activation of uterine involution and be 
erroneously considered as a requirement for labour activation. This pitfall was also recently 
highlighted in a RNA-Seq study by Chan Y.W. et al. designed to assess transcriptome 
changes in human myometrium prior and following the onset of labour [406]. The authors of 
this work expressed the necessity of time-course experiments in order to be able to infer 
causality between gene expression and labour onset. 
Experiments described in this chapter were designed to evaluate global transcriptome 
changes occurring throughout a wide time frame across gestation in the mouse as well as 
immediately after birth of the first pup. The aim was to capture a comprehensive picture of 
the gene changes causative of labour, which are likely to take place earlier than the actual 
onset of labour in order to allow the uterus to acquire the phenotype necessary to respond 
rapidly with contractions at term. 
Previous animal studies have shown that LPS is able to induce PTL [260, 342, 495] and this 
event occurs without changes in the levels of circulating progesterone [530]. Norman and 
colleagues have recently demonstrated Rho/ROCK signalling pathway activation in uterine 
myocytes in a murine model of LPS-induced PTL. TNF-α was one of the cytokines more 
strongly induced by LPS and able itself to induce PTL [531, 532]. Interestingly, while it was 
possible to abrogate LPS-induced contractions using specific ROCK pathway inhibitors, 
TNF-blocking antibodies were unable to prevent this event, suggesting the ability of LPS to 
act directly on contractile pathways even upon impairment of the inflammatory response 
[532]. Similarly in humans, while the majority of very early PTB cases are associated with 
infection, most late PTB cases are not [533, 534] and spontaneous PTL with unknown 
etiology still represents half of all cases of preterm deliveries [535]. Further, the presence of 
inflammatory cells in the gestational tissue does not necessarily results in PTL. Indeed, 
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preterm tissues delivered by caesarean section without labour were found to contain bacteria 
as frequently as PTL or PPROM samples [536]. 
Consistent with these observations from both mice models and human, the data described in 
this chapter show that inflammation appears to be sufficient to override the repressive effects 
of progesterone and induce labour prematurely in the mouse, as observed in the LPS-induced 
PTL model. Pharmacological withdrawal of progesterone function by the progesterone 
receptor antagonist RU486 is, on the other hand, sufficient to induce PTL without changes in 
inflammatory gene expression indicating that, at least at the gene expression level, PTL can 
occur in the absence of inflammatory stimuli and its associated inflammatory response. 
PCA (Fig. 6.1) examining the genome-wide transcriptome profiles of mice undergoing term 
or preterm gestation enabled the simultaneous analysis of genome-wide gene expression 
changes associated with each model of parturition. The visualization of individual 
transcriptome profiles indicated consistency within each experimental group, as shown by 
high homogeneity among samples within the same experimental group. We showed that 
while mice experiencing term gestation and RU486-induced PTL exhibited similar global 
gene expression changes, mice induced to PTL by LPS exhibited distinctive transcriptome 
profiles developing along a remarkably divergent trajectory throughout gestation. A total of 
4142 DEGs were identified using this approach (Fig. 6.2). These results outperformed a 
previous microarray study that reported only 503 genes changing between E14 and E16 and 
between E14 and E18 [411]. Here we reported a 40% increase in the number of genes 
detected at analogous comparisons using a FDR<0.001, 50 times more stringent than the cut-
off used by Bethin et al., further highlighting the greater detection power of RNA-seq 
compared to microarrays [419]. 
In the PTL models, the majority of uterine transcriptome changes were observed prior to 
labour onset, between 6h and 18h post-injection in the RU486-induced PTL model and 
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between 2h and 6h post-injection in the LPS-induced PTL model. These data indicate that, as 
hypothesised, most of uterine transcriptome changes associated with labour occur prior to the 
start of contractions regardless of the stimulus (RU486 or LPS), highlighting the value of 
temporal transcriptome profiling in investigating transcriptional mechanisms of labour. 
Visualisation of each individual transcriptome profile by hierarchical clustering confirmed 
results obtained with PCA, indicating high similarity in myometrium samples collected from 
mice belonging to the same experimental group (Fig. 6.4). However, in the term model, high 
variability was observed at E18, with two samples clustering with E16 group and one sample 
clustering with LAB. The proximity to labour, which will occur in about half day in these 
mice, may be responsible for this heterogeneity. 
This analysis also allowed visualisation of gene expression patterns in each model and 
identification of three main trends shared among all models of parturition. These analyses 
confirmed high similarity between gene expression profiles of term gestation and RU486-
induced PTL model, i.e. a similar sets of genes were consistently down- or up-regulated 
throughout gestation in the two models. Although exhibiting a largely similar profile, the LPS 
model featured a group of genes down-regulated at early gestation and specifically up-
regulated 6 hours following LPS and during labour (Cluster 2, Fig 6.4 C). Process network 
analysis showed that these genes were mainly inflammatory or involved in tissue remodelling 
pathways activated by LPS treatment (Fig.6.5). Hierarchical clustering of canonical pathway 
enrichment performed by IPA
®
 on DEGs identified across all models showed similarly that 
the most significant pathways enriched with genes affected by LPS treatment were mainly 
inflammatory pathways (Fig.6.6) which were all predicted as activated, according to their Z-
score (Fig. 6.7). These data collectively indicated the presence of a gene expression signature 
specifically associated with inflammation-induced PTL. This idea was partially suggested in 
a study by Muhle R.A. et al. that presented a cDNA microarray analysis of mouse 
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myometrium collected from four different models of gestation: infection with PTB, infection 
with term labour, labour induced without infection via ovariectomy, and vehicle controls 
[412]. In this study 68 genes were identified as differentially expressed in the infection with 
PTB group, 13 of which were exclusive to the model and not changing in the others. Despite 
the limited number of differentially expressed genes identified likely due to the low 
resolution of the technique, this work provided a valuable indication on the existence of a set 
of genes specifically activated upon LPS treatment that was further developed in our study.  
Cross-comparison of DEGs identified in each model of parturition identified a core gene set 
likely to be representative of transcriptome changes required for both term and PTL (Fig 6.8 
A, B). Of these, two thirds were downregulated and one third was upregulated. Pathways 
including cell proliferation, adhesion and tissue remodelling, ion transport, muscle 
contraction, NFκB and MAPK signalling were highly enriched with core genes. These data 
add to the parturition paradigm involving a common terminal pathway, which supports the 
existence of a set of common molecular and physiological mechanisms underlying the onset 
of both term and PTL, regardless of the underlying etiology [5]. This group included genes 
previously associated with myometrium activation and contractions such as the 
prostaglandin-endoperoxide synthase 2 Ptgs2 (i.e. Cox2) [145], prostaglandin E synthase 2 
(Ptges2) [119], apolipoproteins [521], progesterone-regulated genes such as Cyp26a1 [537] 
all up-regulated in the three models, while genes encoding for a variety of potassium voltage-
gated channels [27], G-protein coupled receptors and solute carriers were all down-regulated 
perhaps providing a compensatory mechanisms to attenuate sensitivity of the myometrium to 
contraction-promoting signals as labour approaches [522-525]. Among these genes some 
novel candidates were identified with a potential role in promoting myometrial contractions 
including genes encoding for components of the contractile machinery (Myo1d Mtmr1, Smtn 
and Thbs1), and several potassium channel isoforms (Kcne2, Kcne4, Kcnd2 and, Kcng1). 
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Transcriptome changes uniquely observed in the normal term labour model (Fig 6.8 A, C) 
were mainly related to muscle contraction, chemotaxis and inflammation indicating that the 
process of normal labour involves an inflammatory component as well as involving 
modulation of genes with a role in muscle contractions. 
These data are in agreement with the idea that although term labour in the mouse is mediated 
by withdrawal of progesterone which occurs between E16 and E18 [73], labour still involves 
activation of inflammation, consistent with data presented in Chapter 5 [68, 187]. As shown 
in other studies, term labour is associated with an influx of inflammatory cells into the 
myometrium yet depletion of a range of immune cells does not block labour [159-162]. 
Furthermore, activation of inflammatory pathways is sufficient but not required for cervical 
ripening [162, 538, 539]. In RU486-induced PTL there is no infiltration of macrophages or 
neutrophils during labour, although this is seen after delivery [157]. In this chapter was 
shown that genes changing uniquely in the RU486 model (Fig 6.8 A, D) were mostly 
involved in tissue remodelling pathways consistent with the role of progesterone in regulating 
extracellular matrix remodelling during gestation [85]. The observation that most of gene 
changes associated with RU486 treatment were not inflammatory, taken together with 
previous studies from our laboratory showing that knockout of PR in myocytes does not 
affect inflammatory gene expression [91], suggests that while progesterone does suppress 
expression of specific inflammatory genes in vitro, it may not have a global anti-
inflammatory effect in the uterus in vivo. In contrast, a set of genes uniquely upregulated with 
proximity to labour following LPS treatment was identified and it included genes mainly 
involved in inflammatory pathways (Fig 6.8 A, E). Others studies have suggested that 
synthesis of inflammatory mediators and infiltration of inflammatory cells may be involved 
in uterine involution postpartum [157]. Both proinflammatory and immunosuppressive 
responses were found to be associated with postpartum repair of the cervix instead of 
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ripening in both mouse models and women [55, 162, 408]. Since we found the great majority 
of genes detected solely in the LPS-induced PTL model (1848/2312) to be inflammatory 
genes, it is indeed plausible they may not be needed for labour itself, but rather be involved in 
involution of the uterus post-partum, still potentially causing maternal, and importantly, fetal 
damage [186, 347, 540-543]. 
By identifying differentially expressed genes and comparing them across the three models, a 
considerable overlap was observed with DEGs seen prior to and with the onset of labour in 
mice labouring spontaneously at term and with genes changing between 6 hours and 18 hours 
following RU486, indicating that the majority of transcriptome changes preceding labour in 
the mouse are progesterone regulated (Fig. 6.9 A). When Causal Network Analysis by IPA
®
 
was used to predict possible upstream regulators of the observed gene changes, RU486 was 
predicted as top regulator potentially regulating the observed gene changes occurring in both 
RU486 and term gestation models (Fig. 6.9 B). The calcium/calmodulin dependent protein 
kinase (CaMK) and epidermal growth factor (EGF) were predicted as alternative potential 
upstream regulators of the gene expression changes observed. CaMK was previously reported 
to modulate the activity of transcription activators involved in immune response and 
inflammation [544, 545] while EGF was shown to mediate gene expression changes via 
MAPKs and NFκB [546, 547]. By assessing the degree of overlap between gene changing 
throughout normal term gestation and in the RU486-induced PTL model, two sets of genes 
were identified to be induced by RU486 and whose expression changed similarly early (E16 
vs E18, Appendix B – Table B8 and Appendix B – Table B9) or late (E18 vs LAB, Appendix 
B – Table B10 and Appendix B – Table B11) throughout gestation. Several genes known to 
be regulated by progesterone as well as novel potential candidates were identified including 
the homeobox gene Hoxa11 [548], several structural/cytoskeletal proteins such as small 
proline-rich proteins including 2D, 2F, 2A2-A3-A1, and extracellular matrix proteins such as 
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laminins (α2-4, β2-3, γ1-2), some of which were previously identified as progesterone-
regulated during implantation in the mouse uterus [549]. These data further support the 
validity of this approach in identifying progesterone-regulated genes throughout gestation. 
Process Network analysis revealed that these two waves of gene expression in the uterus were 
involved firstly in tissue remodelling, presumably for preparation of the uterus for labour, and 
subsequently, in activation of the uterine contractions (Fig. 6.9 C,D). 
Considering E16 as the start point of the time-course experiment, gene expression changes 
associated with ongoing gestation were acquired across a different time scale in each mouse 
model. While mice experiencing term gestation delivered within three days of E16, those 
mice delivering preterm gave birth within 20 hours or 7 hours following RU486 or LPS 
treatment respectively. OSC-PLS modelling (Fig. 6.10) uses genes and their relative loading 
scores (a measurement of their relative importance to each model of parturition) to test for 
correlation between different models. If two models shared a similar set of genes consistently 
changing throughout the time-course the correlation score would be positive and a similarity 
in the genetic mechanisms underlying labour onset may be inferred. These results showed 
firstly that it was possible to distinguish between different sample groups of both RU486 and 
LPS models based on the time-associated gene changes characterising term gestation. This 
analysis suggests that gene changes acquired throughout a normal term gestation also occur 
in a similar fashion in the RU486- and LPS-induced PTL models although within a shorter 
time frame. Secondly, by using each murine model alternatively as a training set, it was 
possible to test if similar or different genes are important for the acquisition of a labouring 
phenotype in each model. These results showed that similar transcriptome changes govern the 
onset of both term and RU486-induced PTL (Fig. 6.10 A, B). In contrast, time-dependent 
transcriptome changes induced by LPS treatment did not correlate with term gestation and 
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RU486 models (Fig. 6.10 C), further supporting the existence of a set of inflammatory genes 
controlling the onset of labour specifically in the LPS model. 
Although numerous differences exist at both the anatomical and physiological level between 
murine and human reproductive systems, mice are still the most widely used animal model 
for examining molecular pathways of parturition [324]. Despite these differences, various 
components of the parturition process are conserved between these organisms. For instance 
an important role is played by prostaglandins in stimulating contractions at term and 
contraction-associated proteins such as connexin-43 and oxytocin receptor are found 
upregulated in both human and mouse at labour onset [66, 358, 364]. Intriguingly, even 
though the loss of oxytocin signalling and its receptor in mice does not compromise fertility 
and parturition [361, 362, 371], the combined loss of OT with COX-1 delays parturition 
[358]. These data give examples of the complex interdependence between different signalling 
pathways leading to parturition. 
To examine how our murine models of parturition relate to human, we re-analysed an 
available dataset reporting transcriptome changes characterising human myometrium prior 
and during spontaneous labour [406]. We identified a total of 357 orthologous genes 
differentially expressed in both human myometrium and in our murine models (Fig. 6.10A). 
Among these, a number of genes with a recognised role in parturition were identified 
including: the zinc finger E-box binding homeobox 1 (Zeb1), which has been found 
downregulated in murine models of PTL [550] as well as in human during spontaneous 
labour. This gene was down-regulated in murine model of term gestation, between E16 and 
labour. A recent study by Roger Smith and colleagues reported downregulation of the ether-
a-go-go-related (ERG) K
+
 channel (Kcnh2) in human myometrium at term and correlated this 
event with potentiation of myometrial contractions [27]. We also found Kcnh2 down-
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regulation in both human and mouse term gestation at labour onset, as well as during LPS-
induced PTL. As we showed in the previous chapter, murine term labour and PTL are 
associated with increased activation of AP-1 family members [68]. Others studies have 
showed similar up-regulation of AP-1 family members both at gene and protein levels in 
myometrium samples collected during human labour [406, 551]. As we have recently 
reported, inhibition of AP-1 activation by blocking the MAPK responsible for its activation, 
JNK, is effective in delaying PTL in the mouse and improving pup outcome [68, 540]. 
Additionally, upregulation of the AP-1 members JunB, Fos and FosB in both human and 
mouse datasets further supports a role for this transcription factor in parturition. 
OSC-PLS modelling was then used to test for correlation between gene changes observed in 
the two organisms. A significantly positive correlation was found between the three murine 
models and the human datasets (Fig. 6.11 B). These findings are consistent with the 
hypothesis that even if human labour occurs without systemic withdrawal of progesterone, it 
likely involves functional progesterone withdrawal mediated by changes in PR isoforms 
expression [75, 78, 552] and/or activation of inflammatory transcription factors [187, 209]. 
Since genes with similar expression profiles may cooperate in the same biological functions, 
we used hierarchical clustering to divide the 357 shared genes into further sub-groups based 
upon their expression profile across the time-course (Fig. 6.12). Two clusters named Cluster 
1 and Cluster 6, representing 40% of all changes shared between mouse and human, included 
genes similarly modulated in all models. Process Network analysis of genes downregulated 
throughout gestation (Cluster 1) showed high representation in cell adhesion pathways likely 
to be progesterone-dependent [553], including neural cell adhesion molecule 1 (Ncam1), 
collagen, type IV, alpha 6 (Col4a6), extracellular matrix protein 2 (Ecm2), and phospholipase 
C (Plce1). Some of these genes as well as their alternative isoforms were previously found 
upregulated by progesterone in neonatal mouse uterus [554], further supporting a role for 
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RU486 therefore progesterone signalling in modulating their expression throughout gestation. 
Genes up-regulated throughout gestation (Cluster 6) were strongly enriched in gonadotropin 
regulation of reproduction, cell cycle, and inflammatory pathways and included known pro-
labour genes such as Ptgs2 [450], leukemia inhibitory factor (Lif) which was shown to 
promote trophoblast invasion [555] as well as AP-1 member Fos. The interleukin 1 receptor 
antagonist (Il-1rn) and the anti-inflammatory cytokine Il-11 were both up-regulated, 
suggesting a potential compensation mechanism against exacerbation of the inflammatory 
response at term [556]. Clusters 4 and 7 are noteworthy since genes belonging to these 
clusters exhibited opposite direction of change in the human samples compared to the three 
murine models. We speculate this is because the human samples were collected well after the 
onset of labour, and thus may reflect gene expression changes induced by labour itself or by 
the initiation of involution mechanisms necessary for remodelling the uterus post-delivery 
[406]. This hypothesis is supported by the increased expression seen in human samples of 
genes involved in response to unfolded proteins (heat shock protein 5, calreticulin), 
proteolysis (matrix metallopeptidase Mmp2 and Mmp17 and Adamts9), and blood 
coagulation (plasminogen activator, reticulocalbin 3). In contrast, genes belonging to Cluster 
7 are up-regulated across gestation in the mouse but not in the human and included several 
members with a known or potential role in stimulating myometrium contractions. For 
example, two members of the Rho/ROCK pathway, Rho guanine nucleotide exchange factor 
(GEF) 26 (Arhgef26) and Rho GTPase activating protein 6 (Arhgap6) were included in this 
cluster. These two enzymes regulate the cycle of RHO–GTP-binding proteins between two 
conformations: an active GTP-bound state catalysed by ARHGEFs [557] and an inactive 
GDP-bound state mediated by GTP hydrolysis catalysed by ARHGAPs[558]. This results in 
ROCK activation which mediates actin polymerisation and myosin phosphorylation in 
smooth muscle cells, as shown in both mouse and human [532, 559]. 
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The findings presented in this chapter allowed the evaluation of the relative contribution of 
specific gene changes to each model of parturition, denoting a prominent role for 
progesterone-modulated pathways in both term gestation and non-inflammatory PTB, while 
implicating inflammatory genes to be sufficient but not necessary to the onset of labour. We 
showed that LPS treatment induces activation of inflammation which is sufficient to override 
the repressive effects of progesterone on contraction- and tissue remodelling- associated 
genes, thus inducing labour when progesterone levels are still high (7 hours post-injection on 
E16). On the other hand, pharmacological withdrawal of progesterone function by RU486 is 
sufficient to trigger PTL without inducing robust expression of inflammatory genes. 
Examination of correlation between mouse and human transcriptome changes associated with 
labour showed high similarity in gene expression patterns in both organisms, further 
supporting the validity of the murine model in the investigation of transcriptional 
mechanisms of parturition. OSC-PLS modelling allowed assessment of the relative 
contribution of inflammatory (LPS) or progesterone-regulated (RU486) pathways to human 
labour. Although a significantly positive correlation was found between human and all 
murine models, human myometrial transcriptome changes at the time of labour most closely 
resemble the mouse LPS model (Fig. 6.11 B). Examination of the temporal gene changes 
associated with murine LPS-induced PTL with gene changes captured at labour onset in 
human allowed the identification of Cluster 1 and 6 including genes with similar expression 
profiles in both organisms (Fig. 6.12). Cluster 1 was enriched with genes belonging to cell 
adhesion pathways likely to be progesterone-dependent [91]. Cluster 6 included genes 
consistently upregulated in both mouse and human myometrium most of which were 
inflammatory genes. These evidences are in agreement with previous in vitro studies 
performed by our group [91] and suggest that inflammation may represent a mechanism to 
antagonise progesterone-induced gene expression. Additionally, we showed that a proportion 
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of those genes similarly modulated in LPS-induced murine PTL model and in human labour 
(Cluster 4 and 5) were enriched in tissue degradation and response to unfolded protein 
pathways. These data indicate that a significant percentage of gene expression changes 
observed in human at labour onset are likely to represent the activation of involution 
pathways rather than pathways involved in activation of myometrial contractions.  
In summary, cross-comparison between murine models and human labour suggest a dual role 
for inflammation in human labour. Inflammation may represent a possible mechanism of 
functional progesterone withdrawal as well as play a role in uterine involution after labour 
onset. These data are concordant with the paradigm that murine labor is initiated by 
progesterone withdrawal through fetal signaling that involves induction of inflammatory 
transcription factors and subsequent inflammatory gene activation in the uterus. However 
parturition can be induced by progesterone withdrawal alone and inflammation is not 
required for the acquisition of the laboring phenotype in the mouse. Conversely, LPS 
activation of inflammation is sufficient to override the repressive effects of high circulating 
concentrations of progesterone and induce labor in the mouse. Human myometrial 
transcriptome changes at the time of labor most closely resemble the mouse LPS model 
indicating a dominant role for inflammatory pathways in human labor. These results have 
important implications for the understanding of the underlying mechanism of labor onset and 
the development of future prevention strategies for preterm birth. 
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7 SUMMARY AND FINAL CONCLUSIONS 
 
In this thesis, the relative contribution of inflammatory and hormonal pathways to the onset 
of labour was investigated by comparing molecular changes occurring in myometrium tissue 
collected from mice throughout normal term gestation, and during PTL induced by two 
different stimuli that mimic the human patho-physiology of PTL: LPS injection recapitulating 
the scenario of infection/inflammation-induced PTL, and RU486 treatment representing a 
model of PTL induced by functional progesterone withdrawal. Considering the high risk 
encountered by the fetus when exposed in utero to inflammation, fetal responses to LPS were 
also assessed. 
Previous studies from our group and others have shown that labour in the human is 
accompanied by activation of inflammatory responses within the fetal membranes [42, 209, 
402, 434, 457] and myometrium [145, 208, 406, 411, 435]. NFκB is considered a prototypical 
pro-inflammatory transcription factor, additionally regulating pro-labour genes in both human 
and in murine models [187, 224]. Many factors associated with the onset of both normal and 
PTL, including TNFα, IL-1β, IL-8, COX-2, oxytocin receptor and phospholipase-A2, have 
been shown to be regulated by NFκB in the myometrium [208, 213, 217, 560, 561]. Some of 
these genes have also been shown to be regulated by two other inflammatory transcription 
factors, AP-1 and C/EBPβ [217, 220, 221]. Several studies have reported AP-1 activation in 
human gestational tissues at term and shown its capacity to stimulate pro-labour genes in 
vitro [231, 232, 437, 551]. The role of AP-1 in vivo was less clear before the work presented 
in this thesis, although ex vivo studies on myometrial strips showed a stretch-induced 
upregulation of AP-1 suggesting a role for this factor in vivo [108]. Previous work from our 
group performed by Lindström et al. also showed that the anti-inflammatory prostaglandin J2  
(PJ2) successfully inhibited IL-1β-induced NFκB activation in human amnion and 
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myometrium cells [188]. Additionally, PJ2 was able to delay the onset of LPS-induced PTL 
in the mouse by inhibiting NFκB activation in the myometrium, as well as the pro-labour 
gene cPLA2, and blocked phosphorylation and activation of JNK [186]. This data suggested 
a link between NFκB activation and AP-1 regulation and the possibility of targeting this 
pathway to block PTL. 
In this project the relative contribution of NFκB, AP-1 and C/EBPβ was examined in vivo in 
term and preterm murine gestation to gain more insights into the molecular mechanisms that 
regulate the switch between myometrial quiescence and activation of uterine contractions 
preceding the onset of labour. Activation of the cyclic AMP (cAMP)-CREB signalling 
pathway was also assessed since it is known to promote relaxation by inhibiting calcium 
mobilization and the contractile apparatus [194]. Murine term parturition was found to be 
characterised by CREB activation at early stages of gestation before E14, and this was 
followed by the sequential activation of NFκB at gestation day E18 prior to labour, and 
JNK/AP-1 during labour onset. Results concerning NFκB were in agreement with human 
data previously obtained by our group that showed NFκB activation in human amnion prior 
to labour [209] and with murine studies reporting increased nuclear localisation of NFκB 
monomers p50 and p65 in mouse uterus as term approaches [187]. The observed JNK/AP-1 
activation and nuclear translocation in myometrium during labour reported in this thesis 
constitutes a novel finding. Whilst it is possible that AP-1 activation occurs as a consequence 
of labour, the subsequent AP-1 downregulation detected in post-partum samples, as well as 
the similar expression pattern shown by CX-43, a pro-labour gene regulated by AP-1 [95, 
437], support a role for AP-1 in the physiological mechanisms of murine parturition.  
We next sought to examine the role of AP-1 and NFκB in the context of inflammation-
induced PTL. If a role for AP-1 was found in this context as well, AP-1 could represent a 
potential therapeutic target as its inhibition would suppress both the inflammatory and 
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contractile response in the myometrium thus preventing PTL. Bacterial-derived agents 
including LPS are frequently used in murine models to reproduce the human scenario of 
infection/inflammation-induced PTL as they stimulate TLR-4 signalling and induce an intra-
cellular inflammatory cascade culminating typically with AP-1 and NFκB activation and 
expression of pro-inflammatory genes some of which have also a pro-labour effect [465]. The 
majority of published studies to date report inconsistent use of differing E.coli-derived LPS 
serotypes in order to mimic the most frequent scenario of PTL seen in clinic, i.e. 
inflammation within intrauterine tissues in the absence of an overt infection [260, 480]. We 
hypothesised that this could partially explain the high variability reported in terms of 
maternal and fetal outcome. Moreover, a functional disparity between different LPS 
serotypes had been previously demonstrated in animal models of inflammation in terms of 
symptoms as well as response to treatment [467, 468, 493, 494]. Indeed, when we tested the 
effects of intrauterine injection with the four most commonly used serotypes (O111:B4, 
O155:B5, O127:B8 and O128:B12), striking differences were observed in the time of PTL as 
well as fetal outcome. One serotype in particular, O111:B4, was the most effective in 
inducing PTL, within 7 hours following injection, and caused complete fetal demise. Similar 
results were previously obtained by Salminen et al. who injected a similar dose of LPS 
O111:B4 intraperitoneally and observed similar rates of PTL but a higher number of 
surviving pups when mice were injected at E17 compared to E16. [349]. Since we assessed 
pup survival rates consistently at E16, 6 hours following maternal administration of the LPS, 
our results support a correlation between LPS serotype and fetal demise, regardless of the 
gestational age. In our study, LPS O111:B4 was the only serotype to induce complete 
intrauterine fetal demise. This severe phenotype was associated with strong activation of AP-
1 but not NFκB or C/EBPβ in the myometrium. Although all serotypes were able to induce 
expression of some pro-inflammatory and pro-labour genes, O111:B4 had the greater effect 
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in upregulating TNF-α, IL-6, IL-8 and MMP-10. Furthermore, O111:B4 induced increased 
protein levels of IL-1β, a classic interleukin implicated with infection-induced PTL [506]. 
Increased expression of IL-1β and TNF-α in the fetal brain has been linked with adverse 
neonatal outcome in premature neonates [487]. Elovitz et al. showed in murine models of 
LPS-induced PTL, that maternal inflammation in the gestational tissue was also associated 
with activation of a robust inflammatory response in fetal brains 6 hours after LPS injection, 
resulting in brain damage. Of note, this study used a much higher dose (250 μg) of a different 
LPS serotype (O55:B5) [311], which could explain the fetal response observed. Another 
study showed that using a low dose of 50 μg LPS O55:B5 triggered a modest increase of 
inflammatory mRNA markers expression in the pup brain seven days after delivery [347]. In 
our study, no activation of inflammatory transcription factors or downstream genes (apart 
from an increase in Il-8 mRNA) was observed in fetal brains collected 6 hours following 
maternal administration of LPS O111:B4. This may be due to the relatively low dose of LPS 
used in our study which intriguingly, even if not sufficient to activate inflammation, was still 
able to cause complete fetal demise. In the light of previous studies, it is possible that this 
might be due to the collection time as longer latency time may be needed to develop 
activation of inflammation in pup brains, as shown by Elovitz et al. [347]. Nevertheless our 
study showed that intrauterine fetal death is not associated with activation of inflammation in 
the fetal brain. In summary this study showed that different LPS serotypes elicit remarkably 
different maternal and fetal responses, providing not only an explanation for the observed 
variability between murine models of LPS-induced PTL, but also suggesting the existence of 
an additional levels of complexity in TLR-4 signalling, that may be of interest for a broader 
audience interested in dissecting the specificity of inflammatory pathways activation induced 
by specific bacteria [495]. 
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Next a detailed characterisation of the maternal response to LPS O111:B4 was undertaken to 
identify the key molecular components essential for PTL in this model. Results showed that 
LPS O111:B4-induced PTL is preceded and accompanied by activation of JNK/AP-1-
mediated inflammatory response in the myometrium, without NFκB activation. These events 
are concurrent with increasing levels of genes encoding for inflammatory and anti-
inflammatory cytokines (IL-1β, TNFα, IL-8, IL-6, IL-10), uterine activation proteins (COX-
2, CX-43), and remodelling enzymes (MMP-3, MMP-9 and MMP-10), most of which rise 
prior to labour. LPS treatment was also associated with increased processing of IL-1β in its 
cleaved product. These results suggest a role for AP-1 in regulating not only expression of 
inflammatory genes but also key pro-labour genes encoding for proteins essential to promote 
myometrial contractility, as recently showed by Hutchinson et al. [532]. Knock-out 
experiments also showed that TLR-4 was essential to induce PTL in this model and the 
associated inflammatory response since both were abrogated in the absence of a functional 
receptor in TLR-4-KO mice. Although not as efficient as TLR-4 deletion in blocking PTL, 
the use of a specific JNK inhibitor (SP600125) successfully delayed the onset of PTL. These 
results were comparable to a previous study conducted by Condon and colleagues showing 
that inhibition of NFκB, although not preventing completely PTL, was still able to delay this 
event [187]. Additionally, a previous study from our group showed that in mice injected with 
Salmonella abortus LPS, which activates both JNK/AP-1 and NF-kB, inhibition of NFkB by 
PJ2 similarly delayed labour and improved pup outcome [186]. More recently, another study 
from our group similarly showed that inhibition of JNK in the S. abortus LPS-induced PTL 
delays PTL and improves pup outcome [540], further supporting a role for the JNK/AP-1 axis 
in LPS-induced PTL model. Progesterone receptor downregulation in myometrial cells has 
previously been shown to have minimal effect up inflammatory gene expression on a global 
scale, as assessed by microarray analysis [91]. In this thesis, functional downregulation of 
 224 
 
progesterone receptor was achieved chemically by subcutaneous injection of the progesterone 
receptor antagonist RU486. Similarly to previous reports, RU486 treatment led to PTL within 
20 hours [81], although this had no effect upon activation of the inflammatory transcription 
factors AP-1 and NFkB, prior to labour. AP-1 was however up-regulated during active 
labour. Collectively these findings suggest that progesterone withdrawal does not affect 
inflammatory pathways activation in vivo and that AP-1 plays an important role in parturition 
regardless of the stimulus starting the onset of labour. 
Although numerous studies, including data presented in this thesis, have consistently reported 
activation of inflammation during labour in both animal models and human samples, it 
remains unclear whether the inflammatory response observed during labour is a cause or a 
consequence of this event. Several microarray studies have reported gene expression changes 
characterising mouse myometrium throughout normal gestation and human samples before 
and after spontaneous delivery [404, 411, 413]. As highlighted in a recently published meta-
analysis, all these studies have been restricted by the relatively low resolution of the 
technology that translated to a rather limited overlap of genes identified as differentially 
expressed across studies [399]. To date, only one RNA-Seq study has examined gene 
expression changes in human myometrial tissue prior to and after spontaneous labour onset 
[406]. No study thus far has reported temporal gene changes occurring in the led up to labour 
in any model. Work presented in this thesis addressed these limitations and knowledge gaps. 
To capture a comprehensive picture of the genes associated with the acquisition of a 
labouring phenotype, we used RNA-Seq to examine global transcriptome changes occurring 
throughout a time-course across gestation in the mouse myometrium as well as during active 
labour. By combining multivariate approaches (PCA, hierarchical clustering and OSC-PLS) 
with canonical pathway analysis and detailed examination of the set of genes shared or 
unique to each model of parturition this thesis showed that: 1) mice experiencing term 
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gestation and RU486-induced PTL exhibited similar gene expression changes, while mice 
induced to PTL by an inflammatory stimulus (LPS) developed divergent transcriptome 
profiles across gestation within a much contracted time-frame; 2) most of the DEGs 
identified in the two PTL models were detected before labour onset supporting the hypothesis 
that major uterine transcriptome changes required for labour are manifested prior to this 
event; 3) the LPS model features a distinct cluster of DEGs, mostly inflammation-related 
genes that do not change throughout gestation in the other models; 4) a core set of genes 
changing regardless of the model of gestation was identified and included both known and 
novel potentially labour-associated genes; 5) a positive correlation exits between uterine gene 
changes preceding term gestation and RU486-induced PTL, while LPS-induced PTL is 
characterised by a unique set of gene changes; 6) a set of orthologous gene are shared and 
similarly change in both human and mouse with the onset of labour; and 7) correlations exits 
between human transcriptome changes associated with labour onset and uterine transcriptome 
changes observed in three murine models of term and PTL. 
These data taken together indicated that LPS-induced inflammation is sufficient to override 
the repressive effects of progesterone on contraction- and tissue remodelling- associated 
genes, thus inducing the onset of labour when progesterone levels are still high (at E16). 
Additionally, abrogation of progesterone receptor signalling by RU486 is sufficient to prompt 
PTL without stimulating the expression of inflammatory genes, in agreement with previous 
data from our group showing minimal effect of PR knock-down on inflammatory gene 
expression in human myometrial cells [91]. These results support the paradigm of a “common 
terminal pathway” of labour [31], since term and PTL, at least when this is induced by 
progesterone withdrawal, do share similar gene changes in the journey towards labour. 
Nevertheless, activation of inflammatory genes does not seem to be a strong feature of term 
labour or RU486-induced PTL model. This concept finds support in other studies where 
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inhibition of either inflammatory cells infiltration or specific cytokines was not successful in 
blocking LPS-induced PTL and inflammation was instead proposed to be involved in uterine 
post-partum involution rather than in labour onset [46, 161, 406, 531, 532]. 
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8 FUTURE PERSPECTIVES 
A truly comprehensive picture of gene changes characterising parturition cannot be achieved 
without investigating the role played by the non-coding portion of the transcriptome. Among 
the various families of non-coding RNAs, the importance of small non-coding RNAs in 
reproductive tissues represents a relatively recent discovery as several microRNAs have been 
shown to play a role in embryo implantation, hormone receptiveness, parturition and 
pathology such as cancer [562]. However, to date few studies have addressed the role of these 
molecules in normal physiology of parturition. Renthal et al. firstly reported a microarray 
study of microRNAs differentially expressed in mouse myometrium by comparing tissue 
collected at E15.5 with E18.5 (prior to labour onset) [550]. Only 5 microRNAs were 
identified as differentially expressed by this study, including the miR-200 family that was 
found up-regulated in both mouse and human during labour. Work from our group recently 
identified a panel of 12 microRNAs differentially expressed in human myometrium prior to 
and following oxytocin-induced term labour [563]. 
Future experiments will be thus focussed on identifying the full catalogue of small non-
coding RNAs differentially expressed in myometrium in the three models of parturition using 
small RNA-Seq. Matching samples from those analysed with RNA-Seq as described in this 
thesis have been processed in our laboratory and small RNA have been isolated. A library of 
small RNAs is currently being prepared for RNA-Seq on an Illumina
®
 platform. By 
performing the first comprehensive RNA-Seq study of mouse myometrium in three different 
parturition models we aim to broaden the collection of small RNAs differentially expressed 
in mouse myometrium. The ultimate goal of such study is to build an integrative picture of 
co-regulated microRNA/mRNA networks that could be eventually targeted to affect the 
timing of labour onset. 
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In this direction, future studies will also focus on functional characterization of genes 
differentially expressed to determine the biological relevance of specific microRNA/mRNA 
networks and to design experiments based on the clinical relevance of the study. 
Furthermore, in-depth investigation of gene splice isoforms will also contribute to expand the 
collection of transcriptome data available and provide further insights into the transcriptomic 
landscape in physiologic and patho-physiologic onset of labour. 
Such integrative analyses hold remarkable promise to identify and prioritise candidate gene 
networks involved in parturition that will contribute in advancing our understanding of the 
basic molecular mechanisms underlying birth timing. 
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Table B.1 Total number of reads generated for each murine myometrium sample sequenced 
on an Illumina HiSeq2000 platform using paired-end sequencing (2 × 100bp). n≥4 biological 
replicates for each experimental group. 
MODEL: 
TERM 
GESTATION   LPS   RU486 
Sample Reads (million) Sample 
Reads 
(million) Sample 
Reads 
(million) 
E14.1 102,489,746 PBS_2.1 107,969,646 DMSO_6.1 87,408,092 
E14.2 
 
88,914,076 
PBS_2.2 
81,230,484 
DMSO_6.2 
74,188,540 
E14.3 60,822,386 PBS_2.3 77,399,894 DMSO_6.3 65,729,356 
E14.4 81,608,278 PBS_2.4 110,227,790 DMSO_6.4 75,735,384 
E16.1 65,399,892 LPS_2.1 85,602,490 RU486_6.1 78,563,156 
E16.2 
111,067,720 
LPS_2.2 
106,324,428 
RU486_6.2 
131,948,16
4 
E16.3 108,932,866 LPS_2.3 112,716,142 RU486_6.3 69,206,718 
E16.4 
62,579,678 
LPS_2.4 
83,795,360 
RU486_6.4 
103,039,08
8 
E18.1 
137,762,894 
PBS_6.1 
127,670,610 
DMSO_18.1 
141,236,50
6 
E18.2 108,330,410 PBS_6.2 71,810,470 DMSO_18.2 75,533,464 
E18.3 88,021,834 PBS_6.3 87,660,598 DMSO_18.3 58,591,702 
E18.4 69,436,978 PBS_6.4 76,254,592 DMSO_18.4 62,915,942 
Lab.1 59,640,128 LPS_6.1 63,363,360 RU486_18.1 61,429,738 
Lab.2 74,273,750 LPS_6.2 82,479,198 RU486_18.2 86,507,916 
Lab.3 103,151,136 LPS_6.3 75,870,178 RU486_18.3 82,402,872 
Lab.4 
68,086,182 
LPS_6.4 
86,974,526 
RU486_18.4 
109,805,26
6 
  
LABLPS.1 
122,670,278 LABRU486.1 
81,020,652 
  
LABLPS.2 
101,168,334 LABRU486.2 
72,001,356 
  
LABLPS.3 
63,946,124 LABRU486.3 
67,452,642 
  
LABLPS.4 
101,545,712 
LABRU486.4 
114,912,19
4 
    
LABRU486.5 
95,969,152 
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Table B.2. R script for outlier detection in a multivariate dataset. 
outlier.detection = function(data,class){ 
  class=as.numeric(as.factor(class)) 
  n=max(class) 
  pro=rep(NA,n) 
  me=NULL 
  TOTdist=rep(NA,n) 
   
  med=matrix(nrow=n,ncol=ncol(data)) 
  nn=nrow(data) 
  for(j in 1:nn){ 
    dataCV=data 
    classCV=class 
    for(i in 1:n){ 
      da=dataCV[classCV==i,] 
      med[i,]=colMeans(da) 
    } 
    CVdist=NULL 
    for(i in 1:nrow(data)){ 
      mediana=med[class[i],] 
      CVdist[i]=dist(rbind(mediana,data[i,])) 
    } 
     
    pro[j]=pnorm(CVdist[j], mean=mean(CVdist[-j]),  
           sd=sqrt(sd(CVdist[-j])^2*(nn-1)/nn), lower.tail=FALSE)  
  } 
  pro 
} 
 
# Example ################ 
data=iris[,-5] 
labels= rep(1:3,each=50) 
pca=prcomp(data)$x 
pp=outlier.detection(data,labels) 
plot(pca,col=labels,pch=(pp<0.05)+1) 
########################## 
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Table B.3 Canonical pathways enrichment calculated by Ingenuity Pathway analysis. A total 
of 46 pathways were detected as significantly enriched with genes differentially expressed in 
the pairwise comparisons indicated in the first row of the table (P<0.05). First column on the 
left indicates GO name associated with the canonical pathway. P values are reported for each 
pathway.  
 
Canonical Pathway   E16  
vs 
E18 
  E16  
vs 
LAB 
  E18  
vs 
LAB 
6h RU486  
vs  
18h RU486 
6h RU486 
 vs 
LABRU486 
 18h RU486  
vs  
LABRU486 
2h LPS  
vs 
6h LPS 
2h LPS  
vs  
LABLPS 
Agrin Interactions at 
Neuromuscular Junction 
0.00 1.95 0.87 3.11 1.29 0.00 0.00 0.00 
PAK Signalling 0.00 0.94 0.00 2.65 1.15 0.00 1.12 1.07 
Cardiac Hypertrophy Signalling 0.00 0.86 0.45 2.41 1.02 0.00 0.43 0.69 
Tumoricidal Function of Hepatic 
Natural Killer Cells 
0.00 2.53 0.00 2.19 1.58 0.00 1.00 0.38 
Acute Phase Response Signalling 1.72 2.64 0.69 2.18 1.16 4.58 3.40 2.26 
Death Receptor Signalling 0.58 5.49 1.28 2.15 1.89 0.00 4.40 3.55 
Glioma Invasiveness Signalling 0.00 2.03 0.38 2.05 1.23 0.00 0.86 0.35 
VEGF Signalling 0.00 1.38 1.90 1.95 2.59 0.00 0.71 0.92 
Cytotoxic T Lymphocyte-mediated 
Apoptosis of Target Cells 
0.00 2.51 0.59 1.66 1.18 0.00 1.07 0.00 
CXCR4 Signalling 0.00 1.12 0.37 1.46 0.62 0.00 0.67 1.31 
UVA-Induced MAPK Signalling 0.00 2.46 0.00 1.43 0.86 0.00 3.09 3.19 
Wnt/β-catenin Signalling 0.97 3.42 0.00 1.28 2.09 0.00 0.30 0.70 
Eicosanoid Signalling 0.00 1.89 2.17 1.24 2.73 0.00 0.58 0.69 
RhoA Signalling 0.00 1.34 2.25 0.99 0.84 0.00 0.35 0.36 
β-Adrenergic Signalling 0.00 0.40 0.00 0.91 0.73 0.00 0.97 1.24 
VEGF Family Ligand- 
Receptor Interactions 
0.00 0.39 0.00 0.90 2.23 0.00 1.39 1.30 
Inhibition of Angiogenesis by TSP1 0.92 0.65 0.52 0.87 0.93 0.00 3.36 2.79 
GDNF Family Ligand- 
Receptor Interactions 
0.00 0.34 0.00 0.81 1.27 0.00 0.36 0.39 
Production of Nitric Oxide and Reactive 
 Oxygen Species in Macrophages 
0.34 1.91 1.04 0.81 1.18 0.00 1.94 1.34 
IL-8 Signalling 0.33 1.33 1.03 0.78 1.42 0.00 1.89 2.47 
Cholecystokinin/Gastrin- 
mediated Signalling 
0.53 1.83 0.60 0.76 0.86 0.00 0.00 0.00 
Wnt/Ca+ pathway 0.00 0.51 0.00 0.74 0.81 0.00 0.35 0.58 
Acute Myeloid Leukemia Signalling 0.00 0.60 0.00 0.70 0.78 0.00 2.82 2.30 
LXR/RXR Activation 1.17 3.00 1.53 0.69 0.00 3.02 2.17 2.48 
CD40 Signalling 0.00 1.31 0.93 0.63 1.04 0.00 0.27 0.27 
cAMP-mediated signalling 0.28 0.80 0.83 0.60 0.73 0.00 0.40 1.66 
Interferon Signalling 0.00 0.45 0.57 0.60 0.00 0.00 4.66 4.78 
MIF-mediated  
Glucocorticoid Regulation 
0.00 0.00 1.39 0.58 2.22 0.00 0.94 0.83 
Dopamine-DARPP32 Feedback 
 in cAMP Signalling 
0.00 0.27 0.00 0.55 0.33 0.00 0.00 0.64 
Thrombopoietin Signalling 0.00 0.51 0.00 0.45 0.81 0.00 1.53 1.25 
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EGF Signalling 0.00 0.28 0.00 0.44 0.49 0.00 0.54 0.86 
Fc Epsilon RI Signalling 0.00 0.37 0.00 0.43 1.30 0.00 0.83 0.63 
MIF Regulation of Innate Immunity 0.00 0.28 1.21 0.41 1.74 0.00 0.64 0.59 
Estrogen-Dependent Breast  
Cancer Signalling 
0.00 0.39 0.00 0.36 0.00 0.00 0.66 0.72 
Retinoic acid Mediated Apoptosis Signalling 0.70 0.91 0.00 0.35 0.00 0.00 1.59 1.80 
Role of Pattern Recognition Receptors in 
Recognition of Bacteria and Viruses 
0.00 1.57 0.49 0.33 0.39 0.00 4.70 6.51 
Non-Small Cell Lung Cancer Signalling 0.00 0.00 0.00 0.31 0.59 0.00 0.56 0.92 
Neurotrophin/TRK Signalling 0.00 1.46 0.85 0.30 0.58 0.00 0.78 0.89 
JAK/Stat Signalling 0.00 0.53 0.00 0.30 0.34 0.00 2.18 2.52 
Dopamine Receptor Signalling 0.00 0.29 0.24 0.29 0.34 0.00 0.00 0.34 
LPS-stimulated MAPK Signalling 0.00 0.52 0.31 0.29 0.56 0.00 0.33 0.00 
Induction of Apoptosis by HIV1 0.00 2.43 0.98 0.00 0.25 0.00 2.36 0.86 
TREM1 Signalling 0.00 0.47 0.00 0.00 0.00 0.00 1.26 1.12 
ERK5 Signalling 0.00 0.43 1.68 0.00 0.00 0.00 0.00 0.00 
Renal Cell Carcinoma Signalling 0.00 0.32 0.00 0.00 0.00 0.00 2.58 2.01 
Cardiac β-adrenergic Signalling 0.00 0.28 0.00 0.00 0.00 0.00 0.00 0.91 
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Table B.4 Canonical pathways enrichment calculated by Ingenuity Pathway analysis. A total 
of 46 pathways were detected as significantly enriched with genes differentially expressed in 
the pairwise comparisons indicated in the first row of the table (Z-score>|2|). First column on 
the left indicates GO name associated with the canonical pathway. Z scores are reported for 
each pathway. 
Canonical Pathway E16  
vs 
E18 
E16  
vs 
LAB 
E18  
vs  
LAB 
6h RU486  
vs 
 18h RU486 
6h RU486  
vs  
LABRU486 
18h RU486  
   vs 
LABRU486 
    2h LPS 
vs 
6h LPS 
2h LPS  
vs  
LABLPS 
Production of Nitric Oxide and  
Reactive Oxygen Species  
in Macrophages 
0.00 2.68 1.00 1.94 1.60 0.00 1.88 1.70 
Retinoic acid Mediated  
Apoptosis Signalling 
0.00 1.89 0.00 2.00 0.00 0.00 3.16 3.00 
IL-8 Signalling 0.00 1.41 2.00 0.83 0.77 0.00 1.96 2.52 
EGF Signalling 0.00 2.00 0.00 2.00 2.00 0.00 1.63 1.63 
LXR/RXR Activation 0.00 -2.67 -2.00 -0.38 -1.63 0.00 -1.00 -1.07 
PAK Signalling 0.00 2.33 0.00 0.90 1.89 0.00 1.90 1.67 
GDNF Family Ligand- 
Receptor Interactions 
0.00 1.34 0.00 2.45 1.89 0.00 1.63 1.34 
VEGF Family Ligand- 
Receptor Interactions 
0.00 0.82 0.00 1.89 1.26 0.00 2.53 2.12 
Wnt/β-catenin Signalling 0.00 1.34 0.00 1.94 1.60 0.00 1.51 2.11 
JAK/Stat Signalling 0.00 1.63 0.00 1.00 2.00 0.00 1.73 2.11 
Dopamine-DARPP32 Feedback 
 in cAMP Signalling 
0.00 -1.00 0.00 -1.00 -0.82 0.00 -2.71 -2.89 
cAMP-mediated signalling 0.00 -1.41 -2.00 -1.07 -0.53 0.00 -1.41 -1.96 
Fc Epsilon RI Signalling 0.00 1.13 0.00 2.65 1.90 0.00 1.15 1.00 
Death Receptor Signalling 0.00 0.23 0.00 0.30 0.00 0.00 3.90 3.36 
Cholecystokinin/Gastrin- 
mediated Signalling 
0.00 1.94 0.00 0.71 1.41 0.00 1.13 2.45 
RhoA Signalling 0.00 -1.73 -2.24 -1.41 -1.41 0.00 -0.63 0.00 
UVA-Induced  
MAPK Signalling 
0.00 1.51 0.00 1.00 1.13 0.00 1.50 2.14 
Glioma Invasiveness  
Signalling 
0.00 1.67 0.00 1.41 2.45 0.00 -0.38 1.00 
CXCR4 Signalling 0.00 1.15 0.00 1.15 1.00 0.00 1.39 2.14 
Agrin Interactions at  
Neuromuscular Junction 
0.00 -1.89 0.00 -1.67 -2.24 0.00 0.00 1.00 
LPS-stimulated  
MAPK Signalling 
0.00 1.63 0.00 2.00 1.34 0.00 0.82 1.00 
Cardiac Hypertrophy  
Signalling 
0.00 -1.21 0.00 -0.89 0.00 0.00 -2.36 -2.00 
Cardiac β-adrenergic  
Signalling 
0.00 -0.82 0.00 0.00 0.00 0.00 -2.45 -3.16 
Acute Phase Response  
Signalling 
0.00 2.00 0.00 -0.38 0.00 0.00 1.89 1.94 
Non-Small Cell Lung  
Cancer Signalling 
0.00 1.00 0.00 2.00 1.34 0.00 0.82 0.82 
Interferon Signalling 0.00 0.00 0.00 0.00 0.00 0.00 2.71 3.16 
Neurotrophin/TRK  
Signalling 
0.00 1.41 0.00 2.00 1.34 0.00 0.71 0.38 
MIF Regulation  0.00 0.00 0.00 0.00 2.45 0.00 1.34 2.00 
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of Innate Immunity 
Acute Myeloid Leukemia Signalling 0.00 2.24 0.00 1.63 1.63 0.00 -0.28 0.00 
VEGF Signalling 0.00 0.30 0.00 -0.63 -0.30 0.00 2.33 2.12 
Thrombopoietin Signalling 0.00 1.34 0.00 2.00 1.34 0.00 0.33 0.38 
?-Adrenergic Signalling 0.00 -2.45 0.00 -0.82 -0.82 0.00 -0.71 -0.38 
Tumoricidal Function of Hepatic Natural 
Killer Cells 
0.00 0.82 0.00 1.34 2.00 0.00 1.00 0.00 
CD40 Signalling 0.00 1.63 0.00 0.00 2.00 0.00 1.34 0.00 
Renal Cell Carcinoma Signalling 0.00 2.00 0.00 0.00 0.00 0.00 1.63 1.00 
Eicosanoid Signalling 0.00 0.00 0.00 1.00 1.34 0.00 2.00 0.00 
Wnt/Ca+ pathway 0.00 0.00 0.00 -0.45 0.00 0.00 -2.24 -1.34 
Role of Pattern Recognition Receptors in 
Recognition of Bacteria and Viruses 
0.00 2.33 0.00 0.00 0.00 0.00 1.39 0.26 
Cytotoxic T Lymphocyte-mediated 
Apoptosis of Target Cells 
0.00 0.38 0.00 1.34 2.00 0.00 0.00 0.00 
Inhibition of Angiogenesis by TSP1 0.00 0.00 0.00 0.00 0.00 0.00 1.63 2.00 
TREM1 Signalling 0.00 2.45 0.00 0.00 0.00 0.00 0.63 0.00 
Induction of Apoptosis by HIV1 0.00 0.00 0.00 0.00 0.00 0.00 2.11 0.82 
MIF-mediated Glucocorticoid Regulation 0.00 0.00 0.00 0.00 2.24 0.00 0.45 0.00 
Dopamine Receptor Signalling 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -2.24 
Estrogen-Dependent Breast Cancer 
Signalling 
0.00 2.00 0.00 0.00 0.00 0.00 0.00 0.00 
ERK5 Signalling 0.00 2.00 0.00 0.00 0.00 0.00 0.00 0.00 
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Table B.5 List of genes exclusively changing throughout normal murine gestation 
(FDR<0.001). Gene names and Ensembl gene identification number (ID) are reported. (Mus 
musculus version GRCm38.p4). 
Gene name Ensembl gene ID  Gene name Ensembl gene ID 
Mx1 ENSMUSG00000000386 Sh3pxd2b ENSMUSG00000040711 
Egfl6 ENSMUSG00000000402 Rcsd1 ENSMUSG00000040723 
Ccl3 ENSMUSG00000000982 Zmynd15 ENSMUSG00000040829 
S100a4 ENSMUSG00000001020 Ostc ENSMUSG00000041084 
Scn4a ENSMUSG00000001027 Rusc1 ENSMUSG00000041263 
Ckb ENSMUSG00000001270 Meis3 ENSMUSG00000041420 
Nrip2 ENSMUSG00000001520 5730559C18Rik ENSMUSG00000041605 
Tat ENSMUSG00000001670 Pde3a ENSMUSG00000041741 
Naglu ENSMUSG00000001751 Plekha6 ENSMUSG00000041757 
Rin2 ENSMUSG00000001768 Sgsm1 ENSMUSG00000042216 
Ssr4 ENSMUSG00000002014 Tmc7 ENSMUSG00000042246 
Napsa ENSMUSG00000002204 Maff ENSMUSG00000042622 
Klf4 ENSMUSG00000003032 Zc3h12a ENSMUSG00000042677 
Elf3 ENSMUSG00000003051 Sbk1 ENSMUSG00000042978 
Fkbp11 ENSMUSG00000003355 Tmem212 ENSMUSG00000043164 
Pld3 ENSMUSG00000003363 2510009E07Rik ENSMUSG00000043391 
Fosb ENSMUSG00000003545 Ubxn10 ENSMUSG00000043621 
Mmd ENSMUSG00000003948 Als2cl ENSMUSG00000044037 
Ptrf ENSMUSG00000004044 S100a1 ENSMUSG00000044080 
Hspb1 ENSMUSG00000004951 Bcl2l15 ENSMUSG00000044165 
Upk3bl ENSMUSG00000006143 Krt84 ENSMUSG00000044294 
Snai3 ENSMUSG00000006587 Zfp354c ENSMUSG00000044807 
Casq1 ENSMUSG00000007122 Sowahb ENSMUSG00000045314 
Fgfrl1 ENSMUSG00000008090 Pqlc3 ENSMUSG00000045679 
Gprc5b ENSMUSG00000008734 Prr15 ENSMUSG00000045725 
Dqx1 ENSMUSG00000009145 Sprn ENSMUSG00000045733 
Tmem8c ENSMUSG00000009214 Fam179a ENSMUSG00000045761 
Fer1l4 ENSMUSG00000013338 Cd109 ENSMUSG00000046186 
Trnt1 ENSMUSG00000013736 Gm11223 ENSMUSG00000046341 
Gzmb ENSMUSG00000015437 Gjb2 ENSMUSG00000046352 
Hsd11b1 ENSMUSG00000016194 C77370 ENSMUSG00000046449 
Eef1a2 ENSMUSG00000016349 Gprc5a ENSMUSG00000046733 
Rnd3 ENSMUSG00000017144 Tmem45a2 ENSMUSG00000046748 
Traf4 ENSMUSG00000017386 Dnah14 ENSMUSG00000047369 
Aldoc ENSMUSG00000017390 Tgif1 ENSMUSG00000047407 
Stac2 ENSMUSG00000017400 Dlgap2 ENSMUSG00000047495 
Dbndd2 ENSMUSG00000017734 Cldn4 ENSMUSG00000047501 
Eya2 ENSMUSG00000017897 Krt83 ENSMUSG00000047641 
Prl8a2 ENSMUSG00000018259 BC025446 ENSMUSG00000047728 
Alox12e ENSMUSG00000018907 Ccdc88b ENSMUSG00000047810 
Cxcl16 ENSMUSG00000018920 Stx19 ENSMUSG00000047854 
Alox15 ENSMUSG00000018924 A4galt ENSMUSG00000047878 
Ccl4 ENSMUSG00000018930 Tmem229a ENSMUSG00000048022 
Rab3d ENSMUSG00000019066 Col6a3 ENSMUSG00000048126 
Aldh3a1 ENSMUSG00000019102 Amigo2 ENSMUSG00000048218 
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Trip10 ENSMUSG00000019487 Zbtb8b ENSMUSG00000048485 
Cyb561 ENSMUSG00000019590 Gm9826 ENSMUSG00000048538 
Tmc4 ENSMUSG00000019734 Igf2 ENSMUSG00000048583 
Rev3l ENSMUSG00000019841 Acap2 ENSMUSG00000049076 
Lrriq1 ENSMUSG00000019892 Krt8 ENSMUSG00000049382 
Enpp3 ENSMUSG00000019989 Cdc42ep1 ENSMUSG00000049521 
Moxd1 ENSMUSG00000020000 Tmie ENSMUSG00000049555 
Tacr2 ENSMUSG00000020081 Omg ENSMUSG00000049612 
Slc16a7 ENSMUSG00000020102 BC048671 ENSMUSG00000049694 
Usp15 ENSMUSG00000020124 Prss46 ENSMUSG00000049719 
Peli1 ENSMUSG00000020134 Grem2 ENSMUSG00000050069 
Apc2 ENSMUSG00000020135 Ces2b ENSMUSG00000050097 
Gamt ENSMUSG00000020150 Mrgprg ENSMUSG00000050276 
Ptprr ENSMUSG00000020151 Amer1 ENSMUSG00000050332 
Gabrp ENSMUSG00000020159 Krt78 ENSMUSG00000050463 
Cpm ENSMUSG00000020183 Fam171a1 ENSMUSG00000050530 
Phlda1 ENSMUSG00000020205 Arhgap42 ENSMUSG00000050730 
Havcr2 ENSMUSG00000020399 Adgb ENSMUSG00000050994 
Pttg1 ENSMUSG00000020415 Fam83a ENSMUSG00000051225 
Btg2 ENSMUSG00000020423 Islr2 ENSMUSG00000051243 
Myl7 ENSMUSG00000020469 Gdf6 ENSMUSG00000051279 
Xbp1 ENSMUSG00000020484 Tacstd2 ENSMUSG00000051397 
Tom1l1 ENSMUSG00000020541 Kctd14 ENSMUSG00000051727 
Myocd ENSMUSG00000020542 Casr ENSMUSG00000051980 
Tspan13 ENSMUSG00000020577 D630039A03Rik ENSMUSG00000052117 
Apob ENSMUSG00000020609 Serpinb6c ENSMUSG00000052180 
Adi1 ENSMUSG00000020629 Ppp1r36 ENSMUSG00000052221 
Mboat2 ENSMUSG00000020646 Plekhg3 ENSMUSG00000052609 
Galr2 ENSMUSG00000020793 Junb ENSMUSG00000052837 
Sec14l1 ENSMUSG00000020823 Glis3 ENSMUSG00000052942 
Fam101b ENSMUSG00000020846 Nrgn ENSMUSG00000053310 
Plcd3 ENSMUSG00000020937 Tnfaip6 ENSMUSG00000053475 
Clmn ENSMUSG00000021097 Ier2 ENSMUSG00000053560 
Akr1c18 ENSMUSG00000021214 1700016K19Rik ENSMUSG00000053783 
Rgs6 ENSMUSG00000021219 D630008O14Rik ENSMUSG00000054006 
Fos ENSMUSG00000021250 Tceal5 ENSMUSG00000054034 
Fdft1 ENSMUSG00000021273 Pkp3 ENSMUSG00000054065 
Ryr2 ENSMUSG00000021313 Lrrc36 ENSMUSG00000054320 
Aspn ENSMUSG00000021388 Kcnn4 ENSMUSG00000054342 
Syk ENSMUSG00000021457 Msra ENSMUSG00000054733 
Auh ENSMUSG00000021460 Rnd1 ENSMUSG00000054855 
Slc25a48 ENSMUSG00000021509 Nyap2 ENSMUSG00000054976 
Marveld2 ENSMUSG00000021636 Cstl1 ENSMUSG00000055177 
Naip1 ENSMUSG00000021640 Ntrk2 ENSMUSG00000055254 
Iqgap2 ENSMUSG00000021676 Adh7 ENSMUSG00000055301 
F2rl1 ENSMUSG00000021678 Tns1 ENSMUSG00000055322 
Plk2 ENSMUSG00000021701 Ces2a ENSMUSG00000055730 
Rnf180 ENSMUSG00000021720 Nod2 ENSMUSG00000055994 
Emb ENSMUSG00000021728 Grik2 ENSMUSG00000056073 
Plau ENSMUSG00000021822 Lipm ENSMUSG00000056078 
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Samd4 ENSMUSG00000021838 1810011O10Rik ENSMUSG00000056313 
Btd ENSMUSG00000021900 Ier5 ENSMUSG00000056708 
Parg ENSMUSG00000021911 Ide ENSMUSG00000056999 
Ctsb ENSMUSG00000021939 Bcl2 ENSMUSG00000057329 
Gdf10 ENSMUSG00000021943 Mettl7a3 ENSMUSG00000058057 
Mtmr6 ENSMUSG00000021987 Cxcl2 ENSMUSG00000058427 
Clu ENSMUSG00000022037 Thra ENSMUSG00000058756 
Stmn4 ENSMUSG00000022044 Cfi ENSMUSG00000058952 
Spry2 ENSMUSG00000022114 Pde1a ENSMUSG00000059173 
Mcpt8 ENSMUSG00000022157 Zfp36l3 ENSMUSG00000059334 
Atp12a ENSMUSG00000022229 Plg ENSMUSG00000059481 
Matn2 ENSMUSG00000022324 Rgs3 ENSMUSG00000059810 
Csnk1e ENSMUSG00000022433 Hydin ENSMUSG00000059854 
Trp63 ENSMUSG00000022510 Atp8b4 ENSMUSG00000060131 
Cd96 ENSMUSG00000022657 Layn ENSMUSG00000060594 
P2rx6 ENSMUSG00000022758 Tmsb15a ENSMUSG00000060726 
Ccdc116 ENSMUSG00000022768 Gstp1 ENSMUSG00000060803 
Spag6 ENSMUSG00000022783 Krt5 ENSMUSG00000061527 
Clcn2 ENSMUSG00000022843 Ssbp3 ENSMUSG00000061887 
Slc11a2 ENSMUSG00000023030 Myt1l ENSMUSG00000061911 
Nr4a1 ENSMUSG00000023034 Gm10108 ENSMUSG00000062038 
Krt7 ENSMUSG00000023039 Cttnbp2nl ENSMUSG00000062127 
Ache ENSMUSG00000023328 Ppef1 ENSMUSG00000062168 
Mx2 ENSMUSG00000023341 Nrg1 ENSMUSG00000062991 
Tnfrsf12a ENSMUSG00000023905 Slc39a4 ENSMUSG00000063354 
Pla2g7 ENSMUSG00000023913 Lppr1 ENSMUSG00000063446 
Ptk7 ENSMUSG00000023972 Cycs ENSMUSG00000063694 
Guca1a ENSMUSG00000023982 Tnfrsf11b ENSMUSG00000063727 
Tspo2 ENSMUSG00000023995 Mir214 ENSMUSG00000065516 
Stk38 ENSMUSG00000024006 Cldn9 ENSMUSG00000066720 
Pim1 ENSMUSG00000024014 Klra7 ENSMUSG00000067599 
Tff1 ENSMUSG00000024032 Zfp948 ENSMUSG00000067931 
Themis3 ENSMUSG00000024105 Gtf2f2 ENSMUSG00000067995 
Dusp1 ENSMUSG00000024190 Cst7 ENSMUSG00000068129 
Zeb1 ENSMUSG00000024238 D430041D05Rik ENSMUSG00000068373 
Thada ENSMUSG00000024251 Efcab1 ENSMUSG00000068617 
Stard4 ENSMUSG00000024378 Prl6a1 ENSMUSG00000069259 
Lims2 ENSMUSG00000024395 4930572O03Rik ENSMUSG00000069720 
Tnf ENSMUSG00000024401 Slc35g2 ENSMUSG00000070287 
Hbegf ENSMUSG00000024486 Scn2b ENSMUSG00000070304 
Scgb1a1 ENSMUSG00000024653 Ppapdc1a ENSMUSG00000070366 
Efemp2 ENSMUSG00000024909 Mesdc1 ENSMUSG00000070462 
Nt5c2 ENSMUSG00000025041 Fcrl6 ENSMUSG00000070504 
Habp2 ENSMUSG00000025075 DXBay18 ENSMUSG00000071745 
Ubtd1 ENSMUSG00000025171 Gm10384 ENSMUSG00000072618 
Cyp2c44 ENSMUSG00000025197 Gm2016 ENSMUSG00000072905 
Ndufb8 ENSMUSG00000025204 Sh2d1b2 ENSMUSG00000073494 
Sema4g ENSMUSG00000025207 Pgap1 ENSMUSG00000073678 
Ptprj ENSMUSG00000025314 Sh3d21 ENSMUSG00000073758 
Fscn2 ENSMUSG00000025380 Klhl40 ENSMUSG00000074001 
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Cd163l1 ENSMUSG00000025461 Wfdc9 ENSMUSG00000074594 
Taldo1 ENSMUSG00000025503 Nynrin ENSMUSG00000075592 
Rbfox3 ENSMUSG00000025576 Igkv4-56 ENSMUSG00000076557 
Rptor ENSMUSG00000025583 Igkv6-20 ENSMUSG00000076587 
Sdc3 ENSMUSG00000025743 Ighv3-8 ENSMUSG00000076674 
Homer2 ENSMUSG00000025813 Ighv6-6 ENSMUSG00000076680 
Sox17 ENSMUSG00000025902 Klhdc7a ENSMUSG00000078234 
Gsta3 ENSMUSG00000025934 Serpina3m ENSMUSG00000079012 
Ccdc150 ENSMUSG00000025983 Serpina3i ENSMUSG00000079014 
Slc40a1 ENSMUSG00000025993 Gm5662 ENSMUSG00000079029 
Il1r2 ENSMUSG00000026073 Gm15737 ENSMUSG00000079462 
2010300C02Rik ENSMUSG00000026090 C1qtnf5 ENSMUSG00000079592 
Gls ENSMUSG00000026103 Gm14862 ENSMUSG00000079694 
Slc16a14 ENSMUSG00000026220 Gm14601 ENSMUSG00000081119 
Nppc ENSMUSG00000026241 Gm12551 ENSMUSG00000081169 
Serpine2 ENSMUSG00000026249 Gm6568 ENSMUSG00000082002 
Rgs1 ENSMUSG00000026358 Gm15806 ENSMUSG00000082554 
Ptprc ENSMUSG00000026395 Naip3 ENSMUSG00000082956 
Cacna1s ENSMUSG00000026407 Gm8812 ENSMUSG00000083289 
Ifi202b ENSMUSG00000026535 Gm12892 ENSMUSG00000083679 
Tagln2 ENSMUSG00000026547 Gm14593 ENSMUSG00000084308 
Astn1 ENSMUSG00000026587 Gm13415 ENSMUSG00000085057 
Bpnt1 ENSMUSG00000026617 Gm14066 ENSMUSG00000085071 
Atf3 ENSMUSG00000026628 Gm16150 ENSMUSG00000085391 
Mrc1 ENSMUSG00000026712 Gm13936 ENSMUSG00000085444 
Col5a1 ENSMUSG00000026837 Gm13053 ENSMUSG00000085574 
Pax8 ENSMUSG00000026976 A730032A03Rik ENSMUSG00000085649 
Il1rn ENSMUSG00000026981 Arhgap27os1 ENSMUSG00000085733 
Il1f6 ENSMUSG00000026984 2610307P16Rik ENSMUSG00000085936 
Il1f8 ENSMUSG00000026985 Gm15318 ENSMUSG00000086010 
Galnt3 ENSMUSG00000026994 Gm15929 ENSMUSG00000086032 
Slc25a12 ENSMUSG00000027010 AV064505 ENSMUSG00000086381 
Gatm ENSMUSG00000027199 Susd5 ENSMUSG00000086596 
Fam227b ENSMUSG00000027209 Gm15482 ENSMUSG00000086711 
Ell3 ENSMUSG00000027246 Bcas1os2 ENSMUSG00000086999 
F2 ENSMUSG00000027249 Gm5530 ENSMUSG00000087008 
Map1a ENSMUSG00000027254 2610035D17Rik ENSMUSG00000087259 
Gfra4 ENSMUSG00000027316 Gm15866 ENSMUSG00000087290 
Gpcpd1 ENSMUSG00000027346 0610040F04Rik ENSMUSG00000087341 
Fermt1 ENSMUSG00000027356 Gm13398 ENSMUSG00000087364 
Tgm6 ENSMUSG00000027403 C430049B03Rik ENSMUSG00000087365 
E2f5 ENSMUSG00000027552 Gm11752 ENSMUSG00000087404 
Ahcy ENSMUSG00000027597 Coro2a ENSMUSG00000028337 
Adgrl2 ENSMUSG00000028184 Tmem38b ENSMUSG00000028420 
Rragd ENSMUSG00000028278 Gne ENSMUSG00000028479 
Arhgap6 ENSMUSG00000031355 Gfi1 ENSMUSG00000029275 
Ap1s2 ENSMUSG00000031367 Cdc7 ENSMUSG00000029283 
Car5b ENSMUSG00000031373 Rasgef1b ENSMUSG00000029333 
Nxf7 ENSMUSG00000031410 Cxcl1 ENSMUSG00000029380 
F7 ENSMUSG00000031443 Shroom3 ENSMUSG00000029381 
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Myom2 ENSMUSG00000031461 Rasal1 ENSMUSG00000029602 
Dusp4 ENSMUSG00000031530 Mtus2 ENSMUSG00000029651 
Ank1 ENSMUSG00000031543 Fam3c ENSMUSG00000029672 
Mt1 ENSMUSG00000031765 1700034O15Rik ENSMUSG00000029867 
Cntnap4 ENSMUSG00000031772 Mogs ENSMUSG00000030036 
BC021891 ENSMUSG00000031853 Bhlhe40 ENSMUSG00000030103 
Ces2e ENSMUSG00000031886 Clec2e ENSMUSG00000030155 
Birc3 ENSMUSG00000032000 Olr1 ENSMUSG00000030162 
Rexo2 ENSMUSG00000032026 Klrd1 ENSMUSG00000030165 
Abhd12 ENSMUSG00000032046 Cidec ENSMUSG00000030278 
Olfm2 ENSMUSG00000032172 Tspan9 ENSMUSG00000030352 
Kank2 ENSMUSG00000032194 Faap24 ENSMUSG00000030493 
Rab27a ENSMUSG00000032202 Nucb2 ENSMUSG00000030659 
Myo1e ENSMUSG00000032220 Dkkl1 ENSMUSG00000030792 
Itga11 ENSMUSG00000032243 Fbxl19 ENSMUSG00000030811 
Calml4 ENSMUSG00000032246 Acsm2 ENSMUSG00000030945 
Lrrc1 ENSMUSG00000032352 Mrgprf ENSMUSG00000031070 
Plscr1 ENSMUSG00000032369 Vgll1 ENSMUSG00000031131 
Snx1 ENSMUSG00000032382 Porcn ENSMUSG00000031169 
Igdcc3 ENSMUSG00000032394 Srpx2 ENSMUSG00000031253 
Eomes ENSMUSG00000032446 Smlr1 ENSMUSG00000096546 
Nmnat3 ENSMUSG00000032456 Galntl6 ENSMUSG00000096914 
Pik3cb ENSMUSG00000032462 A330023F24Rik ENSMUSG00000096929 
Nme6 ENSMUSG00000032478 Gm26580 ENSMUSG00000097109 
Trib1 ENSMUSG00000032501 Gm4890 ENSMUSG00000097174 
Csrnp1 ENSMUSG00000032515 2010300F17Rik ENSMUSG00000097289 
Acpp ENSMUSG00000032561 Gm26532 ENSMUSG00000097296 
Pygm ENSMUSG00000032648 Gm26568 ENSMUSG00000097315 
Bet1 ENSMUSG00000032757 Gm26592 ENSMUSG00000097535 
P2ry2 ENSMUSG00000032860 Gm26751 ENSMUSG00000097542 
Cspg4 ENSMUSG00000032911 Gm26902 ENSMUSG00000097558 
Rasgrp2 ENSMUSG00000032946 Gm26799 ENSMUSG00000097579 
Cdo1 ENSMUSG00000033022 Dleu2 ENSMUSG00000097589 
Rtp4 ENSMUSG00000033355 Gm26714 ENSMUSG00000097654 
Casp4 ENSMUSG00000033538 Gm26642 ENSMUSG00000097680 
1300017J02Rik ENSMUSG00000033688 4833412C05Rik ENSMUSG00000097697 
Akr1c14 ENSMUSG00000033715 Gm6556 ENSMUSG00000097806 
2310007B03Rik ENSMUSG00000034159 Gm26704 ENSMUSG00000097875 
Rasl10a ENSMUSG00000034209 Gm26577 ENSMUSG00000097923 
Arhgap27 ENSMUSG00000034255 Gm26578 ENSMUSG00000097928 
Tbc1d10a ENSMUSG00000034412 Arl14 ENSMUSG00000098207 
Pkd1l2 ENSMUSG00000034416 2810468N07Rik ENSMUSG00000091475 
Ifit1 ENSMUSG00000034459 Gm17019 ENSMUSG00000091897 
Dgkh ENSMUSG00000034731 Serpina4-ps1 ENSMUSG00000092075 
Mfrp ENSMUSG00000034739 4833427F10Rik ENSMUSG00000092171 
Cxcl10 ENSMUSG00000034855 Gm20444 ENSMUSG00000092258 
Tbxa2r ENSMUSG00000034881 BB365896 ENSMUSG00000092323 
5031414D18Rik ENSMUSG00000034959 Gm1604a ENSMUSG00000094083 
Brinp3 ENSMUSG00000035131 9430069I07Rik ENSMUSG00000094447 
Mia2 ENSMUSG00000035349 Ighv1-84 ENSMUSG00000094940 
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Nfkbiz ENSMUSG00000035356 Hsd3b4 ENSMUSG00000095143 
Foxa1 ENSMUSG00000035451 Gm10681 ENSMUSG00000095388 
Cdcp1 ENSMUSG00000035498 Igkv14-100 ENSMUSG00000096515 
Midn ENSMUSG00000035621 Gm15646 ENSMUSG00000087554 
Zswim4 ENSMUSG00000035671 4930447M23Rik ENSMUSG00000087674 
Thrsp ENSMUSG00000035686 Gm11762 ENSMUSG00000087675 
Plekhs1 ENSMUSG00000035818 Gm15641 ENSMUSG00000089779 
Pknox2 ENSMUSG00000035934 Gm15954 ENSMUSG00000089979 
Fam65b ENSMUSG00000036006 Nhlrc4 ENSMUSG00000090113 
Prickle1 ENSMUSG00000036158 Usp49 ENSMUSG00000090115 
Sh3bp4 ENSMUSG00000036206 Trim34b ENSMUSG00000090215 
Micall2 ENSMUSG00000036718 Gm4450 ENSMUSG00000090817 
Hspb6 ENSMUSG00000036854 Gm20458 ENSMUSG00000090996 
Setd7 ENSMUSG00000037111 Gm17114 ENSMUSG00000091237 
Ppp1r14a ENSMUSG00000037166 Gm17641 ENSMUSG00000091272 
Htra4 ENSMUSG00000037406 Gm17509 ENSMUSG00000091423 
Uggt1 ENSMUSG00000037470 Dnajc5b ENSMUSG00000027606 
Ankrd13b ENSMUSG00000037907 Rpn2 ENSMUSG00000027642 
Smim3 ENSMUSG00000038059 Ctnnbl1 ENSMUSG00000027649 
AW551984 ENSMUSG00000038112 Skil ENSMUSG00000027660 
Gstp2 ENSMUSG00000038155 Ngf ENSMUSG00000027859 
Slc22a23 ENSMUSG00000038267 Hsd3b1 ENSMUSG00000027871 
Galnt18 ENSMUSG00000038296 Bcar3 ENSMUSG00000028121 
Sesn1 ENSMUSG00000038332 Slco4a1 ENSMUSG00000038963 
Egr1 ENSMUSG00000038418 Chad ENSMUSG00000039084 
Rgs4 ENSMUSG00000038530 Mycbpap ENSMUSG00000039110 
Fam63a ENSMUSG00000038712 Ifi44l ENSMUSG00000039146 
Elovl3 ENSMUSG00000038754 2300002M23Rik ENSMUSG00000039269 
Stap2 ENSMUSG00000038781 AF529169 ENSMUSG00000039313 
Cuzd1 ENSMUSG00000040205 Cfap70 ENSMUSG00000039543 
Ctsg ENSMUSG00000040314 Mrps6 ENSMUSG00000039680 
Ufl1 ENSMUSG00000040359 Dag1 ENSMUSG00000039952 
Spns2 ENSMUSG00000040447 Bmf ENSMUSG00000040093 
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Table B.6 List of genes exclusively changing in the RU486-induced preterm labour model 
(FDR<0.001). Gene names and Ensembl gene identification number (ID) are reported. (Mus 
musculus version GRCm38.p4). 
Gene Name Ensembl Gene ID Gene Name Ensembl Gene ID 
Igsf5 ENSMUSG00000000159 Foxq1 ENSMUSG00000038415 
Nalcn ENSMUSG00000000197 C1s1 ENSMUSG00000038521 
Cdh4 ENSMUSG00000000305 Sycp2l ENSMUSG00000038651 
Itga5 ENSMUSG00000000555 Pak1ip1 ENSMUSG00000038683 
Dynlt1c ENSMUSG00000000579 Ttll6 ENSMUSG00000038756 
Gm2a ENSMUSG00000000594 Nexn ENSMUSG00000039103 
Serpinf1 ENSMUSG00000000753 Prune2 ENSMUSG00000039126 
Txnrd3 ENSMUSG00000000811 1110008P14Rik ENSMUSG00000039195 
Cyp51 ENSMUSG00000001467 Sec24d ENSMUSG00000039234 
Folh1 ENSMUSG00000001773 Atp6v0e2 ENSMUSG00000039347 
Cd320 ENSMUSG00000002308 Prss23 ENSMUSG00000039405 
Irf9 ENSMUSG00000002325 Mtmr7 ENSMUSG00000039431 
Edar ENSMUSG00000003227 Ccdc27 ENSMUSG00000039492 
Phyhip ENSMUSG00000003469 Cdsn ENSMUSG00000039518 
Dusp3 ENSMUSG00000003518 Rcan2 ENSMUSG00000039601 
Calb2 ENSMUSG00000003657 Sdk1 ENSMUSG00000039683 
Mast2 ENSMUSG00000003810 Kmo ENSMUSG00000039783 
Nqo1 ENSMUSG00000003849 2600006K01Rik ENSMUSG00000039798 
Gstm5 ENSMUSG00000004032 Slc44a3 ENSMUSG00000039865 
Hif3a ENSMUSG00000004328 Clstn1 ENSMUSG00000039953 
9330159F19Rik ENSMUSG00000004360 Ccdc40 ENSMUSG00000039963 
Nkg7 ENSMUSG00000004612 Dtx4 ENSMUSG00000039982 
Abca13 ENSMUSG00000004668 Tph1 ENSMUSG00000040046 
Ap1s1 ENSMUSG00000004849 Gjb6 ENSMUSG00000040055 
Fgfr4 ENSMUSG00000005320 Ildr2 ENSMUSG00000040612 
Pafah1b3 ENSMUSG00000005447 Oard1 ENSMUSG00000040771 
Htra1 ENSMUSG00000006205 S100g ENSMUSG00000040808 
Hspb7 ENSMUSG00000006221 Plekhh2 ENSMUSG00000040852 
Epor ENSMUSG00000006235 Kcnd3 ENSMUSG00000040896 
Neurl1a ENSMUSG00000006435 Npnt ENSMUSG00000040998 
Itih3 ENSMUSG00000006522 Nacad ENSMUSG00000041073 
P3h4 ENSMUSG00000006931 Nbl1 ENSMUSG00000041120 
Pcdha11 ENSMUSG00000007440 Pla2g2d ENSMUSG00000041202 
Id3 ENSMUSG00000007872 Chd7 ENSMUSG00000041235 
Fbxw9 ENSMUSG00000008167 Kcnj1 ENSMUSG00000041248 
Relt ENSMUSG00000008318 Mdfic ENSMUSG00000041390 
Slc47a1 ENSMUSG00000010122 Irf8 ENSMUSG00000041515 
Optc ENSMUSG00000010311 Rbp3 ENSMUSG00000041534 
Dazl ENSMUSG00000010592 Fmod ENSMUSG00000041559 
Adssl1 ENSMUSG00000011148 Nppa ENSMUSG00000041616 
Adam19 ENSMUSG00000011256 Wipi1 ENSMUSG00000041895 
Ttll5 ENSMUSG00000012609 2010003K11Rik ENSMUSG00000042041 
Ptprs ENSMUSG00000013236 Klhdc8a ENSMUSG00000042115 
Zfp651 ENSMUSG00000013419 Slc35f2 ENSMUSG00000042195 
Lypd8 ENSMUSG00000013643 Gzmk ENSMUSG00000042385 
Ly6g6e ENSMUSG00000013766 Adora1 ENSMUSG00000042429 
Aldh1a3 ENSMUSG00000015134 Mfap4 ENSMUSG00000042436 
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Eps8 ENSMUSG00000015766 C1galt1 ENSMUSG00000042460 
Cd5l ENSMUSG00000015854 Fam124b ENSMUSG00000043230 
1700016C15Rik ENSMUSG00000015962 Psapl1 ENSMUSG00000043430 
Stard13 ENSMUSG00000016128 Gjc2 ENSMUSG00000043448 
Scube1 ENSMUSG00000016763 Adamts3 ENSMUSG00000043635 
Plcg1 ENSMUSG00000016933 Kcns3 ENSMUSG00000043673 
Tnnc2 ENSMUSG00000017300 F830045P16Rik ENSMUSG00000043727 
C1qtnf1 ENSMUSG00000017446 Chil5 ENSMUSG00000043873 
Timp2 ENSMUSG00000017466 Tnip3 ENSMUSG00000044162 
Baiap2l2 ENSMUSG00000018126 Ctla2a ENSMUSG00000044258 
Wfdc15b ENSMUSG00000018211 Apol7c ENSMUSG00000044309 
Mmp20 ENSMUSG00000018620 Snhg11 ENSMUSG00000044349 
Lsp1 ENSMUSG00000018819 Sptssa ENSMUSG00000044408 
Sfrp5 ENSMUSG00000018822 Fam46c ENSMUSG00000044468 
Gdpd2 ENSMUSG00000019359 Serpinb1a ENSMUSG00000044734 
Arhgef25 ENSMUSG00000019467 Psg22 ENSMUSG00000044903 
Pkib ENSMUSG00000019876 Cfap43 ENSMUSG00000044948 
Lims1 ENSMUSG00000019920 Gm5514 ENSMUSG00000045104 
Kitl ENSMUSG00000019966 Lhfpl2 ENSMUSG00000045312 
Il20ra ENSMUSG00000020007 Cenpe ENSMUSG00000045328 
4632428N05Rik ENSMUSG00000020101 Ifne ENSMUSG00000045364 
Sgcd ENSMUSG00000020354 Hcar2 ENSMUSG00000045502 
Ltc4s ENSMUSG00000020377 Lrtm1 ENSMUSG00000045776 
Cnot8 ENSMUSG00000020515 Sdpr ENSMUSG00000045954 
Galnt10 ENSMUSG00000020520 Sbsn ENSMUSG00000046056 
Fam49a ENSMUSG00000020589 Igfals ENSMUSG00000046070 
Rhbdf2 ENSMUSG00000020806 Tusc5 ENSMUSG00000046275 
Timm22 ENSMUSG00000020843 Defb14 ENSMUSG00000046354 
Nxn ENSMUSG00000020844 Camk2n1 ENSMUSG00000046447 
Tmem107 ENSMUSG00000020895 Scn4b ENSMUSG00000046480 
Krt12 ENSMUSG00000020912 C1qtnf2 ENSMUSG00000046491 
Trim9 ENSMUSG00000021071 Hrk ENSMUSG00000046607 
Galnt16 ENSMUSG00000021130 Pkd1l1 ENSMUSG00000046634 
Slc10a1 ENSMUSG00000021135 Gm5637 ENSMUSG00000046993 
Tshz3 ENSMUSG00000021217 Irs3 ENSMUSG00000047182 
Papln ENSMUSG00000021223 BC048546 ENSMUSG00000047228 
Tgfb3 ENSMUSG00000021253 Flrt2 ENSMUSG00000047414 
Ogn ENSMUSG00000021390 Antxrl ENSMUSG00000047441 
Cxcl14 ENSMUSG00000021508 Arl4a ENSMUSG00000047446 
Nkd2 ENSMUSG00000021567 Adamts12 ENSMUSG00000047497 
Slc6a18 ENSMUSG00000021612 Lxn ENSMUSG00000047557 
Hmgcr ENSMUSG00000021670 Nccrp1 ENSMUSG00000047586 
Serinc5 ENSMUSG00000021703 Lix1 ENSMUSG00000047786 
Glud1 ENSMUSG00000021794 Sstr2 ENSMUSG00000047904 
Nid2 ENSMUSG00000021806 Lmod1 ENSMUSG00000048096 
Txndc16 ENSMUSG00000021830 Nags ENSMUSG00000048217 
Bmp4 ENSMUSG00000021835 Sacs ENSMUSG00000048279 
1700011H14Rik ENSMUSG00000021850 Fam171b ENSMUSG00000048388 
Dnah12 ENSMUSG00000021879 Tmprss11f ENSMUSG00000048764 
Tkt ENSMUSG00000021957 Lonrf2 ENSMUSG00000048814 
4930578I06Rik ENSMUSG00000021961 4930539E08Rik ENSMUSG00000048905 
Diap3 ENSMUSG00000022021 Elfn1 ENSMUSG00000048988 
Pebp4 ENSMUSG00000022085 Clec4a1 ENSMUSG00000049037 
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Dnah5 ENSMUSG00000022262 Rapgef4 ENSMUSG00000049044 
Angpt1 ENSMUSG00000022309 Sephs2 ENSMUSG00000049091 
Sqle ENSMUSG00000022351 Frmpd4 ENSMUSG00000049176 
Mtss1 ENSMUSG00000022353 Syt12 ENSMUSG00000049303 
Josd1 ENSMUSG00000022426 Gpr55 ENSMUSG00000049608 
Hdac7 ENSMUSG00000022475 Rasd1 ENSMUSG00000049892 
Boc ENSMUSG00000022687 BC030500 ENSMUSG00000049946 
Serpind1 ENSMUSG00000022766 Spink8 ENSMUSG00000050074 
Fstl1 ENSMUSG00000022816 Bpifc ENSMUSG00000050108 
Muc13 ENSMUSG00000022824 Foxl2 ENSMUSG00000050397 
St6gal1 ENSMUSG00000022885 Ftl1 ENSMUSG00000050708 
Adamts5 ENSMUSG00000022894 1700020N01Rik ENSMUSG00000050844 
Fam3b ENSMUSG00000022938 Tmem125 ENSMUSG00000050854 
Slc10a2 ENSMUSG00000023073 Plcb1 ENSMUSG00000051177 
Fhl1 ENSMUSG00000023092 9230109A22Rik ENSMUSG00000051237 
Kcnk5 ENSMUSG00000023243 Cacna1c ENSMUSG00000051331 
Guca2a ENSMUSG00000023247 Plagl2 ENSMUSG00000051413 
Acat2 ENSMUSG00000023832 Apon ENSMUSG00000051716 
Calcr ENSMUSG00000023964 Lax1 ENSMUSG00000051998 
Pi16 ENSMUSG00000024011 Hbb-y ENSMUSG00000052187 
Vit ENSMUSG00000024076 Hbb-bh1 ENSMUSG00000052217 
Rhoq ENSMUSG00000024143 Nav2 ENSMUSG00000052512 
Prss28 ENSMUSG00000024171 Dlg2 ENSMUSG00000052572 
Sox8 ENSMUSG00000024176 Asap2 ENSMUSG00000052632 
Syt4 ENSMUSG00000024261 Rab7b ENSMUSG00000052688 
Dsc2 ENSMUSG00000024331 Nrk ENSMUSG00000052854 
Ttc39c ENSMUSG00000024424 Cntn2 ENSMUSG00000053024 
Pcdh12 ENSMUSG00000024440 Btn2a2 ENSMUSG00000053216 
Hdac3 ENSMUSG00000024454 Tgm5 ENSMUSG00000053675 
Dctn4 ENSMUSG00000024603 Fam83e ENSMUSG00000054161 
Prpf19 ENSMUSG00000024735 Gimap4 ENSMUSG00000054435 
Syt7 ENSMUSG00000024743 Adam10 ENSMUSG00000054693 
Tm7sf2 ENSMUSG00000024799 Phactr1 ENSMUSG00000054728 
Apba1 ENSMUSG00000024897 Fsd1l ENSMUSG00000054752 
Ltbp3 ENSMUSG00000024940 Cntn1 ENSMUSG00000055022 
Xpnpep1 ENSMUSG00000025027 M5C1000I18Rik ENSMUSG00000055125 
Gfra1 ENSMUSG00000025089 Pld5 ENSMUSG00000055214 
Kazald1 ENSMUSG00000025213 Slc6a2 ENSMUSG00000055368 
Abhd6 ENSMUSG00000025277 Nell1 ENSMUSG00000055409 
Caly ENSMUSG00000025468 Hba-x ENSMUSG00000055609 
Fgf14 ENSMUSG00000025551 Cep70 ENSMUSG00000056267 
Cpeb1 ENSMUSG00000025586 Capg ENSMUSG00000056737 
Tmem47 ENSMUSG00000025666 Prl3d1 ENSMUSG00000057170 
Pigq ENSMUSG00000025728 Arhgap24 ENSMUSG00000057315 
Clec3b ENSMUSG00000025784 Unc13d ENSMUSG00000057948 
Pdia4 ENSMUSG00000025823 Adamts17 ENSMUSG00000058145 
Col5a2 ENSMUSG00000026042 Idi1 ENSMUSG00000058258 
1500015O10Rik ENSMUSG00000026051 Serpina9 ENSMUSG00000058260 
Slc23a3 ENSMUSG00000026205 Gm15590 ENSMUSG00000058542 
Bok ENSMUSG00000026278 Samd12 ENSMUSG00000058656 
Trp53bp2 ENSMUSG00000026510 Frem1 ENSMUSG00000059049 
Opn3 ENSMUSG00000026525 Skap2 ENSMUSG00000059182 
Ptpn14 ENSMUSG00000026604 Fdps ENSMUSG00000059743 
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Hsd17b7 ENSMUSG00000026675 Irak4 ENSMUSG00000059883 
Kif5c ENSMUSG00000026764 Mug1 ENSMUSG00000059908 
Itga8 ENSMUSG00000026768 Fcrl1 ENSMUSG00000059994 
Ak1 ENSMUSG00000026817 Nrg2 ENSMUSG00000060275 
Dolpp1 ENSMUSG00000026856 Tmc2 ENSMUSG00000060332 
Grin1 ENSMUSG00000026959 Csmd1 ENSMUSG00000060924 
Lrrc26 ENSMUSG00000026961 Tmem263 ENSMUSG00000060935 
Tfpi ENSMUSG00000027082 Copz1 ENSMUSG00000060992 
Hsd17b12 ENSMUSG00000027195 Myl4 ENSMUSG00000061086 
Creb3l1 ENSMUSG00000027230 BC048679 ENSMUSG00000061877 
Mal ENSMUSG00000027375 Gm10116 ENSMUSG00000062382 
Prom2 ENSMUSG00000027376 Ncr1 ENSMUSG00000062524 
Tgm3 ENSMUSG00000027401 Platr26 ENSMUSG00000064263 
Mylk2 ENSMUSG00000027470 Cntn4 ENSMUSG00000064293 
Fam210b ENSMUSG00000027495 Mirlet7g ENSMUSG00000065440 
Fabp5 ENSMUSG00000027533 Cd209b ENSMUSG00000065987 
Stmn3 ENSMUSG00000027581 Adamtsl1 ENSMUSG00000066113 
Procr ENSMUSG00000027611 Capn6 ENSMUSG00000067276 
Schip1 ENSMUSG00000027777 Gng5 ENSMUSG00000068523 
Spag17 ENSMUSG00000027867 Ptprz1 ENSMUSG00000068748 
Hao2 ENSMUSG00000027870 Selenbp2 ENSMUSG00000068877 
Chil6 ENSMUSG00000027902 Fam149a ENSMUSG00000070044 
Crct1 ENSMUSG00000027913 Mmp27 ENSMUSG00000070323 
Lelp1 ENSMUSG00000027927 Gad1 ENSMUSG00000070880 
Tpm3 ENSMUSG00000027940 A830039N20Rik ENSMUSG00000071567 
Fga ENSMUSG00000028001 Lrrn4cl ENSMUSG00000071656 
Npy2r ENSMUSG00000028004 Plac9b ENSMUSG00000072674 
Pdgfc ENSMUSG00000028019 Ly6g6d ENSMUSG00000073413 
Thbs3 ENSMUSG00000028047 Mob3b ENSMUSG00000073910 
Ecm1 ENSMUSG00000028108 Ttpa ENSMUSG00000073988 
Tspan5 ENSMUSG00000028152 Fam169b ENSMUSG00000074071 
Cdh17 ENSMUSG00000028217 BC030870 ENSMUSG00000074300 
Murc ENSMUSG00000028348 Fam83c ENSMUSG00000074647 
Uts2 ENSMUSG00000028963 Plekhm1 ENSMUSG00000034247 
Angptl7 ENSMUSG00000028989 Igsf9b ENSMUSG00000034275 
Cwh43 ENSMUSG00000029154 Myo15b ENSMUSG00000034427 
Rhof ENSMUSG00000029449 Asb16 ENSMUSG00000034768 
Arpc1b ENSMUSG00000029622 Filip1 ENSMUSG00000034898 
Medag ENSMUSG00000029659 Cobll1 ENSMUSG00000034903 
Pon3 ENSMUSG00000029759 Gm6781 ENSMUSG00000035129 
Gm22133 ENSMUSG00000076036 Ccl7 ENSMUSG00000035373 
Gm22774 ENSMUSG00000076038 Kank4 ENSMUSG00000035407 
Gm13030 ENSMUSG00000078518 Igfbpl1 ENSMUSG00000035551 
Crnn ENSMUSG00000078657 Tmprss11b ENSMUSG00000035861 
Naip6 ENSMUSG00000078942 Colec12 ENSMUSG00000036103 
C7 ENSMUSG00000079105 Slc2a13 ENSMUSG00000036298 
Gm6614 ENSMUSG00000079263 Btg1 ENSMUSG00000036478 
C1s2 ENSMUSG00000079343 Cpz ENSMUSG00000036596 
Utp14b ENSMUSG00000079470 Noxa1 ENSMUSG00000036805 
Gm5640 ENSMUSG00000079534 Slc39a12 ENSMUSG00000036949 
Aox2 ENSMUSG00000079554 Ovol2 ENSMUSG00000037279 
Gm11620 ENSMUSG00000081965 Jade3 ENSMUSG00000037315 
Ftl2-ps ENSMUSG00000082062 Fbxo34 ENSMUSG00000037536 
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Gm15776 ENSMUSG00000082241 Fermt2 ENSMUSG00000037712 
B4galt1 ENSMUSG00000028413 Cpe ENSMUSG00000037852 
Npr2 ENSMUSG00000028469 Ccdc129 ENSMUSG00000037973 
Gpx7 ENSMUSG00000028597 Dnah10 ENSMUSG00000038011 
Hspa12b ENSMUSG00000074793 Dennd4c ENSMUSG00000038024 
Lcmt2 ENSMUSG00000074890 Socs1 ENSMUSG00000038037 
Mir692-3 ENSMUSG00000076033 Hand2 ENSMUSG00000038193 
Creld1 ENSMUSG00000030284 Edem2 ENSMUSG00000038312 
Kctd15 ENSMUSG00000030499 Pcp4l1 ENSMUSG00000038370 
Fam189a1 ENSMUSG00000030518 4921507P07Rik ENSMUSG00000029828 
Cib1 ENSMUSG00000030538 Nfe2l3 ENSMUSG00000029832 
Me3 ENSMUSG00000030621 Add2 ENSMUSG00000030000 
Prss23os ENSMUSG00000030623 Gxylt2 ENSMUSG00000030074 
Ptpn5 ENSMUSG00000030854 Nup210 ENSMUSG00000030091 
Cpxm2 ENSMUSG00000030862 Ret ENSMUSG00000030110 
Crym ENSMUSG00000030905 Clec1b ENSMUSG00000030159 
Anks4b ENSMUSG00000030909 Ldhb ENSMUSG00000030246 
Pgap2 ENSMUSG00000030990 Kcnj8 ENSMUSG00000030247 
Syt8 ENSMUSG00000031098 Abcc9 ENSMUSG00000030249 
Gpc4 ENSMUSG00000031119 Bhlhe41 ENSMUSG00000030256 
Itm2a ENSMUSG00000031239 Gm15157 ENSMUSG00000082560 
Sh3bgrl ENSMUSG00000031246 Ctsf ENSMUSG00000083282 
Il13ra2 ENSMUSG00000031289 Gm13502 ENSMUSG00000083287 
Bgn ENSMUSG00000031375 Gm8051 ENSMUSG00000083588 
L1cam ENSMUSG00000031391 Gm15880 ENSMUSG00000084821 
Cd209a ENSMUSG00000031494 A830036E02Rik ENSMUSG00000084890 
Sfrp1 ENSMUSG00000031548 Gm15958 ENSMUSG00000085055 
Adam5 ENSMUSG00000031554 Egfros ENSMUSG00000085091 
Msmo1 ENSMUSG00000031604 Nr6a1os ENSMUSG00000085201 
Hpgd ENSMUSG00000031613 Gm14866 ENSMUSG00000085314 
Pdlim3 ENSMUSG00000031636 Gm12320 ENSMUSG00000085502 
Ucp1 ENSMUSG00000031710 Rgag1 ENSMUSG00000085584 
Irx6 ENSMUSG00000031738 9130409J20Rik ENSMUSG00000085683 
Mmp2 ENSMUSG00000031740 Grin1os ENSMUSG00000085830 
Mt2 ENSMUSG00000031762 Gm12530 ENSMUSG00000085967 
Herpud1 ENSMUSG00000031770 A830012C17Rik ENSMUSG00000085996 
Cdh13 ENSMUSG00000031841 Gm13362 ENSMUSG00000086418 
Jam3 ENSMUSG00000031990 Gm15199 ENSMUSG00000086428 
Sc5d ENSMUSG00000032018 9130204K15Rik ENSMUSG00000086474 
Cryab ENSMUSG00000032060 Gm11747 ENSMUSG00000086514 
Mcam ENSMUSG00000032135 Gm13716 ENSMUSG00000086905 
Car12 ENSMUSG00000032373 Gm16277 ENSMUSG00000087002 
Rbpms2 ENSMUSG00000032387 Gm11586 ENSMUSG00000087339 
Slco2a1 ENSMUSG00000032548 Zmiz1os1 ENSMUSG00000087535 
Trf ENSMUSG00000032554 Gm13031 ENSMUSG00000087698 
Col6a4 ENSMUSG00000032572 Gm3470 ENSMUSG00000089659 
Cd59a ENSMUSG00000032679 5330439A09Rik ENSMUSG00000089708 
Bmp8a ENSMUSG00000032726 Gm16567 ENSMUSG00000089961 
Gtf3c1 ENSMUSG00000032777 Palm2 ENSMUSG00000090053 
Alas1 ENSMUSG00000032786 Gm1965 ENSMUSG00000090254 
Pkd1 ENSMUSG00000032855 Gm3571 ENSMUSG00000090610 
Afap1l1 ENSMUSG00000033032 Gm20425 ENSMUSG00000090639 
Clec1a ENSMUSG00000033082 A530084C06Rik ENSMUSG00000090863 
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BC016579 ENSMUSG00000033187 Gm17197 ENSMUSG00000090990 
Wnt6 ENSMUSG00000033227 Vgll3 ENSMUSG00000091243 
Ctnnd1 ENSMUSG00000034101 Gm7701 ENSMUSG00000091363 
Golim4 ENSMUSG00000034109 Otogl ENSMUSG00000091455 
Tspan8 ENSMUSG00000034127 C2cd4b ENSMUSG00000091956 
Gm5847 ENSMUSG00000082280 Kcnb2 ENSMUSG00000092083 
Gm15693 ENSMUSG00000082485 Gm4246 ENSMUSG00000092240 
Foxl2os ENSMUSG00000097072 Gm5873 ENSMUSG00000093651 
2210008F06Rik ENSMUSG00000097165 Gm4303 ENSMUSG00000094228 
Miat ENSMUSG00000097767 Gm4301 ENSMUSG00000094314 
Gm26777 ENSMUSG00000097801 D430019H16Rik ENSMUSG00000094910 
Gm10605 ENSMUSG00000097974 Igkv6-25 ENSMUSG00000094930 
Gm26953 ENSMUSG00000097986 Gm14328 ENSMUSG00000095419 
Gm5300 ENSMUSG00000098052 A630023A22Rik ENSMUSG00000095493 
P3h1 ENSMUSG00000028641 Dynlt1f ENSMUSG00000095677 
Pla2g2e ENSMUSG00000028751 Gm1045 ENSMUSG00000096035 
Cda ENSMUSG00000028755 Gm3150 ENSMUSG00000096173 
Tinagl1 ENSMUSG00000028776 Dynlt1b ENSMUSG00000096255 
Rspo1 ENSMUSG00000028871 Gm4980 ENSMUSG00000096606 
Padi2 ENSMUSG00000028927 Gm2670 ENSMUSG00000097002 
Pgd ENSMUSG00000028961   
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Table B.7 List of genes exclusively changing in the LPS-induced preterm labour model 
(FDR<0.001). Gene names and Ensembl gene identification number (ID) are reported. (Mus 
musculus version GRCm38.p4). 
Gene 
Name 
Ensembl Gene ID Gene 
Name 
Ensembl ID Gene 
Name 
Ensembl  ID 
Scml2 ENSMUSG00000000037 Gpr85 ENSMUSG00000048216 Plac8 ENSMUSG00000029322 
Tbx4 ENSMUSG00000000094 Gng7 ENSMUSG00000048240 Antxr2 ENSMUSG00000029338 
Ngfr ENSMUSG00000000120 Mfsd6l ENSMUSG00000048329 Tpst2 ENSMUSG00000029344 
Xpo6 ENSMUSG00000000131 Pdp2 ENSMUSG00000048371 Alb ENSMUSG00000029368 
Slfn4 ENSMUSG00000000204 Fitm2 ENSMUSG00000048486 Cxcl5 ENSMUSG00000029371 
Tspan3
2 
ENSMUSG00000000244 8430408
G22Rik 
ENSMUSG00000048489 Ppbp ENSMUSG00000029372 
Dbt ENSMUSG00000000340 Phldb1 ENSMUSG00000048537 Cxcl3 ENSMUSG00000029379 
Tmprss
2 
ENSMUSG00000000385 4732456
N10Rik 
ENSMUSG00000048699 Ccng2 ENSMUSG00000029385 
Pdgfb ENSMUSG00000000489 Ccdc6 ENSMUSG00000048701 Ddx55 ENSMUSG00000029389 
Acvrl1 ENSMUSG00000000530 Gm1218
5 
ENSMUSG00000048852 G3bp2 ENSMUSG00000029405 
Tom1l2 ENSMUSG00000000538 Zfp710 ENSMUSG00000048897 U9092
6 
ENSMUSG00000029409 
Sox9 ENSMUSG00000000567 Efna5 ENSMUSG00000048915 Sdad1 ENSMUSG00000029415 
Icosl ENSMUSG00000000732 Gm5540 ENSMUSG00000048916 Cxcl9 ENSMUSG00000029417 
Fmr1 ENSMUSG00000000838 Prex2 ENSMUSG00000048960 Rnf34 ENSMUSG00000029474 
Pxmp4 ENSMUSG00000000876 Hcar1 ENSMUSG00000049241 Ncor2 ENSMUSG00000029478 
Sec24b ENSMUSG00000001052 Kcnk3 ENSMUSG00000049265 Ankle2 ENSMUSG00000029501 
Lgals9 ENSMUSG00000001123 Ogfr ENSMUSG00000049401 Prkab1 ENSMUSG00000029513 
Oas1c ENSMUSG00000001166 Tmem67 ENSMUSG00000049488 Cit ENSMUSG00000029516 
Gramd
1a 
ENSMUSG00000001248 Proser1 ENSMUSG00000049504 Tfec ENSMUSG00000029553 
Rrp15 ENSMUSG00000001305 Sall2 ENSMUSG00000049532 Tmem1
06b 
ENSMUSG00000029571 
Tulp3 ENSMUSG00000001521 Polr1a ENSMUSG00000049553 Zfp12 ENSMUSG00000029587 
Eef1e1 ENSMUSG00000001707 Ap5b1 ENSMUSG00000049562 Dtx1 ENSMUSG00000029603 
Tspan3
3 
ENSMUSG00000001763 Aknad1 ENSMUSG00000049565 Oas1b ENSMUSG00000029605 
Nfix ENSMUSG00000001911 Tifab ENSMUSG00000049625 Rph3a ENSMUSG00000029608 
Siae ENSMUSG00000001942 Aftph ENSMUSG00000049659 Aimp2 ENSMUSG00000029610 
Grik3 ENSMUSG00000001985 Nckap5 ENSMUSG00000049690 Arpc1a ENSMUSG00000029621 
Nr1h3 ENSMUSG00000002108 Lig4 ENSMUSG00000049717 Glcci1 ENSMUSG00000029638 
Rmnd5
a 
ENSMUSG00000002222 Zbtb12 ENSMUSG00000049823 Limk1 ENSMUSG00000029674 
Angptl
4 
ENSMUSG00000002289 Suox ENSMUSG00000049858 Gcc1 ENSMUSG00000029708 
Dbf4 ENSMUSG00000002297 Rlf ENSMUSG00000049878 Agfg2 ENSMUSG00000029722 
Daxx ENSMUSG00000002307 Gm7984 ENSMUSG00000049891 Mepce ENSMUSG00000029726 
Slc9a3r
2 
ENSMUSG00000002504 Plekhf2 ENSMUSG00000049969 Asns ENSMUSG00000029752 
Ikzf4 ENSMUSG00000002578 Glt1d1 ENSMUSG00000049971 Plxna4 ENSMUSG00000029765 
Axl ENSMUSG00000002602 Idnk ENSMUSG00000050002 Irf5 ENSMUSG00000029771 
Lcp2 ENSMUSG00000002699 Grrp1 ENSMUSG00000050105 Gars ENSMUSG00000029777 
Naa20 ENSMUSG00000002728 Gsg2 ENSMUSG00000050107 Adcyap
1r1 
ENSMUSG00000029778 
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Jag2 ENSMUSG00000002799 Foxc1 ENSMUSG00000050295 Nt5c3 ENSMUSG00000029780 
Il17ra ENSMUSG00000002897 Rictor ENSMUSG00000050310 Herc6 ENSMUSG00000029798 
Cd36 ENSMUSG00000002944 Il31ra ENSMUSG00000050377 Zc3hav
1 
ENSMUSG00000029826 
Med25 ENSMUSG00000002968 Sept6 ENSMUSG00000050379 Casp2 ENSMUSG00000029863 
Cdkn1b ENSMUSG00000003031 Ppp1r3g ENSMUSG00000050423 Ephb6 ENSMUSG00000029869 
Efna2 ENSMUSG00000003070 Tor1aip2 ENSMUSG00000050565 Mad2l1 ENSMUSG00000029910 
Keap1 ENSMUSG00000003308 Mmp13 ENSMUSG00000050578 C13006
0K24Ri
k 
ENSMUSG00000029917 
Etv3 ENSMUSG00000003382 Zscan29 ENSMUSG00000050619 Hmces ENSMUSG00000030060 
Fcgrt ENSMUSG00000003420 Plekho2 ENSMUSG00000050721 Frmd4b ENSMUSG00000030064 
Cyp4f1
8 
ENSMUSG00000003484 Rtn4rl2 ENSMUSG00000050896 Prok2 ENSMUSG00000030069 
Klc4 ENSMUSG00000003546 Cdr2l ENSMUSG00000050910 Usp18 ENSMUSG00000030107 
Insig2 ENSMUSG00000003721 Ankrd37 ENSMUSG00000050914 Tuba8 ENSMUSG00000030137 
Itpkc ENSMUSG00000003752 Olfml1 ENSMUSG00000051041 Clec4a
2 
ENSMUSG00000030148 
Gys1 ENSMUSG00000003865 Mb21d2 ENSMUSG00000051065 Klrk1 ENSMUSG00000030149 
Ruvbl2 ENSMUSG00000003868 Rgs13 ENSMUSG00000051079 Erc1 ENSMUSG00000030172 
Il7r ENSMUSG00000003882 Gm1544
0 
ENSMUSG00000051107 Ybx3 ENSMUSG00000030189 
Fam16
2a 
ENSMUSG00000003955 Zfp46 ENSMUSG00000051351 Etv6 ENSMUSG00000030199 
Stat5a ENSMUSG00000004043 Irf2bp2 ENSMUSG00000051495 Ptpro ENSMUSG00000030223 
Hmox2 ENSMUSG00000004070 Wdfy4 ENSMUSG00000051506 Lrmp ENSMUSG00000030263 
Kifc2 ENSMUSG00000004187 Mical3 ENSMUSG00000051586 Necap1 ENSMUSG00000030327 
Il12b ENSMUSG00000004296 Rap2a ENSMUSG00000051615 Clec2h ENSMUSG00000030364 
Clcn3 ENSMUSG00000004319 Xrcc1 ENSMUSG00000051768 Asb7 ENSMUSG00000030509 
Gpx5 ENSMUSG00000004344 Nlgn2 ENSMUSG00000051790 Tjp1 ENSMUSG00000030516 
Utp20 ENSMUSG00000004356 Sox12 ENSMUSG00000051817 Apba2 ENSMUSG00000030519 
Zfp324 ENSMUSG00000004500 Mest ENSMUSG00000051855 Sema4
b 
ENSMUSG00000030539 
Cd33 ENSMUSG00000004609 Cd209f ENSMUSG00000051906 Idh2 ENSMUSG00000030541 
Aqp1 ENSMUSG00000004655 Erich1 ENSMUSG00000051978 Dpf1 ENSMUSG00000030584 
Hdac9 ENSMUSG00000004698 Rgs14 ENSMUSG00000052087 Xylt1 ENSMUSG00000030657 
Cd244 ENSMUSG00000004709 Gm9869 ENSMUSG00000052143 Pik3c2
a 
ENSMUSG00000030660 
Adgre1 ENSMUSG00000004730 Pld4 ENSMUSG00000052160 Pde3b ENSMUSG00000030671 
Rab23 ENSMUSG00000004768 Gm1496
4 
ENSMUSG00000052188 Ppme1 ENSMUSG00000030718 
Ccl24 ENSMUSG00000004814 Ankrd44 ENSMUSG00000052331 Nfatc2i
p 
ENSMUSG00000030722 
Fxyd4 ENSMUSG00000004988 Cx3cr1 ENSMUSG00000052336 Slco2b
1 
ENSMUSG00000030737 
Wisp1 ENSMUSG00000005124 Cemip ENSMUSG00000052353 Myh14 ENSMUSG00000030739 
Ndrg1 ENSMUSG00000005125 Acot4 ENSMUSG00000052392 Il21r ENSMUSG00000030745 
Tbl2 ENSMUSG00000005374 Tmco1 ENSMUSG00000052428 Lcmt1 ENSMUSG00000030763 
Adcy9 ENSMUSG00000005580 C130026
I21Rik 
ENSMUSG00000052477 Rbbp6 ENSMUSG00000030779 
Mthfd2 ENSMUSG00000005667 Robo2 ENSMUSG00000052516 Adm ENSMUSG00000030790 
Apoa2 ENSMUSG00000005681 Adarb2 ENSMUSG00000052551 Itgal ENSMUSG00000030830 
Tfap4 ENSMUSG00000005718 Gan ENSMUSG00000052557 Chp2 ENSMUSG00000030865 
Appendix B 
 
327 
 
Ranbp1 ENSMUSG00000005732 Cpne8 ENSMUSG00000052560 Gga2 ENSMUSG00000030872 
Bloc1s
6 
ENSMUSG00000005804 D930048
N14Rik 
ENSMUSG00000052563 Trim30
a 
ENSMUSG00000030921 
Tpr ENSMUSG00000006005 Sh2d6 ENSMUSG00000052631 Trim21 ENSMUSG00000030966 
Crkl ENSMUSG00000006134 Kcnt2 ENSMUSG00000052726 Ctbp2 ENSMUSG00000030970 
Eps8l1 ENSMUSG00000006154 Oas1a ENSMUSG00000052776 Mki67 ENSMUSG00000031004 
Ttc5 ENSMUSG00000006288 Gm9892 ENSMUSG00000052825 Dock11 ENSMUSG00000031093 
Tek ENSMUSG00000006386 Cdh22 ENSMUSG00000053166 Rab33a ENSMUSG00000031104 
Rnf114 ENSMUSG00000006418 Ddx10 ENSMUSG00000053289 Slc9a9 ENSMUSG00000031129 
Pola1 ENSMUSG00000006678 Slamf8 ENSMUSG00000053318 Ccdc12
0 
ENSMUSG00000031150 
Hap1 ENSMUSG00000006930 Tarm1 ENSMUSG00000053338 Wdr13 ENSMUSG00000031166 
Atp1a2 ENSMUSG00000007097 Adamts1
8 
ENSMUSG00000053399 Msn ENSMUSG00000031207 
Lrrc8a ENSMUSG00000007476 Cbx7 ENSMUSG00000053411 Ophn1 ENSMUSG00000031214 
Twist2 ENSMUSG00000007805 Kdm3a ENSMUSG00000053470 Chic1 ENSMUSG00000031327 
Zmiz1 ENSMUSG00000007817 Trim60 ENSMUSG00000053490 Gpm6b ENSMUSG00000031342 
Fnbp4 ENSMUSG00000008200 Cstf2t ENSMUSG00000053536 Trex2 ENSMUSG00000031372 
Cd163 ENSMUSG00000008845 Gm4759 ENSMUSG00000053541 Bmx ENSMUSG00000031377 
Hdac5 ENSMUSG00000008855 Dennd4a ENSMUSG00000053641 Abcd1 ENSMUSG00000031378 
Tmem1
84b 
ENSMUSG00000009035 Camk2d ENSMUSG00000053819 Piga ENSMUSG00000031381 
Ascl2 ENSMUSG00000009248 Lipg ENSMUSG00000053846 Angpt2 ENSMUSG00000031465 
Trpm2 ENSMUSG00000009292 Slc39a8 ENSMUSG00000053897 Agpat5 ENSMUSG00000031467 
Met ENSMUSG00000009376 Ech1 ENSMUSG00000053898 Eif4ebp
1 
ENSMUSG00000031490 
Slc16a
12 
ENSMUSG00000009378 Pde5a ENSMUSG00000053965 Gpm6a ENSMUSG00000031517 
Nav1 ENSMUSG00000009418 A930004
D18Rik 
ENSMUSG00000054057 Wwc2 ENSMUSG00000031563 
Apobec
3 
ENSMUSG00000009585 Iigp1 ENSMUSG00000054072 Gtf2e2 ENSMUSG00000031585 
Tex15 ENSMUSG00000009628 Skp2 ENSMUSG00000054115 Slc7a2 ENSMUSG00000031596 
Ick ENSMUSG00000009828 Adm2 ENSMUSG00000054136 Sap30 ENSMUSG00000031609 
Tmem8
6a 
ENSMUSG00000010307 Slfn5 ENSMUSG00000054404 Ednra ENSMUSG00000031616 
Ifi35 ENSMUSG00000010358 Gm4793 ENSMUSG00000054412 Irf2 ENSMUSG00000031627 
Fads1 ENSMUSG00000010663 Sytl5 ENSMUSG00000054453 Lrp2bp ENSMUSG00000031637 
Slc5a1 ENSMUSG00000011034 Kcnn2 ENSMUSG00000054477 F11 ENSMUSG00000031645 
Tbrg1 ENSMUSG00000011114 Gm9947 ENSMUSG00000054493 Adcy7 ENSMUSG00000031659 
Exoc3l
2 
ENSMUSG00000011263 Parp4 ENSMUSG00000054509 Sall1 ENSMUSG00000031665 
Mlkl ENSMUSG00000012519 Sh3bp2 ENSMUSG00000054520 Cdyl2 ENSMUSG00000031758 
Atad1 ENSMUSG00000013662 Tmprss1
1e 
ENSMUSG00000054537 Pllp ENSMUSG00000031775 
Tnfaip8
l2 
ENSMUSG00000013707 Mettl7a1 ENSMUSG00000054619 Adgrg1 ENSMUSG00000031785 
Pax5 ENSMUSG00000014030 Tmem11
9 
ENSMUSG00000054675 Kifc3 ENSMUSG00000031788 
Cacybp ENSMUSG00000014226 Ankrd24 ENSMUSG00000054708 Map1lc
3b 
ENSMUSG00000031812 
Glis2 ENSMUSG00000014303 Vmac ENSMUSG00000054723 Cotl1 ENSMUSG00000031827 
Strip1 ENSMUSG00000014601 Atrnl1 ENSMUSG00000054843 Mphos
ph6 
ENSMUSG00000031843 
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Cmc2 ENSMUSG00000014633 Kbtbd13 ENSMUSG00000054978 Hsd11b
2 
ENSMUSG00000031891 
Gadd45
b 
ENSMUSG00000015312 Agtr1b ENSMUSG00000054988 Psmb1
0 
ENSMUSG00000031897 
Dennd6
b 
ENSMUSG00000015377 Lrtm2 ENSMUSG00000055003 Zfp90 ENSMUSG00000031907 
Cd83 ENSMUSG00000015396 Rab39 ENSMUSG00000055069 Has3 ENSMUSG00000031910 
Mocs2 ENSMUSG00000015536 A630012
P03Rik 
ENSMUSG00000055110 Maml2 ENSMUSG00000031925 
Arnt2 ENSMUSG00000015709 Sertad3 ENSMUSG00000055200 Ankrd4
9 
ENSMUSG00000031931 
Capza2 ENSMUSG00000015733 Ankrd17 ENSMUSG00000055204 Gpr83 ENSMUSG00000031932 
Plekho
1 
ENSMUSG00000015745 9430025
C20Rik 
ENSMUSG00000055216 Kars ENSMUSG00000031948 
Sqstm1 ENSMUSG00000015837 Tead1 ENSMUSG00000055320 Cdh15 ENSMUSG00000031962 
Fcrls ENSMUSG00000015852 4933427
D06Rik 
ENSMUSG00000055403 231002
2B05Ri
k 
ENSMUSG00000031983 
H2afy ENSMUSG00000015937 Maf ENSMUSG00000055435 Egln1 ENSMUSG00000031987 
Gtf2ird
2 
ENSMUSG00000015942 Cd47 ENSMUSG00000055447 Bace1 ENSMUSG00000032086 
Gatsl2 ENSMUSG00000015944 Tcf7l1 ENSMUSG00000055799 Slc37a
2 
ENSMUSG00000032122 
Fcgr1 ENSMUSG00000015947 Fto ENSMUSG00000055932 Lysmd
2 
ENSMUSG00000032184 
Ncf1 ENSMUSG00000015950 A430033
K04Rik 
ENSMUSG00000056014 Dock6 ENSMUSG00000032198 
H2-M3 ENSMUSG00000016206 Rgs9bp ENSMUSG00000056043 Rora ENSMUSG00000032238 
Wt1 ENSMUSG00000016458 S100a9 ENSMUSG00000056071 Cln6 ENSMUSG00000032245 
Cd274 ENSMUSG00000016496 H2-T22 ENSMUSG00000056116 Fam46
a 
ENSMUSG00000032265 
Pdcd1l
g2 
ENSMUSG00000016498 AI50443
2 
ENSMUSG00000056145 Thsd4 ENSMUSG00000032289 
Lnx2 ENSMUSG00000016520 Col8a2 ENSMUSG00000056174 Pkm ENSMUSG00000032294 
Cmah ENSMUSG00000016756 Gpr50 ENSMUSG00000056380 Stra6 ENSMUSG00000032327 
Il13ra1 ENSMUSG00000017057 Mettl7a2 ENSMUSG00000056487 Col12a
1 
ENSMUSG00000032332 
Brca1 ENSMUSG00000017146 Ptafr ENSMUSG00000056529 Stoml1 ENSMUSG00000032333 
Suz12 ENSMUSG00000017548 Prelid2 ENSMUSG00000056671 Adamts
7 
ENSMUSG00000032363 
Ttpal ENSMUSG00000017679 D17Wsu
92e 
ENSMUSG00000056692 Plscr4 ENSMUSG00000032377 
Hnf4a ENSMUSG00000017950 Gulp1 ENSMUSG00000056870 Xrn1 ENSMUSG00000032410 
Pmp22 ENSMUSG00000018217 Jmjd6 ENSMUSG00000056962 Tfdp2 ENSMUSG00000032411 
Myo1b ENSMUSG00000018417 Slc35f3 ENSMUSG00000057060 Cmtm6 ENSMUSG00000032434 
Slc13a
3 
ENSMUSG00000018459 Gja5 ENSMUSG00000057123 Cdc25a ENSMUSG00000032477 
Kcnab3 ENSMUSG00000018470 Tmem14
0 
ENSMUSG00000057137 Cish ENSMUSG00000032578 
Kdm6b ENSMUSG00000018476 AB1246
11 
ENSMUSG00000057191 Nckips
d 
ENSMUSG00000032598 
Slc2a4 ENSMUSG00000018566 Cep170 ENSMUSG00000057335 Nicn1 ENSMUSG00000032606 
Dusp14 ENSMUSG00000018648 Apol9a ENSMUSG00000057346 Colgalt
2 
ENSMUSG00000032649 
Aatf ENSMUSG00000018697 Birc2 ENSMUSG00000057367 1700025
G04Rik 
ENSMUSG00000032666 
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Dync1h
1 
ENSMUSG00000018707 Pus7 ENSMUSG00000057541 Oas2 ENSMUSG00000032690 
Heatr9 ENSMUSG00000018925 Lgals8 ENSMUSG00000057554 Nlrp3 ENSMUSG00000032691 
Ccl6 ENSMUSG00000018927 Trim30d ENSMUSG00000057596 Syde1 ENSMUSG00000032714 
Dnah1 ENSMUSG00000019027 Lmcd1 ENSMUSG00000057604 Trib3 ENSMUSG00000032715 
Slc25a
22 
ENSMUSG00000019082 Gapdh ENSMUSG00000057666 Tpcn1 ENSMUSG00000032741 
Rab5c ENSMUSG00000019173 Bak1 ENSMUSG00000057789 Slc8b1 ENSMUSG00000032754 
Scn1b ENSMUSG00000019194 Itpk1 ENSMUSG00000057963 Mctp2 ENSMUSG00000032776 
Ptger1 ENSMUSG00000019464 Mdn1 ENSMUSG00000058006 Srxn1 ENSMUSG00000032802 
Rab4a ENSMUSG00000019478 Gstm1 ENSMUSG00000058135 Arap1 ENSMUSG00000032812 
Akt3 ENSMUSG00000019699 Chsy3 ENSMUSG00000058152 Mycbp
2 
ENSMUSG00000033004 
Esr1 ENSMUSG00000019768 Gm5431 ENSMUSG00000058163 Nfatc1 ENSMUSG00000033016 
Cep57l
1 
ENSMUSG00000019813 Rrp1b ENSMUSG00000058392 1700088
E04Rik 
ENSMUSG00000033029 
Smpd2 ENSMUSG00000019822 Adra2b ENSMUSG00000058620 Calhm2 ENSMUSG00000033033 
Slc16a
10 
ENSMUSG00000019838 Gda ENSMUSG00000058624 Micall1 ENSMUSG00000033039 
Prep ENSMUSG00000019849 Lin9 ENSMUSG00000058729 Npat ENSMUSG00000033054 
Gopc ENSMUSG00000019861 Vwa8 ENSMUSG00000058997 Pfkm ENSMUSG00000033065 
Dcbld1 ENSMUSG00000019891 Fcgr4 ENSMUSG00000059089 Tbc1d4 ENSMUSG00000033083 
P4ha1 ENSMUSG00000019916 Sept9 ENSMUSG00000059248 Podxl2 ENSMUSG00000033152 
Tmpo ENSMUSG00000019961 Max ENSMUSG00000059436 Ttc28 ENSMUSG00000033209 
Vnn3 ENSMUSG00000020010 Ptk2b ENSMUSG00000059456 AA467
197 
ENSMUSG00000033213 
Cdk17 ENSMUSG00000020015 Nhs ENSMUSG00000059493 Scaf11 ENSMUSG00000033228 
Hal ENSMUSG00000020017 Gm1637
9 
ENSMUSG00000059658 Antxr1 ENSMUSG00000033420 
Socs2 ENSMUSG00000020027 Atl2 ENSMUSG00000059811 Mcee ENSMUSG00000033429 
Tcp11l
2 
ENSMUSG00000020034 Kprp ENSMUSG00000059832 Zbtb1 ENSMUSG00000033454 
Cry1 ENSMUSG00000020038 Zfp341 ENSMUSG00000059842 Fam16
0b1 
ENSMUSG00000033478 
Igf1 ENSMUSG00000020053 Ptp4a3 ENSMUSG00000059895 Fndc3a ENSMUSG00000033487 
Ppa1 ENSMUSG00000020089 Tmem40 ENSMUSG00000059900 Apol6 ENSMUSG00000033576 
Plek ENSMUSG00000020120 Adamts1
4 
ENSMUSG00000059901 Myo6 ENSMUSG00000033577 
Egfr ENSMUSG00000020122 Unc5c ENSMUSG00000059921 Tmem3
5 
ENSMUSG00000033578 
Vps54 ENSMUSG00000020128 Tmem26 ENSMUSG00000060044 Fa2h ENSMUSG00000033579 
Ptprb ENSMUSG00000020154 Cxcl11 ENSMUSG00000060183 AW554
918 
ENSMUSG00000033632 
Cobl ENSMUSG00000020173 Gtf2i ENSMUSG00000060261 Smyd5 ENSMUSG00000033706 
Rab36 ENSMUSG00000020175 Xcr1 ENSMUSG00000060509 Egr3 ENSMUSG00000033730 
Adora2
a 
ENSMUSG00000020178 0610040
J01Rik 
ENSMUSG00000060512 D930015
E06Rik 
ENSMUSG00000033767 
Nav3 ENSMUSG00000020181 Tor3a ENSMUSG00000060519 Exoc6b ENSMUSG00000033769 
Mknk2 ENSMUSG00000020190 Pla2g16 ENSMUSG00000060675 Asb13 ENSMUSG00000033781 
Rel ENSMUSG00000020275 Mkx ENSMUSG00000061013 Fam20
8b 
ENSMUSG00000033799 
Xpo1 ENSMUSG00000020290 Zfp143 ENSMUSG00000061079 Pla2g4
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Clca3a
2 
ENSMUSG00000028262 Gdap10 ENSMUSG00000096954 Wdr72 ENSMUSG00000044976 
Lmo4 ENSMUSG00000028266 E230013
L22Rik 
ENSMUSG00000096957 Proser2 ENSMUSG00000045319 
Gbp3 ENSMUSG00000028268 Gm2688
3 
ENSMUSG00000096972 Sh2d5 ENSMUSG00000045349 
Gbp2 ENSMUSG00000028270 Gm2652
6 
ENSMUSG00000096980 Tnfrsf2
6 
ENSMUSG00000045362 
Stra6l ENSMUSG00000028327 9530082
P21Rik 
ENSMUSG00000097006 1190002
N15Rik 
ENSMUSG00000045414 
Anp32
b 
ENSMUSG00000028333 Gm2678
6 
ENSMUSG00000097026 Tmem6
0 
ENSMUSG00000045435 
Brinp1 ENSMUSG00000028351 Ptgs2os ENSMUSG00000097028 Mettl24 ENSMUSG00000045555 
Pappa ENSMUSG00000028370 Fam120a
os 
ENSMUSG00000097059 Plekha
7 
ENSMUSG00000045659 
Col27a
1 
ENSMUSG00000045672         
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Table B8 Genes upregulated between E16 and E18 and between 6 and 18 hours post-
RU486 
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Table B9 Genes downregulated between E16 and E18 and between 6 and 18 hours post-
RU486 
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Appendix B - Table B10 Genes upregulated between E18 and LAB and between 6 and 
18 hours post-RU486 
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Table B11 Genes downregulated between E18 and LAB and between 6 and 18 hours 
post-RU486 
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Table B.12 BioMart Ensembl gene annotation for a total of 357 genes orthologous genes 
differentially expressed in murine and human labour.MGI, 
Ensembl ID Mouse 
Ensembl ID 
Human Description 
ENSMUSG00000069793 ENSG00000172716 schlafen 9 [MGI:2445121] 
ENSMUSG00000020676 ENSG00000172156 chemokine (C-C motif) ligand 11 [MGI:103576] 
ENSMUSG00000032860 ENSG00000175591 purinergic receptor P2Y, G-protein coupled 2 [MGI:105107] 
ENSMUSG00000034520 ENSG00000182963 gap junction protein, gamma 1 [MGI:95718] 
ENSMUSG00000076431 ENSG00000124766 SRY (sex determining region Y)-box 4 [MGI:98366] 
ENSMUSG00000032115 ENSG00000149428 hypoxia up-regulated 1 [MGI:108030] 
ENSMUSG00000026604 ENSG00000152104 protein tyrosine phosphatase, non-receptor type 14 [MGI:102467] 
ENSMUSG00000027435 ENSG00000125810 CD93 antigen [MGI:106664] 
ENSMUSG00000037731 ENSG00000130775 thymocyte selection associated family member 2 [MGI:2446213] 
ENSMUSG00000028766 ENSG00000162551 alkaline phosphatase, liver/bone/kidney [MGI:87983] 
ENSMUSG00000026483 ENSG00000135842 family with sequence similarity 129, member A [MGI:2137237] 
ENSMUSG00000021822 ENSG00000122861 plasminogen activator, urokinase [MGI:97611] 
ENSMUSG00000064246 ENSG00000133048 chitinase-like 1 [MGI:1340899] 
ENSMUSG00000035064 ENSG00000103319 eukaryotic elongation factor-2 kinase [MGI:1195261] 
ENSMUSG00000025877 ENSG00000160883 hexokinase 3 [MGI:2670962] 
ENSMUSG00000054263 ENSG00000113594 leukemia inhibitory factor receptor [MGI:96788] 
ENSMUSG00000003814 ENSG00000179218 calreticulin [MGI:88252] 
ENSMUSG00000031760 ENSG00000087250 metallothionein 3 [MGI:97173] 
ENSMUSG00000019082 ENSG00000177542 
solute carrier family 25 (mitochondrial carrier, glutamate), 
member 22 
 [MGI:1915517] 
ENSMUSG00000023393 ENSG00000101194 solute carrier family 17, member 9 [MGI:1919107] 
ENSMUSG00000026179 ENSG00000127838 paroxysmal nonkinesiogenic dyskinesia [MGI:1930773] 
ENSMUSG00000057191 ENSG00000214212 cDNA sequence AB124611 [MGI:3043001] 
ENSMUSG00000025400 ENSG00000166863 tachykinin 2 [MGI:98476] 
ENSMUSG00000039910 ENSG00000164442 
Cbp/p300-interacting transactivator, with Glu/Asp-rich 
 carboxy-terminal domain, 2 [MGI:1306784] 
ENSMUSG00000007805 ENSG00000233608 twist basic helix-loop-helix transcription factor 2 [MGI:104685] 
ENSMUSG00000024190 ENSG00000120129 dual specificity phosphatase 1 [MGI:105120] 
ENSMUSG00000025059 ENSG00000198814 glycerol kinase [MGI:106594] 
ENSMUSG00000024238 ENSG00000148516 zinc finger E-box binding homeobox 1 [MGI:1344313] 
ENSMUSG00000022237 ENSG00000164236 ankyrin repeat domain 33B [MGI:1917904] 
ENSMUSG00000036879 ENSG00000102893 phosphorylase kinase beta [MGI:97578] 
ENSMUSG00000004371 ENSG00000095752 interleukin 11 [MGI:107613] 
ENSMUSG00000031119 ENSG00000076716 glypican 4 [MGI:104902] 
ENSMUSG00000043099 ENSG00000177374 hypermethylated in cancer 1 [MGI:1338010] 
ENSMUSG00000069793 ENSG00000154760 schlafen 9 [MGI:2445121] 
ENSMUSG00000046687 ENSG00000130707 predicted gene 5424 [MGI:3643173] 
ENSMUSG00000063568 ENSG00000153814 JAZF zinc finger 1 [MGI:2141450] 
ENSMUSG00000046731 ENSG00000213859 
potassium channel tetramerisation domain containing 11  
[MGI:2448712] 
ENSMUSG00000026582 ENSG00000007908 selectin, endothelial cell [MGI:98278] 
ENSMUSG00000046329 ENSG00000125648 
solute carrier family 25 (mitochondrial carrier; phosphate carrier),  
member 23 [MGI:1914222] 
ENSMUSG00000028989 ENSG00000171819 angiopoietin-like 7 [MGI:3605801] 
ENSMUSG00000038418 ENSG00000120738 early growth response 1 [MGI:95295] 
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ENSMUSG00000053846 ENSG00000101670 lipase, endothelial [MGI:1341803] 
ENSMUSG00000047407 ENSG00000177426 TGFB-induced factor homeobox 1 [MGI:1194497] 
ENSMUSG00000035711 ENSG00000146094 docking protein 3 [MGI:1351490] 
ENSMUSG00000031722 ENSG00000261701 haptoglobin [MGI:96211] 
ENSMUSG00000031722 ENSG00000257017 haptoglobin [MGI:96211] 
ENSMUSG00000047419 ENSG00000164309 cardiomyopathy associated 5 [MGI:1923719] 
ENSMUSG00000096606 ENSG00000261594 predicted gene 4980 [MGI:3646425] 
ENSMUSG00000046186 ENSG00000156535 CD109 antigen [MGI:2445221] 
ENSMUSG00000027581 ENSG00000197457 stathmin-like 3 [MGI:1277137] 
ENSMUSG00000032515 ENSG00000144655 cysteine-serine-rich nuclear protein 1 [MGI:2387989] 
ENSMUSG00000057948 ENSG00000092929 unc-13 homolog D (C. elegans) [MGI:1917700] 
ENSMUSG00000007655 ENSG00000105974 caveolin 1, caveolae protein [MGI:102709] 
ENSMUSG00000027422 ENSG00000125844 ribosome binding protein 1 [MGI:1932395] 
ENSMUSG00000031825 ENSG00000103196 
cysteine-rich secretory protein LCCL domain containing 2  
[MGI:1926142] 
ENSMUSG00000031283 ENSG00000101938 chordin-like 1 [MGI:1933172] 
ENSMUSG00000026581 ENSG00000188404 selectin, lymphocyte [MGI:98279] 
ENSMUSG00000040010 ENSG00000103257 
solute carrier family 7 (cationic amino acid transporter, y+ 
system),  
member 5 [MGI:1298205] 
ENSMUSG00000025161 ENSG00000141526 
solute carrier family 16 (monocarboxylic acid transporters),  
member 3 [MGI:1933438] 
ENSMUSG00000033960 ENSG00000165757 RIKEN cDNA 9430020K01 gene [MGI:2685174] 
ENSMUSG00000024736 ENSG00000006118 transmembrane protein 132A [MGI:2147810] 
ENSMUSG00000035828 ENSG00000198355 proviral integration site 3 [MGI:1355297] 
ENSMUSG00000031805 ENSG00000105639 Janus kinase 3 [MGI:99928] 
ENSMUSG00000049265 ENSG00000171303 potassium channel, subfamily K, member 3 [MGI:1100509] 
ENSMUSG00000028893 ENSG00000130766 sestrin 2 [MGI:2651874] 
ENSMUSG00000023903 ENSG00000008516 matrix metallopeptidase 25 [MGI:2443938] 
ENSMUSG00000042429 ENSG00000163485 adenosine A1 receptor [MGI:99401] 
ENSMUSG00000020151 ENSG00000153233 protein tyrosine phosphatase, receptor type, R [MGI:109559] 
ENSMUSG00000028019 ENSG00000145431 platelet-derived growth factor, C polypeptide [MGI:1859631] 
ENSMUSG00000024486 ENSG00000113070 heparin-binding EGF-like growth factor [MGI:96070] 
ENSMUSG00000036218 ENSG00000165966 PDZ domain containing RING finger 4 [MGI:3056996] 
ENSMUSG00000008318 ENSG00000054967 RELT tumor necrosis factor receptor [MGI:2443373] 
ENSMUSG00000070436 ENSG00000149257 
serine (or cysteine) peptidase inhibitor, clade H, member 1 
 [MGI:88283] 
ENSMUSG00000042284 ENSG00000213949 integrin alpha 1 [MGI:96599] 
ENSMUSG00000020737 ENSG00000189159 
hematological and neurological expressed sequence 1 
 [MGI:1096361] 
ENSMUSG00000028152 ENSG00000168785 tetraspanin 5 [MGI:1928096] 
ENSMUSG00000051790 ENSG00000169992 neuroligin 2 [MGI:2681835] 
ENSMUSG00000028944 ENSG00000106617 
protein kinase, AMP-activated, gamma 2 non-catalytic 
 subunit [MGI:1336153] 
ENSMUSG00000025930 ENSG00000178860 musculin [MGI:1333884] 
ENSMUSG00000036381 ENSG00000174944 purinergic receptor P2Y, G-protein coupled, 14 [MGI:2155705] 
ENSMUSG00000043631 ENSG00000106823 
extracellular matrix protein 2, female organ and adipocyte 
specific  
[MGI:3039578] 
ENSMUSG00000049420 ENSG00000164484 transmembrane protein 200A [MGI:1924470] 
ENSMUSG00000024302 ENSG00000134769 dystrobrevin alpha [MGI:106039] 
ENSMUSG00000048701 ENSG00000108091 coiled-coil domain containing 6 [MGI:1923801] 
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ENSMUSG00000031273 ENSG00000197565 collagen, type IV, alpha 6 [MGI:2152695] 
ENSMUSG00000020437 ENSG00000136286 myosin IG [MGI:1927091] 
ENSMUSG00000041120 ENSG00000158747 neuroblastoma, suppression of tumorigenicity 1 [MGI:104591] 
ENSMUSG00000041120 ENSG00000270136 neuroblastoma, suppression of tumorigenicity 1 [MGI:104591] 
ENSMUSG00000024998 ENSG00000138193 phospholipase C, epsilon 1 [MGI:1921305] 
ENSMUSG00000020108 ENSG00000168209 DNA-damage-inducible transcript 4 [MGI:1921997] 
ENSMUSG00000019960 ENSG00000139318 dual specificity phosphatase 6 [MGI:1914853] 
ENSMUSG00000058794 ENSG00000123405 nuclear factor, erythroid derived 2 [MGI:97308] 
ENSMUSG00000033059 ENSG00000100994 brain glycogen phosphorylase [MGI:97828] 
ENSMUSG00000027858 ENSG00000134198 tetraspanin 2 [MGI:1917997] 
ENSMUSG00000054855 ENSG00000172602 Rho family GTPase 1 [MGI:2444878] 
ENSMUSG00000056962 ENSG00000070495 jumonji domain containing 6 [MGI:1858910] 
ENSMUSG00000025880 ENSG00000101665 SMAD family member 7 [MGI:1100518] 
ENSMUSG00000031740 ENSG00000087245 matrix metallopeptidase 2 [MGI:97009] 
ENSMUSG00000023951 ENSG00000112715 vascular endothelial growth factor A [MGI:103178] 
ENSMUSG00000044060 ENSG00000069712 RIKEN cDNA A830010M20 gene [MGI:2445097] 
ENSMUSG00000044224 ENSG00000168724 
DnaJ (Hsp40) homolog, subfamily C, member 21 
[MGI:1925371] 
ENSMUSG00000056071 ENSG00000163220 S100 calcium binding protein A9 (calgranulin B) [MGI:1338947] 
ENSMUSG00000038349 ENSG00000115896 phospholipase C-like 1 [MGI:3036262] 
ENSMUSG00000005732 ENSG00000099901 RAN binding protein 1 [MGI:96269] 
ENSMUSG00000054196 ENSG00000164932 collagen triple helix repeat containing 1 [MGI:1915838] 
ENSMUSG00000042622 ENSG00000185022 
v-maf musculoaponeurotic fibrosarcoma oncogene family, protein 
F (avian)  
[MGI:96910] 
ENSMUSG00000025006 ENSG00000095637 sorbin and SH3 domain containing 1 [MGI:700014] 
ENSMUSG00000023456 ENSG00000111669 triosephosphate isomerase 1 [MGI:98797] 
ENSMUSG00000018476 ENSG00000132510 KDM1 lysine (K)-specific demethylase 6B [MGI:2448492] 
ENSMUSG00000054640 ENSG00000183023 
solute carrier family 8 (sodium/calcium exchanger),  
member 1 [MGI:107956] 
ENSMUSG00000029664 ENSG00000105825 tissue factor pathway inhibitor 2 [MGI:108543] 
ENSMUSG00000040209 ENSG00000164684 zinc finger protein 704 [MGI:2180715] 
ENSMUSG00000029379 ENSG00000163734 chemokine (C-X-C motif) ligand 3 [MGI:3037818] 
ENSMUSG00000029379 ENSG00000081041 chemokine (C-X-C motif) ligand 3 [MGI:3037818] 
ENSMUSG00000029122 ENSG00000072840 Ellis van Creveld gene syndrome [MGI:1890596] 
ENSMUSG00000026670 ENSG00000117143 
UDP-N-acetylglucosamine pyrophosphorylase 1 
 [MGI:1334459] 
ENSMUSG00000036565 ENSG00000136295 tweety homolog 3 (Drosophila) [MGI:1925589] 
ENSMUSG00000035356 ENSG00000144802 
nuclear factor of kappa light polypeptide gene enhancer in B cells 
inhibitor,  
zeta [MGI:1931595] 
ENSMUSG00000024534 ENSG00000064692 synuclein, alpha interacting protein (synphilin) [MGI:1915097] 
ENSMUSG00000045502 ENSG00000255398 hydroxycarboxylic acid receptor 2 [MGI:1933383] 
ENSMUSG00000045502 ENSG00000182782 hydroxycarboxylic acid receptor 2 [MGI:1933383] 
ENSMUSG00000031246 ENSG00000131171 
SH3-binding domain glutamic acid-rich protein like 
 [MGI:1930849] 
ENSMUSG00000059040 ENSG00000074800 enolase 1B, retrotransposed [MGI:3648653] 
ENSMUSG00000027254 ENSG00000166963 microtubule-associated protein 1 A [MGI:1306776] 
ENSMUSG00000030116 ENSG00000197614 microfibrillar associated protein 5 [MGI:1354387] 
ENSMUSG00000028957 ENSG00000049246 period circadian clock 3 [MGI:1277134] 
ENSMUSG00000027848 ENSG00000116774 olfactomedin-like 3 [MGI:1914877] 
ENSMUSG00000020814 ENSG00000182534 matrix-remodelling associated 7 [MGI:1914872] 
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ENSMUSG00000034612 ENSG00000171310 carbohydrate sulfotransferase 11 [MGI:1927166] 
ENSMUSG00000024300 ENSG00000142347 myosin IF [MGI:107711] 
ENSMUSG00000038210 ENSG00000005073 homeobox A11 [MGI:96172] 
ENSMUSG00000028896 ENSG00000180198 regulator of chromosome condensation 1 [MGI:1913989] 
ENSMUSG00000048572 ENSG00000181778 transmembrane protein 252 [MGI:3583948] 
ENSMUSG00000001248 ENSG00000089351 GRAM domain containing 1A [MGI:105490] 
ENSMUSG00000090231 ENSG00000244255 complement factor B [MGI:105975] 
ENSMUSG00000090231 ENSG00000243649 complement factor B [MGI:105975] 
ENSMUSG00000034810 ENSG00000136546 sodium channel, voltage-gated, type VII, alpha [MGI:102965] 
ENSMUSG00000027339 ENSG00000101265 
Ras association (RalGDS/AF-6) domain family member 2  
[MGI:2442060] 
ENSMUSG00000022309 ENSG00000154188 angiopoietin 1 [MGI:108448] 
ENSMUSG00000003865 ENSG00000104812 glycogen synthase 1, muscle [MGI:101805] 
ENSMUSG00000030732 ENSG00000054938 chordin-like 2 [MGI:1916371] 
ENSMUSG00000053113 ENSG00000184557 suppressor of cytokine signalling 3 [MGI:1201791] 
ENSMUSG00000045672 ENSG00000196739 collagen, type XXVII, alpha 1 [MGI:2672118] 
ENSMUSG00000039328 ENSG00000133874 ring finger protein 122 [MGI:1916117] 
ENSMUSG00000017386 ENSG00000076604 TNF receptor associated factor 4 [MGI:1202880] 
ENSMUSG00000035621 ENSG00000167470 midnolin [MGI:1890222] 
ENSMUSG00000027035 ENSG00000172292 ceramide synthase 6 [MGI:2442564] 
ENSMUSG00000025597 ENSG00000102271 kelch-like 4 [MGI:2442829] 
ENSMUSG00000026235 ENSG00000116106 Eph receptor A4 [MGI:98277] 
ENSMUSG00000040663 ENSG00000175505 cardiotrophin-like cytokine factor 1 [MGI:1930088] 
ENSMUSG00000039405 ENSG00000150687 protease, serine 23 [MGI:1923703] 
ENSMUSG00000006724 ENSG00000111012 
cytochrome P450, family 27, subfamily b, polypeptide 1 
 [MGI:1098274] 
ENSMUSG00000015944 ENSG00000274070 GATS protein-like 2 [MGI:1933384] 
ENSMUSG00000015944 ENSG00000239521 GATS protein-like 2 [MGI:1933384] 
ENSMUSG00000054843 ENSG00000107518 attractin like 1 [MGI:2147749] 
ENSMUSG00000038205 ENSG00000131791 
protein kinase, AMP-activated, beta 2 non-catalytic subunit 
 [MGI:1336185] 
ENSMUSG00000031490 ENSG00000187840 
eukaryotic translation initiation factor 4E binding protein 1  
[MGI:103267] 
ENSMUSG00000070427 ENSG00000137496 interleukin 18 binding protein [MGI:1333800] 
ENSMUSG00000049112 ENSG00000180914 oxytocin receptor [MGI:109147] 
ENSMUSG00000053475 ENSG00000123610 tumor necrosis factor alpha induced protein 6 [MGI:1195266] 
ENSMUSG00000053644 ENSG00000164904 aldehyde dehydrogenase family 7, member A1 [MGI:108186] 
ENSMUSG00000002289 ENSG00000167772 angiopoietin-like 4 [MGI:1888999] 
ENSMUSG00000035373 ENSG00000108688 chemokine (C-C motif) ligand 7 [MGI:99512] 
ENSMUSG00000028803 ENSG00000001461 NIPA-like domain containing 3 [MGI:1921802] 
ENSMUSG00000034563 ENSG00000260916 cell cycle progression 1 [MGI:1196419] 
ENSMUSG00000000340 ENSG00000137992 
dihydrolipoamide branched chain transacylase E2 
 [MGI:105386] 
ENSMUSG00000015766 ENSG00000151491 
epidermal growth factor receptor pathway substrate 8 
 [MGI:104684] 
ENSMUSG00000059991 ENSG00000106236 neuronal pentraxin 2 [MGI:1858209] 
ENSMUSG00000032501 ENSG00000173334 tribbles homolog 1 (Drosophila) [MGI:2443397] 
ENSMUSG00000021388 ENSG00000106819 asporin [MGI:1913945] 
ENSMUSG00000030554 ENSG00000182253 synemin, intermediate filament protein [MGI:2661187] 
ENSMUSG00000029838 ENSG00000105894 pleiotrophin [MGI:97804] 
ENSMUSG00000074934 ENSG00000166923 gremlin 1 [MGI:1344337] 
ENSMUSG00000026463 ENSG00000058668 ATPase, Ca++ transporting, plasma membrane 4 [MGI:88111] 
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ENSMUSG00000041773 ENSG00000171617 ectodermal-neural cortex 1 [MGI:109610] 
ENSMUSG00000066392 ENSG00000021645 neurexin III [MGI:1096389] 
ENSMUSG00000022756 ENSG00000099960 
solute carrier family 7 (cationic amino acid transporter, y+ 
system),  
member 4 [MGI:2146512] 
ENSMUSG00000019539 ENSG00000142552 
reticulocalbin 3, EF-hand calcium binding domain 
 [MGI:1277122] 
ENSMUSG00000031788 ENSG00000140859 kinesin family member C3 [MGI:109202] 
ENSMUSG00000035673 ENSG00000064932 strawberry notch homolog 2 (Drosophila) [MGI:2448490] 
ENSMUSG00000046480 ENSG00000177098 sodium channel, type IV, beta [MGI:2687406] 
ENSMUSG00000063142 ENSG00000156113 
potassium large conductance calcium-activated channel, 
subfamily M,  
alpha member 1 [MGI:99923] 
ENSMUSG00000031661 ENSG00000140807 naked cuticle 1 homolog (Drosophila) [MGI:2135954] 
ENSMUSG00000046402 ENSG00000114115 retinol binding protein 1, cellular [MGI:97876] 
ENSMUSG00000032006 ENSG00000170962 platelet-derived growth factor, D polypeptide [MGI:1919035] 
ENSMUSG00000040699 ENSG00000136490 LIM domain containing 2 [MGI:1915053] 
ENSMUSG00000003355 ENSG00000134285 FK506 binding protein 11 [MGI:1913370] 
ENSMUSG00000062300 ENSG00000130202 poliovirus receptor-related 2 [MGI:97822] 
ENSMUSG00000042272 ENSG00000187231 SEC14 and spectrin domains 1 [MGI:1916262] 
ENSMUSG00000028859 ENSG00000119535 
colony stimulating factor 3 receptor (granulocyte) 
[MGI:1339755] 
ENSMUSG00000023092 ENSG00000022267 four and a half LIM domains 1 [MGI:1298387] 
ENSMUSG00000028413 ENSG00000086062 
UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, 
polypeptide 1 
 [MGI:95705] 
ENSMUSG00000020407 ENSG00000183696 uridine phosphorylase 1 [MGI:1097668] 
ENSMUSG00000036885 ENSG00000114790 
Rho guanine nucleotide exchange factor (GEF) 26 
[MGI:1918053] 
ENSMUSG00000037685 ENSG00000124406 
ATPase, aminophospholipid transporter (APLT), class I, type 8A, 
member 1  
[MGI:1330848] 
ENSMUSG00000024014 ENSG00000137193 proviral integration site 1 [MGI:97584] 
ENSMUSG00000031765 ENSG00000244020 metallothionein 1 [MGI:97171] 
ENSMUSG00000031765 ENSG00000125144 metallothionein 1 [MGI:97171] 
ENSMUSG00000031765 ENSG00000205358 metallothionein 1 [MGI:97171] 
ENSMUSG00000031765 ENSG00000198417 metallothionein 1 [MGI:97171] 
ENSMUSG00000031765 ENSG00000169688 metallothionein 1 [MGI:97171] 
ENSMUSG00000031765 ENSG00000205362 metallothionein 1 [MGI:97171] 
ENSMUSG00000070462 ENSG00000140406 mesoderm development candidate 1 [MGI:1891420] 
ENSMUSG00000041757 ENSG00000143850 
pleckstrin homology domain containing, family A member 6 
 [MGI:2388662] 
ENSMUSG00000040451 ENSG00000198964 sphingomyelin synthase 1 [MGI:2444110] 
ENSMUSG00000032575 ENSG00000145050 
mesencephalic astrocyte-derived neurotrophic factor 
 [MGI:1922090] 
ENSMUSG00000053158 ENSG00000182511 feline sarcoma oncogene [MGI:95514] 
ENSMUSG00000032717 ENSG00000112559 MyoD family inhibitor [MGI:107687] 
ENSMUSG00000036390 ENSG00000116717 
growth arrest and DNA-damage-inducible 45 alpha  
[MGI:107799] 
ENSMUSG00000027993 ENSG00000109654 tripartite motif-containing 2 [MGI:1933163] 
ENSMUSG00000003545 ENSG00000125740 FBJ osteosarcoma oncogene B [MGI:95575] 
ENSMUSG00000025140 ENSG00000183010 pyrroline-5-carboxylate reductase 1 [MGI:2384795] 
ENSMUSG00000029371 ENSG00000163735 chemokine (C-X-C motif) ligand 5 [MGI:1096868] 
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ENSMUSG00000029371 ENSG00000124875 chemokine (C-X-C motif) ligand 5 [MGI:1096868] 
ENSMUSG00000022769 ENSG00000128228 stromal cell-derived factor 2-like 1 [MGI:2149842] 
ENSMUSG00000037820 ENSG00000198959 transglutaminase 2, C polypeptide [MGI:98731] 
ENSMUSG00000020592 ENSG00000115884 syndecan 1 [MGI:1349162] 
ENSMUSG00000038332 ENSG00000080546 sestrin 1 [MGI:2155278] 
ENSMUSG00000023328 ENSG00000087085 acetylcholinesterase [MGI:87876] 
ENSMUSG00000021187 ENSG00000165929 tandem C2 domains, nuclear [MGI:1921663] 
ENSMUSG00000004665 ENSG00000064666 calponin 2 [MGI:105093] 
ENSMUSG00000058979 ENSG00000069998 
cat eye syndrome chromosome region, candidate 5 
 [MGI:2136976] 
ENSMUSG00000052062 ENSG00000116117 par-3 family cell polarity regulator beta [MGI:1919301] 
ENSMUSG00000009628 ENSG00000133863 testis expressed gene 15 [MGI:1934816] 
ENSMUSG00000046719 ENSG00000182575 neurexophilin 3 [MGI:1336188] 
ENSMUSG00000026249 ENSG00000135919 
serine (or cysteine) peptidase inhibitor, clade E, member 2 
 [MGI:101780] 
ENSMUSG00000029501 ENSG00000176915 ankyrin repeat and LEM domain containing 2 [MGI:1261856] 
ENSMUSG00000025921 ENSG00000121039 retinol dehydrogenase 10 (all-trans) [MGI:1924238] 
ENSMUSG00000048096 ENSG00000163431 leiomodin 1 (smooth muscle) [MGI:2135671] 
ENSMUSG00000043518 ENSG00000131831 retinoic acid induced 2 [MGI:1344378] 
ENSMUSG00000042331 ENSG00000128487 
sperm antigen with calponin homology and coiled-coil domains 1  
[MGI:2442356] 
ENSMUSG00000019699 ENSG00000117020 thymoma viral proto-oncogene 3 [MGI:1345147] 
ENSMUSG00000019838 ENSG00000112394 
solute carrier family 16 (monocarboxylic acid transporters),  
member 10 [MGI:1919722] 
ENSMUSG00000086040 ENSG00000122574 
WAS/WASL interacting protein family, member 3 
[MGI:3044681] 
ENSMUSG00000025473 ENSG00000151651 a disintegrin and metallopeptidase domain 8 [MGI:107825] 
ENSMUSG00000031214 ENSG00000079482 oligophrenin 1 [MGI:2151070] 
ENSMUSG00000030087 ENSG00000163884 Kruppel-like factor 15 [MGI:1929988] 
ENSMUSG00000025504 ENSG00000177106 EPS8-like 2 [MGI:2138828] 
ENSMUSG00000041624 ENSG00000152402 guanylate cyclase 1, soluble, alpha 2 [MGI:2660877] 
ENSMUSG00000040430 ENSG00000154217 
phosphatidylinositol transfer protein, cytoplasmic 1  
[MGI:1919045] 
ENSMUSG00000022842 ENSG00000145194 endothelin converting enzyme 2 [MGI:1101356] 
ENSMUSG00000047409 ENSG00000144677 
CTD (carboxy-terminal domain, RNA polymerase II, polypeptide 
A)  
small phosphatase-like [MGI:1916524] 
ENSMUSG00000028494 ENSG00000147872 perilipin 2 [MGI:87920] 
ENSMUSG00000015312 ENSG00000099860 growth arrest and DNA-damage-inducible 45 beta [MGI:107776] 
ENSMUSG00000038058 ENSG00000106100 
nucleotide-binding oligomerization domain containing 1  
[MGI:1341839] 
ENSMUSG00000001131 ENSG00000102265 tissue inhibitor of metalloproteinase 1 [MGI:98752] 
ENSMUSG00000020846 ENSG00000183688 family with sequence similarity 101, member B [MGI:1923816] 
ENSMUSG00000059901 ENSG00000138316 
a disintegrin-like and metallopeptidase (reprolysin type) with 
 thrombospondin type 1 motif, 14 [MGI:2179942] 
ENSMUSG00000003752 ENSG00000086544 inositol 1,4,5-trisphosphate 3-kinase C [MGI:2442554] 
ENSMUSG00000040659 ENSG00000142634 EF hand domain containing 2 [MGI:106504] 
ENSMUSG00000031355 ENSG00000047648 Rho GTPase activating protein 6 [MGI:1196332] 
ENSMUSG00000042677 ENSG00000163874 zinc finger CCCH type containing 12A [MGI:2385891] 
ENSMUSG00000023272 ENSG00000184164 cysteine-rich with EGF-like domains 2 [MGI:1923987] 
ENSMUSG00000020250 ENSG00000198431 thioredoxin reductase 1 [MGI:1354175] 
ENSMUSG00000000120 ENSG00000064300 
nerve growth factor receptor (TNFR superfamily, member 16)  
[MGI:97323] 
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ENSMUSG00000059895 ENSG00000184489 protein tyrosine phosphatase 4a3 [MGI:1277098] 
ENSMUSG00000030255 ENSG00000123096 sarcospan [MGI:1353511] 
ENSMUSG00000022860 ENSG00000154645 chondrolectin [MGI:2179069] 
ENSMUSG00000062980 ENSG00000106034 
cadherin-like and PC-esterase domain containing 1 
 [MGI:2444814] 
ENSMUSG00000050931 ENSG00000164023 sphingomyelin synthase 2 [MGI:1921692] 
ENSMUSG00000029379 ENSG00000163739 chemokine (C-X-C motif) ligand 3 [MGI:3037818] 
ENSMUSG00000074480 ENSG00000254726 mex3 homolog A (C. elegans) [MGI:1919890] 
ENSMUSG00000029674 ENSG00000106683 LIM-domain containing, protein kinase [MGI:104572] 
ENSMUSG00000019850 ENSG00000118503 tumor necrosis factor, alpha-induced protein 3 [MGI:1196377] 
ENSMUSG00000044252 ENSG00000141447 oxysterol binding protein-like 1A [MGI:1927551] 
ENSMUSG00000020363 ENSG00000131459 glutamine fructose-6-phosphate transaminase 2 [MGI:1338883] 
ENSMUSG00000054342 ENSG00000104783 
potassium intermediate/small conductance calcium-activated 
channel,  
subfamily N, member 4 [MGI:1277957] 
ENSMUSG00000040280 ENSG00000185633 
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex,  
4-like 2 [MGI:3039567] 
ENSMUSG00000030069 ENSG00000163421 prokineticin 2 [MGI:1354178] 
ENSMUSG00000020644 ENSG00000115738 inhibitor of DNA binding 2 [MGI:96397] 
ENSMUSG00000027398 ENSG00000125538 interleukin 1 beta [MGI:96543] 
ENSMUSG00000025854 ENSG00000177706 family with sequence similarity 20, member C [MGI:2136853] 
ENSMUSG00000031558 ENSG00000145147 slit homolog 2 (Drosophila) [MGI:1315205] 
ENSMUSG00000034127 ENSG00000127324 tetraspanin 8 [MGI:2384918] 
ENSMUSG00000026494 ENSG00000162849 kinesin family member 26B [MGI:2447076] 
ENSMUSG00000023885 ENSG00000186340 thrombospondin 2 [MGI:98738] 
ENSMUSG00000021820 ENSG00000148660 
calcium/calmodulin-dependent protein kinase II gamma 
 [MGI:88259] 
ENSMUSG00000020572 ENSG00000105835 nicotinamide phosphoribosyltransferase [MGI:1929865] 
ENSMUSG00000040836 ENSG00000143147 G protein-coupled receptor 161 [MGI:2685054] 
ENSMUSG00000030103 ENSG00000134107 basic helix-loop-helix family, member e40 [MGI:1097714] 
ENSMUSG00000022867 ENSG00000155313 ubiquitin specific peptidase 25 [MGI:1353655] 
ENSMUSG00000047557 ENSG00000079257 latexin [MGI:107633] 
ENSMUSG00000027217 ENSG00000157570 tetraspanin 18 [MGI:1917186] 
ENSMUSG00000041731 ENSG00000154330 phosphoglucomutase 5 [MGI:1925668] 
ENSMUSG00000035441 ENSG00000176658 myosin ID [MGI:107728] 
ENSMUSG00000034394 ENSG00000128342 leukemia inhibitory factor [MGI:96787] 
ENSMUSG00000070366 ENSG00000203805 
phosphatidic acid phosphatase type 2 domain containing 1A 
 [MGI:2685936] 
ENSMUSG00000074622 ENSG00000204103 
v-maf musculoaponeurotic fibrosarcoma oncogene family, protein 
B (avian)  
[MGI:104555] 
ENSMUSG00000052837 ENSG00000171223 jun B proto-oncogene [MGI:96647] 
ENSMUSG00000071604 ENSG00000135063 family with sequence similarity 189, member A2 [MGI:2685813] 
ENSMUSG00000052087 ENSG00000169220 regulator of G-protein signalling 14 [MGI:1859709] 
ENSMUSG00000020806 ENSG00000129667 rhomboid 5 homolog 2 (Drosophila) [MGI:2442473] 
ENSMUSG00000004328 ENSG00000124440 hypoxia inducible factor 3, alpha subunit [MGI:1859778] 
ENSMUSG00000022389 ENSG00000167074 thyrotroph embryonic factor [MGI:98663] 
ENSMUSG00000043421 ENSG00000135245 hypoxia inducible lipid droplet associated [MGI:1916823] 
ENSMUSG00000004698 ENSG00000048052 histone deacetylase 9 [MGI:1931221] 
ENSMUSG00000033207 ENSG00000165072 MAM domain containing 2 [MGI:1918988] 
ENSMUSG00000002897 ENSG00000177663 interleukin 17 receptor A [MGI:107399] 
ENSMUSG00000031274 ENSG00000188153 collagen, type IV, alpha 5 [MGI:88456] 
Appendix B 
 
359 
 
ENSMUSG00000023034 ENSG00000123358 nuclear receptor subfamily 4, group A, member 1 [MGI:1352454] 
ENSMUSG00000012519 ENSG00000168404 mixed lineage kinase domain-like [MGI:1921818] 
ENSMUSG00000024236 ENSG00000197321 supervillin [MGI:2147319] 
ENSMUSG00000022475 ENSG00000061273 histone deacetylase 7 [MGI:1891835] 
ENSMUSG00000034898 ENSG00000118407 filamin A interacting protein 1 [MGI:1917848] 
ENSMUSG00000025576 ENSG00000167281 
RNA binding protein, fox-1 homolog (C. elegans) 3  
[MGI:106368] 
ENSMUSG00000029571 ENSG00000106460 transmembrane protein 106B [MGI:1919150] 
ENSMUSG00000023206 ENSG00000134470 interleukin 15 receptor, alpha chain [MGI:104644] 
ENSMUSG00000007682 ENSG00000211448 deiodinase, iodothyronine, type II [MGI:1338833] 
ENSMUSG00000045954 ENSG00000168497 serum deprivation response [MGI:99513] 
ENSMUSG00000040022 ENSG00000107560 RAB11 family interacting protein 2 (class I) [MGI:1922248] 
ENSMUSG00000030790 ENSG00000148926 adrenomedullin [MGI:108058] 
ENSMUSG00000038193 ENSG00000164107 
heart and neural crest derivatives expressed transcript 2  
[MGI:103580] 
ENSMUSG00000062866 ENSG00000112419 phosphatase and actin regulator 2 [MGI:2446138] 
ENSMUSG00000057604 ENSG00000071282 LIM and cysteine-rich domains 1 [MGI:1353635] 
ENSMUSG00000031639 ENSG00000164342 toll-like receptor 3 [MGI:2156367] 
ENSMUSG00000030539 ENSG00000185033 
sema domain, immunoglobulin domain (Ig), transmembrane 
domain (TM) and short  
cytoplasmic domain, (semaphorin) 4B [MGI:107559] 
ENSMUSG00000037447 ENSG00000196843 AT rich interactive domain 5A (MRF1-like) [MGI:2443039] 
ENSMUSG00000015134 ENSG00000184254 aldehyde dehydrogenase family 1, subfamily A3 [MGI:1861722] 
ENSMUSG00000075707 ENSG00000197406 deiodinase, iodothyronine type III [MGI:1306782] 
ENSMUSG00000036006 ENSG00000111913 family with sequence similarity 65, member B [MGI:2444879] 
ENSMUSG00000040852 ENSG00000152527 
pleckstrin homology domain containing, family H (with MyTH4 
domain) member 2  
[MGI:2146813] 
ENSMUSG00000026204 ENSG00000054356 protein tyrosine phosphatase, receptor type, N [MGI:102765] 
ENSMUSG00000039542 ENSG00000149294 neural cell adhesion molecule 1 [MGI:97281] 
ENSMUSG00000003882 ENSG00000168685 interleukin 7 receptor [MGI:96562] 
ENSMUSG00000027832 ENSG00000163661 pentraxin related gene [MGI:104641] 
ENSMUSG00000029919 ENSG00000163106 hematopoietic prostaglandin D synthase [MGI:1859384] 
ENSMUSG00000026180 ENSG00000180871 chemokine (C-X-C motif) receptor 2 [MGI:105303] 
ENSMUSG00000026180 ENSG00000163464 chemokine (C-X-C motif) receptor 2 [MGI:105303] 
ENSMUSG00000035671 ENSG00000132003 zinc finger SWIM-type containing 4 [MGI:2443726] 
ENSMUSG00000030022 ENSG00000163638 
a disintegrin-like and metallopeptidase (reprolysin type) with 
thrombospondin type 1 motif,  
9 [MGI:1916320] 
ENSMUSG00000031375 ENSG00000182492 biglycan [MGI:88158] 
ENSMUSG00000074575 ENSG00000026559 
potassium voltage-gated channel, subfamily G, member 1  
[MGI:3616086] 
ENSMUSG00000009281 ENSG00000106538 
retinoic acid receptor responder (tazarotene induced) 2 
 [MGI:1918910] 
ENSMUSG00000047945 ENSG00000175130 MARCKS-like 1 [MGI:97143] 
ENSMUSG00000031093 ENSG00000147251 dedicator of cytokinesis 11 [MGI:1923224] 
ENSMUSG00000053560 ENSG00000160888 immediate early response 2 [MGI:104815] 
ENSMUSG00000038319 ENSG00000055118 
potassium voltage-gated channel, subfamily H (eag-related), 
 member 2 [MGI:1341722] 
ENSMUSG00000030748 ENSG00000077238 interleukin 4 receptor, alpha [MGI:105367] 
ENSMUSG00000022419 ENSG00000155792 
DEP domain containing MTOR-interacting protein 
[MGI:2146322] 
ENSMUSG00000020154 ENSG00000127329 protein tyrosine phosphatase, receptor type, B [MGI:97809] 
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ENSMUSG00000032487 ENSG00000073756 prostaglandin-endoperoxide synthase 2 [MGI:97798] 
ENSMUSG00000032194 ENSG00000197256 KN motif and ankyrin repeat domains 2 [MGI:2384568] 
ENSMUSG00000028599 ENSG00000028137 
tumor necrosis factor receptor superfamily, member 1b 
 [MGI:1314883] 
ENSMUSG00000026864 ENSG00000044574 heat shock protein 5 [MGI:95835] 
ENSMUSG00000042302 ENSG00000115504 EH domain binding protein 1 [MGI:2667252] 
ENSMUSG00000027208 ENSG00000140285 fibroblast growth factor 7 [MGI:95521] 
ENSMUSG00000004768 ENSG00000112210 RAB23, member RAS oncogene family [MGI:99833] 
ENSMUSG00000031765 ENSG00000169715 metallothionein 1 [MGI:97171] 
ENSMUSG00000050315 ENSG00000172403 synaptopodin 2 [MGI:2153070] 
ENSMUSG00000019124 ENSG00000136193 secernin 1 [MGI:1917188] 
ENSMUSG00000038059 ENSG00000256235 small integral membrane protein 3 [MGI:1917088] 
ENSMUSG00000025993 ENSG00000138449 
solute carrier family 40 (iron-regulated transporter),  
member 1 [MGI:1315204] 
ENSMUSG00000026981 ENSG00000136689 interleukin 1 receptor antagonist [MGI:96547] 
ENSMUSG00000021109 ENSG00000100644 hypoxia inducible factor 1, alpha subunit [MGI:106918] 
ENSMUSG00000042759 ENSG00000184730 apolipoprotein B receptor [MGI:2176230] 
ENSMUSG00000038291 ENSG00000109762 sorting nexin 25 [MGI:2142610] 
ENSMUSG00000005124 ENSG00000104415 WNT1 inducible signalling pathway protein 1 [MGI:1197008] 
ENSMUSG00000053897 ENSG00000138821 
solute carrier family 39 (metal ion transporter), member 8  
[MGI:1914797] 
ENSMUSG00000030747 ENSG00000062282 diacylglycerol O-acyltransferase 2 [MGI:1915050] 
ENSMUSG00000052632 ENSG00000151693 
ArfGAP with SH3 domain, ankyrin repeat and PH domain 2  
[MGI:2685438] 
ENSMUSG00000029436 ENSG00000198598 matrix metallopeptidase 17 [MGI:1346076] 
ENSMUSG00000028036 ENSG00000122420 prostaglandin F receptor [MGI:97796] 
ENSMUSG00000021250 ENSG00000170345 FBJ osteosarcoma oncogene [MGI:95574] 
ENSMUSG00000001750 ENSG00000110719 
T cell, immune regulator 1, ATPase, H+ transporting, lysosomal 
V0 protein A3 
 [MGI:1350931] 
ENSMUSG00000053411 ENSG00000100307 chromobox 7 [MGI:1196439] 
ENSMUSG00000041347 ENSG00000100739 bradykinin receptor, beta 1 [MGI:88144] 
ENSMUSG00000039103 ENSG00000162614 nexilin [MGI:1916060] 
ENSMUSG00000093661 ENSG00000163412 
eukaryotic translation initiation factor 4E member 3  
[MGI:1914142] 
ENSMUSG00000042726 ENSG00000135148 TRAF type zinc finger domain containing 1 [MGI:1923551] 
ENSMUSG00000063234 ENSG00000139572 G protein-coupled receptor 84 [MGI:1934129] 
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Table B13 Cluster 1 genes. Genes downregulated throughout gestation in all mouse models 
and with labour onset in the human. 
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Table B14 Cluster 2 genes. Genes decreased in LPS induced PTL and human labour. 
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Table B15 Cluster 3 genes. Genes upregulated only in LPS-induced PTL model. 
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Table B16 Cluster 4 genes. Genes upregulated only with the onset of human labour. 
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Table B17 Cluster 5 genes. Genes increased in LPS-induced PTL model and human. 
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Table B18 Cluster 6 genes. Genes increased across gestation in all murine models and 
human. 
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Table B19 Cluster 7 genes. Genes upregulated throughout murine gestation and 
downregulated with human labour onset. 
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Table B20 Cluster 8 genes. Genes downregulated only in the murine LPS model. 
 
